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Abstract 
Evaluating Digital Health Technologies to Advance Parkinson’s Disease Care 
Thea Dominey 
Parkinson’s disease (PD) is a common progressive neurological disorder characterised by a 
complex range of motor and non-motor symptoms (NMS). Current PD service provision does 
not meet the needs of patients, and puts pressure on services with limited capacity. Digital 
Health Technologies (DHTs), including body-worn sensors and portable devices, may provide 
advantages, by enabling continual and objective monitoring of symptoms, and facilitating 
patient self-management.  
I carried out a series of studies and evaluations of DHTs for use in PD, to evaluate their ability 
to identify and monitor symptoms in both a clinical and research context. These included: 
1. The evaluation of a computerised paced finger tapping task (PFT) that was found to 
correlate with a measure of verbal fluency, suggesting there may be potential to 
implement the PFT as part of a wider finger tapping battery to be used as a screening 
tool for PD executive dysfunction. 
2. The iterative, user-centred design and formative evaluation of NMS Assist, a 
smartphone-based app to enable regular assessment of NMS as well as provide 
education for patients. The app was found to be highly usable, and key areas of 
amendment were identified. 
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3. A clinical service evaluation of the PKGTM, a PD remote monitoring device. The findings 
revealed the PKGTM is useful for identifying patients with unmet treatment need, even 
in newly diagnosed people with Parkinson’s (PwP) who experience more frequent 
clinic review. 
4. A systematic review of neuroprotective trial design in PD. The results demonstrated a 
wide range of primary outcome measures is used across trials, and there is little 
evidence of patient stratification. The findings highlighted the potential for DHTs to 
improve various aspects of clinical trial design. 
I discuss the potential value of DHTs, as well as challenges associated with their use, identified 
as a result of this research.  
298 words 
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Chapter 1 Overview of Thesis and General Introduction 
1.1 Overview of Thesis 
This thesis contains a general introduction, followed by four experimental chapters, a general 
discussion and a conclusion. 
Chapter 1 is the general introduction, and provides an overview of Parkinson’s disease (PD), 
PD service provision, and Digital Health Technologies (DHTs).  
Chapter 2 details the introduction, methods, results and discussion of the development and 
evaluation of a digital objective motor (finger tapping) assessment tool to provide information 
on potential PD cognitive impairment. 
Chapter 3 details the development and evaluation of a novel smartphone based app to enable 
regular remote monitoring of non-motor symptoms (NMS) and provide self-help information 
for people with Parkinson’s (PwP) and carer partners. Chapter 3 has an introduction, and is 
then split into three parts. Part 1 relates to the identification of app users and uses, Part 2 
relates to the iterative design process of a) the app wireframe and b) the self-help materials, 
and Part 3 relates to the methods and results of the formative evaluation. There is an overall 
discussion.  
Chapter 4 details the introduction, methods, results and discussion of a clinical service 
evaluation, evaluating the utility of an existing wearable device, The Parkinson’s Kinetigraph 
(PKGTM) to identify patients with unmet treatment needs between clinic appointments. 
Chapter 5 details the introduction, methods, results and discussion of a systematic evaluation 
of PD neuroprotective trial design to evaluate the potential for DHTs to add value. 
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Finally, prior to the main conclusions, references and appendices, Chapter 6 details the overall 
discussion.  
1.2 General Introduction  
1.2.1 Parkinson’s disease (PD) 
Parkinson’s disease (PD) is a chronic progressive neurodegenerative disorder characterised 
by motor symptoms including slowness of movement (bradykinesia), rigidity and tremor, and 
non-motor symptoms (NMS) including neuropsychiatric symptoms (e.g. anxiety, depression) 
sleep disturbances, and autonomic disturbance (e.g. orthostatic hypotension, constipation). 
The presentation of symptoms varies between patients and throughout the progression of 
the disease, with symptoms having a significant impact on quality of life for people with 
Parkinson’s (PwP) and their carer partners (Global Parkinson’s Disease Survey (GPDS) Steering 
Committee., 2002; Schrag, Hovris, Morley, Quinn, & Jahanshahi, 2006).  
The motor symptoms associated with PD are thought to be caused by the death of 
dopaminergic neurons in the midbrain, whereas the presence of non-motor symptoms 
provide evidence of neuronal loss in additional areas of the brain (DeMaagd & Philip, 2015) 
and autonomic nervous system (Orimo, Ghebremedhin, & Gelpi, 2018). While no drug has 
been shown to slow or reverse the neurodegenerative process of PD, there are effective 
treatments for both the motor and non-motor symptoms of PD; however long term use 
together with disease progression can lead to adverse effects that may limit function or dose. 
1.2.2 Epidemiology  
Parkinson’s disease is a common neurodegenerative disorder. A recent report on the 
prevalence and incidence of PD in the UK (Parkinson's UK, 2017), estimated that 22 in every 
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10,000 women and 32 in every 10,000 men are living with PD in the UK . As these figures 
suggest, PD is more common in men, with men accounting for 57.5% of the PD population in 
the UK.  Prevalence increases with age, doubling roughly every 5 years between 50 and 69 
years for both men and women. From 85 onwards, prevalence appears to decrease slightly, 
however this may be due to mortality, or due to the difficulty in diagnosing PD in very elderly 
populations, where symptoms may be confused with normal ageing.  
Due to an increasing life expectancy and an ageing population, the prevalence for PD in the 
UK was estimated as 145,519 in 2018 (up 6.4% from 136,816 in 2015) and the incidence 
18,461 (up 6.6% from 17,314 in 2015) (Parkinson's UK, 2017). Furthermore, by 2025, the 
prevalence of PD is expected to have increased by 18%, and by 2065, both the incidence and 
prevalence of PD in the UK is expected to have doubled (see Figure 1). 
The prevalence of PD is also increasing globally (Dorsey et al., 2018). In 2016, 6.1 million 
people had PD globally, compared with 2.5 million in 1990 (Dorsey et al., 2018). This continual 
rise in prevalence and incidence of PD in the UK and globally is expected to have significant 
social, health and economic impacts.  
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Figure 1 Projected incidence and prevalence of PD in the UK. Based on data from the Parkinson’s UK 
Clinical Practice Research Datalink Summary Report  (Parkinson's UK, 2017). 
1.2.3 Economic impact of PD 
Due to an increasing life expectancy, people are living longer with PD, which, coupled with 
increased incidence and prevalence of the disease means the economic impact of PD is 
substantial and complex. 
The economic impact of PD can be measured from a variety of different perspectives, as 
outlined in Figure 2.  
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Figure 2 The different economic costs contributing towards the overall economic impact of Parkinson's 
disease. Figure based on McCrone (2007). 
In 2015, Parkinson’s UK (PUK) commissioned a national survey to provide an estimate of the 
economic impact of PD for someone living with the condition in the UK (Gumber et al., 2017). 
The research revealed that on average, a household in the UK where someone has a diagnosis 
of PD will incur an annual cost of £16,582, which was broken down as higher health costs 
(£2,229), higher social costs (£3,622) and loss of income (£10,731).  
Of interest, previous research into the economic impact of PD identified several predictors of 
cost in PD including problems with depression, communication and gait, as well as longer 
duration of illness (McCrone, Allcock, & Burn, 2007). Gender was associated with total costs, 
with men having higher costs than women.  
This research indicates the overall economic impact of PD for households living with the 
condition and to services is high. Furthermore, overall societal costs are expected to rise given 
the increasing age-related prevalence of the disease in the UK.   
Economic impact of Parkinson’s disease 
Other direct costs, e.g. home 
care workers, social workers 
Direct health care costs, e.g. 
neurologists, GPs, 
physiotherapists, drugs 
Informal care from family and 
friends 
Productivity costs from lost 
employment due to illness 
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1.2.4 Aetiology  
Despite extensive research, the cause of PD remains elusive. The current view is that both 
environmental factors and genetic factors contribute to the onset of disease, with genetic 
predisposition increasingly seen as a major influence to the cause of PD (Schapira & Jenner, 
2011). Age is strongly related to the onset of PD, and remains the biggest risk factor for 
developing idiopathic Parkinson’s disease (IPD) (Reeve, Simcox, & Turnbull, 2014). This is 
thought to be explained by an increased vulnerability of dopaminergic neurons to toxic insult 
with age (Schapira & Jenner, 2011).   
1.2.5 Familial PD 
While the cause of PD in the majority of cases remains unknown (IPD) in less than 10% of 
cases, the cause of PD is thought to be genetic, known as familial PD. In familial cases of PD, 
if the leucine rich repeat kinase 2 (LRRK2) or a-Synuclein (SNCA) gene is altered, the disorder 
is inherited in an autosomal dominant manner, whereas if the Parkin, PTEN-induced putative 
kinase 1 (PINK1), DJ-1 and ATP13A2 genes are altered, the disease is inherited in an autosomal 
recessive manner (Corti, Lesage, & Brice, 2011). A list of known gene mutations associated 
with PD are summarised in Table 1. 
1.2.6 Genetic associations with IPD 
The genetic factors associated with IPD have been extensively studied, in the hope that it may 
lead to effective treatments and early detection of disease (Schapira, 2015). The accumulation 
of a-synuclein protein is thought to underlie the pathogenesis of PD, with mutations of the 
SNCA gene leading to the presence of abnormal protein associated with PD. Despite several 
gene mutations having been identified in familial PD, these are relatively rare, and account 
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for approximately less than 10% of all cases (Mullin, Schapira, & Leonard, 2015). Genome-
wide association (GWA) studies have allowed for the identification of a number of additional 
significant genetic associations with PD (Edwards et al., 2010), which include SNCA and MAPT.   
Importantly, mutations of the glucocerebrosidase gene (GBA1) have been recently identified 
as a significant risk factor for PD (Aharon-Peretz, Rosenbaum, & Gershoni-Baruch, 2004) and 
are substantially more common in PD than other associated genes including LRRK2 or SNCA 
(Schapira, 2015). The lifetime risk of developing PD for those with a GBA1 mutation has been 
estimated as 20% for someone at 70 years of age, increasing to 30% at 80 years of age (Beavan 
& Schapira, 2013). Estimates of the proportion of PwP that carry the GBA1 mutation vary, but 
is thought to be between 5 to 10% (Schapira, 2015). 
The genetic mutations associated with PD are summarised in Table 1 below. 
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Table 1 Table of genetic mutations associated with Parkinson’s disease.  
Name Gene Inher.-Onset-Type Function 
PARK1 α-synuclein (SNCA), 2% of AD cases AD-E-PD/PDD Vesicle tracking 
PARK2 Parkin, 50% of AR hereditary cases AR-J/E-PD Ubiquitination 
PARK3 Unknown – not found since identified 1998 AD-L-PD Unknown ?risk factor 
PARK4 α-synuclein (=PARK1 gene multiplication) AD-E-PD/PDD Vesicle tracking 
PARK5 Ubiquitin-C-terminal hydrolase L1 (UCH-L1) AD-L-PD Ubiquitination 
PARK6 PTEN-induced kinase 1 (PINK1) AR-E-PD Mitochondrial function 
PARK7 DJ-1 AR-L-PD ?apoptosis 
PARK8 Leucine-rich repeat kinase 2 (LRRK2), 10% of AD cases AD-L-PD ?mitochondrial fusion/fission 
PARK9 Lysosomal ATPase (ATP13A2) AR-J/E-PD/PD+ Lysosomal ATPase  
PARK10 Unknown  AR-?-PD Unknown ?risk factor 
PARK11 Unknown  AD-?-PD Unknown ?risk factor 
PARK12 Unknown  XR-?-? Unknown ?risk factor 
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Name Gene Inher.-Onset-Type Function 
PARK13 Serine protease (HTRA2) AD-?-? Serine protease  
PARK14 Phospholipase A2 (PLA2G6) AR-E-PD+ Phospholipase A2  
PARK15 F-box only protein 7 (FBX07) AR-E-PD+ Ubiquitination 
PARK16 Unknown – identified in GWAS as risk factor ?-?-PD Unknown 
PARK17 VPS35 AD-E/L-PD Endosome protein trafficking 
PARK18 EIF4G1 AD-L-PD mRNA protein production 
PARK19 DNAJC6 AR-J-PD/PD+ Endocytosis 
PARK20 SYNJ1 AR-E-PD/PD+ Vesicle recycling 
Glucosidase GBA (Gauchers disease) AD-L-PD/PD+ Lysosomal enzyme 
POLG1 Polymerase gamma AR-E-PD+ DNA polymerase gamma 1 
AD=autosomal dominant; AR=autosomal recessive; J=juvenille (<20yrs); E=early (<50yrs); L=late (>=50yrs);PD=Typical PD; PDD=PD with 
dementia; PD+=PD with additional neurological features (* of familial cases only) 
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The discovery of GBA1 as a significant risk factor for PD provides valuable insights into disease 
pathophysiology, which may help efforts to predict PD prior to the development of symptoms, 
and help to develop neuroprotective therapies.  
1.2.7 Environmental Factors:  
There are a variety of known environmental influences that are associated with the 
occurrence of PD, including bacterial or viral infection, and exposure to chemicals such as 
carbon monoxide and carbon disulphide (Schapira & Jenner, 2011.). Pesticide exposure has 
been increasingly identified as a potential environmental influence, however it has not been 
possible to identify specific pesticide substances that might be responsible (Richardson et al., 
2009).  
Some environmental factors including caffeine and alcohol have been associated with a 
decreased risk of developing PD (Lees, Hardy, & Revesz, 2009), with non-smokers twice as 
likely to develop PD (Hernán et al., 2001) and people who do not consume caffeine daily at a 
25% increased risk of disease (Ascherio et al., 2004). Indeed, recent studies have supported 
the potential use of caffeine (an adenosine A2 receptor antagonist) as an anti-PD drug 
(Prediger, 2010).  
1.2.8 (Patho) physiology of movement 
Intentional movement occurs in response to initiation by the cerebral motor cortex that 
directly (or indirectly via local premotor circuits) reaches the brain stem or spinal motor 
neurons, and projects to the relevant muscles (Groenewegen, 2003). Several cortical and 
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subcortical centres including the basal ganglia receive input from the primary motor cortex 
and send processed information via the thalamus to the descending corticospinal motor 
pathways that originate in the motor and premotor areas of the cerebral cortex. The basal 
ganglia thereby influence the final motor output (eg. magnitude and timing of movements) 
(Groenewegen, 2003).  
The basal ganglia are composed of four main nuclei (see Figure 3): the striatum, the pallidum, 
the subthalamic nucleus and the substantia nigra. The substantia nigra consists of the pars 
compacta, which contains dopaminergic neurons, and the pars reticula. The basal ganglia 
receives input from almost all parts of the cerebral cortex, with the striatum being the main 
input structure. Dopamine neurons stemming from the substantia nigra pars compacta (SNpc) 
project to the striatum via the nigrostriatal pathway.  
 
Figure 3 Anatomy of the basal ganglia and major anatomical connections between the basal ganglia 
and cortex. From Brittain & Brown (2014) 
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A hallmark feature of PD pathology is the loss of dopaminergic neurons of the substantia nigra 
pars compacta (SNpc), with neuronal loss estimated to be 60-70% at the onset of symptoms 
(Lang & Lozano, 1998).  
In addition to the selective loss of dopaminergic neurons, pathological confirmation of 
diagnosis focuses on the finding of Lewy bodies, which are primarily made up of the protein 
a-synuclein (see Figure 4).  Despite the presence of Lewy bodies representing a defining 
feature of PD, the relevance of Lewy bodies to the disease process remains uncertain 
(Schapira & Jenner, 2011).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 A typical Lewy Body in the cytoplasm of a pigmented dopaminergic neuron in the substantia 
nigra. Taken from Lang & Lozano (1998). 
 
The effect of this dopaminergic loss is a malfunction of the complex direct and indirect 
pathways (see Figure 5). A loss of dopaminergic neurons means it is not possible to initiate 
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more movement in the direct pathway, nor prevent an excessive reduction in movement in 
the indirect pathway, resulting in a slowness of movement.  
 
Figure 5 Schematic summary of the basal ganglia model in normal and Parkinsonian State. Thicker 
arrows illustrate hyperactive pathways, whereas thinner arrows represent hypoactive circuits. 
 
The mechanisms of cell death that contribute to neuronal loss in PD are not fully understood, 
however considerable advances in understanding have been made in recent years (Schapira 
& Jenner, 2011). Mitochondrial dysfunction (Gu et al., 1998), oxidative stress (Schapira, 1995), 
altered protein handling (Schapira et al., 2009) and inflammatory change (Iravani, Kashefi, 
Mander, Rose, & Jenner, 2002) are all events considered to lead to cell death in PD, however 
the combination and sequence of these events leading to cell death remains to be ascertained 
(Schapira & Jenner, 2011). 
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Braak and collegues (2003) have challenged the traditional view that the degeneration of 
dopaminergic neurons starts in the substantia nigra (Braak et al., 2003). Instead, Braak (2003) 
described a pathological process of degeneration comprising six stages (see Figure 6). 
In stages 1 and 2, Braak (2003) describes how neurodegeneration may have already begun 
outside of the substantia nigra, but is not progressed to the point of a formal diagnosis of PD, 
which is dependent on the presence of motor symptoms. This phase (whereby symptoms and 
signs are present but not yet sufficient to meet diagnostic criteria for classical PD) is known 
as prodromal PD (Postuma et al., 2015).  
The main brain areas implicated in Stages 1 and 2 of Braak’s hypothesis (including the 
olfactory bulb, the anterior olfactory nucleus and the lower brain stem) are thought to 
mediate NMS including olfacation, and sleep (Chaudhuri, Healy, & Schapira, 2006).  
Manifestation of NMS may therefore be indicators of prodromal PD. Indeed, the Movement 
Disorders Society (MDS) has published diagnostic criteria for prodromal PD (Berg et al., 2015) 
based on a variety of non-motor manifestations including rapid eye movement (REM) Sleep 
Behaviour Disorder (RBD), olfactory dysfunction, constipation, excessive daytime sleepiness 
(EDS), symptomatic hypotension, erectile dysfunction, urinary dysfunction and depression. 
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Figure 6 Progression of PD-related pathology in accordance with Braak’s staging hypothesis. Taken 
from Sakakibara, Fowler, & Hattori (2010). 
 
1.2.9 Clinical Features  
Parkinson’s disease is characterised by a multifaceted picture of motor and non-motor 
symptoms that varies between patients and throughout the progression of the disease. The 
marked heterogeneity in the clinical presentation of PD adds to the complexity of managing 
the condition.  
38 
 
 
1.2.10 Motor Symptoms  
The four cardinal symptoms of PD are:  
1.2.10.1 Bradykinesia  
Bradykinesia initially manifests as slowness in performing activities of daily living (ADL) and 
slow reaction times, but also encompasses difficulties with planning and executing 
movements, and loss of spontaneous movements and/or gestures (Jankovic, 2008).  
Bradykinesia is the most characteristic clinical feature of PD and its presence is required for a 
diagnosis of PD to be made (Gibb, 1988). Bradykinesia is typically assessed by asking the 
patient to perform rapid and repetitive movements of the hand and feet (finger taps, heel 
taps). The clinician aims to identify slowness of movement and decreasing amplitude.  
1.2.10.2 Rigidity  
Rigidity is characterised by resistance throughout the range of limb movement and is typically 
accompanied by the ‘cog-wheeling’ phenomenon, whereby limbs move with small, jerky 
motions. PD rigidity can occur distally (wrists, ankles) or proximally (neck, shoulders, hips). 
Voluntary movements of the contralateral limb can be used to help detect mild cases, by 
increasing rigidity in the limb being examined (Jankovic, 2008).   
1.2.10.3 Rest tremor  
Rest tremor is a common symptom in PD and occurs unilaterally at a frequency between 4 
and 6 Hz. Rest tremor may appear in the thumb and index finger (often described as “pill-
rolling”) but can also appear in lips, chin, jaw and legs. The tremor does not generally appear 
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when the limb is in motion but when at rest, and characteristically disappears with action and 
during sleep (Jankovic, 2008).    
1.2.10.4 Postural Instability  
Postural instability usually occurs in the later stages of PD, after the onset of other motor 
symptoms. It is caused by the loss of postural reflexes and assessed by ‘The Pull Test’ whereby 
a clinician pulls the patient sharply backwards by the shoulders. The number of steps taken 
by the patient to recover indicates the level of instability (>2 or no response indicative of an 
abnormal response) (Jankovic, 2008).   
Other motor symptoms, which are not necessary for a diagnosis of PD include: 
1.2.10.5 Gait 
Gait disturbances in PD are varied, and can include episodic disturbances, which occur 
intermittently, as well as continuous disturbances, which are persistent and lead to changes 
in walking pattern (Hausdorff, 2009). Some examples of episodic gait disturbances are 
festination, meaning a quickening and shortening of normal strides, and freezing of gait 
(FOG). FOG typically manifests as a sudden inability to move, and can occur when beginning 
to walk (hesitation), when turning, or an inability to walk through a doorway or across a street. 
Freezing is not a symptom experienced by all patients, and typically occurs later in the course 
of the disease. Patients frequently develop techniques to help overcome this disabling 
symptom, including stepping over a cane, counting or marching (Jankovic, 2008).   
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Examples of continuous gait disturbances include slowed ambulation with decreased or 
absent arm swing, and impaired postural control (Hausdorff, 2009). A key gait problem for 
PwP is the inability to generate sufficient stride length, leading to a reduced and shortened 
stride length with increased variability.  
Gait disturbances can occur early on in the disease (Rochester et al., 2012), and become more 
marked as the disease progresses. A significant consequence of disturbed gait is falls, which 
can have important consequences including hospitalisation or nursing home placement, loss 
of independence, and increased mortality (Farombi, Owolabi, & Ogunniyi, 2016).  
1.2.10.6 Postural Tremor  
Postural tremor can be differentiated from rest tremor as it occurs when the patient has their 
arms outstretched in a horizontal position.  
1.2.11 Non Motor Symptoms (NMS) 
The range of NMS that can occur in PD fall into 5 groups of symptoms; neuropsychiatric 
symptoms, sleep disorders, autonomic symptoms, gastrointestinal symptoms and sensory 
symptoms (Chaudhuri, Healy, & Schapira, 2006).  As mentioned previously, the cause of some 
of the NMS in PD is thought to be associated with the distribution of α-synuclein outside the 
nigrostriatal system (Dickson et al., 2009), which affects multiple subcortical nuclei including 
nucleus basalis of Meynert (NBM)(cholinergic), locus coeruleus (LC) (noradrenergic), dorsal 
raphe nucleus (DRN) (serotonergic) and the dorsal motor nucleus of the vagus nerve (DMV) 
(Jellinger, 2017). The early loss of innervation from these nuclei and degeneration of 
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dopaminergic, serotonergic, cholinergic and noradrenergic pathways are thought to 
contribute to various NMS experienced in PD (Jellinger, 2017). In line with Braak’s (2003) 
staging theory, many of these symptoms are present prior to the emergence of motor 
symptoms. Indeed, RBD, olfactory dysfunction, constipation, excessive daytime sleepiness 
(EDS), symptomatic hypotension, erectile dysfunction, urinary dysfunction and depression, all 
form part of the MDS criteria for prodromal PD (Berg et al., 2015). Additionally, the peripheral 
autonomic nervous system and enteric nervous system are affected at early stages in PD, and 
underlie some of the NMS experienced (Ferrer, 2011).  
Figure 7 displays the different pathways affected in PD that may contribute towards the 
relevant motor and non-motor symptoms listed beneath each image.  
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Figure 7 The various pathways affected in PD, with corresponding motor and non-motor symptoms 
taken from Titova, Padmakumar, Lewis, & Chaudhuri (2017) 
 
A brief description of the NMS experienced in PD is given below, with relevant treatment 
recommendations summarised in Table 2.  
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1.2.11.1  Neuropsychiatric Symptoms: 
1.2.11.1.1 Depression: 
Depression is experienced in up to 45% of PwP, and amongst other signs, can manifest as 
pessimism about the future, a sense of guilt and heightened irritability (Pellicano et al., 2007). 
Depression has been identified as the most significant predictor of quality of life in PD (GDPS, 
2002), and is highly comorbid with anxiety (Menza, Robertson-Hoffman, & Bonapace, 1993).  
As outlined in a review by Dickson (2009), the anatomic substrate of depression in PD is not 
well defined, although norepinephrine and serotonin deficiencies are well documented in PD, 
and PD depression responds well to drugs that enhance noradrenergic or serotonergic 
neurotransmission (Dickson et al., 2009). As mentioned previously, the LC and DRN are 
examples of neurons that use these transmitters, and are targets of PD pathology (Dickson et 
al., 2009).  
1.2.11.1.2 Psychotic Symptoms (Visual Hallucinations and Delusions): 
Up to 40% of PD patients experience visual hallucinations of varying intensity (Diederich, 
Goetz, & Stebbins, 2005), whereas delusions become more frequent as the disease progresses 
(Chaudhuri et al., 2006). Visual hallucinations are commonly viewed as treatment related, 
although some research has suggested neuronal degeneration of the pedunculopontine 
nucleus, locus coeruleus, and the dopaminergic raphe nuclei may play a causative role 
(Diederich et al., 2005). Visual hallucinations can be distressing for patients and their families, 
and psychotic symptoms including paranoid ideation and delirium have been found to 
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strongly correlate with nursing home placement for people with PD, and with morality 
(Fénelon, Mahieux, Huon, & Ziégler, 2000). These symptoms can also be distressing for 
families due to their paranoid and accusatory nature.  
1.2.11.1.3 Cognitive impairment: 
Cognitive impairment is common in PD, with Mild Cognitive Impairment (MCI) occurring in up 
to 50% of PwP (referred to as PD-MCI) (Litvan et al., 2011). The cognitive deficits experienced 
in PD are heterogeneous with regards to the domains affected, including executive 
dysfunction (attention, planning, monitoring, and inhibition), memory and visuospatial 
impairment (Kehagia, Brandt, Antoniades, Collins, & Williams-Gray, 2016).  
Additionally, the type of cognitive deficits experienced is thought to contribute to the rate at 
which PwP with MCI are likely to progress to dementia. For instance, in a 10 year follow up 
study, (Williams-Gray et al., 2013) patients with early deficits on tests with a posterior cortical 
basis (eg. semantic fluency) were found to progress to dementia more quickly than patients 
with frontostriatally based executive deficits, as displayed in Figure 8. 
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Figure 8 Schematic representation of Frontal Executive vs Posterior Cortical impairment in PD. Taken 
from Williams-Gray (2013) 
In line with these findings, recent research by Bohnen (2015) demonstrated that cortical 
cholinergic denervation is very frequent in PwP with greatest cognitive deficits. Importantly 
however, the authors highlighted that cortical cholinergic denervation occurs mainly in 
subjects with significant caudate nucleus dopaminergic denervation. This finding indicates  
deficits of the caudate nucleus dopaminergic and forebrain cholinergic pathways exhibit both 
independent and interactive contributions to cognitive impairment in PD with dopaminergic 
denervation inducing compensatory over-activity of cortical cholinergic afferents (Bohnen et 
al., 2015).  
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1.2.11.2 Sleep Disorders 
1.2.11.2.1.1  Sleep Fragmentation:  
Sleep disruption is common in PD, and affects the majority of patients. Although the causes 
of sleep fragmentation are multifactorial, the pathological degeneration of central sleep 
regulation centres in the brainstem likely play a causative role (Chaudhuri, Healy, & Schapira, 
2006). In addition, other NMS can have an effect on the quality of sleep, such as restless-leg 
syndrome, which can cause frequent arousal.  
1.2.11.2.1.2 REM Sleep Behaviour Disorder (RBD): 
REM Sleep Behaviour Disorder (RBD) is characterised by a loss of muscle atonia that is 
normally experienced during REM sleep. As a result, patients are able to physically enact their 
dreams, which can involve making vocalisations (shouting, talking) as well as violent, 
abnormal movements (Muzerengi, Contrafatto, & Chaudhuri, 2007) which can be distressing 
for patients and their bed partners (Comella, Nardine, Diederich, & Stebbins, 1998). RBD is 
common in PD, affecting around a third of patients (Olson, Boeve, & Silber, 2000), as well as 
being a strong predictor of future PD development (Noyce, Lees, & Schrag, 2016); however 
the pathological cause is not well defined. It has been suggested that RBD occurs due to 
degeneration of the lower brainstem nuclei, including the pedunculopontine and 
subcoeruleal nucleus (Chaudhuri et al., 2006).  
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1.2.11.2.1.3 Excessive Daytime Sleepiness (EDS): 
Excessive daytime sleepiness (EDS) is commonly experienced by PwP, affecting up to 50% of 
patients (Arnulf, 2005). There are several factors that are thought to play a role in the 
causation of EDS, including the disease process, the effect of disturbed night-time sleep, and 
the effects of antiparkinsonian medication (Muzerengi et al., 2007). The presence of EDS has 
also been linked with the development of sudden onset sleep, which has been linked to road 
traffic accidents in PwP, therefore posing a threat to patient safety (Frucht, Rogers, Greene, 
Gordon, & Fahn, 1999).  
1.2.11.2.2  Autonomic Symptoms:  
Autonomic symptoms in PD including orthostatic dizziness, constipation, bladder dysfunction 
and erectile dysfunction are commonly experienced by PwP, and can have a significant impact 
on daily living (Magerkurth, Schnitzer, & Braune, 2005). The pathological basis for 
dysautonomia is thought to involve the degeneration and dysfunction of the dorsal vagal 
nucleus, nucleus ambiguous, and other centres including the rostral ventrolateral medulla, 
ventromedial medulla and caudal raphe nuclei (Chaudhuri et al., 2006). In addition, 
abnormalities of modulatory effects within the peripheral and central autonomic network are 
thought to occur due to the degeneration of cholinergic and monoaminergic nuclei 
(Chaudhuri et al., 2006). Some of the autonomic symptoms in PD will be described in more 
detail below. 
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1.2.11.2.2.1 Gastrointestinal Dysfunction: 
In recent years, there has been increasing evidence to suggest that the gastrointestinal tract 
may be the site of initiation of PD (Tredici & Braak, 2008). The presence of Lewy bodies in the 
enteric nervous system (ENS) has led to the suggestion that a-synuclein deposition may 
originate within the ENS before spreading to the brain (Hill-Burns et al., 2017). However, 
mixed findings regarding the specificity of enteric α-synuclein has prevented it from becoming 
an established biomarker for the diagnosis of PD (Visanji, Marras, Hazrati, Liu, & Lang, 2014).  
The dysfunction of the gastrointestinal system in PD can lead to a variety of complications, 
including drooling and swallowing problems, delays in gastric emptying and constipation. 
1.2.11.2.2.2 Constipation: 
Constipation is   the   most   common   gastrointestinal   symptom in PD, experienced by 80–
90% of patients  (Fasano, Visanji, Liu, Lang, & Pfeiffer, 2015). Constipation does not respond 
well to dopaminergic treatment (Muzerengi et al., 2007) and can impede the absorption of 
anti-PD medications, leading to Urinary Tract Infections (UTIs), confusion and falls, which are 
common causes of hospital admission (Muzerengi et al., 2007). 
1.2.11.2.2.3 Genitourinary dysfunction: 
Genitourinary dysfunction includes several PD NMS including bladder dysfunction (urinary 
urgency or frequency). The pathological basis for the overactivity of the bladder is thought to 
be due to an altered dopamine-basal ganglia circuit which normally suppresses the 
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micturition reflex (Sakakibara, Uchiyama, Yamanishi, & Kishi, 2010). However, some patients 
may experience an underactive bladder whereby they have difficulty starting urination.  
Another symptom that comprises genitounirnary dysfunction is sexual dysfunction (including 
erectile dyfunction and a decreased libido). Hypothalamic dysfunction is thought to be 
responsible for sexual dysfunction experienced in PD, via altered dopamine-oxytocin 
pathways which normally promote sexual function (Sakakibara, Uchiyama, et al., 2010). 
In addition, some patients may experience an increased sex drive due to developing Impulse 
Control Disorder (ICD), which can occur as a result of taking dopamine agonists. Clinicians 
should be alert to the signs of ICD, and regularly check with their patients for symptoms, so 
that medications can be adjusted as necessary. In addition to hypersexuality, other impulse 
control behaviours may include compulsive gambling, binge eating and obsessive shopping 
(NICE Guidelines, 2017). 
1.2.11.2.2.4 Orthostatic Hypotension (OH): 
Orthostatic hypotension (OH) occurs in 20-50% of PwP and is a recognised predictor of falls 
(Farombi et al., 2016). Sympathetic denervation has been suggested as a possible cause for 
OH in PD, and can be assessed via norepinephrine levels in the blood (Dubow, 2007). Patients 
experiencing OH have been found to have lower concentrations of norepinephrine than those 
without OH, and do not experience the same increase in concentration on standing that 
patients without OH experience (Dubow, 2007).   
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1.2.11.2.3  Sensory Symptoms: 
1.2.11.2.3.1 Pain: 
Pain is a common sensory symptom in PD affecting between 40%-85% of patients (Broen, 
Braaksma, Patijn, & Weber, 2012). There are five types of pain associated with PD. These 
include:  
• Musculoskeletal pain; characterised by a dull aching, primarily confined to joints and 
experiences with motion and after rest. This pain is typically worse in an ‘OFF’ 
medication state. 
• Radicular pain; limited to a specific neuronal distribution, this type of pain is 
experienced as a stabbing, throbbing or shooting sensation.  
• Dystonic pain; dystonia causes severe painful and involuntary muscle spasms, which 
are characterised by twisting or jerking repetitive movements.  
• Central neuropathic pain; this pain is constant and not well localised, nor limited to a 
specific neuronal distribution.  
• Akathisia pain: this type of pain is related to dopaminergic deficit and characterised 
by an intolerance of remaining still, with a constant need to move.  
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1.2.12 Treatment for NMS 
If left untreated, NMS can cause detrimental health complications and are a major cause of 
institutionalised care (Chaudhuri et al., 2006). It is therefore essential that effective treatment 
is provided in a timely manner to prevent further complications. 
Treatments for NMS in line with NICE recommendations for the management of PD (NICE, 
2017), in addition to recommendations from the MDS Evidence-Based Medicine Committee 
on the treatment of NMS in PD (Seppi et al., 2019) are summarised in Table 2.  
In line with NICE guidelines (NICE, 2017), a full medications review should be carried out when 
treating NMS, to establish whether any existing treatments are contributing towards 
symptoms. If reducing an existing medication (dosage or frequency), the severity of 
symptoms and possible withdrawal effects must be considered. If adding a medication to an 
existing regime, consideration of risks and side effects of the patient’s current medication is 
essential.  
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Table 2 Treatment guidelines for NMS in PD in line with NICE (2017) and MDS Task Force (2019) recommendations. 
Non-motor Symptom Recommended first line treatment Recommended second line treatment 
Depression • Low intensity psychosocial 
interventions (physical activity 
program, group based peer support, 
or computerised cognitive 
behavioural therapy (CCBT)) 
• Dopamine Agonist Pramipexole 
• Serotonin and Norepinephrine 
Reuptake Inhibitor (SNRI) venlafaxine 
• Individual or group cognitive 
behavioural therapy (CBT) 
Psychotic Symptoms (Visual Hallucinations 
and Delusions) 
• Reduce the dosage of any PD 
medications that may have triggered 
the symptoms 
• Quetiapine (in PwP without cognitive 
impairment) 
• Clozapine if standard treatment is not 
effective. 
 
Cognitive impairment • Cholinesterase inhibitor • Memantine 
Sleep Fragmentation • No formal guidelines  
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Non-motor Symptom Recommended first line treatment Recommended second line treatment 
• Encourage use of bedsheets and 
pyjamas that slip easily (Overeem & 
Reading, 2018) 
• Suggest that items needed 
throughout the night (e.g. medication, 
water) are within easy reach 
(Overeem & Reading, 2018) 
REM Sleep Behaviour Disorder (RBD) • Clonazepan 
• Melatonin 
 
Excessive Daytime Sleepiness (EDS) • Adjust medications to reduce the 
occurrence of EDS 
• Modafinil 
Constipation • Lifestyle recommendations (such as 
increased fibre and fluid intake) 
• Use of probiotics and prebiotic fibers 
• Laxatives 
Urinary urgency/frequency • Advise pt to avoid excessive tea and 
coffee consumption 
• Advise pt to stay hydrated 
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Non-motor Symptom Recommended first line treatment Recommended second line treatment 
• Bladder training exercises 
• anticholinergics 
Erectile Dysfunction • Sildenafil  
Orthostatic Hypotension (OH) • Midodrine • Fludrocortisone 
Pain • Dopaminergic therapy 
• Nonsteroidal anti-inflammatory drugs 
(NSAIDs) 
• Physiotherapy and exercise programs 
 
55 
 
 
1.2.13 Parkinson’s Subtypes: 
The clinical manifestations of PD are heterogeneous in nature, and their varied presentation 
across PwP has led researchers to propose the existence of underlying motor and non-motor 
subtypes of PD. 
In one of the largest natural history studies of PD (the DATATOP trial, 1990), 800 participants 
with early PD were classified using the Movement Disorders Unified Parkinson’s Disease 
Rating Scale (MDS-UPDRS) (Goetz, Tilley, et al., 2008) (a widely used scale to assess symptom 
severity in PD), as having either postural instability and gait difficulty-predominant disease 
(n= 441), tremor-predominant disease (n= 233), or an indeterminate subtype (n= 126) 
(Jankovic et al., 1990). Interestingly, these groups had differences in their abilities to complete 
ADL and in their NMS, which led to the conceptualisation of discrete clinical subtypes in PD 
(Kotagal, 2016).  
Over the past decade, there have been various further attempts to provide well-defined 
criteria for PD phenotypic subgroups based on the presentation of motor and non-motor 
symptoms (Erro et al., 2013; S. J. G. Lewis et al., 2005; Selikhova et al., 2009).  
Most recently, Lawton and colleagues (2018) have suggested 4 possible PD phenotypic 
subgroups based on a sample of  patients with early PD from Tracking Parkinson’s (n=1601) 
and Discovery cohorts (n=944) (Lawton et al., 2018).  
The 4 identified phenotypic subgroups with associated levodopa response, non-motor 
features and motor progression rates are as follows: (1) fast motor progression with 
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symmetrical motor disease, poor olfaction, cognition and postural hypotension; (2) mild 
motor and non-motor disease with intermediate motor progression; (3) severe motor 
disease, poor psychological well-being and poor sleep with an intermediate motor 
progression; (4) slow motor progression with tremor- dominant, unilateral disease. Figure 9 
describes each of the subgroups identified (Lawton et al., 2018). 
These cohort cluster findings highlight the potential value of identifying different PD 
phenotypic subgroups, with implications for early access to personalised, preventative 
treatment, and allowing for patient stratification in future clinical trials. 
Figure 9 Salient clinical features of the four PD subgroup clusters across the Tracking Parkinson’s and Discovery cohorts. 
Taken from Lawton (2018)  
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1.2.14 Diagnosis  
As there is no definitive test to confirm the diagnosis of PD, NICE guidelines recommend a 
patient with suspected PD (patients presenting with tremor, stiffness, slowness, balance 
problems and/or gait disorders) should be referred quickly and untreated to a specialist with 
expertise in the differential diagnosis of PD (NICE, 2017). A diagnosis of PD is given following 
a detailed clinical examination, and in line with the UK Parkinson's Disease Society Brain Bank 
Clinical Diagnostic Criteria (Gibb et al., 1988), which requires the presence of bradykinesia in 
addition to at least one other symptom including: rest tremor, rigidity, or postural instability. 
The UK Brain Bank Diagnostic Criteria are outlined in Table 3. 
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Table 3 The UK Parkinson’s Disease Society Brain Bank Clinical Diagnostic Criteria (Gibb et al., 1988) 
Step 1. Diagnosis of Parkinsonian Syndrome 
• Bradykinesia 
• At least one of the following 
▪ Muscular rigidity 
▪ 4-6 Hz rest tremor 
▪ Postural instability not caused by primary visual, vestibular, cerebellar, or proprioceptive dysfunction 
Step 2. Exclusion criteria for Parkinson’s disease 
• History of repeated strokes with stepwise progression of parkinsonian features 
• History of repeated head injury 
• History of definite encephalitis 
• Oculogyric crises 
• Neuroleptic treatment at onset of symptoms 
• More than one affected relative 
• Sustained remission 
• Strictly unilateral features after 3 years 
• Supranuclear gaze palsy 
• Cerebellar signs 
• Early severe autonomic involvement 
• Early severe dementia with disturbances of memory, language, and praxis 
• Babinski sign 
• Presence of cerebral tumor or communication hydrocephalus on imaging study 
• Negative response to large doses of levodopa in absence of malabsorption 
• MPTP exposure 
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In addition to the diagnostic criteria for Prodromal PD described previously (see section 1.2.8) 
(Berg et al., 2015), the MDS Task Force have also published clinical diagnostic criteria for PD 
(Postuma et al., 2015). In line with previous versions, the MDS diagnostic criteria detail a two-
step process for a PD diagnosis, whereby parkinsonism is firstly identified (as bradykinesia 
with rest tremor, rigidity or both) and then defined as to whether it is attributable to PD 
(Postuma et al., 2015). In addition, the updated diagnostic criteria incorporate non-motor 
manifestations such as sleep dysfunction (sleep fragmentation, excessive daytime 
somnolence, symptoms of RBD), autonomic dysfunction (constipation, daytime urinary 
urgency), or psychiatric dysfunction (depression, anxiety, or hallucination). 
1.2.15 Parkinson’s disease - Treatment 
Due to the multifaceted picture of motor and non-motor symptoms and the variable rates of 
progression experienced, a comprehensive and multidisciplinary approach is required in the 
treatment of PD. In line with recent NICE Guidance referrals to Physiotherapists, Speech and 
Step 3. Supportive prospective positive criteria for Parkinson’s disease 
Three or more required for diagnosis of definite Parkinson’s disease in combination with step one 
• Unilateral onset 
• Rest tremor present 
• Progressive disorder 
• Persistent asymmetry affecting side of onset most 
• Excellent response (70-100%) to levodopa 
• Severe levodopa-induced chorea 
• Levodopa response for 5 years or more 
• Clinical course of ten years or more 
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Language Therapists, Dieticians, Occupational Health and Palliative Care should be considered 
throughout the disease course (NICE, 2017). All PwP should have a comprehensive care plan 
in place, agreed between their PD specialist (consultant neurologist or consultant 
geriatrician), their families and carers.  
Current NICE Guidelines recommend that patients with early PD should be seen at regular 
intervals of 6-12 months to review their diagnosis, with follow-up review increasing to 2-3 
monthly intervals according to clinical need to assess the response to medication, titrate 
dosage, and re-visit the diagnosis (NICE,2017). In addition, NICE guidelines recommend that 
people with advanced PD may require review at frequent intervals (every 2–3 months) 
(NICE,2017).  
In practice, different models of care provision are experienced by patients dependent on their 
local service provision; some patients are reviewed every 3 months; some annually or 
anywhere in between; and some secondary care services offer no follow-up.  
NICE guidelines further recommend that all PwP should have access to a Parkinson’s disease 
Specialist Nurse (PDNS) (NICE,2017). However, differences in capacity across services means 
there are varied models of care provision experienced by patients (see Table 4). In addition, 
a geographically large rural caseload, such as in the Plymouth area, adds to PDNS pressures. 
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Table 4 Differences in PDNS service provision 
Model of PDNS Care 
Provision 
Description  Limitations 
Emergency only  Some PDNS teams have no 
capacity for regular review and 
so rely on patients to contact 
them when in difficulty.  
This model of care does not 
facilitate anticipatory care and 
prevention of complications.  
 
 
Clinic appointments only A service based almost 
exclusively on clinic 
appointments. 
This model of care provides no 
capacity for monitoring changes 
to medication regime or 
development of complications, 
and means it is difficult for the 
service to be a useful adjunct to 
consultant care.  
 
Combination  Some services provide a 
combination of clinic 
appointments, routine review, 
supplemented with triggered 
review (telephone, clinic or 
home visit), close liaison with 
the consultant (usually by 
email) and the ability to triage 
patients for consultant clinics.  
While this model of care allows 
for delivery of best practice, 
issues are still apparent. For 
example, some nurses are able 
to prescribe and others are not, 
introducing delay and lack of 
consistency in some aspects of 
management. 
 
The differences in provision of care between services highlights the importance of managing 
patient’s expectations of care from the point of diagnosis. By managing patients’ expectations 
as to the regularity with which they will be seen from the outset, frustrations can be 
minimised and patient education can be promoted. Indeed, the recognition of the patient as 
an ‘active player’ in their health care is revolutionising traditional models of care, and 
encourages patients to take part in shared decision making with their clinician, rather than 
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assuming a passive role (Van der Eijk, Nijhuis, Faber, & Bloem, 2013). Engagement in 
healthcare has been found to have improved health outcomes (Bauman, Fardy, & Harris, 
2003), and will be discussed in more detail (see section 1.2.27). 
1.2.15.1 Pharmacological Treatment 
As yet, there is no neuroprotective therapy available in PD, and so management of PD is 
guided by severity of motor and non-motor symptoms, complications and side effects of 
pharmacological therapy. The time to initiate pharmacological treatment in PD varies 
between patients, and largely depends on the interference of symptoms with the patient’s 
ability to carry out ADL whilst remaining independent.  
Once the decision to begin pharmacological treatment has been made, there are several first-
line treatment of motor symptoms available, as outlined in the NICE guidelines (NICE, 2017). 
These include: levodopa, dopamine agonists and monoamine oxidase B (MAO-B) inhibitors. 
Levodopa: 
Initial treatment with levodopa (L-dopa) has well established benefits for patients including 
better symptom control and improved quality of life (QoL) (Gray et al., 2014), and continues 
to be considered the gold standard for PD treatment (Mercuri & Bernardi, 2005). Despite 
initial benefits, more than 50% of patients will go on to experience motor complications 
(including motor response fluctuations and dyskinesias) between 5-10 years after 
commencing L-dopa therapy (Davie, 2008). Motor complications pose a major challenge for 
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patients and clinicians, and negatively impact on QoL (Chapuis, Ouchchane, Metz, Gerbaud, 
& Durif, 2005).  
1.2.16 Motor response fluctuations  
1.2.16.1 End-of-dose wearing off 
The end-of-dose wearing-off phenomenon refers to the shortened effectiveness of a single 
dose of L-dopa, with motor symptoms (eg. tremor) as well as NMS (eg. anxiety) remerging 
towards the end of a treatment interval (Fackrell et al., 2018). The frequency and severity of 
wearing off is increased with disease progression and duration of drug treatment, and 
eventually affects the majority of patients (Olanow et al., 2013).  
In addition to wearing off, another motor complication frequently experienced by patients is 
the re-emergence of symptoms in the morning prior to a patient’s first dose of L-dopa, known 
as an ‘early-morning off’ period. Early morning off periods are common in PD, experienced by 
up to 80% of patients in a recent survey (n=2205) (Onozawa et al., 2016).  
Other types of motor response fluctuations associated with long term treatment of L-dopa 
are ‘delayed-on periods’, whereby the beneficial effect of a dose of L-dopa is delayed, and 
‘dose-failures’, whereby the dose of L-dopa fails to achieve the desired ‘on state’ (Fackrell et 
al., 2018). 
Guidelines on the management of different types of wearing off were recently published by 
a panel of UK PD specialists (Fackrell et al., 2018). Prior to altering a patient’s medication 
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regime, the panel highlight several modifiable factors that affect wearing off to be considered, 
including:  
• Therapy compliance; influenced by depression, cognitive function and apathy. 
• Dietary factors; a large protein meal can delay gastric emptying and competes with 
the absorption of L-dopa, meaning the quantity and timing of protein intake should 
be considered.  
• Gastrointestinal (GI) absorption; constipation is a common GI symptom of PD and may 
interfere with L-dopa absorption, worsening motor fluctuations. 
1.2.16.2 Dyskinesia: 
There are several risk factors identified for the development of L-dopa -induced dyskinesia, 
including younger age of disease onset (Kumar, Van Gerpen, Bower, & Ahlskog, 2005) and 
higher L-dopa dose (Thanvi, Lo, & Robinson, 2007). The treatment of L-dopa -induced 
dyskinesia remains challenging, with reductions in daily dose of L-dopa often rendering 
patients highly bradykinetic and sometimes immobile (Davie, 2008). This challenge highlights 
the difficult balancing act for clinicians to control motor symptoms without inducing further 
motor complications, such as L-dopa-induced dyskinesia. 
1.2.16.3  Non-motor fluctuations: 
Non-motor fluctuations affect two-thirds of patients receiving long term L-dopa treatment 
(Quinn, 1998). Non-motor fluctuations are typically experienced as fluctuations in mood, and 
can present as a combination of depression, anxiety, panic, irritability, or apathy in “off state” 
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periods. In the “on state”, patients usually experience normal mood, but can occasionally be 
euphoric, hypersexual, or hypomanic, and sometimes withdrawn (Quinn, 1998). 
1.2.17 Treatment of motor fluctuations 
Due to the significant adverse motor complications associated with L-dopa use, many 
clinicians consider the use of drug therapy adjuvants to L-dopa as the disease progresses, 
including dopamine agonists, Monoamine Oxidase B (MAO-B) Inhibitors, Catechol-O-Methyl 
Transferase (COMT) Inhibitors, and amantadine (NICE 2017).  The different pharmacological 
treatment options available in PD are outlined in Table 5, adapted from NICE guidance 2017 
(NICE 2017).  
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Table 5 A summary of the different pharmacological treatment options available in PD based on NICE Guidelines (2017) 
Drug Class Examples Mode of Action Benefits  Disadvantages 
Levodopa  co-careldopa 
(sinemet)  
 
co-beneldopa 
(madopar) 
Uptake by remaining 
dopaminergic neurons, 
allowing for conversion to 
dopamine.  
Improved motor symptoms and 
improved ADL, fewer adverse 
events*, different forms 
available (eg. controlled 
release/dispersable) 
Development of motor 
complications, increased 
risk of dyskinesia, half-life 
approx. 60 mins 
Dopamine agonists 
(oral/transdermal) 
pramipexole - oral 
(mirapexin) 
ropinerole - oral 
(requip) 
rotigotine - transdermal 
(neupro) 
apomorphine 
Direct stimulation of 
dopamine receptors 
 
Improved motor symptoms and 
improved ADL, more OFF-time 
reduction, non-oral route 
(apomorphine) 
Intermediate risk of 
adverse events, greater 
risk of hallucinations, 
expensive (apomorphine) 
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Drug Class Examples Mode of Action Benefits  Disadvantages 
Monoamine Oxidase B 
Inhibitors (MAO-B) 
rasagiline  
(azilect) 
selegiline 
(eldepryl) 
Inhibits MAO-B and 
increases available 
dopamine in synaptic cleft  
Improved motor symptoms and 
improved ADL, fewer adverse 
events*,OFF-time reduction, 
lower risk of hallucinations 
Comparatively limited 
symptom control 
COMT Inhibitors entacapone 
tolcapone 
opicapone 
Inhibits COMT and 
increases half-life of 
levodopa 
Improved motor symptoms and 
improved ADL, OFF-time 
reduction, lower risk of 
hallucinations 
More adverse events 
Amantadine amantadine A glutamate receptor 
agonist that increases 
dopamine release and 
blocks reuptake 
Reduced dyskinesia  Limited evidence of benefit 
to motor symptom or ADL 
improvement 
* Adverse events refer to an increased risk of impulse control disorder, psychotic symptoms and sudden onset of sleep  associated with dopaminergic therapy 
(Voon et al., 2011). Patients should be regularly warned of the signs so that intervention can be put in place.
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1.2.18 Advanced Therapies  
For patients experiencing severe motor complications, advanced therapies (AT) can increase 
the time the patient experiences at their best (reduced OFF time), and can lead to an 
improved quality of life for the PwP and carer (Lezcano et al., 2004). 
1.2.18.1 Apomorphine 
Apomorphine is a highly potent dopamine agonist acting at D1 and D2 dopamine receptors 
(Trenkwalder et al., 2015), and is typically used to manage sudden and unexpected levodopa-
induced ‘off states’ (Deleu, Hanssens, & Northway, 2004). Apomorphine is administered by 
the subcutaneous route, either intermittently as an injection (pen-injection formulation) or 
as a continuous infusion (the pump formulation) (Trenkwalder et al., 2015) and has been 
shown to achieve anti-parkinsonian efficacy comparable to that of orally-administered L-dopa 
(Deleu et al., 2004).  
1.2.18.2 Duodopa  
Duodopa (also known as L-dopa /carbidopa intestinal gel (LCIG)) is an aqueous gel comprising 
a combination of L-dopa and carbidopa in a 4:1 ratio, and can be delivered continuously to 
the proximal jejunum via a percutaneous gastrojejunostomy tube connected to a portable 
infusion pump (Olanow et al., 2014). Duodopa has been found to be clinically effective in 
improving symptoms of advanced PD, and improving overall quality of life in comparison with 
standard therapy (Fasano, Ricciardi, Lena, Bentivoglio, & Modugno, 2012; Nyholm, 2012). 
However, maintaining the positioning of the tube can be problematic, and there is a risk of 
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local infections developing at the site of insertion (Trenkwalder et al., 2015). NHS England has 
provided strict guidance regarding patient selection and use of Duodopa (NHS England, 2015), 
and Duodopa is not currently recommended for use by NICE, due to lack of cost-effectiveness 
(NICE, 2017).  
1.2.18.3 Deep Brain Stimulation (DBS)  
Deep brain stimulation (DBS) is the administration of high-frequency continuous electrical 
stimulation to the subthalamic nucleus through a surgically implanted device (Deuschl et al., 
2006). DBS has been shown to be very effective for patients who are not well controlled, or 
who cannot tolerate dopaminergic therapy (Fasano, Daniele, & Albanese, 2012). A five year 
follow up study found patients had improved motor symptoms, with improved mobility and 
reductions in dyskinesias observed (Krack et al., 2003). However despite its effectiveness, due 
to the risks associated with the necessary surgery, DBS is not encouraged in patients of older 
age.  
Due to the surgical risks and costs associated with DBS, there are strict eligibility criteria that 
candidates must fulfil in order to be offered the treatment (Munhoz et al., 2016). In reality, a 
very small sub group of PwP meet the clinical eligibility criteria for DBS, ranging from 1% to 
10% (of PwP). In 2013, NHS England estimated that the total number of DBS per year would 
indicate about 300 Parkinson’s patients per year receive DBS (plus patients for dystonia and 
tremor) (NHS England, 2013).  
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Despite the benefits of AT, access to these therapies is limited, due to their expense, the lack 
of familiarity of ATs amongst clinicians, and limited time to carry out necessary assessment in 
clinic (Worth, 2013). Furthermore, selecting patients that are suitable for AT can be 
challenging, and inappropriate referrals to specialist AT centres cause frustration, and are 
costly in terms of time and resource (Worth, 2013). 
To assist in the identification of patients with advanced disease and those who may be 
suitable candidates for advanced therapies, several guidelines have been published via 
consensus from international experts (Antonini et al., 2018; Luquin, Kulisevsky, Martinez-
Martin, Mir, & Tolosa, 2017; Worth, 2013).    
1.2.19 Service Provision at University Hospitals Plymouth NHS Trust (UHPNT) 
1.2.19.1 UHPNT Catchment area 
The University Hospitals Plymouth NHS Trust (UHPNT) service catchment area covers three 
geographical regions comprising West Devon, North East Cornwall and Plymouth.  Based on 
current prevalence figures (NICE, 2017) it is estimated that there are approximately 1,500 
PwP living in the UHPNT population footprint. 
1.2.19.2 UHPNT Parkinson’s Service  
All UHPNT neurologists (n=8) manage patients with PD. There are two consultant 
neurologists specialising in PD (Dr Simon Edwards and Dr Camille Carroll). In addition, there 
are five specialist PD nurses based in the community (Plymouth n=2; Cornwall n=2; West 
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Devon n=1), and two hospital specialist PD nurses who provide both an in-patient and out-
patient service, supported by an assistant practitioner. 
1.2.20 Challenges to UHPNT Parkinson’s Service 
1.2.20.1 Insufficient capacity to meet service demand 
As mentioned previously, national standards of PD care suggest that patients with early mild 
symptoms of PD should be reviewed by a specialist (PD consultant or PDNS) every 6-12 
months to review diagnosis and the need for treatment (NICE, 2017). Once treatment is 
commenced, follow-up is recommended to be more frequent (2-3 months) to assess response 
to medication, titrate dosage and re-visit the diagnosis.  Within our service, we have recently 
audited patient experience of PD care, and found that 46% of patients have consultant 
appointments delayed by more than 6 months, and 60% have not seen the community nurse 
within the last year. Our current waiting time is 12-24 months for a routine review 
appointment in the consultant clinic. Table 6 displays the shortfall of clinics in our service 
required to achieve minimum and standard level of service in accordance with NICE guidelines 
(NICE, 2017). 
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Table 6. Number of clinic slots per week needed to achieve minimum and standard levels of PD care, 
in accordance with NICE guidelines and those currently available at UHPNT 
 
1.2.20.2  Service Threats 
Providing sub-optimal care further contributes to staff dissatisfaction, stress and poor 
retention, which is a cause of significant threat to PD services. Parkinson’s UK recently carried 
out an evaluation of threats to PD services across the UK. Forty-seven active threats were 
identified, with the majority of these (82%) being from within the PDNS Community. The type 
of threat identified is summarised in Figure 10. The biggest identified challenge was the 
number of vacancies due to resignations, which may reflect the high demands on staff and 
services. Within our service, we have had reduced community PDNS capacity for the last year 
due to retirement and long-term sick leave. The resulting increased demand on the hospital 
PDNS team has led to increased delays within the hospital-based care pathways. 
 
Level of Service Number of slots 
required 
Number of slots 
available 
Shortfall (%) 
Minimum (1 per 12 
months) 
32 22 10 (31%) 
Standard (1 per 6 
months) 
63 22 40 (63%) 
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Figure 10 Types of threats facing Parkinson's Disease Nurse (PDNS) Community teams. Taken from 
personal communications (Parkinson's UK). 
 
1.2.20.3 Increasing prevalence and incidence of PwP in the UHPNT catchment area:  
The challenges associated with providing a timely and patient-centred service are expected 
to increase due to an ageing population and increased life expectancy. Figure 11 and Figure 
12 demonstrate the projected prevalence and incidence of PwP in the UHPNT catchment 
area from 2015 to 2025, based on current prevalence and incidence figures for the UK 
(Parkinson's UK, 2017).  
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Figure 11 Projected prevalence of PwP living in the UHPNT catchment area per annum (pa) 
 
 
Figure 12 Projected incidence of PwP living in the UHPNT catchment area per annum (pa) 
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1.2.20.4 Inappropriate method of review: 
It has been suggested that time locked clinic review is unable to meet the demands of a 
condition which progresses at a variable rate and affects individuals in multiple ways 
(Maetzler, Domingos, Srulijes, Ferreira, & Bloem, 2013). A recent BMJ essay written by a ‘E-
patient’ describes the frustration associated with time-locked clinical reviews (Riggare, 2018, 
p.2): 
“I see my neurologist once or twice a year for about 30 minutes each time. So he observes my 
symptoms, and assesses the effect of the treatment he prescribes, for one hour a year.” 
This extract highlights the limitations of a 30 minute clinic review, whereby the clinician is 
only provided with a mere snapshot of the patient’s condition, on the basis of which 
treatment decisions are made that will impact on the patient for the rest of that year, or until 
their next review.  
A further challenge of a short clinic review, is that a clinician is unable to carry out a 
comprehensive assessment of symptoms in this time frame. Treatment decisions are 
therefore based on a limited amount of information and observations that is obtainable 
within 30 minutes. In reality, many neurology appointments are less than 30 minutes, 
sometimes lasting just 15 or 20 minutes. 
Other than observations that are made by the clinician within these 30 minutes, evaluation is 
also dependent on patient recall, the validity of which may be limited due to poor patient 
awareness of symptoms (Pietracupa, Latorre, Berardelli, & Fabbrini, 2014) or a tendency for 
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PwP to under or over-estimate symptom severity (Zach, Dirkx, Pasman, Bloem, & Helmich, 
2017). Inaccuracies in patient recall can therefore lead to erroneous assessment and 
inappropriate or inadequate interventions being implemented.  
Furthermore, attending clinics can be arduous for both patient and carer, presenting logistical 
and physical challenges that add to burden and distress. Dorsey et al (2016) outlined several 
limitations of current care models of PD care (summarised in Table 7) and highlighted how 
current models of care fail to meet the needs of PwP. These challenges are particularly valid 
for our service with its rural catchment and poor public transport provision. 
Table 7 How current care models fail to meet the need of PwP. Table based on Dorsey et al (2016)  
Feature PwP Current care models 
Location Primarily suburban and rural areas Primarily urban centres 
Driving Impaired ability Usually requires driving 
Mobility Limited Generally required to access 
care 
Cognition Frequently impaired Often demanding to navigate 
Disease Course Progressive Least accessible for those with 
most advanced disease 
Caregivers Burdened Increases the burden 
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1.2.21 Current measures of disease  
In addition to the issues with current service provision already identified, there are further 
limitations surrounding the assessment tools used in both clinical and research settings in PD 
to assess symptom severity and monitor disease progression.  
There is no well-established bio-marker (a naturally occurring molecule, gene, or 
characteristic by which progression of disease can be identified (Strimbu & Tavel, 2010)) of 
disease progression in PD. Therefore, clinical assessment is the primary means of evaluation 
in clinic, with rater-dependent clinical scales often the primary endpoints in PD research 
(Espay et al., 2016).  
1.2.21.1 Motor Symptom Measures: 
There are a number of measurement instruments and scales to assess the motor symptoms 
of PD, including posture, gait and balance (see (Bloem et al., 2016) for a review). Some of the 
most commonly used motor symptoms measures are described in more detail below. 
1.2.21.1.1 Movement Disorders Unified Parkinson’s Disease Rating Scale (MDS-UPDRS)  
The most widely used scale to assess symptom severity in PD is the MDS-UPDRS (Goetz, Tilley, 
et al., 2008). In addition to use in disease management, the MDS-UPDRS is one of the most 
widely used efficacy measures to investigate the potential neuroprotective effects of a PD 
therapy in clinical trials (Athauda & Foltynie, 2016). The MDS-UPDRS requires training to 
administer, and is divided into four parts (described below). Responses for each item are rated 
on a 5 point scale; 0 (normal), 1 (slight impairment), 2 (mild impairment), 3 (marked 
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impairment), 4 (severe impairment). Scores for each item are summed to produce a total 
score, with higher scores reflecting more severe impairment. 
The four parts of the MDS-UPDRS are described below: 
Part I: Part I concerns “non-motor experiences of daily living” and comprises 13 items. Seven 
of these items are in a questionnaire format and designed to be self-completed by the patient, 
while the remaining items that deal with complex behaviours require the investigator to 
conduct the interview. Rater involvement time for administering Part I is estimated to require 
less than 10 minutes (Goetz, Tilley, et al., 2008). 
Part II: Part II concerns “motor experiences of daily living” and comprises 13 items, all of which 
are designed to be self-completed by the patient.  
Part III: Part III is the “motor examination”. Part III can be used in isolation to assess motor 
performance and is comprised of 33 scores based on 18 items which the rater asks the patient 
to perform on their right and left side. The rater observes performance and rates each item 
on the 4-point scale described previously. Rater involvement time for administering Part III is 
estimated to require 15 minutes (Goetz, Tilley, et al., 2008). 
Part IV: Part IV concerns “motor complications” and comprises 6 items which are asked by 
the investigator and expected to take 5 minutes to administer.  
The total rater involvement time required to administer the MDS-UPDRS is therefore 
approximately 30 minutes, extending to approximately 45 minutes for the patient (to include 
the self-completed items).  
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1.2.21.1.2  The Timed Up & Go (TUG) Test 
The Timed Up & Go (TUG) Test is a physical measure, whereby a patient is asked to rise from 
a seated chair position, walk 3 meters, turn, walk back and sit down. The performance is 
timed, with longer test times associated with decreased mobility and a higher falls risk 
(Foreman, Addison, Kim, & Dibble, 2011). The measure requires little equipment, is easy to 
administer and only takes a few minutes, thereby making it a useful test in an outpatient 
setting  (Nocera et al., 2013).  
1.2.21.1.3  The Finger Tapping (FT) Test  
The Finger Tapping (FT) Test is a timed test whereby two buttons are attached to a counter 
30cm apart. Subjects are asked to alternately tap each button as fast as they can with their 
left hand for one minute. This procedure is then repeated using their right hand. The sum of 
the taps is calculated for each hand with an increased number of alternate taps indicating 
better performance. The FT is used to assess the impact of bradykinesia in the upper 
extremity, and has been found to have high validity and reliability (Shimoyama, Ninchoji, & 
Uemura, 1990). Furthermore, the FT has been shown to successfully distinguish PwP from 
controls (Shimoyama et al., 1990).  
1.2.21.2 Non-motor symptom measures 
There are a number of clinical scales and screening tools developed for use in PD. Non-motor 
symptoms scales allow for an assessment of the severity of a NMS to be carried out, whereas 
NMS screening tools are used to alert clinicians that a patient may be experiencing an NMS. 
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1.2.21.2.1 Pain 
King’s Parkinson’s disease Pain Scale (KPPS) 
The King’s Parkinson’s Disease Pain Scale (KPPS) is a screening tool for pain, comprising 14 
items across 7 domains (musculoskeletal pain (1 item), chronic pain (2 items), fluctuation-
related pain (3 items), nocturnal pain (2 items), oro-facial pain (3 items), discoloration (2 
items) and radicular pain (1 item)) (Chaudhuri et al., 2015). Each item is scored by severity (0, 
none to 3, very severe) multiplied by frequency (0, never to 4, all the time) resulting in a 
subscore of 0 to 12, the sum of which gives the total score with a possible range from 0 to 
168. The scale is administered by an investigator and takes approximately 10-15 minutes to 
complete. The scale has been internationally validated, and found to have excellent inter-
rater and test-retest reliability (Chaudhuri et al., 2015).  
1.2.21.2.2  Sleep:  
There are a number of scales available to measure sleep in PD (see (Kurtis, Balestrino, 
Rodriguez-Blazquez, Forjaz, & Martinez-Martin, 2018) for a review), including the SCOPA-
Sleep scale for the assessment of overnight sleep and Excessive Daytime Sleepiness (EDS) 
(Marinus, Visser, van Hilten, Lammers, & Stiggelbout, 2003), and the Epworth Sleepiness Scale 
(ESS), that measures the risk of falling asleep during daily activities (Johns, 1991).  
The Parkinson’s disease Sleep Scale (PDSS-2) 
The Parkinson’s disease Sleep Scale (PDSS -2) is a common scale used to assess sleep in PD 
(Trenkwalder et al., 2011). The scale comprises 15 items evaluating nocturnal sleep 
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disturbances. Items are scored from 0 (never) to 4 (very frequent). Total scores can range 
from 0-60, with higher scores indicating more sleep problems. 
1.2.21.2.3  Depression 
There are several depression scales available in PD (see (Schrag et al., 2007) for a review). 
Beck Depression Inventory (BDI) 
The  Beck Depression Inventory (BDI) is a widely used sale in PD (Beck, Ward, Mendelson, 
Mock & Erbaugh, 1961), used to both to measure severity of depression and as a screening 
tool.  The BDI is self-completed by patients, and comprises 21 items with each response 
assigned a score ranging from zero to three, with a higher score indicating greater severity of 
the symptom. The BDI has been validated for use in PwP and found to have high test-retest 
reliability (Visser, Leentjens, Marinus, Stiggelbout, & van Hilten, 2006).  
1.2.21.2.4  Cognitive impairment: 
There are a number of cognitive assessments for use in PD (see (Kulisevsky & Pagonabarraga, 
2009) for a review), including the Scales For Outcomes Of Parkinson’s Disease—Cognition 
(SCOPA-COG).  Although not specific to PD, the Montreal Cognitive Assessment (MoCA) and 
the Mini-Mental State Examination (MMSE) are widely used screening instruments for 
cognitive impairment. Both scales are quick to administer, taking around 10-15 minutes to 
complete. In recent years, stricter copyright protection has been enforced, meaning the 
MMSE is no longer freely accessible in the public domain (Newman & Feldman, 2011) .  
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1.2.21.2.5  Disability:  
A number of disability scales are available for use in PD (see Shulman et al (2016) for a review).  
Functional Status Questionnaire (FSQ) 
The functional status questionnaire (FSQ) is a self-administered questionnaire comprising 36 
items across six summary scales: 1) basic and intermediate activities of daily living (ADLs); 2) 
mental health; 3) social activity; 4) work performance and quality of interactions, plus six 
single-item scores. Items are rated on scales of 1 to 4 and 1 to 6, with summary scores 
standardized to 100 based on percentage (Shulman et al., 2016). The FSQ has been validated 
in a PD cohort (Rubenstein et al., 1998) and was shown to have good internal consistency and 
content validity.  
1.2.21.2.6  Quality of Life (QoL): 
There are several quality of life (QoL) scales validated for use in PD (see Martinez-Martin et. 
al (2011) for a review), however the 39 item Parkinson’s Disease Questionnaire (PDQ-39) is 
the most commonly used (Martinez-Martin et al., 2011).  
The Parkinson’s Disease Questionnaire (PDQ-39) 
The Parkinson’s Disease Questionnaire (PDQ-39) is a 39 item disease specific questionnaire, 
designed to characterise the impact of PD on patients (Jenkinson, Peto, Fitzpatrick,Greenhall 
& Hyman, 1995).  The items cover eight dimensions (mobility, ADL, emotional well-being, 
stigma, social support, cognitions, communication, and bodily discomfort). Factor analysis 
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was used to create an overall single index figure (Parkinson’s disease summary index (PDSI)) 
from the eight dimension scores. The PDQ-39 has been extensively validated and is widely 
used as a patient completed measure of QoL in research (Peto, Jenkinson, & Fitzpatrick, 1998). 
A shorter form version (PDQ-8) has since been developed and validated (Jenkinson et al., 
1997).  
Quality of Life Measure for the Carers of People with Parkinson’s disease (the PDQ-Carer) 
Parkinson’s disease can have detrimental effects on quality of life (QoL) not only for the 
people diagnosed with PD, but also for the informal care givers who provide the majority of 
support to PwP.  
The PDQ-Carer is a 29 item self-completed questionnaire designed to assess the effects of PD 
on QoL for carers (Jenkinson et al., 2012). Items are spread across four domains including; 
personal and social activities (12 items), anxiety and depression (6 items), self-care (5 items), 
and strain (6 items). Response categories for each item include 
“Never”/”Occasionally”/”Sometimes”/”Often”/”Always”.   
Responses for each item are transformed to have a range from 0 (best, i.e. no problem at all) 
through to 100 (worst, i.e. maximum level of problem), with scores >60 suggesting seriously 
compromised aspects of quality of life (Jenkinson et al., 2012). 
A carers quality of life questionnaire has since been developed for Atypical Parkinsonism 
(PQoL Carers) (Pillas et al., 2016). 
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1.2.21.2.7  Non-Motor Symptom Burden: 
Non-Motor Symptoms Questionnaire (NMS Quest) 
In order to enhance the identification of NMS in PD patients and allow for appropriate and 
timely treatment, a self-rated Non-Motor Symptoms Questionnaire was developed (NMS 
Quest) (Chaudhuri et al., 2006). This 30-item screening questionnaire allows for a 
comprehensive assessment of the range of non-motor symptoms that occur in PD (see Table 
8), and provides an opportunity for the patient to self-declare any possible problems to their 
clinician for further investigation. Furthermore, the NMS Quest was designed to be completed 
by the patient in the waiting room, which provides an economic solution to screen for possible 
problems prior to clinical consultation (Chaudhuri et al., 2006). The NMS Quest has been 
internationally validated (Chaudhuri et al., 2006), and is used extensively as part of routine 
clinical care. The Non Motor Symptom Scale (NMSS) was later developed mainly for use as a 
research tool, to measure the frequency and severity of symptoms (4). The NMSS was found 
to highly correlate with the NMS-Quest and measures of Quality of Life (both r=.7) (Chaudhuri 
et al., 2007). 
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Table 8 Domains in the NMS-Quest 
Domain Number of items 
Gastrointestinal tract 7 
Urinary tract 2 
Sexual function 2 
Cardiovascular 2 
Apathy/attention/memory 3 
Hallucinations/delusions 2 
Depression/anxiety 2 
Sleep disorder 5 
Miscellaneous (e.g., diplopia, weight loss) 5 
 
1.2.22 Limitations of current measures of Parkinson’s disease  
There are several limitations surrounding the use of rater-dependent clinical scales as the 
primary assessment tools in PD care. 
As mentioned previously, the MDS-UPDRS is the most widely used and accepted measure to 
assess motor symptoms in PD in both clinical and research settings (Goetz, Tilley, et al., 2008). 
The MDS-UPDRS Part III is a subjective measurement, assessed by an independent rater. 
However, despite objective instructions for use, and a mandatory rater training process, there 
is evidence of notable intra and inter-rater variability associated with the scale which limits 
its use as a reliable measure of disease progression (Post, Merkus, de Bie, de Haan, & 
Speelman, 2005). In addition, the MDS-UPDRS assessment is typically administered during 
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clinic visits often weeks or months apart, and only provides a ‘snap-shot’ of a patient’s 
symptoms, which, as identified previously, can be variable from a day to day, or even hour to 
hour basis (Papapetropoulos, Mitsi, Espay, Kaji, & Colosimo, 2015). In addition, many patients 
find the requirement to carry out the MDS-UPDRS Part III in the OFF medication state highly 
burdensome, which can be a barrier to trial participation and retention (Athauda & Foltynie, 
2016). 
Also, a number of the measures described previously are reliant on patient recall of symptom 
severity. Self-completed measures including patient diaries have been  previously associated 
with poor compliance, recall bias and diary fatigue which impacts on their usefulness as a 
reliable indicator of symptom severity (Athauda & Foltynie, 2016.; Papapetropoulos, 2012). 
This is particularly poignant in patients with cognitive dysfunction, which is commonly 
experienced in PD (Aarsland et al., 2009). Moreover, patient diaries frequently do not 
correlate with quantitative measures (Utsumi et al., 2012). 
1.2.23 Limitations of Parkinson’s disease Clinical Trials 
Similar limitations are also pertinent in the field of PD clinical trials, with no pharmacological 
agent having been shown to slow, halt or reverse the progression of PD, despite many agents 
showing promise in pre-clinical studies (Athauda & Foltynie, 2016).  
Dorsey and colleagues (2017a) suggested that the failure of Phase III trials to replicate earlier 
successful Phase II results is partly due to the use of artificial and imperfect outcome 
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measures, which may reduce confidence in the replicability of findings, and can lead to 
considerable economic costs (Dorsey, Papapetropoulos, Xiong, & Kieburtz, 2017). 
Several other challenges facing PD neuroprotective trials have been identified (Athauda & 
Foltynie, 2016) including selection of inappropriate endpoints, and poor selection of patient 
cohorts, which do not take into account the heterogeneity of PD. 
1.2.24 Summary of challenges facing Parkinson’s disease care and research 
To summarise, there are a number of limitations surrounding current PD service provision, 
which does not meet the needs of PwP or carers. As discussed, current issues include; limited 
clinic capacity, inappropriate time-locked clinic review, the need for patients to travel to clinic, 
and the use of rater-dependent clinical scales with limited sensitivity. 
Moreover, some of these challenges may also be applied to PD research, whereby the 
selection of inappropriate endpoints and lack of patient stratification in clinical trial design 
have been identified as potential reasons for the lack of discovery of a neuroprotective agent 
(Dorsey, Papapetropoulos, et al., 2017a). 
There is a clear need to provide patients, clinicians and researchers with the tools and 
resources to overcome the current issues described, and ultimately improve the standard of 
PD care and research.  
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1.2.25 Digital Health Technologies (DHTs) 
In recent years, a multitude of Digital Health Technologies (DHTs) for the objective 
measurement of PD symptoms have emerged, that may provide potential solutions to some 
of the shortcomings described previously. 
The term DHT refers to a broad range of technologies, including wearable devices such as 
body-worn sensors, and portable systems such as smartphone-based devices. DHTs can 
therefore be utilised by clinicians in a clinical or research setting to objectively measure 
specific behaviours, or self-administered by patients to detect and monitor impairments 
occurring in everyday life (Espay et al., 2016).  
1.2.25.1 Non-motor DHTs 
The majority of DHTs that have been developed for use in PD are for the assessment of motor 
symptoms, with few technologies having been developed for the assessment of Parkinson’s 
NMS (Espay et al., 2016). Several existing DHTs are commercially available for use in industry 
that have potential to be applied to the measurement of Parkinson’s NMS. Some of these, in 
addition to existing non-motor DHTs for use in PD, are explored below.  
1.2.25.1.1 Sleep: 
Accelerometer technology offers potential for carrying out assessment of sleep quality in PD. 
The DynaPort MiniMod is a tri-axial accelerometer validated as a measurement device for 
physical activity during sleep (Bossenbroek et al., 2010). Quantitative analysis of axial 
nocturnal movements (including mean acceleration of nocturnal movements) obtained using 
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the DynaPort MiniMod has been used to differentiate PwP from healthy controls (Louter, 
Maetzler, & Prinzen, 2015). PwP were found to have overall decreased acceleration of 
movements as well as smaller and shorter and nocturnal axial movements.  
Also, home-based polysomnography devices are available for monitoring sleep 
("Somnomedics", 2019)  which have potential to be used in PD. 
1.2.25.1.1 Cognition:  
There are a number of online cognitive assessments available for use in research and clinical 
practice.  
The Cats-and-Dogs Test is an online tool designed to identify visuoperceptual deficits in PD 
(Weil et al., 2017), which is a risk factor for developing PD dementia (Williams-Gray et al., 
2013). The tool is accessible online, and requires participants to identify skewed images of 
cats and dogs (see Figure 13), with poorer identification performance suggesting impaired 
visuosperceptual ability.  
 
Figure 13 An example of a test image from the Cats-and-Dogs Test (Weil et al., 2017) 
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1.2.25.1.2  Autonomic Dysfunction:  
Several technologies are available to monitor different NMS related to autonomic 
disturbance. BioWatch is a wrist watch-based system that has been validated to continuously 
measure blood pressure via ECG electrodes, which may be useful for PwP experiencing 
orthostatic hypotension (Thomas et al., 2016).  
In addition, there are wearable sensors available to measure galvanic skin response for 
monitoring excessive sweating (Mindfield, 2019) and other causes of physiological arousal 
such as stress (Picard & Scheirer, 2001). 
1.2.25.1.3  Pain:  
Digital health technologies designed to measure pain have been developed for use clinically, 
that may be applicable to PD. The PMD-200TM is a stand-alone monitoring device that 
quantifies patients’ physiological response to pain (“PMD-200TM, 2019). The device comprises 
a non-invasive finger probe and sensors that acquire multiple physiological signals which are 
analysed using proprietary algorithms to produce a pain index, where 0 represents no pain 
response and 100 represents extreme pain response. PMD-200 TM is commercially available in 
Europe, Canada, Australia and Israel, and may be useful for monitoring and quantifying levels 
of PD related pain discussed previously (see section 1.2.11.2.3.1).   
1.2.25.2 Motor DHTS 
As mentioned previously, the majority of DHTs that have been developed for use in PD are 
for the assessment of motor symptoms, allowing for the objective measurement of a range 
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of symptoms (Maetzler et al., 2013). A clear advantage of objective measures is they offer 
potential to improve the sensitivity, accuracy and reproducibility of assessment in PD motor 
symptoms over and above traditional clinical scales (Espay et al., 2016), with both clinical and 
research application.  
1.2.25.2.1  Smartphone-based Measures: 
A number of studies have investigated the use of smartphones to objectively quantify a range 
of PD symptoms.  For instance, a PD smartphone-based software application, comprising 
measures of finger tapping, voice, posture, gait and reaction time has been found to 
differentiate between PwP and controls with high sensitivity (96.2%) and specificity (96.9%) 
and predicted disease severity, as measured by the MDS-UPDRS (Arora et al., 2015). The 
smartphone application (developed by the Oxford Parkinson’s Disease Centre (OPDC) has 
since been used in a more extensive study, to identify individuals with RBD from controls and 
PwP (Arora et al., 2018), which can be indicative of prodromal PD (Noyce, Lees, Schrag, & 
Schrag, 2016).  
Additionally, a number of other studies have investigated the use of smartphones to quantify 
PD motor symptoms including bradykinesia (Lee et al., 2016), gait (Steins, Sheret, Dawes, 
Esser, & Collett, 2014) and tremor (Woods, Nowostawski, Franz, & Purvis, 2014). Moreover, 
the ubiquity and affordability of smartphones make them an appealing platform for DHT 
development (Trister, Dorsey, & Friend, 2016). 
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1.2.25.2.2  Wearable Devices: 
In recent years, a multitude of wearable technologies for the objective measurement of 
different PD symptoms have emerged (Maetzler et al., 2013). Wearable devices are able to 
capture the frequency and intensity of a variety of movements throughout the day, 
predominantly via inertial sensors (Espay et al., 2016). Movement data collected by these 
sensors is then processed using proprietary algorithms, to identify PD related symptoms.  
In addition to objectively quantifying specific symptoms in a clinical or research setting, 
wearable devices (including body-worn sensors) offer potential to remotely monitor and 
assess patients’ symptoms from within the home environment, resulting in data that is high 
in ecological validity (Stamford, Schmidt, & Friedl, 2015).  
A recent RAND report on the future of health (Corbett, d’Angelo, Gangitano, & Freeman, 
2017) identified wearable technology as an important trend, allowing patients to self-manage 
long term conditions at home, while reducing the demand on services. Furthermore, 
wearable devices have the potential to closely monitor individual responses to therapy, and 
provide tailored information for patients that can be used to optimise treatment (Barker, 
2017).  
In addition, wearable devices potentially confer specific advantages with respect to PD. The 
ability to monitor status over a prolonged period of time, as opposed to the snapshot 
measurements observed in clinic mentioned previously, is likely to be more reflective of true 
symptom severity (Maetzler et al., 2013) and avoids an over-reliance on patient recall.   
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Del Din et al (2016) carried out a review on the acceptability and feasibility of wearable 
technologies to continuously monitor a range of PD symptoms in the home environment, 
defined as ‘free living’ (Del Din, Godfrey, Mazzà, Lord, & Rochester, 2016). The review 
comprised predominantly single-sensor based devices including accelerometers and 
gyroscopes.  
Del-Din and colleagues (2016) included three classifications of validity as part of their review; 
1) whether the study demonstrated accurate detection of the clinical feature under 
investigation, or method of appraisal; 2) criterion validity: the relationship between the 
outcome obtained via the wearable device and traditional measures (eg. clinical scales) and 
3) discriminative validity: the ability of the wearable outcomes to discriminate between 
groups. Formal testing of utility (e.g. feasibility) of the wearable device was also reported (Del 
Din, Godfrey, et al., 2016). A number of studies included as part of the review are displayed 
in Table 9 below.  
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Table 9 Studies examining free-living monitoring of PD using wearable technology. Based on Del Din (2016) (128) 
Study (year), 
N,  
Type of 
wearable 
Placement on 
body 
Clinical 
feature 
Accurate 
detection of 
clinical feature 
Measures Criterion Validity Discriminative 
Validity 
Utility 
Das et al 
(2012) 
2 PwP 
Accelerometers Lower back, 
ankles, wrists 
Dyskinesia, 
tremor 
Yes against 
patient diaries 
Acceleration derived 
features (Mean 
energy, high 
frequency energy 
content, correlation, 
frequency domain 
entropy) 
Acceleration 
No No No 
Griffiths et al 
(2012) 
 64 PwP 
Parkinson’s 
Kinetigraph 
(PKGTM; Global 
Kinetics) 
Wrist Bradykinesia, 
dyskinesia,  
Yes, for 
bradykinesia 
against dot slide 
task (spec 88%, 
sens 95%) 
Acceleration derived 
features: Mean 
Spectral Power 
within specific bands, 
peak, amount of time 
with no movement 
Yes dyskinesia 
against the AIMS 
score and both 
dyskinesia and 
bradykinesia 
against UPDRS III 
and IV 
No  No 
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Study (year), 
N,  
Type of 
wearable 
Placement on 
body 
Clinical 
feature 
Accurate 
detection of 
clinical feature 
Measures Criterion Validity Discriminative 
Validity 
Utility 
Mera et al 
(2012) 
10 PwP 
KinesiaTM  Wrist Motor tasks, 
tremor, 
bradykinesia, 
motor 
fluctuations 
No Symptoms severity 
scale (0-4 points), 
voluntary movement 
threshold evaluated 
with gyro- scope 
derived features 
(RMS, peak of power 
spectrum) 
Yes, for tremor 
and bradykinesia. 
Yes against videos 
in lab for 
symptom severity 
scale validated 
against UPDRS. 
No Yes formal 
testing in 
subsequent 
work 
(Giuffrida, 
Riley, 
Maddux, & 
Heldman, 
2009) 
Tzallas et al 
(2014) 
12 PwP 
ALA-6g 
(PERFORM) 
Lower back, 
ankles, wrists 
Tremor, 
Bradykinesia, 
FOG 
Yes in the lab 
and during 
structured test 
(eg. for FOG 
events opening 
door) against 
video 
annotations 
Acceleration derived 
measures (time and 
frequency domains, 
range, energy) 
Yes, techniques 
developed in lab 
and applied in 
free lving 
conditions, 
compared against 
patient diaries 
No Yes, formal 
testing 
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Study (year), 
N,  
Type of 
wearable 
Placement on 
body 
Clinical 
feature 
Accurate 
detection of 
clinical feature 
Measures Criterion Validity Discriminative 
Validity 
Utility 
Ferreira et al 
(2015), 
11 PwP,  
SENSE-PARK 
System 
Lower back, ankle, 
wrist 
Gait, 
hypokinesia, 
dyskinesia, 
tremor, sleep 
NA (feasibility 
and usability 
study) 
NA (feasibility and 
usability study) 
NA (feasibility 
and usability 
study) 
NA (feasibility 
and usability 
study) 
NA 
(feasibility 
and 
usability 
study) 
Hammerla et al 
(2015) 
34 PwP 
Axivity AX3 Wrists  Sleeping, 
ON/OFF state, 
dyskinesia 
Yes in the lab 
(against video 
recordings) 
Acceleration derived 
measures 
(magnitude, jerk) 
No No Yes formal 
testing in 
subsequent 
work 
(Fisher, 
2016)  
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The review revealed a number of challenges to clinical adoption of wearable devices. The 
studies included in the review had small sample sizes, and there were no consistent 
definitions of clinical features that were being measured (Del Din, Godfrey, et al., 2016). 
Furthermore, the placement of the wearable device differed between studies, as did the 
study protocols, making it hard to compare study findings. In addition, the majority of studies 
were carried out in a controlled, lab environment which does not reflect the unstructured and 
unpredictable qualities of a real life environment. Finally, the feasibility and usability of 
devices was not frequently reported across studies, which is necessary to determine before 
clinical adoption of wearables can take place.  
1.2.25.2.3  Wearable measures of gait:  
Wearable sensors further provide opportunity to measure complex and multi-dimensional 
parameters like gait, which are typically difficult to assess in a clinic environment (Del Din, 
Hickey, et al., 2016). Of importance, gait disturbance has been identified as a potential marker 
of disease progression (Maetzler, Liepelt, & Berg, 2009), with gait variability having been 
reported to correlate more strongly than bradykinesia with disease duration (Hausdorff, 
Balash, & Giladi, 2003). In addition, wearable devices designed to assess gait are able to 
capture rare incidents such as freezing of gait (FOG) (Delval et al., 2010) and falls (Klenk et al., 
2011) which may otherwise go undetected or unreported by patients. Due to the high utility 
of wearable devices in this field, there is an extensive literature on wearable gait assessments 
(see (Muro-de-la-Herran et al., 2014) for a review) which is outside the scope of this 
introduction.   
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Two of the studies included as part of the Del Din (2016) review described wearable systems 
that have been extensively validated in subsequent work (The KinesiaTM system (Mera et al., 
2012) and The Parkinson’s Kinetigraph (PKGTM) (Griffiths et al., 2012), which are now 
commercially available for the assessment of PD symptoms. Details of these systems are 
described in more detail below. 
1.2.25.2.3.1 The KinesiaTM system 
The KinesiaTM system, (described in Table 9 above) is a finger-worn motion sensor containing 
three orthogonal accelerometers and three orthogonal gyroscopes to measure linear 
accelerations and angular velocities (see Figure 14) (Mera et al., 2012). 
The KinesiaTM software (available on a laptop, and more recently an iPad, see Figure 14), 
guides the patients through a workflow comprising three tremor tasks (measuring rest, 
postural and kinetic tremor) and three bradykinesia motor tasks (including finger tapping, 
hand grasping and pronation supnation) based on the MDS-UPDRS motor examination. 
Proprietary algorithms are used to process the motion data to severity ratings from 0 
(symptom absent) to 4 (severe impairment). 
99 
 
 
 
Figure 14 The Kinesia Workflow, from Siteboss (2014) 
 
The KinesiaTM system algorithms have been extensively validated to quantify upper extremity 
bradykinesia (Heldman et al., 2011), tremor (Giuffrida et al., 2009), and dyskinesia (Mera, 
Burack, & Giuffrida, 2013). In each of these studies, the algorithms were highly correlated 
with clinician ratings. Moreover, in a compliance study, participants correctly completed 97% 
of all motor tasks at home over a 6-day period, which demonstrates the device is feasible and 
acceptable to patients. In addition, The KinesiaTM system has been identified as clinically 
useful in identifying patients who may be suitable candidates for AT (Heldman, Giuffrida, & 
Cubo, 2016) and has been identified as cost-effective in the management of patients with 
advanced PD (Cubo et al., 2017). 
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The KinesiaTM system is commercially available, and in 2007 The KinesiaTM system received 
Food and Drug Administration (FDA) approval for the measurement of bradykinesia, tremor 
and dyskinesia (Siteboss, 2014).  
1.2.25.2.3.2 The Parkinson’s Kinetigraph (PKGTM) 
In addition to wearable systems that require active interaction from the patient (such as the 
KinesiaTM System), monitoring devices are also commercially available for use in PD that are 
passively worn by the patient and require little to no interaction. One such device that was 
included as part of the Del Din review (2016) is the Parkinson’s Kinetigraph (PKGTM) (Figure 
15). 
The PKGTM is a wrist worn monitoring device comprising 3-axis accelerometers, and has been 
validated to detect bradykinesia (Griffiths et al., 2012), dyskinesia (Griffiths et al., 2012) and 
tremor (Braybrook et al., 2016) as well as several NMS including an immobility summary 
indicative of excessive day time sleepiness (Kotschet et al., 2014) and potential signs of 
impulse control disorder (ICD) (Evans et al., 2014).  
The PKGTM is commercially available and has also received FDA approval to quantify tremor, 
bradykinesia and dyskinesia (“Brandon Captial”, 2016). I will describe a clinical evaluation of 
the PKGTM as part of the PD service at UHPNT in Chapter 4.    
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Figure 15 An image of the PKGTM system (Gen 2) 
1.2.26 Remote care 
The use of DHTs (including wearable and portable devices such as smartphones) to monitor 
and assess PD symptoms offers the potential to move PD care to a home setting, which could 
provide clear benefits to both patients and health care providers (Dorsey et al., 2016). Remote 
care models can be tailored to meet patients’ needs and deliver interventions when required, 
resulting in targeted and timely management of complications (Kelsey & Cavendish, 2014), 
thereby reducing disease burden on the patient and caregiver (Papapetropoulos et al., 2015) 
and reduced use of healthcare resource. People with Parkinson’s (PwP) are hospitalised one 
and a half times more frequently than non-PwP and have generally longer durations of 
hospital stay, and increased mortality (Gerlach, Winogrodzka, & Weber, 2011). Timely 
intervention may therefore prevent (and subsequently reduce) PD hospital admission rates. 
In support of this view, engagement with a remotely deliverable PD education network has 
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been found to reduce the annual rate of hip fractures and lead to fewer in-patient admissions 
(Beersen, Marc Berg, Mirte van Galen, Kees Huijsmans, & Niels Hoeksema, 2011). 
In addition, remote monitoring technologies may provide a means of dealing with increased 
capacity requirements within services, given the prevalence of PD in the UK is expected to 
rise (Parkinson's UK, 2017). For example, recent initiatives have shown that remote contact 
with patients, such as web-based video conferencing and tele-heath calls, is a feasible and 
cost effective method for PD care delivery that can produce similar health outcomes as in-
person care from a specialist (Dorsey et al., 2013).  
With regards to PD research, DHTs offer the potential to carry out daily active tests, and can 
monitor status continuously over a prolonged period of time in highly naturalistic 
environments, which would provide a more accurate reflection of the patient’s symptom 
severity and be ideally suited to longitudinal studies (Espay et al., 2019). In addition, the 
increased test frequency could lead to increased statistical power, allowing for the 
identification of impairment that may otherwise go undetected using infrequent in-clinic 
assessments (Dorsey, Papapetropoulos, et al., 2017). 
1.2.27 Patient self-management  
A further advantage of DHTs is they have been found to increase participants’ perceived 
involvement in their healthcare (Ferreira et al., 2015). As discussed previously, increasing 
involvement allows patients to identify themselves as ‘active players’ in their treatment (Van 
der Eijk et al., 2013), which is in line with the ‘participatory’ nature of P4 medicine, meaning 
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medicine that is predictive, personalised, preventative and participatory (Flores, Glusman, 
Brogaard, Price, & Hood, 2013). Of interest, patient engagement in health care has been 
found to increase treatment adherence, improve quality of life, and result in better health 
outcomes (Bauman et al., 2003).  
There is a need to empower people living with long term conditions to become better at 
managing their own health, make informed treatment choices and avoid complications 
(Hibbard, Stockard, Mahoney, & Tusler, 2004). To help meet this need, NHS England have 
launched the Patient Activation Tool (PAM) which aims to measure patients’ ability to self-
manage their condition, and tailor services accordingly to increase patient capacity for self-
management (Hibbard et al., 2004).  
Advances in DHTs have the potential to play a role in facilitating self-management of long 
term conditions by providing insight into a patient’s condition, helping patients make 
informed choices, and encouraging engagement in self-care habits (Alpay, Blanson 
Henkemans, Otten, Ro, & Dumay, 2010).  
According to the World Health Organisation (WHO) there is great potential for DHTs to 
transform existing health services in coming years (WHO, 2011). In 2018, The NHS launched 
an ‘Apps Library’ in an attempt to signpost patients towards healthcare apps that meet NHS 
standards for quality, reliability and effectiveness (“NHS Apps Library,” 2018). Parkinson’s UK 
(PUK) have taken a similar approach, and developed  an ‘Apps and Devices Library’ ("Apps for 
Parkinson's", 2018)  with the aim to promote apps and devices that have been tried and tested 
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by a panel of PwP. Only apps and devices that the testing panel find to be genuinely useful, 
and would recommend to other PwP are included as part of the PUK library. 
In addition, there is an increasing number of studies piloting DHT interventions to support the 
management of long term health conditions (Wang et al., 2014). In PD, ‘ParkinsonTV’ 
(launched by the Dutch strategy group ‘parkinsonNet’ (Bloem et al., 2017) broadcasts 
monthly programs for people affected by PD, allowing for easily accessible information on a 
variety of PD related projects. The success of this channel has recently led to episodes being 
broadcast in English.  
Moreover, the MDS Technology Task Force are in the process of developing an e-Diary, with 
the aim of bringing the traditional PD diary (used primarily to assess fluctuations in symptoms 
for research purposes) into the ‘digital age’ (Vizcarra et al., 2019). The e-Diary would be web-
based, and would allow for the integration of individualized assessments of motor and non-
motor symptoms via a selection of hardware components (such as accelerometers and 
gyroscopes) as part of the diary itself. The e-Diary is currently under development, and is 
expected to be delivered over the coming years via a series of ‘milestones’. 
A recent review of studies using DHTs to manage long term conditions identified several 
benefits, including improved patient self-management, patient education tailored to patient 
need, and improved communication between health care professionals (Matthew-Maich et 
al., 2016). All of these recommendations are in line with the NHS Long Term Plan (The NHS 
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Long Term Plan, 2019), which promotes the use of ‘digitally-enabled’ care to provide patients 
with more control over their health and to facilitate personalised care.  
Furthermore, significant reductions in cost have been associated with DHTs in comparison 
with traditional care (Noel, Vogel, Erdos, Cornwall, & Levin, 2004).  
1.2.28 Summary and overall aims 
Current PD service provision in the UK faces several challenges including limited clinic 
capacity, inappropriate time-locked clinic review, the need for patients to travel to clinic, and 
the use of rater-dependent clinical scales with limited sensitivity. 
Moreover, some of these challenges may also be applied to PD research, whereby the 
selection of inappropriate endpoints and lack of patient stratification in clinical trial design 
have been identified as potential reasons for the absence of a neuroprotective finding 
(Dorsey, Papapetropoulos, et al., 2017). 
DHTs offer a number of potential improvements to PD care and research. Firstly, DHTs provide 
potential to objectively quantify PD symptoms with an increased sensitivity than is currently 
achievable using traditional, rater-dependent clinical scales. In addition, DHTs allow for 
continual and unobtrusive monitoring in the home environment, allowing for an increased 
test frequency, reduced patient and carer burden, data that is high in ecological validity, and 
the opportunity to capture complex symptoms and rare incidents. Finally, there is evidence 
to suggest that DHTs may help to improve perceived engagement in healthcare, by providing 
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patients with the tools to self-manage their condition, which has associated improved 
healthcare outcomes (Ferreira et al., 2015). 
However, despite the increase in DHTs that have been developed in recent years, there is no 
gold standard for the digital assessment of non-motor or motor symptoms in PD (Del Din, 
Godfrey, et al., 2016), and few technologies have been validated in a clinical setting to show 
evidence of their impact at the level of the healthcare provider.   
Therefore, in this thesis I: 1) explore the potential for a digital objective motor (finger tapping) 
assessment tool to provide information on potential PD cognitive impairment; 2) develop and 
evaluate a DHT for the remote monitoring of NMS; 3) evaluate the clinical utility of an existing 
DHT (the PKGTM) within a NHS clinical service (UHPNT); and 4) explore the potential of DHTs 
to overcome current challenges in PD neuroprotective trial design. 
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Chapter 2 Exploring the potential of an automated tapping assessment in Parkinson’s 
disease 
2.1 Introduction 
Accurate assessment of motor symptoms is clinically important in Parkinson’s disease (PD), 
both for diagnostic purposes, whereby motor symptoms must be present for a diagnosis to 
be made (Postuma et al., 2015), and throughout the disease course, to assess response to 
therapy and progression of disease. Accurate monitoring and assessment of motor symptoms 
is also integral to research, with motor outcomes often used as the primary endpoints in PD 
clinical trials (Mitchell, Harper, Lau, & Bhalla, 2000).  
Currently, the Movement Disease Society Sponsored Revision of the Unified PD Rating Scale 
(MDS-UPDRS) is the most widely used and accepted measure to assess motor symptoms in 
PD (Goetz, Tilley, et al., 2008). However, there are a number of recognised limitations 
surrounding the MDS-UPDRS that limits its functionality, including intra and inter rater 
reliability and low levels of ecological validity (Palmer et al., 2010) (see section 1.2.22).  
In PD, finger tapping is a task frequently used by clinicians to visually assess symptom severity 
in the upper extremities, characterised by interruptions in rhythm, slowing, and decreased 
amplitude (Yahalom, Simon, Thorne, Peretz, & Giladi, 2004). Finger tapping can therefore be 
a useful measure to detect bradykinesia, freezing (akinesia) as well as dysrhythmicity. 
However, interpretation of finger tapping performance is a subjective judgment which can 
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vary between raters (Post et al., 2005) and has potential to be improved by implementing a 
more quantitative, digital approach.   
The ubiquity of consumer-grade technology has led to an extensive literature on the objective 
measurement of finger tapping in PD (Arora et al., 2015; Lee et al., 2016; Stamatakis et al., 
2013; Wissel et al., 2018). This rise is due in part to the increasing availability of smartphones 
and other smart devices which have built in features such as touch screens (Dorsey, Chan, et 
al., 2017). The development of objective measures using these devices can therefore be 
carried out at low cost and with relative ease. The portable nature of these devices has further 
appeal for assessing patients living in remote areas or who are unable to travel due to disease 
burden, thereby removing geographic barriers to participation in research (Dorsey, Chan, et 
al., 2017). In addition, digital based devices allow for multiple assessments of motor function 
to be carried out per day whilst in the home environment, therefore offering the opportunity 
to capture the impact of ON and OFF state fluctuations.  
We have previously described the development of a finger tapping smartphone based 
software application, named PD-TAP (Dominey et al., 2016). In a pilot investigation, 
participants (16 people with Parkinson’s disease (PwP) and 16 age-matched-controls (AMC)) 
were required to complete a fast tapping task (Fast-50) whereby participants were asked to 
tap as fast as they could for 50 taps. The task was carried out using a smartphone device (with 
taps made on the touch-screen), with the aim to determine the extent to which performance 
(specifically tapping frequency, variance and overall time) could distinguish PwP from AMC 
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and correlate with motor impairment as determined by the motor MDS-UPDRS Part III 
subscore.  
Our results demonstrated that the Fast-50 task is able to distinguish PwP from AMC 
(t(30)=2.27, p = 0.03), based upon the inter-tap interval (ITI). This is line with previous findings, 
whereby at higher frequencies of tapping (>4Hz), rhythm generation has been observed to 
break down in PwP, leading to decreased tapping frequencies (Nagasaki, Nakamura, & 
Taniguchi, 1978). Moreover, in our previous study, inclusion of inter-tap variance (ITV) in a 
combined Fast-50 measurement (ITV x ITI) provided a strong correlation with MDS-UPDRS 
Part III subscores (r =.69, p =.003). Overall, the Fast-50 task, which was completed by patients 
in <1 minute, demonstrated a strong correlation with patients’ MDS-UPDRS Part III subscores, 
which suggested potential for PD TAP to be used to measure disease progression.  
In addition to using quantitative finger tapping measures for diagnostic purposes and to track 
disease progression (Arora et al., 2015),  there is evidence to suggest that finger tapping 
paradigms that measure motor timing may give insight into cognitive ability, specifically 
frontal executive function (Pastor, Jahanshahi, et al., 1992). 
The study of motor timing has suggested the presence of a hypothetical “internal clock” or 
“pacemaker” which compares the passage of time with a criterion stored in working memory 
(Parker, Lamichhane, Caetano, & Narayanan, 2013). Motor timing in the milliseconds and 
seconds range has been found to be impaired in PwP (O’Boyle, Freeman, & Cody, 1996; 
Pastor, Jahanshahi, Artieda, & Obeso, 1992) and may contribute towards motor symptoms 
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such as bradykinesia and akinesia (Jahanshahi et al., 2010). These findings have led to the 
hypothesis that the basal ganglia and the associated dopaminergic system are involved in 
temporal processing, and act as the ‘internal clock’ mentioned previously (Jahanshahi et al., 
2010).  
Furthermore, dopaminergic medication has been found to improve motor timing deficits in 
PwP (Pastor, Jahanshahi, et al., 1992), which supports the role of dopamine in temporal 
processing. 
Motor timing is commonly measured using interval timing tasks such as The Paced Finger 
tapping Task (PFT) (Wing & Kristofferson, 1973). In this task, a participant is required to tap in 
time with a series of audible tones that are separated by a constant interval, usually in the 
range of several hundred milliseconds to seconds (Jones et al., 2011). This phase is known as 
the synchronisation condition. The audible pacing tone is then removed, and the participant 
is required to continue tapping at the same pace as they had been previously; this is known 
as the continuation condition (Elsinger et al., 2003). This task elegantly measures timing in 
two ways; the ability to carry out a motor response to a timed cue (synchronisation phase) 
and then the ability to maintain the learnt rhythm in the absence of a cue (continuation phase) 
(Jones et al., 2011).  
Performance in this task is generally quantified by analysis of accuracy, meaning how close a 
response was to its intended target, and this can be explored by using mean absolute error. 
Variability in performance can also be quantified, by investigating the spread or variance of 
111 
 
 
the responses from the target, and can be explored using standard measures of variance such 
as standard deviation (SD) (Jones et al., 2011).  
The PFT has been widely used in PD research, with many studies demonstrating PwP have 
impaired accuracy and increased variability in PFT performance, in comparison with controls 
(Jones et al., 2011; O’Boyle et al., 1996; Pastor, Jahanshahi, et al., 1992). PwP appear to exhibit 
difficulty in synchronising their tapping with an external auditory cue (Shimoyama, Ninchoji, 
& Uemura, 1990), and synchronous finger tapping performance appears to worsen in PwP 
following removal of an external cue (Yahalom et al., 2004).  
Brain imaging studies have allowed for further exploration of the neural correlates of motor 
timing that underlie performance in the PFT, which may be impaired in PwP.  
A PET study of the PFT by Jahanshahi and colleagues (2010) revealed that for the controls, 
motor timing was associated with increased activation in the left medial prefrontal cortex, 
right hippocampus, bilateral angular gyrus, left posterior cingulate and left nucleus caudate. 
For PwP, the same striato-frontal activation was not observed. Instead, PwP demonstrated 
greater activation in bilateral cerebellum, right thalamus and left midbrain (Jahanshahi et al., 
2010). The authors interpreted the over activation of the cerebellum in PwP as a 
compensatory ‘switch’, to reliance on alternative neural pathways.  
In addition, the continuation phase of the PFT was associated with greater activation in the 
dorsolateral prefrontal cortex in both the controls and in PwP. The dorsolateral prefrontal 
cortex is known to play a role in internally generated actions, which have been found to be 
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impaired in PD relative to controls (Jahanshahi et al., 1995). As mentioned previously, studies 
investigating the PFT with PwP have found greater levels of relative impairment in the 
continuation phase than the synchronisation phase (Yahalom et al., 2004), with PwP 
demonstrating a greater reliance on external cues to maintain rhythm (Elsinger et al., 2003).  
Other behavioural research has supported the idea that PwP demonstrate an inability to 
internally generate strategies to complete a task. Brown and Marsden (1998) demonstrated 
this in a study whereby PwP showed impairments on a version of the Stroop colour word task 
when the response was not cued, however these impairments were not apparent when a cue 
was available. These findings suggest that PwP show deficits in situations when they are not 
able to rely on external cues for task performance; when internal attentional control is 
required (Brown & Marsden, 1988).  
Abnormalities in pre-frontal dopamine signalling in PD are thought to impair attentional 
control and other higher order cognitive processes including reasoning, planning, impulsivity 
and decision making (Miller & Cohen, 2001). These behaviours are referred to as executive 
processes, and are thought to involve the prefrontal cortex, in particular the orbitofrontal and 
dorsolateral areas (Bouquet, Bonnaud, & Gil, 2003).  
The Supervisory Attentional System (SAS) (Norman, 1980) is a well-known model of executive 
function (EF) and presents two systems of human action; content scheduling and supervisory 
attention. Content scheduling is responsible for the execution of routine behaviours that do 
not require deliberate attention, and allows us to prioritise the order of these behaviours by 
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selecting from competing schemas (Norman, 1980). The supervisory attentional mechanism 
is required for action sequences that are novel, or where strong habitual responses have to 
be inhibited, where planning is required, and where deliberate conscious control (or willed 
action) is necessary. The difficulty for PwP to generate internally willed actions is thought to 
provide evidence for reduced resources in the SAS in PD (Brown & Marsden, 1988).  
Performance in the PFT may therefore be influenced by EF, and I was interested to explore 
this further by evaluating whether PFT performance may be influenced by executive 
dysfunction.  
2.1.1 Measures of EF 
Although there is no gold standard for assessment of EF (Chan, Shum, Toulopoulou, & Chen, 
2008), a number of tasks have been designed to test different components of the SAS model, 
including; planning, monitoring, and inhibition of action responses (Chan et al., 2008). Three 
frequently used tasks measuring different aspects of EF are described in detail below: 
(1) Letter fluency: 
Letter fluency tasks require a subject to generate as many words as they can that begin 
with a certain letter (Delis, Kramer, Kaplan & Holdnack, 2004). This task requires 
intrinsic generation of new responses, as individuals cannot use external cues or use 
routine selection of words according to their meaning (Bouquet et al., 2003). In 
addition, an individual is required to monitor responses and update retrieved items in 
order to avoid repetitions (Zgaljardic et al., 2006). The process of maintaining word-
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list generations over time is considered a frontal function, and has been previously 
associated with activation in the dorsolateral pre frontal cortex (MacDonald, Cohen, 
Stenger, & Carter, 2000). 
(2) Brixton Spatial Anticipation Test 
The Brixton Spatial Anticipation Test is a rule-attainment test, which assesses an 
individual’s ability for rule detection and impulsivity. The test is similar to the 
Wisconsin Card Sorting Task (Chelune & Baer, 1986), however is less time consuming 
to complete. An individual is required to detect a rule underlying the placement of 
blue circles amongst a grid. After several presentations of this pattern, the placement 
rule changes, and the individual is required to detect the new rule change. Similar 
tasks involving set-shifting have been previously associated with dorsolateral pre 
frontal cortex function (Nagahama et al., 1998).  
(3) The Stroop Task 
The Stroop task is a widely used measure of EF involving conflict, and is thought to 
require verbal inhibitory processes (Kudlicka, Clare, & Hindle, 2011). The Colour-Word 
Interference Test measures an individual’s ability to suppress a habitual response for 
a novel one (Zgaljardic et al., 2006), whereby an individual is required to state the 
incongruent ink colour a word is printed in, and disregard the verbal content. 
Increased response time in this task is associated with heightened conflict, and 
performance in this task has been found to correlate with anterior cingulate activation 
(MacDonald et al., 2000).  
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The PFT appears to share similar neural circuitry to executive processes, with tasks that load 
EF having been found to worsen performance on interval timing tasks (Brown, 2006). These 
findings support the hypothesis that these tasks draw on similar resources. Executive 
dysfunction experienced in PD may therefore contribute towards patients’ impaired interval 
timing performance. Incorporation of interval timing tasks, such as the PFT task, as part of 
standard tapping paradigms may therefore be useful clinically, as an indicator of executive 
dysfunction in PwP.  
Executive dysfunction is common in PD (Dirnberger, Frith, & Jahanshahi, 2005), and forms 
part of the MDS diagnostic criteria for Parkinson’s Mild Cognitive Impairment (PD-MCI) (Litvan 
et al., 2012). Executive dysfunction can have a significant impact on carrying out activities of 
daily living (ADL). For instance, PwP may initially have difficulty sequencing complex tasks 
such as cooking or planning the events of a day. These difficulties can therefore have a 
significant impact on patients’ independence and their wellbeing (Kudlicka et al., 2011).   
Assessment of EF in PD is therefore important, to allow for personalised intervention and for 
identifying those at cognitive risk. Indeed, several studies have suggested that PwP with PD-
MCI are at a higher risk of developing dementia than those with normal cognition (Aarsland 
& Kurz, 2010). For instance, Janvin et al (2006) demonstrated that in a cohort of people with 
advanced PD, more than 60% of people with PD-MCI had developed dementia after 4 years, 
as opposed to just 20% of people without PD-MCI over the same time frame (Janvin, Larsen, 
Aarsland, & Hugdahl, 2006). 
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To investigate the role of EF in the PFT, and which EF processes in particular might be 
associated with performance in this task, I carried out a computerised version of the PFT task 
with PwP, and compared performance with three classic EF tests: (1) Letter Fluency (2) The 
Stroop Test and (3) The Brixton Spatial Anticipation Test. 
2.1.2 Hypotheses 
My hypotheses for this study were as follows:  
1. Performance in the PFT would correlate with performance in the EF tests. 
2. Participants with poorer levels of EF would exhibit greater levels of relative 
impairment in the continuation phase of the PFT than participants with better levels 
of EF, due to a greater reliance on external cues. 
If successful in establishing a correlation between EF and performance in the PFT in PD, there 
would be grounds to develop an app-based version of the PFT to incorporate as part of the 
existing PD TAP app or other objective tapping paradigm. This would add value to existing 
quantitative tapping measures, by providing insight into possible executive dysfunction. 
2.2 Methods  
This study received approval from the local NHS Research Ethics Committee (ethical approval 
granted 10/2016, see appendix 1 (section 8.1)) and the Faculty Research Ethics Committee at 
Plymouth University (ethical approval granted 11/2016, see appendix 2 (section 8.2)). I was 
responsible for the planning, development, recruitment, data collection and analysis for this 
study.  
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2.2.1 Participant Recruitment 
Participant recruitment commenced in April 2017. One hundred letters of invitation (see 
appendix 3 (section 8.3)) and participant information sheets (PIS) (see appendix 4 (section 
8.4)) were sent out to PwP that were identified from clinical and research registers including 
the Livewell Southwest patient register and the Southwest Dementia and Neurodegenerative 
Diseases Network (PRO-DeNDRON) patient register (patients on these registers had 
previously consented to be contacted regarding research opportunities). Patients were asked 
to fill out a reply slip (attached to the PIS) if they were interested in taking part in the study, 
and send the reply slip back (via freepost envelopes) to the research team. Once the research 
team had received the reply slip, a follow-up phone call was made to assess the PwP’s 
eligibility for the study (see inclusion/exclusion criteria detailed below) and discuss any 
questions the participant may have about taking part in the study. If a patient was willing to 
participate, fulfilled the inclusion criteria and had an absence of exclusion criteria, a study visit 
at the University was arranged, and the patient was sent a confirmation letter or email 
outlining the details of the study visit. 
2.2.2  Sample Size Calculation 
The target recruitment for this study was 128 patients based on a power analysis calculated 
using G*Power (Faul, Erdfelder, Lang, & Buchner, 2007) for a 2x2 mixed design ANOVA (0.05 
alpha and 0.80 power), anticipating a medium  effect size ( f = .25), interpreted using 
guidelines provided by Cohen (1988).  
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2.2.3 Inclusion Criteria 
Inclusion criteria for the study were: 
• Age greater than 18 years 
• Diagnosis of idiopathic Parkinson’s disease (IPD) 
• Willing and able to give informed consent for participation in the study 
• Able and willing to comply with all study requirements 
2.2.4 Exclusion Criteria 
Exclusion criteria for the study were: 
• Inability or unwillingness to comply with study protocol 
• Any other significant disease or disorder that is known to affect cognition 
• Use of alcohol, benzodiazepines, or other sedating drugs in the 12 hours prior to study 
visit 
• Non-fluent English speaker 
• Severe visual impairment 
• Inability to use a pen and paper 
2.2.5 Study Procedures 
Participation involved one study visit at the University of Plymouth. Travel expenses were 
reimbursed. Participants received no payment for participation in the study. The study visit 
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lasted approximately 2 hours, which included time for consent, assessments and debrief, as 
well as breaks where necessary. At the beginning of the session, the investigator read through 
the information sheet with the participant and answered any questions. If patients were still 
interested in participating they were asked to sign a consent form (see appendix 5 (section 
8.5)).  
Each participant was allocated a unique identification number and the date of the study visit 
was recorded. 
2.2.6 Demographic Information 
After obtaining informed consent, patient demographics were obtained including; date of 
birth, gender, dominant hand, ethnicity and years in education. Details about their PD were 
also recorded including; date of diagnosis, symptoms present at onset, and date of symptom 
onset. 
Once demographic information had been obtained, a pre-testing statement was read to 
participants by the investigator that outlined the purpose of the assessments, and reminded 
participants of their right to withdraw or stop at any time. 
The following assessments were then carried out by the investigator in the order that they 
appear below.  All participants were tested in an ON state, within an hour of taking Levodopa. 
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2.2.7 MDS-UPDRS (Part III) 
The Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) is a 
validated PD rating scale that is the current gold standard in research for assessing PD 
symptom severity (Goetz, Tilley, et al., 2008). Please see section 1.2.21.1.1 for a full 
description of the MDS-UPDRS Part III. 
2.2.7.1 Cognitive Measures  
2.2.7.2  ACE III 
The Addenbrooke’s Cognitive Examination (ACE III) is a brief cognitive test, that has been 
validated for use in a PD population (Reyes et al., 2009). The ACE III takes 15-20 minutes to 
complete. It comprises six domains (totalling a maximum possible score of 100 points) 
including orientation (10 points), attention (8 points), memory (35 points), verbal fluency (14 
points), language (28 points), and visuo-spatial abilities (5 points).  
2.2.7.3 Measures of Executive Function (EF) 
All participants completed the measures of EF listed below.  
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2.2.7.4 The Stroop Test 
The Stroop Test comprises a series of trials which are designed to test attention and inhibition 
(Stroop, 1935). In the first trial, the participant is asked to read aloud a series of colour words, 
printed in black ink, as quickly as possible. After 30 seconds have passed, the investigator asks 
the participant to stop reading, and makes a note of how many words were correctly read 
aloud in the time frame. In the second trial, the participant is asked to look at a series of colour 
blocks, and to name the colours as quickly as possible. The number of correct responses in 30 
seconds is recorded as before. In the third trial, the participant is asked to look at a series of 
colour words, printed in incongruent ink colours, and name the colour of the ink instead of 
reading the word (Erdodi et al., 2018). This trial is the key test of inhibition, as the participant 
is required to recruit additional cognitive resource to inhibit themselves from reading aloud 
the colour word, and must instead name the incongruent colour (MacLeod & MacDonald, 
2000). The number of correct responses is recorded.  
2.2.7.5 The Brixton Spatial Anticipation Test 
The Brixton Spatial Anticipation test forms part of the larger Hayling and Brixton test battery, 
and can be administered in isolation (Burgess & Shallice, 1996). The test is a rule attainment 
task, which requires the participant to monitor feedback from the environment and adjust 
rules appropriately. The Brixton is comprised of a 56 page stimulus book containing identical 
2 × 5 displays of 10 empty circles, one of which is coloured solid blue. With each turn of the 
page, the location of the solid blue circle changes in line with a particular rule sequence. 
Participants were read aloud standardized instructions to predict which of the 10 circles will 
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be blue on the subsequent page. The task requires the patient to learn and apply the current 
rule in order to predict the location of the next blue circle correctly (Burgess & Shallice, 1996). 
After completion of the task, the number of errors was counted to produce a total error score. 
A higher number of errors reflected poorer performance.  
2.2.7.6 The DKEFS Verbal Fluency (Letter Verbal Fluency) 
The D-KEFS Verbal Fluency Test forms part of the larger D-KEFS test battery (Delis et al., 2004), 
and can be used in isolation. In the letter fluency trial, the participant is required to name as 
many words beginning with ‘F’ in one minute, followed by ‘A’ and then ‘S’ one minute trials. 
2.2.8 Executive Function Selection Criteria  
We were interested to see which measure of EF would correlate most strongly with tapping 
performance, which was determined using Pearson correlations. Performance on the 
measure of EF with the strongest relationship with tapping performance was then used to 
categorise participants into two groups; executive dysfunction (EFlow) and executive function 
(EFhigh). 
Participants were categorised by using a mean standard deviation criterion as opposed to 
using a median split analysis (MacCallum et al., 2002). It has been discussed previously that 
it is not appropriate to consider values just above or below the median as meaningfully 
different from each other (Jaiswal, Tsai, Juan, Liang, & Muggleton, 2018). We therefore 
adopted a mean ± standard deviation (SD) criteria similar to that used in other studies (eg 
(Jaiswal, Tsai, Juan, Liang, & Muggleton, 2018). 
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2.2.9 Paced Finger Tapping Task 
2.2.9.1 Materials 
Participants were seated comfortably in front of a desktop computer and rested the forearm 
of their dominant hand (handedness determined by participant) on the surface of the desk.  
A bespoke Windows software application was written by the University of Plymouth 
Psychology Tech Office in C# using Microsoft Visual Studio, and this was run on the desktop 
computer. This software was connected via an Arduino Uno to a Force Sensing Resistor.  
Instructions were displayed on screen throughout, and the investigator was present at all 
times.  
All finger taps were carried out with the index finger of the dominant hand. To make a finger 
tap, the index finger was raised, whilst keeping all other digits and the palm flat on the surface 
of the desk. All finger taps were made directly onto a Force Sensing Resistor, which digitally 
recorded each tap made.  
Prior to starting the Paced Finger Tapping Task (PFT), participants were shown the required 
finger tapping technique, and were given an opportunity to practise. Any errors during the 
practice trial were corrected by the investigator.  
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2.2.9.2 PFT Task 
The PFT task consisted of a sequence of repetitive auditory cues at a constant inter-stimulus 
interval (ISI) of either 250ms, 500ms, 1000ms or 2000ms that had been used previously in a 
similar PFT study  (Jones et al., 2011).  
Audio cues were delivered via headphones, which participants were required to wear 
throughout the duration of the task. The presentation order of the ISI was determined using 
a counterbalanced design. The subject was required to listen to the auditory cues and tap in 
time with the index finger of their dominant hand (synchronisation phase). After 20 
presentations, the auditory stimuli stopped, and the subject had to continue reproducing the 
rhythm in the absence of any auditory cues for a further 20 taps (continuation phase). Each 
phase (continuation or synchronization) lasted from 5-40 seconds, depending which ISI was 
being used for any given particular trial. See Figure 16 for a diagram outlining the task design. 
Following completion of a trial, participants had a 30 second break before continuing onto 
the next trial.  
The Paced Finger Tapping Task (PFT) design is displayed in Figure 16. Participants are required 
to tap in time with the auditory stimulus (synchronisation phase). The auditory cues are then 
removed and participants are required to continue reproducing the rhythm as they had been 
previously (continuation phase).  
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2.2.10 Debrief 
Following completion of the assessment battery, participants were debriefed and thanked for 
their involvement in the study.  
Participants were made aware that this study was not a clinical assessment and they will not 
be told the results; however, if participants expressed concern as to their symptoms or test 
performance, they were advised to discuss their concerns with their GP or consultant. 
Participants’ GPs were contacted to inform them of their patient’s participation in the study. 
2.2.11 Data Analysis 
2.2.11.1 Paced Finger Tapping data 
All tapping tasks generated time-series data, whereby the time point of each finger contact 
was recorded in milliseconds (ms).   
Figure 16: Paced Finger Tapping Task (PFT) design. The dark blue bars represent the audio cues and the light blue bars represent the finger 
taps made by the participant. After 20 taps (not shown here), the cue is removed and the participant is required to continue tapping in the 
absence of auditory cues. 
Time 
Auditory Cues 
Finger taps 
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From these data, the inter-tap interval (ITI) was calculated by subtracting each time point 
from the previous time point. An average (mean) percentage error was then calculated for 
each participant: (√((ITI/ISI)-1)2)*100 for each of the four ISIs (250ms, 500ms, 1000ms and 
2000ms) in both the synchronisation and continuation conditions. The root mean square 
(RMS) was calculated, in order to determine the absolute error. This was applied as 
calculation of mean error in positive and negative values (either side of the target) can 
artificially minimise error in those with the greatest performance variance. 
A similar method to previous PFT studies was used (Jones et al., 2011), whereby erroneous 
responses were considered to be those where the ITI was 50% longer or shorter than the 
target ISI. These responses were considered outliers and were excluded from the analysis, 
although the remainder of the run was kept. 
The difference in error values between the two conditions was also calculated, by subtracting 
the continuation phase error from the synchronisation phase error. This was done for each 
ISI (250ms, 500ms, 1000ms and 2000ms). These difference values were transformed by 
calculating the square root of the absolute value to create an adjusted difference measure.  
Participants who were unable to complete all four task speeds were excluded from analysis.  
2.3 Results 
Figure 17 summarises the number of participants recruited to the study, and reasons for 
exclusion.  
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Figure 17 Consort flow diagram detailing the number of participants recruited to the study, and reasons for exclusion 
Letters of invitation sent 
(n=100) 
Expressions of interest received 
and assessed for eligibility 
(n=88) 
No reply (n=12) 
Recruited to the study 
(n=37) 
Excluded (n=25): 
Mobility (n=3) 
Arthritis (n=3) 
Unwell (n=9) 
MSA (n=1) 
Anxiety (n=1) 
Declined  (n=8) 
Study visit postponed until 
second round of testing 
 (n=26) 
Eligible for study (n=63) 
Study terminated earlier than 
planned due to technical 
difficulties  
Excluded from study (n=3): 
Technical error (n=2) 
Severe tremor (n=1) 
Included as part of main analysis 
(n=34) 
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As summarised in Figure 17, 37 people with a diagnosis of idiopathic PD were recruited to the 
study. Three participants were unable to complete the full finger tapping battery due to 
technical error (n=2) and severe tremor (n=1). Unfortunately, I had to terminate recruitment 
after the first 37 participants due to technical difficulties with the equipment, with lack of 
resource to resolve. Therefore a total of 34 participants were included as part of the analysis. 
Participant demographics are presented in Table 10 below. In line with validated ACE III scores 
for discriminating between different cognitive subtypes in PD (Berankova et al., 2015), four 
participants were in the Parkinson’s disease Dementia (PDD) range (≤82.5), 7 participants 
were in the Parkinson’s disease Mild Cognitive impairment (PD-MCI) range (≤88.5) and 23 
were in the normal cognitive range (>88.5). 
Table 10 Participant demographic data (n=34) (median, min-max range) 
Age (years) 
Gender (% 
male) 
Disease 
duration 
(years) 
Years in 
education 
UPDRS III 
Score 
Ace III Score 
70 (49-85) 62% 
4yrs (4 m-24 
yrs) 
13 (12-18) 25 (6-73) 91 (78-100) 
 
2.3.1 Executive Function (EF) Scores 
Mean (SD) scores for each of the EF subtests and the normative values for these (stratified 
by age) are displayed in Table 11. For the letter fluency test and the Stroop Test, a higher 
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score indicates better performance, whereas for the Brixton Spatial Anticipation Test, a 
higher score indicates poorer performance.  
Table 11 Mean (SD) scores for the EF subtests. 
 Letter  
Fluency 
Brixton Spatial 
Anticipation Test 
Stroop (Colour-Word 
Interference Test) 
Normative data* 49.56 (11.57) 20.5 (7) 34 (3) 
Study cohort 41.02 (14.8) 24.9 (8.7) 30.1 (9.8) 
*based on normative values for a healthy population aged 60-79 for FAS (letter fluency) (Tombaugh, Kozak, & Rees, 1999), 
The Brixton Test (Van Den Berg et al., 2009a) and The Stroop Test (Scarpina & Tagini, 2017). 
Relationships between EF tests were investigated visually using a scatterplot matrix (see 
Figure 18) and were followed up using Pearson correlations (see Table 12). 
 
 
 
 
 
 
 
  Figure 18 Scatterplot matrix of relationships between EF Tests (Letter fluency, Brixton and Stroop) 
Letter Fluency Brixton 
Stroop 
Brixton 
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Table 12 Pearson Correlation (r=) among EF test scores, none of these were found to be significant (p>.05)  
 1.Letter Fluency 2.Stroop 3. Brixton 
1. Letter Fluency - - - 
2. Stroop .325 - - 
3. Brixton .017 -.268 - 
 
There were no significant differences detected between measures of EF (see Table 12). 
2.3.2 Tapping error at 250ms, 500ms, 1000ms and 2000ms intervals 
Figure 19 displays the mean tapping percentage error for each interval (250ms, 500ms, 
1000ms and 2000ms) in the synchronisation and continuation conditions. The graph suggests 
that in general, there was a greater amount of mean tapping percentage error in the 
continuation condition than the synchronisation condition, apart from at 1000ms, where 
mean tapping percentage error was less in the continuation condition.  
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Figure 19 Mean tapping percentage error at each of the four tapping intervals (250ms, 500ms, 1000ms, 2000ms). Error bars 
represent standard error (SE). 
Exploration of the data using histograms revealed mean tapping percentage error was not 
normally distributed at any of the ISIs (see appendix 6 (section 8.6)), and this was confirmed 
by a Shapiro-Wilks test for normality  (p<.001 for all interval speeds).  
The ANOVA technique has been found to be robust despite departures from normality (See 
Norton (1952) as cited in (Boneau, 1960)) and so was utilised here rather than using less 
powerful non-parametric alternatives. 
A two-way repeated measures ANOVA was conducted that examined the effect of condition 
(synchronisation vs continuation) and interval speed (250ms, 500ms, 1000ms 2000ms) on 
mean tapping percentage error. Effect sizes were measured using partial eta squared (𝜂p2) 
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and interpreted using guidelines provided by Cohen (1988).  Greenhouse-Geisser corrected 
values are reported where necessary to correct for violations of sphericity. 
There was no main effect of condition detected (F(1,31)= .39, p= .53, 𝜂p2 = .01), with 
participants performing similarly in the synchronisation condition (M= 15.36, SD= 9.1) and the 
continuation condition (M=16.1, SD= 8.48) overall. However, a main effect of speed (F (3, 93) 
= 4.65, p =.01, 𝜂p2 = .13) was revealed. The main effect of speed was investigated using 
Bonferroni corrected pairwise comparisons (summarised in Table 13). The pairwise 
comparisons revealed significant differences in mean tapping percentage error between 
500ms and 2000ms (p=.04) with participants demonstrating a significantly higher level of 
percentage error at the 2000ms interval (M=21.53, SD= 15.27) than at the 500ms interval 
(M=12.69, SD= 11.87). A significant difference was also detected between the 1000ms and 
2000ms intervals (p<.001), with participants demonstrating a significantly higher level of error 
at the 2000ms interval (M=21.53, SD = 11.87) than the 1000ms interval (M=13.64, SD= 9.78).  
There were no significant interactions detected between speed and condition (F (3,93) = 
1.57, p=.21, 𝜂p2=.05). 
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Table 13 Pairwise Comparisons between interval speeds 
 
*significant at the .05 level, ***significant at the .001 level 
2.3.3 Tapping Percentage Error and Motor Performance  
Pearson correlations were used to investigate the relationship between tapping percentage 
error and motor performance (see Table 14). A weak positive correlation between motor 
performance and tapping percentage error was detected at 500ms in the continuation 
condition (r=.35, p=.04). No other statistically significant relationships were detected 
between MDS-UPDRS part III motor subscores and tapping percentage error in the 
synchronisation or continuation conditions, at any of the ISI speeds (250ms, 1000ms or 
2000ms). Pearson correlation coefficients are summarised in Table 14. 
Interval 
speed  
Comparison p 
250ms 
500ms >.99 
1000ms >.99 
2000ms .34 
500ms 
1000ms >.99 
2000ms .04* 
1000ms 2000ms <.001*** 
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Table 14 Pearson correlation (r=) among motor performance and tapping percentage error in the synchronisation and 
continuation conditions 
 Synchronisation Condition  Continuation Condition  
 250ms 500ms 1000ms 2000ms 250ms 500ms 1000ms 2000ms 
UPDRS III .023 .18 .07 .11 -.02 .35* .03 -.008 
* Correlation is significant at the .05 level.  
 
2.3.4 Tapping Percentage Error and Executive Function 
Relationships between tapping percentage error and measures of EF were investigated using 
Pearson correlations. The relationship between tapping performance in the synchronisation 
and continuation condition with each measure of EF is described below, and summarised in 
Table 15 (synchronisation condition) and Table 16 (continuation condition). 
2.3.4.1 Synchronisation Condition 
2.3.4.1.1 Letter word fluency 
In the synchronisation condition, letter word fluency scores were negatively correlated with 
tapping percentage error at the 500ms interval (r=-.55, p=.001). No other significant 
correlations were revealed between letter word fluency and tapping percentage error at any 
of the other interval speeds (see Table 15).  
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2.3.4.1.2 Brixton Spatial Anticipation Test: 
In the synchronisation condition, no significant correlations were observed between Brixton 
Test scores and tapping percentage error at any of the interval speeds (p>.05) (see Table 15). 
2.3.4.1.3 Stroop: 
In the synchronisation condition, no significant correlations were observed between The 
Stroop Test scores and tapping percentage error at any of the interval speeds (p>.05) (see 
Table 15). 
Table 15 Pearson correlations among EF test scores and tapping percentage error in the synchronisation condition  
 250ms 500ms 1000ms 2000ms 
Letter Fluency -.24 -.551** -.063 -.146 
Stroop .061 -.095 -.01 -.12 
Brixton -.28 .015 .03 .08 
** Correlation is significant at the .01 level 
2.3.4.2 Continuation Condition: 
2.3.4.2.1 Letter word fluency: 
In the continuation condition, letter word fluency scores were negatively correlated with 
tapping percentage error at the 500ms interval (r=-.51, p=.002) (see Figure 20). No other 
significant correlations were revealed between letter word fluency and tapping percentage 
error at any of the other interval speeds (p>.05) (see Table 16). 
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2.3.4.2.2 Brixton Spatial Anticipation Test: 
In the continuation condition, no significant correlations were revealed between Brixton Test 
scores and tapping percentage error at any of the other interval speeds (p>.05) (see Table 
16). 
2.3.4.2.3 Stroop: 
In the continuation condition, no significant correlations were revealed between Stroop 
scores and tapping percentage error at any of the other interval speeds (p>.05) (see Table 
16). 
Table 16 Pearson correlations among EF test scores and tapping percentage error in the continuation condition 
 250ms 500ms 1000ms 2000ms 
Letter Fluency -.309 -.514** -.183 -.067 
Stroop .198 -.208 -.127 -.069 
Brixton -.378 -.193 -.101 .199 
** Correlation is significant at the .01 level 
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Figure 20 Relationship between Letter fluency scores and tapping percentage error in the continuation condition (r=-.51, 
p=.002) 
2.3.5 Executive Function and tapping performance  
As letter fluency was the EF measure found to have the strongest relationship with tapping 
performance, letter fluency scores were used to categorise participants into the executive 
function (EFhigh) and executive dysfunction (EFlow) groups (see methods, section 2.2.7.3).  
Appendix 6 (section 8.6) displays a histogram of letter fluency scores across the sample. 
A mean ± 1 SD criteria was initially used to categorise participants into the two EF groups, 
however this did not result in a sufficient number of subjects in each group to compare 
performance (EFhigh n=5). 
The threshold was therefore lowered to a mean ± 0.5 SD criteria, to ensure higher numbers 
of participants in each group.  
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The mean letter fluency score for the entire sample was 41 with a SD of 14.81. Therefore 
participants were selected for the EFhigh group if their letter fluency scores were greater than 
or equal to 48 (41 + 0.5 SD).  If participants’ letter fluency scores were less than or equal to 
34 (41 – 0.5 SD), participants were assigned to the EFlow group.  
This procedure resulted in the following number of participants in each group: EFhigh group 
(n=13) and EFlow group (n=12). 
2.3.5.1 General cognitive function  
ACE III scores were found to be normally distributed across the sample (see Appendix 6 
(section 8.6)). Differences in ACE III scores between EFhigh and EFlow groups were therefore 
investigated using an independent samples t-test. The test revealed a significant difference in 
ACE III scores between groups: t(23)= 3.92, p=.001. Participants in the EFhigh group had higher 
ACE III scores (M=94, SD=3.05) than participants in the EFlow group (M=87 SD= 5.88).  
2.3.5.2 Tapping performance 
Due to the significant relationship between tapping performance and letter fluency at 500ms, 
performance at this interval was explored in more detail.  
Figure 21 displays the mean tapping percentage error in the executive dysfunction group 
(EFlow) and the normal executive function group (EFhigh) at 500ms in both the synchronisation 
and continuation conditions.  As the graph suggests, in the synchronisation condition, the 
EFlow group had a higher level of mean tapping percentage error (M=19.47, SD= 14.31) than 
the EFhigh group (M= 8.63, SD=5.6). This was also observed in the continuation condition, 
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where the EFlow group had a higher level of mean tapping percentage error (M=26.93, SD= 
22.04) than the EFhigh group (M= 10.41, SD=9.1). 
To investigate this further, a 2x2 mixed design ANOVA was carried out on the effect of 
condition (synchronisation vs continuation) and EF group (EFlow vs EFhigh) on mean tapping 
percentage error at the 500ms interval. Effect sizes were measured using partial eta squared 
(𝜂p2) and interpreted using guidelines provided by Cohen (1988).  
A significant main effect of EF group on tapping performance was revealed overall F(1,23)= 
7.7, p=.01, 𝜂p2= .25, with the EFlow group demonstrating a higher percentage of tapping error 
overall (M=23.20, SD= 12.30) than the EFhigh group (M=9.5, SD= 12.29). 
There was no significant main effect of condition (synchronisation vs continuation) on mean 
tapping performance error overall F(1,23)=3.07, p=.09, 𝜂p2=.12, with participants showing 
similar mean tapping percentage error in the synchronisation (M=14.05, SD= 20.9) and 
continuation (M=18.67, SD= 13.53) conditions. 
There was no significant interaction identified between condition and EF group 
F(1,23)=100.29, p=.29, 𝜂p2= .05. Descriptive statistics showed that EFlow participants had a 
lower mean tapping percentage error in the synchronisation condition (M=19.47, SD= 14.31) 
than the continuation condition (M=26.93, SD= 22.04) and this was also true for the EFhigh 
group (synchronisation condition M= 8.63, SD=5.6; continuation condition M= 10.41, SD=9.1). 
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As I was particularly interested in exploring the relative difference in tapping performance 
across conditions between the two groups, the difference in tapping performance between 
the synchronisation and continuation condition at 500ms was calculated for the two groups 
by subtracting performance in the synchronisation condition from performance in the 
continuation condition. As before, the root mean square (RMS) was calculated, in order to 
determine the absolute error (√ (tapping percentage errorcontinuation - tapping percentage 
errorsynchronisation)2).  
A Mann Whitney U test revealed a significant difference between groups (U= 32, p=.01), with 
participants in the EFlow group demonstrating a greater difference in performance between 
the synchronisation and continuation condition (M = 13.76, SD =12.62) than participants in 
the EFhigh group (M = 5.06, SD = 4.19). 
 
Figure 21 Percentage error at the 500ms interval in the executive dysfunction (EFlow) and normal executive function groups 
(EFhigh) in the synchronisation and continuation condition. Error bars represent standard error (SE). 
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2.3.6 Main findings 
To summarise, the main findings from this study were as follows: 
• The letter fluency task was found to correlate significantly with PFT performance at 
the 500ms ISI in both the synchronisation and continuation conditions. 
• A 2x2 mixed ANOVA revealed a main effect of EF group at the 500ms ISI, with 
participants in the EFlow group demonstrating a higher level of tapping percentage 
error than participants in the EFhigh group overall.  
• However there was no significant main effect of condition 
(synchronisation/continuation) overall, and no significant interaction between 
condition and EF group. 
• The difference in tapping performance between conditions 
(synchronisation/continuation) was significantly greater in the EFlow group than in the 
EFhigh group. 
2.4 Discussion 
I carried out a study using a computerised version of the Paced Finger Tapping Task (PFT) to 
evaluate whether tapping performance in PwP was affected by executive function (EF). I 
hypothesised that performance in the PFT would correlate with performance in the EF tests, 
and that participants with poorer levels of EF would exhibit greater levels of relative 
impairment in the continuation phase of the PFT than participants with better levels of EF. 
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Study findings in relation to each of the hypotheses and limitations of these will be discussed 
in detail below. 
2.4.1 Hypothesis 1: Performance in the PFT would correlate with performance in the EF 
tests. 
In relation to my first hypothesis, the study revealed a significant correlation between tapping 
performance at the 500ms interval in the PFT and a measure of letter fluency (FAS). This 
finding provides support for my first hypothesis, and suggests that people with poor letter 
fluency ability will perform more poorly on the PFT. As mentioned previously, letter fluency 
is considered a frontally based task, and has been associated with activation in the 
dorsolateral pre frontal cortex (MacDonald, Cohen, Stenger, & Carter, 2000). Our results 
support previous suggestions there may be shared neural circuitry between frontally based 
tasks and performance in interval timing tasks (Brown, 2006).  
It is important to note however that letter fluency scores were not found to be associated 
with the Stroop Test Scores nor with the Brixton Test scores, and these EF measures were also 
not found to correlate with one another, nor with tapping performance at any of the interval 
speeds in either the synchronisation or continuation condition. These findings provide 
support for the idea that measures of EF can be dissociated in PD (Gurd, 1995), and suggests 
that degeneration in PD may not impact on EF globally. The Stroop Test is a conflict based 
task, designed to assess an individual’s ability to inhibit a habitual response, whereas The 
Brixton Spatial Anticipation Test assesses an individual’s ability to detect a rule, follow a rule 
and switch to a new rule (Van Den Berg et al., 2009).  The lack of a relationship between EF 
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measures highlights the need for specificity when assessing for impairments of EF clinically 
(Mckinlay, Grace, Dalrymple-alford, & Roger, 2009).  
In addition, performance on the letter fluency task was not found to correlate with tapping 
performance at any of the interval speeds other than at 500ms, in either the synchronisation 
or the continuation conditions.  
It is of interest as to why significant relationships between tapping performance and EF were 
only detected at the 500ms interval. Research into motor timing performance at specific 
intervals in the millisecond to second range has revealed that PwP demonstrate the least 
amount of variability in tapping at 500ms, indicating a ‘preferred’ tapping rate (Jones et al., 
2011). Our data support this finding, as of all four interval speeds, tapping error and variability 
were lowest for the 500ms interval in the synchronisation condition. Furthermore, when 
asked to tap at a ‘comfortable pace’, PwP have been found to tap at around 600ms (Yahalom 
et al., 2004). These findings suggest that around 500ms is a tapping rate that PwP find most 
natural or comfortable. 
In addition, previous research has suggested that at cue frequencies higher than 500ms, 
tremor may pace voluntary repetitive movements to go faster than intended by the patient. 
At 500ms and lower frequencies however, PwP do not seem as affected by tremor (Logigian, 
Hefter, Reiners, & Freund, 1991).   
These findings suggest that the noise in tapping performance (variability between subjects) 
at the other interval speeds may have prevented significant correlations between tapping and 
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fluency being detected, and this may be partly explained by our small sample size. The 
inclusion of a larger sample size may have helped to overcome this issue. 
2.4.2 Hypothesis 2: Participants with poorer levels of EF would exhibit greater levels of 
relative impairment in the continuation phase of the PFT than participants with better 
levels of EF, due to a greater reliance on external cues. 
In order to investigate my second hypothesis, and due to the significant relationship between 
performance in the letter fluency task and tapping performance, letter fluency scores were 
used to stratify patients into two EF groups; EFhigh and EFlow. 
The results of the 2x2 mixed ANOVA revealed there was a main effect of EF group on tapping 
performance, with participants in the EFlow  group demonstrating a significantly greater level 
of tapping percentage error than the EFhigh group overall. While these results provide some 
support for my hypothesis, suggesting EF impacts on PFT performance overall, there was no 
main effect of condition (synchronisation or continuation) on tapping performance detected, 
and no interaction effect found between EF group and condition.  
These findings demonstrate that while participants with poorer levels of EF performed worse 
overall, there was no significant difference between performance in the synchronisation 
condition in comparison to the continuation condition.  
This result is not in line with my second hypothesis, and contradicts previous research which 
has indicated that people with low levels of EF may have reduced SAS resources (Brown & 
Marsden, 1988), and so experience difficulty in producing novel responses that are not cued 
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automatically by the environment (Norman, 1980). In addition, findings from previous 
research has suggested that impairments in verbal fluency may reflect a failure for PwP to 
carry out novel responses that are dependent on internal control (Bouquet et al., 2003), 
rather than due to verbal intelligence or difficulties in word production (Flowers, Robertson 
& Sheridan, 1995). Due to the absence of external cues in the continuation condition, 
performance in this condition was entirely reliant on internal action. I therefore expected 
there to be an interaction between executive functioning and condition, with participants in 
the EFlow group expected to perform significantly worse in the continuation condition (in the 
absence of external cues) than participants in the EFhigh group. 
The difference in performance between the synchronisation and continuation condition was 
significantly larger for participants in the executive dysfunction group (EFlow) than participants 
in the normal executive function group (EFhigh) however, indicating that tapping performance 
in the low fluency group was less consistent across the two conditions.  
This finding therefore may suggest that people with low levels of EF are more reliant on 
external cues to maintain consistency in tapping performance than people with high levels of 
EF, and therefore provides some support for my second hypothesis.  
Other variables that may have impacted on tapping performance were also considered: 
2.4.3 Sample size  
As discussed, my power calculation revealed that a sample size of 128 participants was 
required to reach adequate power (0.8) for this study. Unfortunately, due to difficulties with 
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the tapping equipment and a lack of resource to resolve, I was unable to continue with 
recruitment past 37 participants. This study was therefore underpowered, and there were 
small numbers of participants in each EF group, which may partially explain the lack of a main 
effect of condition. However, my data did show a trend for poorer performance in the 
continuation condition, and this difference in performance was found to be significantly 
greater in the EFlow group.  
2.4.4 Tapping performance and motor ability  
Tapping error percentage was found to weakly correlate with MDS-UPDRS III scores only at 
the 500ms interval (r=.35, p=.04), which suggests that tapping performance was not strongly 
associated with motor ability. This was surprising, particularly for performance at the fastest 
(250ms) interval, as my previous study findings (PDTAP Study) revealed tapping performance 
at fast speeds was correlated with UPDRS III scores (Dominey et al., 2016). Furthermore, 
previous research has found impaired reproduction of time intervals to be correlated with 
disease severity (Pastor, Artieda, Jahanshahi, & Obeso, 1992), which suggests people with 
more severe PD would have performed more poorly on the PFT than those with milder PD, 
however I did not find this to be the case.  
There are several possible explanations as to why I was unable to replicate these findings. 
Firstly, as mentioned previously, our sample size was fairly small, which made it difficult to 
draw out relationships between tapping performance and motor ability. In addition, 
participants were only tested in the ON medication state. Inclusion of testing in an OFF 
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medication state may have made relationships between tapping performance and motor 
ability more clear. 
2.4.5 Tapping performance and general cognitive ability 
Findings revealed that the EFhigh group had higher levels of cognitive function (ACE III scores) 
than participants in the EFlow group, which may suggest that differences in tapping 
performance between these groups may be due to general cognitive ability, as opposed to 
purely EF. It would be of interest in future studies to explore this further, by stratifying 
patients by cognitive ability for example. Due to the small number of people in our sample 
with evidence of Parkinson’s disease Dementia (PDD) (n=4) it was not possible to stratify 
patients’ tapping performance based on general cognitive ability. However, recent evidence 
has suggested that cholinergic deficits that occur in some PwP exacerbate fronto-striatal 
dysfunction, due to a loss of compensatory fontal cortical executive functions (Bohnen et al., 
2015). Cortical cholinergic denervation has been found to be significantly less common in PwP 
without cognitive impairment, but strongly associated with PwP with the greatest level of 
cognitive impairment Bohnen et al (2015). It would be of interest to investigate whether there 
were differences in tapping performance between people with and without cognitive 
impairment, to see if performance in the PFT task is reliant on intact cholinergic functioning, 
which is known to help preserve executive functioning in PwP (Bohnen et al., 2015). This could 
be achieved by implementing more robust inclusion criteria and recruiting participants with 
a wider range of cognitive abilities, including participants with normal cognition, MCI and 
PDD, whilst ensuring we had equal numbers of participants in each of these groups.  
148 
 
 
2.4.6 Application of findings 
Our findings demonstrate that a PFT paradigm using intervals of 500ms could be added to 
existing quantitative tapping measures to provide an indication of possible executive 
dysfunction, due to the overall poorer PFT performance by participants with low levels of EF. 
A number of quantitative tapping measures are being used currently to objectively assess 
finger tapping performance in PD that may offer a suitable platform for integration of such a 
test. The Bradykinesia-Akinesia Incoordination Test (BRAIN test) for example is a computer 
based tapping task, based on an alternating finger tapping paradigm (Giovannoni et al., 1999). 
The test uses a computer with a standard keyboard as the test device, and the two tapping 
targets are the “S” and “;” keys, 15cm apart. Subjects are asked to alternately tap the ‘S’ and 
the ‘;’ keys as rapidly and as accurately as they can over a 30-second time period (Giovannoni 
et al., 1999).  The program has been validated to assess kinesia (number of key taps in 30 
seconds), akinesia (mean dwell time on each key (ms)) and incoordination (variance of 
travelling time between key presses). These measures have been shown to successfully 
differentiate PwP and controls, as well as correlating with PD severity measured by MDS-
UPDRS total score and motor MDS-UPDRS sub scores (Giovannoni et al., 1999). Furthermore, 
an online version of the BRAIN test is available, meaning it can be accessed remotely from 
any computer with an internet connection and a keyboard, thereby making the test widely 
accessible (Noyce et al., 2014). The BRAIN test has already been implemented as a remote 
motor assessment in an extensive online Parkinson’s risk study (PREDICT-PD (Noyce et al., 
2017)), whereby differences in kinesia scores were detected between patients with high and 
149 
 
 
low risk scores for PD. In addition, the BRAIN test is being used as a secondary outcome 
measure in a trial of Simvastatin as a neuroprotective agent in Parkinson’s (PD-STAT) (Carroll 
& Wyse, 2017). The BRAIN test has therefore been validated as an objective finger tapping 
tool to measure motor function in established PwP (Noyce et al., 2014), as well as in in pre-
diagnostic cohorts (Noyce et al., 2017).  
Another quantitative measure of finger tapping has been developed as part of a smartphone 
software application to assess motor function. For the finger tapping component, participants 
were required to tap the screen alternately, keeping a regular rhythm. The screen pixel 
position (x,y coordinates) and time of finger touch were recorded, and used to quantify: 
tapping speed, rhythm, inter-tap interval, fatigue, and tremor. The summary measures, which 
in addition to finger tapping, included voice, posture, gait and reaction time, were found to 
differentiate between PwP and controls with high sensitivity (96.2%) and specificity (96.9%) 
and predicted disease severity, as measured by the MDS-UPDRS (Arora et al., 2015).   
Both of these finger tapping measures implement a single instruction paradigm and 
alternating tap locations, on either a computer keyboard or touch screen phone. While these 
measures have been validated to provide useful information on disease severity (as described 
above), it might be possible to add further value to these measures by introducing a 
secondary tapping task that is higher in complexity (such as a paced finger tapping task) which 
has potential to provide insight on the presence of some executive dysfunction.  
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As these devices have already been designed and validated to measure finger tapping in PD, 
it would be hoped the process of adding the PFT to these paradigms would not be too costly 
or complex. 
2.4.7 Study Limitations 
There are several limitations to this study that will be discussed.  
Firstly, unlike other studies investigating the PFT, we did not include a control condition such 
as a simple reaction time test (Jahanshahi et al., 2010). This means I was unable to account 
for aspects of motor function that may contribute towards the findings. This limits the 
interpretability of the results. The weak positive correlation found between tapping 
performance at the 500ms interval in the continuation condition and UPDRS-III scores 
suggests that other aspects of motor function might be influencing PFT performance at this 
frequency. 
Secondly, I did not include an age-matched healthy (non-PD) control group, which meant it 
was not possible to demonstrate whether our findings revealed impairments in tapping and 
EF that were unique to PwP. Previous studies have demonstrated that performance between 
PwP and controls is more similar for the synchronisation phase than the continuation phase 
for instance, which provides support for the view that PwP experience greater difficulty for 
internally generated movements. It would be of interest to include a control group to ensure 
our findings replicated those of previous studies implementing the PFT (Jones et al., 2011).  
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A further limitation to this study is that I only tested participants in a reported ON medication 
state. Differences in PFT performance have been reported previously between ON and OFF 
medication states, with the administration of dopamine found to reliably improve accuracy 
of tapping performance (Koch et al., 2008) with increased activation in the prefrontal areas 
when in an ON state (Jahanshahi et al., 2010). In contrast, dopaminergic modulation has been 
found to both impair and enhance cognitive function in PD, depending on the task demands 
(Cools, Barker, Sahakian, & Robbins, 2001). It would therefore be of interest to test 
participants in an ON and OFF state to evaluate dopaminergic influence on performance in EF 
and tapping measures.     
In addition, my study had limited sensitivity due to the software that was used. This study had 
originally been planned to be carried out as part of a tapping software application on a 
smartphone, by implementing a similar design to our previous PD-TAP study (Dominey et al., 
2016), and would have avoided the need to create an additional computer software program. 
Unfortunately, the support to write the software in iOS code was not available at the time of 
planning the study. A new programme was therefore created for this study, utilising Microsoft 
Visual Studio software to simulate a smartphone experience. Unfortunately a technical error 
was identified during the study. The refresh rate of the computer program was set as 30ms, 
which introduced a <60ms window of uncertainty for the precise timing of taps. While this 
has a relatively minor consequence at lower frequencies, introducing ~0.015Hz variance at 
0.5Hz (2000ms) tapping speed, the potential error is amplified at higher speeds, resulting in 
a ~0.9Hz variance at 4Hz (250ms) tapping speed. This reduction in sensitivity posed a potential 
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limitation to the application of these data. Due to this and other technical difficulties, it was 
not possible to continue the study after the 37th participant, which limited the statistical 
power of the study. This highlights a potential issue when developing software applications 
for research, as these designs can be resource heavy in terms of coding and ongoing technical 
support. 
Therefore, while there is some evidence of a relationship between measures of EF and 
performance on the PFT, a greater sample and finger tapping software with increased 
sensitivity would be needed to explore this in more detail.  
2.4.8 Conclusions 
Our study has revealed interesting relationships between motor timing in PD (as assessed by 
finger tapping performance in the PFT) and levels of EF.  
In relation to my first hypothesis, tapping performance in the PFT was found to correlate with 
performance in the letter verbal fluency task at 500ms in both the synchronisation and 
continuation condition. This finding provides support for my hypothesis, and demonstrates 
that performance in the PFT task at 500ms may provide some insight into levels of executive 
functioning.  
In relation to my second hypothesis, my findings revealed that although participants with 
poorer levels of EF performed worse overall, there was no main effect of condition detected, 
meaning participants in the EFhigh and EFlow groups did not perform significantly differently 
between the synchronisation and continuation conditions. This finding does not support my 
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second hypothesis that people with low levels of EF would perfom relatlively worse in the 
continuation condition due to a greater reliance on extrernal cues, and instead suggests 
performance is similar across the synchronisation and continuation condition for both EFhigh 
and EFlow groups.  
Our findings suggest a quick and simple measure of paced finger tapping at the 500ms interval 
has potential to be incorporated as part of an existing quantitative measure of finger tapping, 
to provide insight into potential deficits of executive function that relate to letter fluency 
including search strategies, inhibition, self-monitoring and self-initiation of response.  
2.4.9 Challenges to the development of Digital Health Technologies (DHTs) 
There were a number of challenges related to the development of Digital Health Technologies 
(DHTs) that I learnt as a result of this study.  
Firstly, the development of a computerised version of a pre-existing measure (in this case the 
PFT) should follow a standardised procedure. There are guidelines that have been published 
since the computer software was developed for this study, that clearly outline stages of 
development and necessary considerations that would have ensured our measure was more 
suitable for intended use (Mhra, 2017; Patient Reported Outcomes-From Paper to ePROs, 
2016):  
• Involvement with end users:  
As outlined in the MHRA guidance for engineering medical devices (Mhra, 2017), the 
first stage in the development of a new DHT should be to involve end users. 
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Involvement from end users throughout the development of a DHT ensures that the 
technology is usable, and easily accessible for users. As reported previously, one 
participant was unable to complete the study due to severe tremor, which meant they 
were unable to accurately press the sensor. In addition, several participants expressed 
discomfort when adopting the required hand position for finger tapping, which could 
have led to inaccuracy. Furthermore, several participants made incorrect finger taps 
(eg. holding down the sensor) which had to be corrected by the researcher. MHRA 
guidance (Mhra, 2017) further recommends that end users should be involved with 
the development of the task instructions to ensure these are clear and understandable 
by users. If there had been greater involvement with patients throughout the 
development of the computer program and selection of accompanying equipment, 
these aspects could have been detected much earlier in the design process, and 
mitigations could have been put in place to overcome these, to ensure the design met 
user needs.  
• Frequent evaluation and iterative design: 
The guidelines further recommend frequent stages of formative evaluation to be 
carried out prior to the technology being implemented as part of a larger study, which 
allows for potential risks and design errors to be detected early on, and iterative 
refinements to be made (Mhra, 2017). As mentioned previously, it was only after the 
data had been collected that a technical error was detected, whereby the sensitivity 
of the computer program (the refresh rate) had been set to a lower sensitivity than 
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expected. This finding highlights the need for extensive pilot testing to be carried out 
prior to the implementation of a DHT as part of a more extensive study. Guidelines 
suggest that equivalence testing is also carried out as part of the development 
process, whereby a novel DHT is assessed against an existing measure to ensure 
performance does not vary significantly across the two measures (Patient Reported 
Outcomes-From Paper to ePROs, 2016). In addition, the technical error we 
experienced demonstrates the need to work closely and collaboratively with IT 
developers throughout the development process, so that channels of communication 
are kept open and clear. By implementing these best practises, the chances of 
detecting a technical error early on, before data collection has taken place, are 
maximised.  
 
In conclusion, while I have found suggestion that PFT performance might be influenced by EF, 
the applicability of our findings is limited due to concerns surrounding the sensitivity of the 
computer software used. The study has highlighted some important considerations when 
implementing novel DHTs, which I have taken forward as learning for the subsequent studies 
in my thesis.   
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Chapter 3 The development and formative evaluation of a smartphone based non-motor 
symptoms application: “NMS Assist” 
3.1 Introduction 
Non-motor symptoms (NMS) are a significant cause of morbidity in Parkinson’s disease (PD), 
and have been shown to have a major impact on quality of life (QoL) (GDPS, 2002), as well as 
being closely associated with increased care partner burden (Schrag et al., 2006). Common 
NMS include psychiatric problems such as depression and confusion, as well as urinary and 
gastro-intestinal dysfunction, and sleep disturbances (Martinez-Martin, Rodriguez-Blazquez, 
Kurtis, & Chaudhuri, 2011.) (see section 1.2.11). NMS are common at first presentation of 
disease (Todorova, Jenner, & Ray Chaudhuri, 2014),  but the frequency of symptoms increases 
with disease progression, leading to a greater burden of NMS in advanced stages (Muzerengi 
et al., 2007). Indeed, NMS have been identified as the major cause of disability in patients 
living with PD for 15 or more years (Hely, Morris, Reid, & Trafficante, 2005). If left untreated, 
NMS can cause detrimental health complications and are a major cause of institutionalised 
care (Muzerengi et al., 2007). 
Despite the evident importance of recognising and appropriately treating these symptoms in 
order to improve patient QoL (GDPS, 2002) reduce care partner burden (Schrag et al., 2006) 
and avoid unplanned hospital admissions (Muzerengi et al., 2007), NMS are frequently not 
declared by patients in routine clinic appointments, and are not often asked about by 
clinicians (Chaudhuri et al., 2010).   This may be due to limited clinic appointment times, which 
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prevent clinicians carrying out comprehensive assessments, or due to lack of NMS awareness 
amongst clinicians (Chaudhuri et al., 2010).  In addition, patients may be unaware their 
symptoms are related to their PD, or they may be too embarrassed to discuss them 
(Chaudhuri et al., 2010). 
In order to enhance the identification of NMS in PD patients and allow for appropriate and 
timely treatment, a self-rated Non-Motor Symptoms Questionnaire was developed (NMS 
Quest) (Chaudhuri et al., 2006b) which can be completed by the patient in the waiting room 
prior to clinical consultation. As described previously (see section 1.2.21.2.7), this 30-item 
screening questionnaire allows for a comprehensive assessment of the range of NMS that 
occur in PD, and provides an opportunity for the patient to self-declare any possible problems 
to their clinician for further investigation. The NMS Quest has been internationally validated 
(Chaudhuri et al., 2006b), and is used extensively as part of routine clinical care.  
3.1.1 Self-management  
In addition to identifying NMS, there is a need to educate patients on simple self-management 
techniques to ameliorate many NMS, facilitate timely medical intervention, and prevent 
further deterioration (Duncan et al., 2013). Patients with knowledge and skills to manage their 
own health conditions have been found to experience better health outcomes, and have 
lower associated costs than patients with poor levels of engagement  (Hibbard & Gilburt, 
2014). In PD, patient involvement and access to information has been linked to reduced 
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length of hospital stay, decreased risk of adverse events, and improved QoL (Bauman et al., 
2003; Michie, Miles, & Weinman, 2003; van der Eijk et al., 2013).   
As outlined in the NHS Long Term Plan (The NHS Long Term Plan, 2019), there is a need to 
empower people living with long term conditions to become better at managing their own 
health, make informed treatment choices and avoid complications (Hibbard & Gilburt, 2014). 
To help meet this need, resources and tools are needed to increase patient capacity for self-
management.  
3.1.2 mHealth Solutions 
Advances in mobile technology have the potential to play a role in facilitating self-
management of long term conditions by providing insight into a patient’s condition, helping 
patients make informed choices, and encouraging engagement in self-care habits (Alpay et 
al., 2010).  
The increased accessibility of smartphones has contributed towards the rapid development 
of mobile health technologies (mHealth) in recent years (Matthew-Maich et al., 2016). Ofcom 
has recently estimated that 66% of adults in the UK own a smartphone, which has increased 
by 27 percentage points since 2012 (Ofcom, 2015). Although older adults are less likely than 
younger age groups to own a smartphone (an estimated 18% of people over the age of 65 
have one, compared with 50% of those aged 55-64), smartphone ownership in older adults 
has more than trebled since 2012, and continues to rise (Ofcom, 2015).   
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According to the World Health Organisation (WHO) there is great potential for mHealth to 
transform existing health services in coming years (WHO, 2011). As mentioned previously (see 
section 1.2.27), The NHS and Parkinson’s UK have recently launched an ‘Apps Library’ in an 
attempt to signpost patients towards healthcare apps that meet high standards for quality, 
reliability and effectiveness ("Apps for Parkinson’s", 2018; "NHS Apps Library", 2018).  
In addition, there are an increasing number of studies piloting mHealth interventions to 
support the management of long term health conditions (Wang et al., 2014). In PD, 
telemedicine has been recognised as a feasible way of providing specialist care for patients at 
home, offering similar clinical benefits to in-person care, and avoiding the need for travel 
(Dorsey et al., 2013). A recent review of studies using mHealth technology to manage long 
term conditions identified several benefits, including improved patient self-management, 
patient education tailored to patient need, and improved communication between health 
care professionals (Matthew-Maich et al., 2016). Furthermore, significant reductions in cost 
have been associated with mHealth technology in comparison with traditional care (Noel et 
al., 2004).  
A particular advantage of utilising smartphone technology, is the ability to incorporate 
educational material in a variety of media, including video. A review on the use of videos 
within clinical practice found that patients who viewed videos had a better understanding of 
their treatment options, and were more likely to be active participants in decision making 
(Krouse, 2001). In PD, ‘ParkinsonTV’ (launched by the Dutch strategy group ‘parkinsonNet’ 
(Bloem et al., 2017) broadcasts monthly programmes for people affected by PD, allowing for 
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easily accessible information on a variety of PD related projects. The success of this channel 
has recently led to episodes being broadcast in English. In addition, videos have been found 
to increase information accessibility for people with poor literacy skills, or those with poor 
vision (Krouse, 2001). Videos are therefore a potentially feasible method for facilitating self-
management of long term conditions. 
3.1.3 Challenges associated with mHealth solutions 
Despite the potential benefits of mHealth interventions, there are a number of associated 
challenges that have recently been identified (Baniasadi, Niakan Kalhori, Ayyoubzadeh, 
Zakerabasali, & Pourmohamadkhan, 2018; Gurupur & Wan, 2017): 
1.  Usability is a key consideration when designing an mHealth intervention, particularly 
for a diverse cohort such as older adults, who would be expected to have differing 
levels of digital literacy (Choi & Dinitto, 2013), as well as cognitive and motor limitations 
(Kruse, Mileski, & Moreno, 2017). Engagement with end users is therefore a priority to 
ensure that the app design is acceptable and meets user needs. Successful integration 
of end users’ considerations throughout the development of mHealth solutions has 
been found to influence engagement with and adoption of mHealth technologies 
(Matthew-Maich et al., 2016). 
2. Compliance and continued use of mHealth solutions is a key issue, with high dropout 
rates identified among app users. Once downloaded, 26% of apps have been found to 
be used only once, and 74% of apps are not used more than 10 times (Espay et al., 
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2016). Sustained engagement with mHealth solutions is thought to be dependent on 
several key variables including satisfaction, confirmation of expectation, and perceived 
usefulness (Bhattacherjee, 2001). These variables should therefore be considered 
when developing and evaluating an mHealth solution.  
3. Infrastructure, including the availability and strength of internet networks to transmit 
and receive data, particularly in emergency situations (Baniasadi et al., 2018) needs to 
be considered. If the necessary infrastructure is not in place or not widely available, 
then it would prevent the use of mHealth solutions.  
4. Data security is of particular importance when managing data that contains personal 
health information (Gurupur & Wan, 2017). Data needs to be stored in a secure 
location in compliance with relevant guidelines, and only accessible through secure 
transmission channels.  
Additional challenges to implementing mHealth solutions include reliability, meaning the 
result provided by the technology must be accurate enough to help the patient, and system 
integration, whereby the design system must be scalable, and allow for integration with other 
pre-existing clinical and data-management systems (Gurupur & Wan, 2017). 
It is therefore important with the design of any new mHealth technology that these challenges 
are considered and addressed, to ensure the successful implementation of the system, with 
user safety being the primary focus.  
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3.1.4 NMS App 
Despite the challenges described above, mHealth technologies such as smartphone based 
applications offer great potential in facilitating patient self-management of long term 
conditions, and provide the opportunity to monitor patients within the home environment 
(Matthew-Maich et al., 2016). 
With regards to NMS in PD, there is a need for tools to help patients self-manage their NMS, 
and provide remote monitoring of these symptoms with triggered response, to allow for 
timely and effective intervention, and to avoid development of complications.  
To meet these needs, the Applied Parkinson’s disease Research Group (led by Camille Carroll) 
set up a project group to develop a mobile app version of the NMS Quest (Chaudhuri et al., 
2006) in collaboration with its author, Prof. Ray Chaudhuri (Kings College London). The main 
aims of the app are to provide remote monitoring of NMS and triggered service support for 
PwP and their care partners, as well as information on self-management of PD NMS. The app 
will also be used by care partners so that ‘carer voice’ can be heard, which can provide insight 
on non-motor issues that might not be recognised or reported by the patient themselves. 
Discordance in cognitive and neuropsychiatric symptom ratings have previously been found 
between carers and patients (Janssen, 2013), which demonstrates the importance of 
obtaining information from care partners to provide the most clinically valid picture of a 
patient’s symptom severity.   
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The self-help information provided as part of the app has been developed in collaboration 
with Ron Postuma, (McGill University), author of ‘A Guide to the Non-Motor Symptoms of 
Parkinson’s Disease’ (Postuma & Galatas, 2012). App development was supported by funding 
from Plymouth Hospitals NHS Trust Charitable Fund and the Hoover Foundation. 
The NMS App project group is an interdisciplinary team made up of clinicians, researchers, 
mHealth designers and end users (PwP, Caregivers and PD Nurse Specialist (PDNS)). Project 
group roles of the main project group and external collaborators are described in appendix 7 
(section 8.7). All members of the main project group contributed to the iterative design 
process, and end users were involved at all stages of the app development process to ensure 
the app design was acceptable and met their needs.  I was responsible for co-ordinating the 
app design process, whilst ensuring the app met user requirements. I was also responsible for 
leading the design, recruitment, delivery and analysis of the formative evaluation of the app 
as well as maintaining the Medicines and Health Products Regulatory Agency (MHRA) Site File. 
3.1.5 App Development 
The process of app development is described in Figure 22. Following identification of app uses 
and users, the development of the app can be broadly divided into three processes that ran 
in parallel to one another: 
• Development of the app wireframe 
• Development of self-help materials  
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• Development of app build  
In addition to the identification of app uses and users, I was involved in the development of 
the app wireframe, the development of the self-help materials, and the formative evaluation 
of the app, ensuring that all regulatory requirements were met.  
3.1.6 Overall Project Aims 
The overall aims of the project were: 
1. To design and develop a non-motor symptoms app using a user-centred, iterative design 
process, in line with MHRA guidance, and with end user engagement throughout. 
2. To evaluate whether the app is usable by the intended users. 
3. To identify key areas of amendment to the app design prior to a summative evaluation of 
the app. 
3.1.7 Chapter Outline 
This chapter will therefore be divided into 3 parts, representative of the app development 
process: 
• Part One relates to the identification of app use and user groups 
• Part Two relates to the iterative design process. This chapter will be split into two 
subsections: 
- Part Two (A) refers to the wireframe development process 
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- Part Two (B) refers to the self-help materials development process 
• Finally, Part Three relates to the formative evaluation of the app 
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Identification 
of app use, 
users and use 
environments 
via: 
• focus 
groups  
• literature 
searches 
Evaluation of 
users’ needs via: 
• Patient 
evaluation 
(n=142) 
 
Identification and risk assessment of potential use errors related to: 
• User characteristics 
• Content 
• Accessibility 
 
WIREFRAME DEVELOPMENT SELF-HELP MATERIALS 
Development of user interface specification 
describing the design characteristics to mitigate 
potential user errors 
APP BUILD DEVELOPMENT 
Development of build requirements New use 
error 
identified 
Development of content and format for 
self-help materials 
Iterative design of app build 
Tendering process for animation and voiceover 
Iterative design of app wireframe prototype Project group 
review 
Project group review 
Iterative design of animation storyboards 
Focus group with end users 
FORMATIVE EVALUATION 
Project group review 
Feedback incorporated into app build 
FORMATIVE EVALUATION 
Identification of high severity issues informing redesign Amendments to 
app design 
IN-SERVICE SUMMATIVE EVALUATION 
Identification of high severity issues 
informing amendments 
Amendments to 
app build 
PART 1 
PART 2 
PART 3 
Figure 22 The NMS App development process and corresponding chapter sections. Part 1 details the identification of app use and user groups, Part 2 details the development of the app wireframe and self-
help materials, and Part 3 details the formative evaluation of the app.  
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3.2 Part One: Identification of app use, users and environment 
3.2.1 Part One Aims 
• To identify app users and their environments via evidence from the literature 
• To evaluate patient experience of NMS via a patient questionnaire 
3.2.2 Part One Hypothesis 
1. There will be a wide range of potential end users identified from the literature, 
including those with a breadth of demographic variables, disease presentation, NMS 
burden and prior experience with digital devices. 
3.2.3 Identifying Users and Environments 
To ensure the app was designed for real world use, it was necessary to identify and 
understand who the end users were, and the intended environment for use. 
We identified two main user groups who will be interacting with the app interface – PwP and 
their care partners. Each of these user groups will be discussed in turn below. 
People with Parkinson’s (PwP) 
There is known heterogeneity in PwP, including a breadth of age, disease severity, and clinical 
presentation. Recent figures published by Parkinson’s UK (Parkinson's UK, 2017) suggest 
potential end users with Parkinson’s could cover a wide age range, from 20-90+ years, with 
prevalence increasing with age. In terms of gender, the prevalence of PD is higher for men 
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than for women, with men accounting for 57.5% of the PD population in the UK. For men aged 
50-89, prevalence is 1.5 times higher than for women in the same age-group (Parkinson's UK, 
2017). 
Disease severity across the PD population is also varied. Studies involving large cohorts of 
patients have found similar distributions of disease stage (Goetz et al., 2004). In these studies, 
Hoehn & Yahr Stages 1 (unilateral involvement only) and 5 (wheelchair bound or bedridden 
unless aided) were found to account for the smallest number of participants, followed by 
Stage 4 (severe disability; still able to walk or stand unassisted). The majority of participants 
(52%-77%) were in Stages 2 (bilateral involvement without impairment of balance) and 3 
(mild to moderate bilateral disease; some postural instability; physically independent) (Goetz 
et al., 2004). 
The clinical presentation of PD is also varied. As mentioned previously, research from two 
early PD cohorts (Tracking Parkinson’s (n=1601 patients) and Discovery (n=944 patients)) has 
identified four subgroups, or ‘clusters’ of PD symptoms that are  associated with levodopa 
response and rates of motor progression (Lawton et al., 2018). These include (1) fast motor 
progression with symmetrical motor disease, poor olfaction, cognition and postural 
hypotension; (2) mild motor and non-motor disease with intermediate motor progression; (3) 
severe motor disease, poor psychological well-being and poor sleep with intermediate 
progression and (4) slow motor progression with tremor dominant unilateral disease.  
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These data highlight the complexity of clinical presentation that is apparent in PD, and 
suggests our end users will likely have a wide range of motor and non-motor symptoms that 
may affect their interactions with the app. For instance, PwP in the severe motor disease 
cluster (cluster 3) may experience impaired dexterity and slowness of movement (which for 
example might limit ability to double-tap), while PwP in the tremor dominant cluster (cluster 
4) may have difficulty tapping where desired, or in maintaining uniform pressure on the 
screen (e.g. to produce a swipe). Furthermore, there is a high level of cognitive impairment in 
PD (Aarsland et al., 2009) which may impact on users’ ability to interact with the app. PwP 
with poor cognition (cluster 1) may experience impairment in attention and concentration 
over sustained periods of time (Muzerengi et al., 2007) which could make it difficult for users 
to successfully complete required tasks. 
Care Partners  
The majority of care to PwP is provided by informal care partners, often spouses or partners 
of the PwP (Alonso, Clínico, Carlos, & Catalan, 2014). Although typically aged over 65 years 
(Mclaughlin, Kernohan, Waldron, & Mclaughlin, 2010), it is important to consider there will 
be some carers using the app who are well below this age, reflective of the wide age range of 
PwP, or of care provided by a younger generation (Parkinson's UK, 2017). There will also be 
differences related to the independence of PwP, where their care partner may not be so 
intimately involved in providing their care needs; compared with more disabled PwP whereby 
their care partner will have much greater knowledge of their symptoms.  
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Carer burden is prevalent in PD, and has been found to increase with increasing disease 
severity (Schrag et al., 2006). Care partners using the app are likely to have varying levels of 
carer burden, including depression and stress, as well as impairments in physical health and 
quality of life (Schrag et al., 2006). As the majority of carers are older adults, some may 
experience limitations associated with normal ageing including visual and hearing 
impairments (Lorenz & Oppermann, 2008) as well as cognitive limitations (Roberts et al., 
2012). In addition, some care partners may have their own long term health condition that 
could affect their interactions with the app. 
Furthermore, levels of digital literacy amongst PwP and care partners  are expected to be 
variable, due to a reported age-based ‘digital divide’ (Fox & Connolly, 2018), whereby 
adoption of technologies is lower amongst older adults than younger populations. As 
mentioned previously, older adults are less likely than younger age groups to own a 
smartphone (Ofcom, 2015), and younger smartphone users are likely to have downloaded a 
greater number of apps than older users (Ofcom, 2015). It is therefore expected that both 
care partners and PwP will have varying degrees of experience with apps and digital literacy 
in general, largely dependent on age (Choi & Dinitto, 2013).  
Identified Environments 
As the app will be available on a smartphone (and therefore portable), it is expected that the 
primary environment for use will be in patients’ homes, particularly as this is the environment 
where older people spend the majority of their time (Gao & Koronios, 2010). The app may 
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also be used in a clinic environment with the PDNS as a point of reference when discussing 
NMS. Some features of the app will require an internet connection. While the patient is able 
to use other features in the app offline, online features will not be available until an internet 
connection has been made. The National Office of Statistics reports that in 2018, 90% of 
homes in the UK had access to the internet  ("Office for National Statistics,” 2018). While this 
figure is lower for households with one adult aged 65 years and over (59%), these households 
had the largest growth in internet access since 2012 (23 percentage points). If the patient 
does not have internet access at home, this may mean the app is used in other environments 
(e.g. libraries, cafés or family or friends’ houses) in order to access an internet connection. 
In line with my first hypothesis, the literature review revealed a wide range of end user 
characteristics including a breadth of demographic variables, disease presentation and levels 
of digital literacy. We therefore had some understanding of the characteristics of our 
expected end users (PwP and care partners), as well as the environments in which we expect 
the app to be used in.  
To survey patient experience of NMS, I developed a patient questionnaire in collaboration 
with the NMS Project Group.  
As this was a survey of patient experience of NMS, ethical approval was not required. 
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3.2.4 Questionnaire Items 
The questionnaire items (n=15) focussed on 4 key areas: NMS burden (6 items), frequency of 
PD clinical appointments (3 items), self-help behaviours (3 items), and interactions with 
technologies (4 items). Demographic data was also collected including date of birth, gender 
and date of diagnosis.  
Prior to starting the questionnaire, responders were provided with a brief explanation as to 
what NMS were, and what kind of symptoms were included within the term. 
See appendix 8 (section 8.8) for a copy of the questionnaire in full. 
Once the items had been developed, the wording and formatting of the questionnaire were 
reviewed by patient representatives within the project group to ensure it was 
understandable. Any necessary changes were made. 
3.2.5 Questionnaire dissemination  
Once finalised, the questionnaire was made suitable for a web platform, accessible via a link, 
using the program ‘Jisc Online Surveys’ which met University standards for General Data 
Protection Regulation (GDPR) compliance. The questionnaire was then disseminated via the 
Cure Parkinson’s Trust (CPT) monthly newsletter and the link was posted to a local PUK 
support group forum. All responses were anonymous. In addition, to ensure responses were 
also collected from people who did not have access to a computer, printed copies of the 
questionnaire were disseminated at a local PUK Support Group in Cornwall. Responses were 
collected over a period of 6 weeks. 
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3.2.6 Questionnaire findings 
One hundred and three responders completed the survey. All included responders were from 
the UK. Fifty-two were male (51%) and 47 were female (47%). Four responders (4%) did not 
give details of their gender. Responders had a median age of 62 years (39-85 years), and a 
median disease duration of 5 years (1 month-25 years).  
The majority of the questionnaires included as part of the main analysis (n=83, 81%) were 
completed online via the CPT website, and 20 of the questionnaires (19%) were completed 
using the paper version and sent via post. 
3.2.6.1 Non-motor symptom burden  
Eighty-six percent of responders reported finding their non-motor symptoms moderately to 
extremely troublesome.  
3.2.6.2 Length between appointments  
Table 17 summarises the reported intervals between appointments with a Parkinson’s Nurse 
and the reported intervals between appointments with a Parkinson’s Doctor.  
19 UK responders (18%) reported not having a Parkinson’s Nurse. 
Overall, 86% (n=88) of responders reported an interval of 6 to 12 months between 
appointments with either a Parkinson’s Nurse or Doctor. 
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Table 17 The interval between appointments with respondents’ Parkinson’s Dr and Parkinson’s Nurse 
 Parkinson’s Dr Parkinson’s Nurse 
<6 months 19 (18%) 18 (18%) 
6-12 months 53 (52%) 38 (37%) 
12-18 months 21 (20%) 10 (10%) 
>18 months 9 (9%) 17 (17%) 
 
3.2.6.3 Frequency of GP visits related to PD  
Forty-two percent of responders reported never seeing their GP about their PD. Of the 
remaining responders, responses ranged from seeing their GP about their PD more than twice 
every six months, to once every 18 months. Responses are summarised in Table 18.  
Table 18 The frequency responders reported seeing their GP about their PD 
 Frequency of repsonse (%) 
More than twice in 6 months 13 (13%) 
Once every 6 months 19 (18%) 
Once a year 12 (12%) 
Once every 18 months 15 (15%) 
Never 43 (42%) 
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3.2.6.4 Frequency with which NMS are discussed in clinic:  
Figure 23 summarises the frequency with which responders discussed their NMS in clinic with 
their GP, their Parkinson’s Dr or their Nurse. Just under half of responders reported discussing 
their NMS symptoms with their Parkinson’s Dr (49%) or Parkinson’s Nurse (45%) at almost all 
clinic appointments. 
 
Figure 23 The frequency with which NMS are discussed in clinic with patients’ GP, Parkinson’s Nurse or Parkinson’s Dr 
3.2.6.5 Seeking help from healthcare professionals for NMS symptoms: 
Half (50%) of responders (n=51) reported seeking help from healthcare professionals about 
their NMS infrequently or very infrequently. Of the remaining responders, 30% reported 
seeking help occasionally and 20% frequently or very frequently.  
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The majority of responders reported seeking help from their Parkinson’s Nurse (55%), 
followed by their GP (40%), their Parkinson’s Dr (38%) and ‘other’ (25%) (no details given). 
Responders were able to select more than one response for this question. 
3.2.6.6 Other self-help behaviour: 
The majority of responders reported seeking self-help advice occasionally (40%). Thirty 
percent of responders reported seeking self-help advice infrequently or very infrequently, 
and 27% reported seeking self-help advice frequently or very frequently.  
Figure 24 summarises the information sources responders reported using to seek self-help 
advice for their NMS. Responders were able to select more than one response. Websites were 
the most frequently used format (78%) and included Cure Parkinson’s Trust, PUK, Health 
Unlocked website, Facebook forums and Michael J Fox. Online videos included YouTube, and 
Michael J Fox webinars. Support groups included PD warrior and local PD drop-in groups. 
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Figure 24 Information sources used by responders to seek self-help advice on non-motor symptoms 
 
3.2.6.7 Preferred format for self-help info: 
The majority of responders reported they would prefer to receive self-help information via a 
video of an expert giving advice (36%) in person (31%) or in a text format (23%). 
3.2.6.8 Current Parkinson’s disease app use:  
Ten percent of responders reported they currently used an app associated with their PD, 
these included a voice volume app, a mindfulness app, a mobility, speech and dexterity app 
(‘Beats Medical’), and a symptom tracker (‘Parkinson’s LifeKit’).  
Seventy-eight percent of responders reported they would consider using an app in the future 
to gain self-help advice on how to manage their NMS. 
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3.2.6.9 Access to devices: 
Six percent of responders reported not having access to any electronic devices. The remaining 
responders reported having access to a smartphone (71%) a tablet or iPad (71%) or computer 
(69%). 
3.2.6.10 Environments of use:  
The majority of responders reported using these devices in the home environment (92%), in 
public (35%) and some reported using these in clinic (2%).  
3.2.7 Discussion of findings: 
I carried out a patient questionnaire to survey patient experience of NMS. Key findings will 
be discussed below.  
3.2.7.1 NMS Burden and current care provision: 
The survey revealed a high level of NMS burden amongst responders, with 86% reporting they 
found their NMS moderately to extremely troublesome. This is also in line with previous 
research on NMS in PD whereby NMS burden has been found to be high. For example an 
international study on the prevalence of non-motor symptoms in 545 PwP found on average, 
and irrespective of cultural background, patients reported experiencing 9-12 different NMS, 
across all stages of disease (Martinez-Martin et al., 2007). In addition, in an assessment of 265 
PwP, a number of NMS including mood, drooling, sleep, pain, as well as bowel and urinary 
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problems, were ranked as part of patients’ top 10 most bothersome PD related symptoms 
(Politis et al., 2010).  
The majority of responders reported waiting between 6-12 months between appointments 
with either their Parkinson’s Nurse or Doctor. Although the average interval observed 
between appointments is therefore broadly in line with NICE guidelines (NICE, 2017), there 
may be unmet clinical need in those who reported waiting more than 12 months between 
consultant and nurse appointments. 
In addition, 18% of responders (n=19) reported not having a Parkinson’s Nurse, which 
highlights a lack of important service provision of care for these patients. 
The frequency with which NMS are discussed in clinic was greater than expected, with around 
45% of responders reporting they discussed their NMS at almost all clinic appointments with 
their Parkinson’s Nurse or Doctor.  
This was surprising as previous research has demonstrated lower levels of self-declaration of 
NMS, although this was dependent on the type of NMS being discussed (Chaudhuri et al., 
2010). For instance in an international study of 242 patients, 31.8% of patients reported not 
declaring diplopia whereas 65.2% reported not declaring delusions. These previous findings 
suggest certain NMS may have more embarrassment or stigma associated with them than 
others, or patients may not realise these symptoms are related to their PD (Chaudhuri et al., 
2010). Our findings may therefore have been different if we had asked responders about the 
frequency they discuss specific NMS in clinic (e.g. delusions).  
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Another potential explanation for our finding may be explained by the attributes of the 
patient cohort, as patients were recruited to the survey via the Cure Parkinson’s Trust mailing 
list and local PUK support groups. The survey responders may therefore represent a generally 
more informed patient cohort than other PwP who do not attend or belong to these groups. 
Our survey responders may therefore already be more aware of the importance of NMS in 
PD.  
Discussion of NMS symptoms with the GP was significantly less however, with 66% of 
responders reporting they never discussed NMS symptoms with their GP.  
Nevertheless, as the majority of patients reported waiting longer than 6 months between 
appointments, the opportunity to discuss NMS is limited. Furthermore, half of responders 
(50%) reported actively seeking out help from professionals for their NMS infrequently or very 
infrequently which may not be enough to meet levels of need, particularly as NMS burden 
was previously described as moderately to extremely burdensome for the majority of 
responders. These findings highlight patients have limited opportunity to discuss their NMS, 
despite experiencing a high NMS burden. 
3.2.7.2 Self-help behaviours:  
The frequency with which responders reported seeking self-help advice for their NMS was 
fairly mixed, with the majority of the responders (40%) reporting they did so occasionally. 
While it is encouraging that patients are already somewhat motivated to engage with self-
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help platforms, it would be of interest to explore methods to encourage this, to ensure 
sustained engagement with self-help tools.  
Most of the responders reported using websites to gain self-help information (78%), with 
well-known PD websites such as PUK and Cure Parkinson’s Trust mentioned frequently, in 
addition to Facebook Forums. This finding suggests the majority of the cohort have access to 
the internet, and are comfortable using technology to find out information on their NMS. A 
minority of the cohort (10%) reported using an app that was associated with their PD. These 
apps ranged from apps for speech, symptom diaries and mindfulness apps. Seventy-eight 
percent of the responders reported they would use an app in future however, which is 
encouraging and demonstrates potential feasibility of the app.  
The majority of responders (94%) reported having access to smart devices including a 
smartphone (71%), a tablet or iPad (71%) and a computer (69%) which demonstrates that the 
app would be accessible to the majority of patients on a range of platforms. It is important to 
consider however that the majority of survey responses were completed online (81%) and so 
the high proportion of responders with access to smart devices observed in our sample may 
not be representative of the general PD population. 
The majority of participants reported using these devices in the home environment (92%) 
while fewer reported using their smart devices in public (35%). This is important when 
considering the functionality and task demands of the app, for instance users would need an 
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internet connection to sync their data with the nurse portal, and would require a quiet 
environment to fill out the symptoms assessments or view the self-help materials.  
3.2.7.3 Self-help format: 
The most popular formats for preferred self-help information to be received in was a video of 
an expert giving advice (36%), in person (31%), or in a text format (23%). We will incorporate 
these preferences in the development of the NMS self-help materials, by providing both text 
and video versions of the self-help information.  
3.2.8 Discussion: Part One 
In Part One, I carried out a literature review and patient questionnaire to identify potential 
app users and their environments, and to survey patient experience of NMS. 
I hypothesised there will be a wide range of potential end users identified from the 
literature, including those with a breadth of demographic variables, disease presentation, 
NMS burden and prior experience with digital devices. 
The results of the literature review carried out in Part One provided support for my 
hypothesis, revealing a wide range of potential end users, including people with varying levels 
of digital literacy. Considerations will need to be taken into account when designing the 
wireframe and self-help materials, to account for the limited dexterity, vision, hearing and 
cognitive ability that PwP may experience, as well as their carers, who may be of an older age. 
The results of Part One further confirmed that the app will be mainly accessed in a home 
environment, although it may be used in public spaces by some users. 
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Furthermore, the patient questionnaire demonstrated that although the majority of patients 
experience a high level of NMS burden, 76% of patients are not able to obtain appointments 
with their PD Nurse or Doctor within 6 months, and 14% patients are not able to obtain 
appointments within the NICE recommended guidelines of between 6-12 months. We have 
therefore identified an unmet need that the app may help to address, by offering self-help 
resources and monitoring of NMS in-between clinic appointments. The evaluation further 
indicated that the majority of PwP surveyed have access to a digital device, and would be 
willing to use an NMS app to help monitor their symptoms, which demonstrates feasibility of 
our app.  
3.3 Part Two: Iterative design process 
3.3.1 Part Two Aims: 
• To design and develop an app wireframe suitable for end users, which prioritises 
patient safety 
• To design and develop suitable and informative self-help content which is delivered in 
an accessible and engaging format 
Part Two will be divided into two subsections:  
• Part Two (A) will describe the wireframe development process 
• Part Two (B) will describe the self-help materials development process 
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3.3.2 Part Two (A) Wireframe development process 
3.3.2.1 Selection process for the app design and build: 
Firstly, a tender process was carried out to select the design and build companies responsible 
for developing NMS Assist. The three tenders received were reviewed by the IT procurement 
team at the University of Plymouth, and the leading tender selected. The tender for the 
wireframe design was awarded to a local app design company (Made with Maturity), and the 
tender for the app build was awarded to a separate local company (Suvo).  
3.3.2.2 Design of the wireframe: 
The wireframe was based on an initial design created by CN (see appendix 10 (section 8.10)), 
following a series of 3 design meetings with CC, JW and SW, during which the user journeys 
through the app were conceptualised.  
The initial wireframe design was then revised in an iterative process led by myself, involving 
the whole project group (09/18 to 12/18), in association with Made with Maturity, leading to 
the creation of an initial prototype. The prototype was also iteratively redesigned, with a final 
prototype being taken forward for the first stage of formative usability testing. Iterations to 
the design of the wireframe and prototype were based around core app functions. 
3.3.2.3 Core Functions: 
As a result of the group discussions (see section 3.3.2.2), six core functions of the app were 
identified including:  
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1. First time log in 
2. Carrying out a full NMS assessment 
3. Carrying out a partial NMS assessment 
4. Viewing symptom summary  
5. Accessing self-help information  
6. Requesting contact from the healthcare team 
Each of the core functions is described in more detail below (see section 3.3.2.3). 
3.3.2.4 Identified issues: 
In line with MHRA guidance, potential issues were identified throughout the development of 
the wireframe and recorded (see Table 19). Issues were grouped into three main areas: those 
related to user characteristics, those related to content and those related to layout. Solutions 
to these issues are also detailed in Table 19 (see ‘solution’ column). These solutions informed 
key design features the app which are described in relation to each of the core functions 
described below (see ‘relevant core function’ column in Table 19).
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Table 19 Issues identified and relevant decisions made throughout app development 
Issue group Issue identified Solution Relevant core function 
Content Users would not understand the purpose 
of the app 
Include a strapline that clearly describes 
the purpose of the app 
See core function 1 
 Users would not understand how to use 
the app 
Include instructions for use that appear 
during first time log in and accessible at 
any time 
See core function 1 
 Users may not give consent for their 
data to be used 
Include a consent page outlining how 
app data will be used  
See core function 1 
 Users would need to be reminded to 
complete regular full symptoms 
assessments 
Send notifications to users to remind 
them when a next assessment is due  
See core function 2 
 Users would need to be reminded to 
complete regular full symptoms 
assessments 
Display the date of upcoming 
assessment on the home screen 
See core function 2 
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Issue group Issue identified Solution Relevant core function 
Content Users may not want notifications on 
their device. 
Provide users with an option to ‘allow’ 
or ‘not allow’ notifications on first time 
login 
See core function 1 
  Allow users to amend notifications in 
settings 
See core function 1 
 Users would need to have an option to 
contact their healthcare team if running 
into trouble. 
Add a ‘request contact’ button to the 
main home screen 
See core function 6 
 Users would need to receive 
acknowledgement their contact request 
had been received, and when they will 
hear back. 
Include a ‘contact request received’ 
message with relevant details 
 
 
 
See core function 6 
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Issue group Issue identified Solution Relevant core function 
Content The healthcare team will need to 
distinguish between a care partner 
assessment and a patient assessment  
Include a page that asks the user to 
identify as either the care partner or the 
patient 
See core function 2 
 We wanted to include a QoL measure Include the PDQ8 as part of the full 
assessment – PDQ39 too burdensome. 
 
See core function 2 
 PDQ8 needs to comply with Oxford 
University Innovation guidelines 
Add a back button and a menu button 
to all PDQ8 screens  
See core function 2 
 Users may not understand the purpose 
of PDQ8 
Include a page prior to the PDQ8 that 
explains the purpose and instructions 
See core function 2 
 Users will want to know how many 
questions they have left to answer 
Include a progress bar that shows how 
many questions are left to complete 
See core function 2 
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Issue group Issue identified Solution Relevant core function 
Content We wanted participants to complete a 
comprehensive assessment of non-
motor symptoms  
Use the NMSQ  See core function 2 
 Users may not understand the purpose 
of NMSQ 
Include a page prior to the NMSQ that 
explains the purpose and instructions 
See core function 2 
 ICD not addressed by NMSQ Add a Q31 that evaluates ICD   See core function 2 
 We needed to assess symptom severity  Include a question that asks how much 
the symptom is troubling the patient 
See core function 2 
 We wanted to include an opportunity for 
interim assessment to evaluate response 
to medication/ other intervention 
Include option for partial assessment See core function 3 
 Users may not realise when they have 
selected a response 
Response is highlighted blue if selected 
 
See core function 3 
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Issue group Issue identified Solution Relevant core function 
Content Users need to be alerted towards 
worsening symptoms 
Include symptom summary  See core function 4 
 Users need to be directed towards self-
help info for worsening symptoms 
Provide a link to self-help information 
for each symptom in the summary 
See core function 4 
 Users might not be attracted to app  Use an attractive and consistent colour 
scheme throughout 
See core function 5 
 Users may want to logout Provide a dropdown menu with logout 
option 
See core function 6 
User Characteristics Users may not be able to read text 
clearly 
Provide an option to increase font size See core function 6 
 Users may not be able to hear the 
voiceover 
Provide a text alternative for each of 
the self-help videos 
Provide option to adjust volume 
See core function 5 
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Issue group Issue identified Solution Relevant core function 
User Characteristics Users may become fatigued/distracted Allow for a pause and return function See core function 2 
 Users or their care teams may wish to 
determine if they are experiencing non-
motor fluctuations   
Include a question that ascertains if 
patient experiences fluctuations 
Include an on/off scale 
See core function 2 
 Users may struggle to press buttons 
accurately 
Ensure buttons are big and widely 
spaced apart 
See core function 2 
Accessibility Users may be unable to access features 
of the app without internet  
Add an ‘online/offline’ symbol to the 
home screen to notify users of their 
connectivity 
See core function 6 
 Non-service users may download the 
app and not have service support 
Service users are provided with a token 
by their healthcare team that is linked 
with their registration details.  
See core function 1 
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Issue group Issue identified Solution Relevant core function 
Layout The display page for the partial 
assessment may look overwhelming/too 
cluttered 
Group symptoms into relevant sub 
domains  
See core function 3 
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3.3.2.5 Wireframe design and core functions:  
Details of the core functions of the app are given in each section below.  
3.3.2.5.1 Core function 1. First time log in 
The first core function of the app was the first time log in. The user journey for Core function 
1 is displayed in Figure 25 below (from left to right). 
 
Figure 25 Screen shots of the user journey for Core function 1 (first time log in) from left to right (A-E) 
To ensure that first time users would understand the purpose of the app prior to using it, a 
strapline was added to the first screen (see Figure 25, A). Additionally, an instructions page 
(see Figure 25, B) was added to ensure participants would understand the various functions 
associated with the app, and what would be expected of them as users (eg. to fill in regular 
assessments). To avoid non service users downloading the app without backend service 
support, a token system was introduced (see Figure 25, C), whereby users will be required to 
enter a token provided by their healthcare team. In line with MHRA guidelines (Mhra, 2017), 
(A) (B) (C) (D) (E) 
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it is necessary to allow users to have the option to ‘allow’ or ‘not allow’ the app to send them 
notifications (e.g. assessment reminders), and so we included the notifications pop up (see 
Figure 25, D). The consent page (see Figure 25, E) was included to obtain consent from users 
to use their data for clinical, research and evaluation processes.  
3.3.2.5.2 Core function 2. Completing a full NMS assessment 
The second core function of the app was completing a full NMS assessment. The user journey 
for Core function 2 is displayed in Figure 26 below. 
  
(A) (B) (C) (D) 
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Figure 26 Screen shots of the user journey for Core function 2 (completing a full NMS assessment) from left to right (A-H) 
To provide regular monitoring of NMS, it was agreed that the app would be based on the 
NMSQ (Chaudhuri et al., 2006). Users would be required to complete a full NMS assessment 
routinely at intervals determined by the Parkinson’s Nurse (or other member of their 
healthcare team). Users would be provided with notifications to remind them to complete an 
assessment, in addition to a reminder displayed on the home screen (see Figure 26, A) (date 
of their next assessment). In addition, we wanted to include a question on Impulse Control 
Disorder (ICD), which is not currently included as part of the NMSQ. After discussion with its 
author (Ray Chaudhuri, Kings College London), a 31st question on ICD was added to the full 
NMS assessment, worded as follows; ‘Had an increase in gambling, sexual, buying, or eating 
behaviours or routinely taken more anti-parkinsonian medications than prescribed?’ 
(E) (F) (G) (H) 
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To distinguish between users that were care partners, and users that were PwP, a screen was 
added asking users to identify themselves (see Figure 26, B). 
In order to include a measure of patient QoL, the PDQ8 was included as part of the full NMS 
assessment, in accordance with licencing stipulations from Oxford University (PDQ8 creators) 
(Patient Reported Outcomes-From Paper to ePROs, 2016) (see Figure 26, C). The shortened 
version of the PDQ39 measure was chosen to avoid over-burdening users, and is 
recommended over the PDQ-39 where a shorter form measure is required (Jenkinson, 
Fitzpatrick, Peto, Greenhall, & Hyman, 1997). Instructions were included prior to completing 
the PDQ8, so that users understood the purpose of the questionnaire, and how to complete 
it.  
Due to dexterity limitations and other motor impairments that are prevalent in PD (Jankovic, 
2007), it was ensured that response buttons had a large surface area, and were well spaced 
apart (see Figure 26, D). A progress bar was also included so that users could see how many 
questions they had left to answer. In order to comply with Oxford University Innovation 
guidelines, a menu button and back button were added to each screen, meaning users could 
leave the assessment at any time.  
Due to limitations in attention that many PwP experience (Cosgrove et al., 2015) and to avoid 
user fatigue, a pause and return function was made available, whereby users would be able 
to pause their assessment and complete it at a later time (within 72 hours).  
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In order to assess the medication state users were in at the time of completion, users were 
asked to indicate the extent to which they were on/off, using a five point scale (see Figure 26, 
F).  
To capture symptom severity, a second question automatically appeared after a user 
responded ‘yes’, asking them to rate how troublesome the symptom was for them. The 
wording and scale response for this question was decided in collaboration with end users (see 
Figure 26, G). Patient representatives were asked whether they would prefer a numerical 
scale, or a visual scale, whereby symptom severity was indicated by pictures of faces 
displaying a range of emotions from happy to sad (see appendix 11 (see section 8.11)). The 
majority of patient representatives reported they preferred the numerical scale, and so this 
was incorporated as part of the app design. 
Selected responses were highlighted blue to ensure users would recognise when they had 
selected an option. 
3.3.2.5.3 Core function 3. Completing a partial NMS assessment 
The third core function of the app was completing a partial NMS assessment. The user journey 
for Core function 3 is displayed in Figure 27 below. 
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Figure 27 Screen shots of the user journey for Core function 3 (completing a partial NMS assessment) from left to right (A-D) 
It was decided that an option for an interim assessment would be made available so that users 
could assess the effectiveness of a medication or treatment for a particular NMS without 
having to do a full assessment.  Users would therefore be able to select which symptom areas 
they would like to assess from a number of options (see Figure 27, C). To avoid the page 
looking too cluttered or overwhelming, individual NMS symptoms were grouped into 
subdomains (see Figure 27, C).  
3.3.2.5.4 Core function 4. Viewing the symptom summary 
The fourth core function of the app was viewing the symptom summary. The user journey for 
Core function 4 is displayed in Figure 28 below. 
(A) (B) (C) (D) 
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Figure 28 Screen shots of the user journey for Core function 4 (viewing the symptom summary) from left to right (A-B) 
It was essential that users would be able to clearly review a summary of their symptoms, 
particularly those symptoms that were emerging or worsening since their last review. To meet 
this need, we developed a symptom summary that categorised symptoms as emerging/ 
worsening/ improving or symptoms that had been suggested by their care partner, based on 
patient and care partner app data (see Figure 28, B). An option to access self-help information 
for these symptoms was also provided on this page (see below) to help facilitate users to self-
manage symptoms.  
(A) (B) 
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3.3.2.5.5 Core function 5. Accessing self-help information  
The fifth core function of the app was accessing self-help information. The user journey for 
Core function 5 is displayed in Figure 29 below. 
 
 
 
 
 
 
 
A full methodology for the development of the self-help materials is described in Part Two 
Section B.  
Self-help information could be accessed via the self-help library. As in the partial assessment, 
to avoid the page looking too cluttered or overwhelming, the NMS symptoms were grouped 
into subdomains (see Figure 29, B).  
In order to cater for users who may have impaired hearing or other impairments that may 
affect their ability to watch the video, facility was incorporated for users to be able to adjust 
(A) (B) (C) (D) 
Figure 29 Screen shots of the user journey for Core function 5 (Accessing self-help information) from left to right (A-D) 
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the self-help videos’ volume, and a text version was also made available (see Figure 29, D). 
Users would be able to pause, stop and rewind the video as they desired. 
To ensure users would be engaged with the app, a bright and aesthetically pleasing colour 
scheme was used throughout. Images (A),(B),(C) and (D) in Figure 29 above are displayed 
using the core colours of the app that will appear in the final version. The core colours had 
not yet been applied to all screens prior to usability testing. 
Please see Part Two section B for more information on the development of the self-help 
materials. 
3.3.2.5.6 Core function 6. Requesting contact from the healthcare team  
The sixth core function of the app was requesting contact from the healthcare team. The user 
journey for Core function 6 is displayed in Figure 30 below. 
 
 
 
 
 
 
 
 
Figure 30 Screen shots of the user journey for Core function 6 (requesting contact) from left to right (A-D) 
(A) (B) (C) (D) 
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Patient safety is an absolute priority within digital solutions (Black et al., 2011). Different 
mechanisms by which patient safety could be achieved were discussed, and it was decided 
that a ‘request contact’ button (see Figure 30, A) would be most appropriate, whereby a 
patient could request contact from their healthcare team if they were to run into difficulty 
from a NMS perspective. Through discussion with EE, our PDNS representative, we developed 
a Standard Operating Procedure (SOP) for responding to a call request that would be 
achievable, acceptable for patients, and prevent duplication of current procedures. Users will 
be provided with a message to acknowledge receipt of their contact request (see Figure 30, 
C) and reminded they would be contacted within 2 working days.   
To ensure users with visual impairments would be able to access the app, font size was made 
adjustable in the ‘settings’ section of the drop down menu, which could be accessed from all 
screens (see Figure 30, D). 
An expert in PD visual perception problems (Dr. Rimona Weil, University College London) also 
reviewed the written text that appeared within the app and gave feedback in terms of 
appropriate font size, contrast and style of text that should be used.  
The drop down menu also provided users with the option to quickly access other areas of the 
app, change alerts settings, and logout. 
To ensure users would be aware of their internet connectivity status, an offline/online status 
symbol was added to the home screen.  
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3.3.2.5.7 Healthcare team portal:  
It was decided that an online portal would facilitate monitoring of patients’ NMS symptom 
burden. The Parkinson’s Nurse would be able to log in and be notified of any contact requests 
that had been made by service users so that they could respond accordingly. It was a priority 
that the portal was simple to use, as ease of use has been previously identified by clinicians 
as barriers to using apps as part of their clinical care (Jebraeily, Fazlollahi, & Rahimi, 2017). To 
meet this need, it was ensured the Parkinson’s Nurse would be able to rapidly evaluate 
patients’ NMS scores via a coloured chart that would indicate if a patient is progressively 
worsening or improving between each routine assessment (see appendix 12 (section 8.12). 
The portal also includes a log of treatment decisions that have been made for each patient, 
with the option to add new entries.  
A focus group was held in February 2019 with 3 healthcare professionals, including 2 PDNS 
and 1 clinical administrator, as well as project group members SM, IM and EE (PDNS) to 
discuss potential design changes to the portal. Formal usability testing is planned for July 
2019. 
3.4 Part Two (B): Development of the self-help materials 
3.4.1 Aims  
• To create accessible content that would support patients in self-managing their NMS. 
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3.4.2 Script development 
The content of the script for the self-help videos was based on the publication ‘A Guide to the 
Non-Motor Symptoms of Parkinson’s Disease’ (Postuma & Galatas, 2012) which maps onto 
the NMSQ (Chaudhuri et al., 2006).  CC met with RC to reword the guide for a UK audience, 
and in line with current clinical practice. Following this, PPI members of the project group 
helped to reduce the script to 45 seconds in length for each non-motor symptom, whilst 
ensuring the content remained clear and understandable by end users.  
The section of script for each NMS was consistent throughout, with subsections entitled; 
“What is it?”;“Why is it important in PD?”; “What can I do?”.  
The script for the NMS symptom orthostatic hypotension is displayed in Figure 31. For the full 
symptom script, please see appendix 13 (section 8.13).  
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Figure 31 The symptom script for the NMS orthostatic hypotension.  
3.4.3 Animation storyboard development  
The results of our patient questionnaire (see section 3.2.6.10) revealed that the majority of 
responders would prefer delivery of self-help information via a video of an expert giving 
advice. It was therefore proposed that the self-help videos should be created in a ‘talking 
heads’ format, whereby PD ‘experts’ would be filmed reading aloud the script. However, in 
order to meet MHRA requirements and maximise accessibility of the app, it was decided the 
videos should be made available in multiple languages.  
Feeling Lightheaded on Standing 
What is it? 
Feeling lightheaded on standing is due to a drop in blood pressure. Headache and shoulder or 
neck pain can also occur. If this is severe, you could black out and fall.  
Why is this important in Parkinson’s disease?  
This blood pressure drop can be due to Parkinson’s itself, and can be made worse by 
Parkinson’s medications and possibly other blood pressure tablets. 
What can I do? 
If you have this problem avoid standing up quickly; try counting to 10 before you move off. 
Increasing salt intake can help. Drink at least 2 litres of water per day and avoid caffeinated 
drinks. Full length compression stockings may be helpful. Specialist treatments are available.  
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In order to achieve this, it was decided that the educational videos would be made in an 
animation format, rather than talking heads. This change would facilitate the recording of the 
voice-over in different languages, whilst ensuring the animations would stay the same 
(regardless of language). It was decided that text would appear onscreen summarising the 
key points from each video, which could easily be replaced by text in an alternative language. 
Similarly, text that appeared as subtitles could be changed as necessary.  
I was responsible for coordinating the tendering process for the animations (see appendix 9 
(section 8.9) for creative brief). Tender submissions were judged by the project group based 
on the animation style, representability of the characters, overall feel of the animation, and 
clarity of the information being provided. 
Following review of the submissions, the tender for the animations was awarded to a local 
animation company, which was also the company that was awarded the design tender (Made 
with Maturity (MwM)). The script was received by the company, and storyboards were 
drafted for each of the non-motor symptoms. Figure 32 and Figure 33 display an example of 
one of the 29 storyboards that were reviewed during the animation development process. 
The draft storyboards were regularly reviewed by the project group in terms of accessibility 
for PD patients, representativeness, and style; comments were fed back to MwM for further 
iterations to be made (see feedback forms appendix 14 (section 8.14)). In total, there were 7 
cycles of review, feedback and iteration to the storyboard design over a period of 4 months 
(from November 2018 to February 2019). Once the project group were satisfied with the 
storyboard designs, they were signed off by CC for development. 
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3.4.4 Voiceover selection process 
The voiceover to read aloud the script was selected by group consensus following review of a 
number of audio samples available (https://www.voiceboxagency.co.uk). It was a priority that 
the voiceover was easy to understand, friendly and relatable.   
Once the voiceover had been selected by the project group, end users (n=12) were shown a 
mock-up of the animation for the NMS constipation (see Figure 32 and Figure 33 for the 
constipation animation storyboard) with the accompanying voiceover recording.  
Users were asked for their views on various aspects of the animation including the style of 
the voiceover, the clarity, and the voiceover speed. Two users reported they felt the speed of 
the voiceover was too quick, however the remaining users (n=10) felt the speed and tone of 
the voiceover were appropriate and easy to understand. User responses were sent as 
feedback to the voiceover artist. 
Once the feedback had been received, the voiceovers were recorded by the selected 
voiceover artist using the finalised version of the script (see appendix 13 (section 8.13)). 
Members of the project group including PPI members and the PDNS listened to a selection of 
the voiceover recordings live, and gave real time feedback to the artist, who then 
incorporated the feedback into the subsequent recordings. 
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Figure 32 Storyboard for the constipation animation (part 1 of 2) 
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Figure 33 Storyboard for the constipation animation (part 2 of 2)  
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3.4.5 Discussion: Part Two 
The results of Part Two led to the creation of the prototype wireframe for NMS Assist, and 
the self-help materials, with input from end users, and informed by issues identified 
throughout the development process.  
A formative evaluation of the prototype wireframe was the essential next step to highlight 
key issues with the existing design and comply with MHRA guidance (Mhra, 2017).  
3.5 Part Three: Formative Evaluation 
3.5.1 Part Three Aims 
• To ensure that the device was usable by the intended user, quantified by effectiveness 
(error free completion rate) and satisfaction measures (including the Single Ease 
Question (SEQ) (Sauro, 2016) and the System Usability Scale (SUS) (Brooke, 2013). 
• To identify key areas of amendment for future design.  
3.5.2 Part Three Hypotheses 
I hypothesised: 
1. There would be no statistically significant difference in measures of effectiveness or 
satisfaction between experienced and non-experienced smartphone users (due to 
the iterative, user centred design process applied in Part Two). 
2. The think aloud method would reveal key areas of amendment for future design. 
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3.5.3 Methods 
This study received approval from the Faculty Research Ethics Committee at the University of 
Plymouth (ethical approval granted (07/2018, see appendix 15 (section 8.15)).  
3.5.3.1 Recruitment 
Two user groups were recruited to the study; a group consisting of PwP (PD group, n=10) and 
a group consisting of people who cared for a person with PD, referred to as Care Partners (CP 
group, n=5). Usability testing guidelines for sample size were followed that recommend the 
use of 5-15 test participants for an iterative usability testing process (Nielsen & Landauer, 
1993).   
In order to ensure the final app would be usable by a broad range of users, it was important 
to recruit a sample that were representative of the demographic of the intended users. I 
therefore aimed to recruit participants with a range of ages, disease duration, cognitive 
ability, and varying experience with smartphones and smartphone-based apps. 
Potential participants were identified via the local PUK Support Group Networks in Cornwall, 
Tavistock and Plymouth. A patient information sheet was provided to those who expressed 
an interest in taking part, which provided information on the study (see appendix 16 (section 
8.16). All individuals were given at least 72 hours to consider the study information, prior to 
being contacted by telephone, when they had the opportunity to ask any outstanding 
questions. During this phone call, participants were screened for inclusion and exclusion 
criteria, and demographic information (including self-described experience with smartphone 
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apps) was collected. Attendance to the usability study was arranged. Participants were 
reimbursed for any travel costs. 
3.5.3.2 Inclusion Criteria 
• Aged ≥40 (to recruit a sample with a wide age range) 
• Diagnosis of PD (PD group only) or Care Partner for a PwP (CP group only) 
• Willing and able to give informed consent for participation in the study 
• Willing and able to comply with study requirements 
3.5.3.3 Exclusion Criteria  
• Inability to comply with study protocol 
• Any other significant disease or disorder that is known to affect motor function or 
cognition  
• Use of alcohol, benzodiazepines, or other sedating drugs in the 12 hours prior to 
study visit  
• Non-fluent English speaker 
3.5.3.4 Usability testing environment:  
Usability testing was performed at Plymouth Science Park (PSP), in a large meeting room. 
Figure 34 illustrates the experimental set-up for usability testing. Participants accessed the 
app using an iPhone 6s (IOS operating system) which was placed flat on the table. Usability 
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testing was carried out on a wireframe prototype of NMS Assist. Video recordings of 
participants’ interactions with the app and audio recordings of participants’ comments were 
recorded using Mr Tappy Software (www.mrtappy.com). The researcher was seated a 
reasonable distance away from the participant, and live video footage was displayed in real 
time on the researcher’s laptop via ManyCam screen recording software 
(https://manycam.com/), allowing the researcher to record observations about the 
participant’s interaction with the app in real time.  
 
Figure 34 An example of the experimental set up for the usability testing procedure 
Mr Tappy camera 
recording interaction 
with screen 
NMS Assist 
displayed on 
iPhone 6s Participant interacts 
with device, placed 
flat on table 
Metal arm holding Mr 
Tappy camera in place 
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3.5.3.5 Usability test procedure  
On arrival to PSP, participants were given a copy of the information sheet and there was an 
opportunity for participants to ask any outstanding questions. Informed consent was then 
obtained via signing of the consent form (see appendix 17 (section 8.17)). After written 
consent had been obtained, participants were asked to complete the following assessments:  
3.5.3.6 Cognitive ability 
• Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005)  
The MoCA is a brief screening tool that takes 10 minutes to administer. The MoCA is 
scored out of 30, with a cut off of <26 indicating mild cognitive impairment. The MoCA is 
made up of questions from different themes including; visuospatial/executive function, 
naming, memory, attention, language, abstraction, delayed recall and orientation.   
3.5.3.7 Non-motor symptom burden (PD group only) 
• Non Motor Symptoms Questionnaire (NMS Quest) (Chaudhuri et al., 2006) (see 
section 1.2.21.2.7 for description). 
3.5.3.8 Disease Severity (PD group only) 
• Hoehn & Yahr Scale (Hoehn & Yahr, 1967). The Hoehn and Yahr Scale describes five 
stages of PD progression, and is completed by an experienced rater.   
Completion of the above assessments took around 30 minutes. Following this, each 
participant was provided with a scripted verbal introduction to the usability study by the 
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researcher. Participants were reminded several times that there were no right or wrong 
answers. Participants were given the opportunity to ask any questions. There were no 
scheduled breaks, however participants were reminded they were able to request a break at 
any time. Medication state (ON/OFF) for PwP was not recorded. 
3.5.3.9 User Tasks 
Prior to usability testing, a discussion guide was created (see appendix 18 (section 8.18)) with 
input from RD, an experienced usability testing researcher. The guide included verbal 
instructions for each of the usability testing tasks to be read aloud by the researcher, as well 
as space for the researcher to make notes in real time while the participant completed the 
relevant tasks.  
Following a short warm up (see think aloud method below) participants were given verbal 
instructions for 1 of 6 tasks to carry out (see Table 20 below). A paper version of the task 
instructions was placed in front of the participant as a reminder throughout the task. The 
selected tasks were developed with input from the NMS App project group and were 
representative of the core functions of the app (as described in Part Two, see section 3.3.2.3), 
thus providing good coverage of real-world use. Tasks are described in Table 20 below. 
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Table 20 Task descriptions and verbal instructions given to participants 
 
3.5.3.10 Task Order 
All participants completed Task One (requesting contact from nurse) first, so that they had an 
opportunity to read the app instructions and enter their login token. To control for order 
effects, the order of the remaining 5 tasks was randomised using a random sequence 
Task 
Number 
Task Description Verbal instruction  
Task One Requesting contact from the 
nurse  
“Please show me how you would request 
contact from the nurse” 
Task Two Carrying out a full NMS 
assessment 
“Please show me how you would carry out a full 
symptoms assessment” 
Task Three Carrying out a partial NMS 
assessment 
“Please show me how you would carry out a 
partial symptoms assessment for the symptoms 
thinking and memory and constipation” 
Task Four Viewing the symptom summary 
and accessing self-help 
information for “improving 
symptoms” 
“Please show me how you would access a 
summary of your symptoms”  
“Please show me how you would access self-
help info for your improving symptoms” 
Task Five  Accessing self-help information 
for “pain” and “hallucinations” 
“Please show me how you would access self-
help for the symptoms “pain” and 
“hallucinations” 
Task Six Turning off the notifications “Please show me how you would turn off the 
alerts function” 
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generator (“random.org”, 2019). This also ensured a range of tasks were completed across 
participants. The time it took to complete each task was not predefined and was expected to 
vary in length across participants. Participants were asked to complete as many of the six 
tasks as possible within the session time (75 minutes, in addition to the first 30 minutes of 
clinical assessment).   
After the participant completed a task, they were asked some questions about their 
experience (see data collection below).  
The participant was then given instructions for the next task. A debrief was performed at the 
end of the study session (see appendix 19 (section 8.19)) and participants were thanked for 
their time. 
3.5.3.11 Data collection and analysis  
3.5.3.11.1 Qualitative and observational data 
Qualitative and observational data were collected via the ‘think aloud method’ (Jaspers, 
Steen, Van Den Bos, & Geenen, 2004), whereby participants were asked to verbalise their 
thoughts during interaction with the app, and think aloud whilst completing all tasks. A short 
warm up was carried out to help participants get used to this methodology (see appendix 18 
(section 8.18)). During the think aloud procedure, the researcher played a neutral role. When 
asked for help by participants, the researcher firstly asked participants to continue as if the 
researcher was not present, and if asked for help a second time, the researcher would prompt 
participants to consider alternative options to complete the task. When necessary, the 
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researcher would ask a participant to elaborate on a comment. If the participant failed to 
‘think aloud’, the researcher would prompt the participant by asking “What do you think of 
this page?” or “What are you thinking here?”.  
The researcher took observation notes throughout, and when an error or issue occurred, the 
location (screen) and the task the user was engaging with at the time was logged by the 
researcher. 
Following usability testing, the video recordings were watched by the researcher to detect 
any further issues that may have been missed at the time of testing, and to cross check the 
observation notes. Emerging categories of usability issues were identified, and logged in a 
database (see Table 25) including when the issue occurred, and a brief description.  
It was necessary to prioritise usability issues in terms of their risk to patient safety.  The 
method for prioritisation of issues was similar to those used previously (Sauro, 2016). In order 
to do this, a severity of harm rating was assigned to each usability issue, which was influenced 
by the following factors: 
1. Task Criticality: Rated in terms of impact on patient safety if the task was not 
accomplished (rated 1 (low) to 5 (high)). 
2. Frequency: The frequency that the issue occurred. Issue frequency was calculated by 
dividing the number of occurrences by the total number of participants that 
completed the task. This was calculated across all participants, in addition to PwP and 
carers separately. 
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3. Impact: Rated in terms of impact on the user trying to accomplish the task. Impact was 
rated using the following scale:  
1= Suggestion: the issue is a suggestion from the participant 
2= Minor: the issue has a minor effect on task performance 
3= Major: the issue causes frustration and/or delay 
4 = Blocker: the issue prevents the user from accomplishing the task  
Once all of the issues had been assigned ratings for criticality, frequency and impact, these 
ratings were multiplied to create a severity of harm score for each issue (severity of harm = 
task criticality x impact x frequency). 
This process for harm rating was repeated independently by a second researcher (CC), and 
any discrepancies in ratings were addressed, and resolved via discussion with the NMS App 
project group. If there was variation in whether group members thought the issue had a minor 
or major impact on performance across participants (score of 2 or 3), the issue was rated as 
having a major impact (score of 3), to ensure ratings reflected the worst case scenario 
experienced.  
Usability issues were then ranked in order of highest to lowest severity of harm for 
participants overall, as well as for PwP and Carers separately. A low (≤2), medium (>2 ≤4) and 
high (>4) severity of harm rating was assigned to each issue.  
Once severity of harm ratings had been assigned to each of the usability issues, they were 
prioritised for amendment accordingly. This was achieved by a colour coded system whereby 
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red indicated high severity issues, orange indicated medium severity issues, and yellow 
indicated low severity issues. In addition, elements of the app design that worked well were 
rated green. Ratings with high severity of harm ratings were prioritised for amendment over 
issues with less high ratings. 
The researcher suggested potential solutions for each of the issues that were identified, and 
these were commented on by the project group before being incorporated as part of a 
usability testing report (see appendix 20 (section 8.20). Once finalised, the usability testing 
report was sent to the app developer for review and incorporation into the app design. 
3.5.3.11.2 Quantitative measures  
In line with the ISO/IEC 9126-4 standard (ISO, 2016), usability metrics for effectiveness and 
satisfaction were included as part of the study protocol, as described below. Unfortunately, 
it was not possible to include metrics for efficiency in this round of usability testing (as 
explained below, section 3.4.2.10.4).  
3.5.3.11.3 Metrics for effectiveness  
Error free completion rate  
A task was considered successfully completed if the user carried out the required task without 
making a critical error (an error that results in the participant not being able to successfully 
complete the task or results in incorrect information). Effectiveness (error free completion 
rate) was measured by the following equation:  
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Error free completion rate = (
number of tasks completed without critical error
total number of tasks undertaken
)
∗ 100
 
 
The results of this equation provided an error free completion rate (%) for each task and for 
task completion overall (median, min-max range).  
3.5.3.11.4 Metrics for Efficiency  
Metrics for efficiency include measures such as the number of clicks made by the participant 
to successfully complete as task, or the time taken to complete a task. It was not possible to 
use number of clicks as a metric for efficiency in this round of testing due to participants 
carrying out exploratory clicks whilst ‘thinking aloud’, which affected the number of clicks 
made during each task. Additionally, we chose not to use time taken to complete a task as a 
metric of efficiency due to confounding symptoms of PD such as slowness of movement and 
problems with attention, and again due to implementation of the think-aloud methodology, 
which affected the time taken to complete tasks.  
3.5.3.11.5 Metrics for Satisfaction  
Task-level satisfaction 
User satisfaction was measured following completion of each task (irrespective of whether 
the participant successfully completed the task or not) via ‘The Single Ease Question’ (SEQ) 
(Sauro, 2016). Participants were asked: “Overall, how difficult or easy was the task 
complete?” Responses were given on a 7 point scale (1= very difficult and 7= very easy). 
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Test-level satisfaction  
User satisfaction at test level was measured at the end of the testing session to measure 
users’ impression of overall ease of use. For this purpose, the 10 item System Usability Scale 
was used (Brooke, 2013). The SUS is a validated usability tool that uses a 5-point Likert scale 
to provide a quantitative measure of the usability of a system. An overall value was calculated 
from the raw score to provide a score between 0 and 100.  
3.5.3.11.6 Statistical Analysis 
I planned to evaluate differences between experienced (frequent smartphone users) and 
inexperienced (never users) groups. 
Due to unequal group size, differences between user groups (Experienced vs Inexperienced 
Users) were investigated using non-parametric measures (Mann-Whiney U). Bivariate 
Pearsons correlations were used to investigate relationships between continuous variables. 
A p value of <.05 was used throughout. A Bonferroni correction was applied for multiple 
comparisons. 
3.5.4 Results 
Two participants (1 PD and 1 CP) were unable to attend the study visit due to illness, therefore 
a total of 13 participants took part in usability testing (9 PD and 4 CP). None of the 13 
participants had used NMS Assist before. Of the total sample, 7 (54%) were frequent 
smartphone users (everyday use), 2 (15%) were occasional users (> once a month use). Due 
to a small number of occasional users (n=2), frequent users (n=7) and occasional users (n=2) 
223 
 
 
were combined to form the ‘experienced users’ group (n=9) for the purposes of the analysis. 
Four participants (31%) were inexperienced users (never used a smartphone before), forming 
the inexperienced group (n=4). Demographic data for participants is displayed in Table 21. 
Almost all participants scored above the MoCA cut-off for cognitive impairment (>26), 
however one participant in the CP group scored 21, which is in the range of mild cognitive 
impairment (MCI) (Nasreddine et al., 2005). 
Table 21 Demographic data (median, min-max range) 
 
PwP (n=9) Care Partners (n=4) All participants (n=13) 
Age 68 (44-82) 75 (69-80) 69 (44-82) 
% Male 89 50 77 
MoCA 28 (26-30) 28 (21-30) 28 (21-30) 
Disease duration (yrs) 10 (1-17) NA NA 
H &Y 2 (1-3) NA NA 
NMSQ 17 (3-22) NA NA 
Smartphone Experience     
Frequent 4 3 7 
Occasional 1 1 2 
Never 3 1 4 
 
3.5.4.1 Effectiveness 
Effectiveness of the app was measured using participants’ error free completion rate (see 
methods, section 3.5.3.11.3). 
224 
 
 
Error free completion rate 
The proportions of users participating in, and successfully completing each task (without 
critical error) are displayed in Table 22.  
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Table 22 The proportions of users participating in, and successfully completing each task without critical error (error free 
completion rate) for all participants, as well as by experience (experienced vs inexperienced users). 
 
 
 
Request 
contact 
Full NMSQ 
Partial 
NMSQ 
View 
Symptom 
Summary 
View self-
help info 
Turn off 
notifications 
All participants       
Number of 
participants 
13 12 8 9 10 10 
Number  
completed 
(error free 
completion 
rate %) 
7/13 (54%) 4/12 (33%) 5/8 (63%) 8/9 (89%) 9/10 (90%) 6/10 (60%) 
Experienced 
Users 
      
Number of 
participants  
9 9 6 6 7 7 
Number 
completed 
(error free 
completion 
rate %) 
6/9 (67%) 5/9 (56%) 5/6 (83%) 6/6 (100%) 7/7 (100%) 6/7 (86%) 
Inexperienced 
Users 
      
Number of 
participants 
4 3 2 3 3 3 
Number 
completed 
(error free 
completion 
rate %) 
1/4 (25%) 0/3 (0%) 0/2 (0%) 2/3 (66%) 2/3 (66%) 0/3 (0%) 
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Across all tasks, the overall median error free completion rate was 67% (0-100) (% of tasks 
successfully completed without critical error). It is important to note that one participant in 
the inexperienced users group (CP03) was the only participant to not successfully complete 
any of the six tasks without critical error (0% error free completion rate). This participant had 
a MoCA score of 21, in the range of MCI. 
As outlined in Table 22, the tasks associated with the biggest discrepancy in error free 
completion rate between the inexperienced users and the experienced users were 
completing a partial NMSQ assessment and turning off notifications, with 83% and 86% 
respectively of experienced users completing these tasks without critical error, in comparison 
to the inexperienced users, whereby none of the participants were able to complete these 
tasks without critical error.  
Potential relationships between overall error free completion rate, age and cognition (MoCA) 
were investigated using Pearson correlations (Table 23). For PwP, it was also of interest to see 
whether disease related variables such as disease duration and NMS burden (NMSQ score) 
had an impact on error free completion rate.  
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Table 23  Pearson correlations between age, cognition, disease duration and NMS burden with error free completion rate 
 (r) p value 
Age* completion rate -.5 .09 
MoCA * completion rate .47 .10 
Disease duration * 
completion rate 
-.33 .38 
NMSQ * completion rate -.43 -.24 
 
As summarised in Table 23 above, none of these relationships were found to be significant 
and were not followed up with further analysis.    
Relationships between error free completion rate and smartphone experience were 
investigated using non-parametric t-tests. There was a significant difference in overall error 
free completion rate between experienced and inexperienced users, with experienced users 
achieving a significantly higher error free completion rate than inexperienced users U= 2, p= 
.01. A post-hoc analysis of power was carried out on this t-test to see if our study was 
adequately powered. The test revealed our power was 0.98 (98%), which was above the level 
of 0.8 (80%), often considered adequate (Cohen, 1992). 
Median error free completion rate between these two groups is displayed in Figure 35. 
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Figure 35 The boxplot shows the lower quartile (Q1), the median, and the upper quartile (Q3) of error free completion rate 
(%) in the experienced (n=9) and inexperienced (n=4) user groups.  
 
3.5.4.2 Satisfaction 
SEQ Scores  
A breakdown of SEQ scores across tasks by smartphone experience is presented in Figure 36 
(whereby 1= very difficult, 7= very easy).   
On average, completing the partial NMS was rated as the most difficult task to complete. 
Inexperienced users generally rated all tasks harder or the same as experienced users to 
complete (with the exception of viewing the symptom summary, which was rated easier to 
complete by inexperienced users than experienced users).  
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Figure 36 Mean SEQ scores across all participants and by smartphone experience. Error bars represent standard error (SE). 
 
Non parametric t-tests were carried out to investigate if any of the differences in SEQ scores 
between experienced and never users were significant. None of the differences between user 
groups were significant however. Results are summarised in Table 24.  
Table 24 Differences in SEQ ratings between experienced and inexperienced user groups. 
Task U p 
Request contact 5.5 .06 
Full NMSQ 7.5 .28 
Partial NMSQ .5 .07 
View symptom summary 10 >.99 
View self-help info 10 >.99 
Turn off notifications 5.5 .26 
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SUS Scores  
The SUS measure was carried out following  completion of all tasks to provide a measure of 
overall satisfaction with the app. Based on previous research comparing SUS scores across 
500 studies (Sauro, 2016), an SUS score above 68 points (50th percentile) is considered to be 
an ‘above average’ score. The median SUS score of our participants overall was 80 out of 100 
points (44-95), meaning our results were well above the average SUS score found in previous 
studies, (Sauro, 2016). Experienced users had higher SUS scores than inexperienced users, 
although this difference was not significant (U= 13, p= .50) (Figure 37).  
 
Figure 37 The boxplot shows the lower quartile (Q1), the median, and the upper quartile (Q3) of SUS scores in the 
experienced (n=9) and inexperienced (n=4) user groups.  
Relationship between Satisfaction and Effectiveness  
Satisfaction ratings (SUS score) were correlated with effectiveness (error free completion 
Experienced users Inexperienced users 
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rate) to investigate a relationship between these variables. No significant relationship 
between satisfaction and effectiveness was found however (r=.20, p=.51). 
3.5.4.3 Usability Issues  
Forty-six usability issues were identified via the think aloud method, captured by observation 
notes and video/audio recordings. Thirty-nine of these issues were task specific, and 7 were 
general, pertaining to all screens.  
A severity of harm rating was assigned for each of the usability issues using the methodology 
described previously (see methods, section 3.5.3.11.1). Table 25 outlines the usability task 
and task criticality rating, the description of the issue that occurred during usability testing, 
the impact score, the frequency with which the issue occurred, and the resultant severity of 
harm score and the severity of harm rating. Severity of harm ratings were calculated for the 
PwP and care partner groups separately as well as overall.  
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Table 25 A description the usability issues experienced and associated severity of harm ratings (severity of harm = task criticality x impact x frequency). 
 ID Task 
Criticality 
(1-5) 
Location Description of issue 
Impact 
(1-4) 
Frequency 
Overall  
Severity 
Overall 
Severity 
Rating 
Task one 
1 
Requesting contact 
from healthcare team 
5 Home Screen At first, user could not find the 'request contact' button 3 0.23 3.46 M 
2 5 
Request 
Contact 
Expected it to initiate an immediate phone call because of 
telephone icon 
2 0.08 0.77 L 
3 5 
Contact 
Request 
received 
Confusion surrounding meaning of contact request received. 
Expected to give details of problem (verbal/written) 
2 0.15 1.54 L 
4 5 
Request 
Contact 
Confusion over the word 'still' troublesome 2 0.08 0.77 L 
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5 
Pressing 'next' on the 
instruction page 
5 
Instruction 
Page 
User did not know how to scroll down (required to access 'next') 4 0.15 3.08 M 
6 Entering token 5 Token Page User entered token incorrectly 4 0.46 9.23 H 
7 Allowing notifications 5 
Notification 
pop up 
Confusion as to what was meant by notifications 4 0.23 4.62 H 
8 
Reading instructions 
5 
Instruction 
Page 
Thought there was too much text to read through 2 0.23 2.31 M 
9 5 
Instruction 
Page 
Thought the instructions did not make sense from a carer's 
perspective 
2 0.08 0.77 L 
10 5 
Instruction 
Page 
Users attempted to click on image, expecting it to take them 
somewhere else 
2 0.23 2.31 M 
234 
 
 
Task Two 
11 
Completing PDQ8 
5 
PDQ8 
questions 
After pressing next, user did not notice that the question page had 
changed 
4 0.42 8.33 H 
12 5 
PDQ8 
questions 
Had not noticed progress bar 1 0.50 2.50 M 
13 5 
PDQ8 
questions 
Confusion whether answering from own perspective or PwP 
perspective 
4 0.33 6.67 H 
14 
Reading the PDQ8 intro 
page 
5 
PDQ8 intro 
page 
User skipped past this page without reading it. 2 0.08 0.83 L 
15 
Reading the NMSQ intro 
page 
5 
NMSQ intro 
page 
User skipped past this page without reading it. 2 0.08 0.83 L 
16 5 
NMSQ intro 
page 
Wanted acknowledgement the PDQ8 had finished and were 
moving onto something new. 
2 0.50 5.00 H 
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17 
Completing 'how 
troublesome' scale in 
NMSQ 
5 
NMSQ 
Questions 
Misinterpreting scale (eg. interpreted as how much saliva) 2 0.33 3.33 M 
18 5 
NMSQ 
Questions 
Did not notice scale 4 0.08 1.67 L 
19 
Completing NMSQ 
5 
NMSQ 
questions 
Misunderstanding as to what non-motor symptoms were. 4 0.25 5.00 H 
20 5 
NMSQ 
Questions 
Daunted by 31 questions 3 0.25 3.75 M 
21 
Completing fluctuations 
question 
5 NMSQ page Confusion regarding the fluctuations question 2 0.17 1.67 L 
22 
Completing ON/OFF 
scale 
5 NMSQ page Thought would make more sense OFF = 0 and ON = 5 1 0.25 1.25 L 
23 5 NMSQ page Misinterpretation of ON/OFF scale 2 0.33 3.33 M 
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Task Three 
24 
Selecting symptoms for 
partial assessment 
4 
Partial 
assessment 
Users did not realise they could select more than one option 3 0.63 7.50 H 
25 4 
Partial 
assessment 
Users were unsure which symptoms were under which domain 3 0.75 9.00 H 
26 
Starting the partial 
assessment 
4 
Partial 
assessment 
Expected assessment to start automatically once had selected 
symptom. 
2 0.25 2.00 L 
27 
Selecting symptoms for 
partial assessment 
4 
Partial 
assessment 
Users did not like the term psychosis 1 0.13 0.50 L 
28 
Carrying out a partial 
assessment 
4 
Partial 
assessment 
Could  not find the Partial assessment button on home screen 4 0.13 2.00 L 
29 4 
Partial 
assessment 
Confusion on meaning/purpose of partial assessment 2 0.63 5.00 H 
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Task Four A 
30 
Accessing symptom 
summary 
3 
Symptom 
summary 
Took two attempts to find the symptom summary 2 0.11 0.67 L 
31 
Viewing symptom 
summary 
3 
Symptom 
summary 
Did not meet expectations 1 0.22 0.67 L 
Task Four B 32 
Viewing improving 
symptoms 
5 
Symptom 
summary 
Difficulty finding improving symptoms (scrolling) 2 0.22 2.22 M 
Task Five 
33 
Selecting symptoms for 
self-help info 
5 
Self-help 
library 
Users expected to be able to select more than one option at a 
time 
2 0.20 2.00 L 
34 5 
Self-help 
library 
User unsure of correct domain to select 3 0.60 9.00 H 
35 
Reading the text version 
of self-help info 
5 
Self-help 
library 
User attempted to swipe across/tap dots for next page (due to 
dots) 
2 0.40 4.00 M 
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Task Six 
36 Turning off alerts 2 Burger Menu Could not find the alerts button within the menu 3 0.30 1.80 L 
37 Accessing burger menu 2 Burger Menu Could not find the burger menu 3 0.60 3.60 M 
38 
Turning off alerts 
2 Alerts page Should change to 'notifications off' when pressed 1 0.10 0.20 L 
39 2 Alerts page Needs to be consistency between word alert/notification 1 0.10 0.20 L 
General 
comments 
40 
Reading text 
5 General Found white text on light blue background hard to read 3 0.08 1.15 L 
41 5 General Found white text on dark background cumbersome 2 0.15 1.54 L 
42 5 General Text could be bigger 2 0.38 3.85 M 
43 Manipulation of buttons 5 General Difficulty selecting buttons 3 0.23 3.46 M 
44 Wording 3 General Does not like term 'disease' 1 0.15 0.46 L 
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45 
Recognising home 
screen 
3 General Home page not recognisable as home page 2 0.15 0.92 L 
46 Going back home 3 
NMSQ 
Questions 
Attempted to press 'NMS Assist' button to go home 2 0.23 1.38 L 
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A report outlining the usability issues prioritised by their associated severity of harm rating 
was sent to Made with Maturity to inform future amendments (see appendix 20 (section 
8.20)). 
Table 26 details the rating system that was used throughout the report to indicate 
high/medium/low severity of harm ratings for each of the issues described. 
Table 26 Severity of harm ratings for the identified usability issues 
Severity of harm rating Descriptive Rating Colour Rating 
>4 High Severity 
 
<2 ≤4  Med Severity 
 
≤2 Low severity 
 
N/A Positive comment 
 
 
Figure 38 displays an extract from the report. Each page of the report includes a screenshot 
of the screen where issues occurred, details of the issues as well as any positive comments 
made by participants. Severity of harm ratings for the group overall, and for the PwP and Care 
Partner group are presented for each of the usability issues, as well as potential solutions 
suggested by the group. Please see appendix 20 (section 8.20) for the report in full.  
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Figure 38 An extract from the report sent to Made with Maturity following usability testing, outlining usability issues, their associated severity of harm rating, and suggested 
solutions made by the project group. 
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Overall, eleven high severity issues were found, from which 3 central themes were identified: 
Navigation, content and accessibility. Table 27 displays the high severity usability issues with 
representative participant quotes, and suggested solutions by the project group following 
discussion. 
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Table 27 Description of high severity usability issues with representative quotes from participants and suggested changes. 
Central Theme Issue description and representative quotes Suggested Change 
Navigation Users were unable to access all of the instructions, as they did not know how to 
scroll down the page.   
“Either I’m doing it wrong or it doesn’t work…there’s an arrow at the top of the 
page (back arrow)...I could try this button (home button)...I think there’s more 
information [on this page] but I’m not sure how to get to it.” 
Provide a training video that explains basic 
functions of app and how to use it. Also, provide a 
floating down arrow in the centre bottom of the 
screen to indicate to users there is more 
information available.  
 
Navigation Users pressed next and did not notice that the question had changed.  
“I didn’t notice it [the page] change...I thought oh I haven’t pressed the button or it 
had died on me or something.” 
Make transition between questions more 
noticeable. 
Navigation Users struggled to find the ‘burger’ menu. 
“I would look in the actual app itself…what about the middle one [home screen] 
would that do it? I don’t know.” 
The location and purpose of this menu would be 
explained as part of the training video. 
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Central Theme Issue description and representative quotes Suggested Change 
Navigation Users wanted acknowledgement that they had finished the PDQ8. 
“I kind of want something else to tell me I’m in a different place.”  
Add another screen following completion of the 
PDQ8 that thanked participants and indicated they 
were to move on the full symptoms assessment 
(NMSQ). 
Navigation Users did not realise they could select more than one symptom to assess. 
“I would push the symptom I wanted and then press start assessment.” 
Add the sentence: “You can select more than one 
symptom to assess” to the text. 
Navigation Users entered their token incorrectly. 
“I’ve pressed an ‘F’ instead of ‘P’.” 
Do not let user progress unless enter valid token. 
Make all tokens lower or upper case to avoid case 
sensitive errors. Consider increasing keyboard 
size. 
Content Users expressed confusion at what was meant by ‘allow notifications’. 
“How do I know that’s not a scam or something that’s coming in…somehow there 
needs to be some reassurance to the person using it...there should be some sort of 
security”.  
Clarify what notifications and alerts are, the 
difference between them, and give 1 or 2 
examples for what they will receive them for. 
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Central Theme Issue description and representative quotes Suggested Change 
Content Care partners expressed confusion about whose perspective they were answering 
the questions from (theirs or the person they care for). 
“Some of these questions do need to have the precursor ‘for the person you’re 
caring for’”.  
A sentence will be included as part of the 
instructions that explicitly asks them to provide 
their opinion of the symptoms shown by the 
person they care for. 
Content Users expressed confusion surrounding the ON/OFF scale. 
“I’ve never understood the ON/OFF...I know it’s a phrase that’s used worldwide in 
Parkinson’s, but I’ve never really understood it…maybe it’s because I’ve never 
experienced ‘off’.” 
 
Provide a glossary of PD related terms, or change 
the wording of the scale to PD medications 
working well’ and ‘PD medications not working’. 
 
Content Users expressed confusion surrounding which symptoms would come under which 
domain.“…[Gastrointestinal tract] that’s what I’d guess for constipation, I would 
click on that hoping it would give me a clue…it would give me an explanation of 
what Gastrointestinal tract means.” 
Provide an information button on each domain 
that shows which symptoms come under each 
domain. 
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Central Theme Issue description and representative quotes Suggested Change 
Accessibility Users commented on the font size being too small.  
“Text is a bit small is all I’d say.” 
Include demonstration of how to enlarge text size 
as part of training video. 
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3.5.5 Discussion: Part Three 
The purpose of this formative study was to evaluate the usability of a wireframe prototype of 
NMS Assist, a smartphone app for the remote monitoring and self-management of PD NMS.  
My hypotheses for the study were as follows:  
1. There would be no statistically significant difference in measures of effectiveness or 
satisfaction between experienced and non-experienced smartphone users. 
2. The think aloud method would reveal key areas of amendment for future design. 
In line with my first hypothesis, there were no significant differences in usability (SUS) scores 
between experienced and inexperienced users (p=.5), meaning that perceived usability of the 
app was not dependent on prior smartphone experience. This is a particularly important 
finding in relation to our intended user group, who are expected to have varying degrees of 
digital literacy (Lorenz & Oppermann, 2008). The overall SUS scores were above average 
(80/100 points) and demonstrates that overall, all participants (PwP and CP) found the app 
highly usable.  
The lowest scoring participant (SUS score of 44 points) was an inexperienced user in the CP 
group, and was the only participant that did not complete any of the tasks attempted without 
critical error. Of interest, this participant had a MoCA score in the Mild Cognitive Impairment 
(MCI) range (Hoops et al., 2009). This finding suggests that the app may not be perceived to 
be usable by users with MCI who have little experience with smartphones, and these users 
may be less able to successfully complete tasks than users with normal cognitive function.  
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MCI has been previously recognised as a barrier to older adults using technology to manage 
long term conditions (Archer, Keshavjee, Demers, & Lee, 2014). As levels of cognitive 
impairment are high in older adults (Roberts et al., 2012), and even greater in a PD population 
(Aarsland et al., 2009), it would be necessary to include mitigations as part of the app design 
to help compensate for cognitive impairment. Previous suggestions to enable people with 
cognitive decline to use mHealth technologies include: making the content less 
comprehensive, minimising demands on memory, and providing tools that can aid the user, 
such as search tools (Czaja et al., 2012). As outlined in the recommendations made previously 
(see results Table 27), in the next iteration of the app we hope to include several tools that 
may aid users with low levels of cognition, including a training video, a glossary of technical 
terminology, and information buttons to explain different symptom domains. 
In future testing, it would be essential to include a greater number of participants with MCI, 
with varying levels of app experience (including experienced and inexperienced users), to 
investigate whether the mitigations put in place enable users with cognitive impairment to 
successfully use the app. If unsuccessful, this may mean normal cognitive functioning is a 
requirement to using NMS Assist, and potential users (both PwP and CP) would need to be 
screened for cognitive impairment prior to use.  
Despite no difference in users’ ratings of usability (SUS scores), the experienced group were 
found to have a significantly higher error free completion rate than inexperienced users 
(p=.01). This highlights the SUS only measures perceived usability and does not reflect actual 
effectiveness (Brooke, 2013). This was further demonstrated by the non-significant 
relationship between SUS scores (user satisfaction) with error free completion rate 
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(effectiveness) (p=.51). Previous studies have similarly suggested that effectiveness and 
satisfaction do not appear to be related, and should instead be considered as independent 
aspects of usability (Frekjmr, 2000). 
The poorer performance by the inexperienced user group is an important finding because, as 
mentioned previously, our intended users will likely have varying degrees of digital literacy 
(Lorenz & Oppermann, 2008). This finding also does not support my first hypothesis, and 
demonstrates usability of the app is somewhat dependent on prior smartphone experience. 
It is essential that the design is further amended to fully compensate for users with little prior 
experience with apps. Matthew-Maich and Colleagues (2016) carried out a review of mHealth 
technologies, and made a number of recommendations for developers to support older adults 
using mHealth technologies, including minimising the number of navigation screens and 
minimising complexity (Matthew-Maich et al., 2016). The recommendations made previously 
for the high severity issues (see results, Table 27) aim to assist users with lower levels of digital 
literacy, for example, the inclusion of a training video on how to use the app, and clear 
definitions of technical vocabulary such as ‘notifications’. These recommendations will 
therefore be incorporated as part of future design iterations of the app to ensure the app is 
usable by older adults with a wide range of digital literacy.  
Furthermore, experienced users rated all tasks as easier to complete than the inexperienced 
user group (with the exception of ‘viewing the symptom summary’ which inexperienced users 
found easier to complete). Although these differences in SEQ ratings were not significant 
between groups (thereby providing support for my first hypothesis), they indicate prior 
experience with a smartphone increases perceived ease of use. Ease of use has been 
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identified as a critical factor in determining future adoption of an mHealth solution (Matthew-
Maich et al., 2016). The review by Matthew-Maich and Colleagues (2016) revealed that if a 
solution was considered too time-consuming or burdensome, it can be perceived by users as 
not being worth the effort, and will ultimately lead to low levels of user adoption (Matthew-
Maich et al., 2016). As part of our recommendations outlined in Table 27 (see results) we aim 
to provide clear instructions and guidance throughout the app (including inclusion of a 
training video) to make interaction with the app as easy as possible, and to ensure high levels 
of adoption and user engagement. SEQ measures will be repeated in future testing to see if 
scores have improved.  
In line with my second hypothesis, the think aloud methodology identified several high 
severity issues which informed necessary amendment in three key areas of design: 
navigation, content and accessibility.   
Regarding navigation, inexperienced users were unable to access some of the information on 
the instruction page because they had no prior knowledge of how to scroll down the page. 
One way in which this could be overcome is by matching the length of message to the screen 
size where possible, which has been found to improve digestibility and readability (Nielsen & 
Mathiassen, 2013) and would eliminate the need to scroll down. Inexperienced users also 
struggled to access the settings, as they did not recognise the menu icon. It was suggested by 
the project group that a training video and prompts such as arrows could be put in place to 
educate users with low levels of digital literacy on these navigation features. Training that has 
been tailored to meet the needs of the end-user is highly valuable, and can improve user 
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attitudes towards and acceptance of the use of technology (Stroulia, Nikolaidisa, Liua, King, 
& Lessard, 2012).  
Another issue users encountered was entering the token. Some of these errors were due to 
dexterity issues, particularly in the PD group. To improve the usability of the app on a 
smartphone platform, an increased keyboard size will be considered, and the keyboard for 
the token will be automatically in upper case, so that no additional keyboard navigation is 
required (see results, Table 27). Additionally, the app will eventually be developed for use on 
multiple platforms, including web-based and tablet versions, which may preferable for some 
users. Indeed, it has been suggested that tablets with touchscreens may be preferable to 
smartphones for users with limited dexterity, due to their bigger surface area (Huang & Hsu, 
2014).  
Regarding content, there was confusion surrounding certain terminology and wording. This 
highlights the importance of ensuring all content is comprehensible by end users. Past 
research has demonstrated that choosing appropriate wording and language is critical when 
developing a digital health intervention, and can have a significant impact on future 
adherence (Ludden, van Rompay, Kelders, & van Gemert-Pijnen, 2015). To ensure this is 
incorporated, a glossary will be made available for PD related terms used throughout the app 
(as outlined in the recommendations made previously, see results, Table 27).   
Regarding accessibility, some users commented that the font size was too small. Visual aids 
such as large text and the use of bold colours have previously been identified as key 
requirements of smartphone apps for older adults (Gao & Koronios, 2010). Lorenz and 
Opperman (2008) recommend using font sizes between 36pt and 48pt for elderly users. We 
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are in the process of developing a feature that will allow users to increase the interface font 
size, however this feature was not available at the time of testing.  
3.5.5.1 Increasing motivation to use the app: 
Following usability testing, an expert in digital healthcare (Professor Jackie Andrade, 
University of Plymouth) was contacted to ask for advice on how to motivate users to engage 
with the app long term. Professor Andrade (University of Plymouth) advised that reminders 
to carry out a behaviour (such as completing an assessment) were most effective when the 
user can choose at what time of day they will receive the reminder (Solbrig et al., 2017). This 
ensures that the reminder notification will arrive at a time of day when the user can actually 
respond e.g. for the app to remind them first thing in morning when they are alert, or in the 
evening when they are relaxed, rather than in middle of day when the user is at work or out 
shopping.  
In addition, positive imagery combined with task reminders has been found to be very 
effective in motivating behaviour (Solbrig et al., 2019). It may be useful therefore for us to 
accompany reminder notifications with some positive imagery such as a cup of tea or other 
image users would find relaxing.  
As a result, we will ensure to include questions regarding a personalised reminder schedule 
as part of the next round of formative evaluation, in order to gauge users’ thoughts on this 
feature. 
It was also suggested that we consider the narrative behind the app. Previous research has 
demonstrated that people are more likely to be motivated to use the app if they are 
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intrinsically motivated to perform a behaviour (e.g. to gain health benefits), rather than when 
they are extrinsically motivated (e.g. advised to do so by Dr) (Solbrig et al., 2017). In order to 
try and intrinsically motivate users to engage with the app, it was suggested that we promote 
the perspective of ‘self-care’ to the patient. For example, reminders could be accompanied 
by the text, ‘Check-up in the comfort of your own home,’ or ‘Do you have 5 minutes to look 
after yourself?’.   
In addition, previous research has found it is necessary to repeat a new behaviour frequently 
over a period of 6 weeks in order for it to become habitual (Breslin, Sobell, Sobell, Buchan, & 
Cunningham, 1997). In order to ensure that users adopt using the app on a regular basis 
(possibly once every 3-6 months to complete full NMS symptoms assessment) we may ask 
users to complete tasks using the app more regularly after first downloading it. For instance, 
users could receive reminders once a week for the first six weeks asking them to complete a 
task, such as watching a symptom video or completing a partial assessment. 
3.5.5.2 Limitations: 
As discussed previously, a limitation of our study was that we did not include participants with 
a range of cognitive abilities. Due to the difficulties the participant with MCI experienced 
completing the tasks, and the high levels of cognitive impairment experienced by older adults 
and PwP (Aarsland et al., 2009; Roberts et al., 2012),  it will be a priority in future studies to 
include participants with a wider range of cognitive impairment, to ensure our sample are 
representative of the end user population. 
Another limitation of the study was that no observers were present during testing, due to the 
last minute unavailability of a second researcher (RD), who it was intended would observe 
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the testing. This may mean that evaluation bias occurred when analysing and interpreting 
usability issues. To overcome this in future rounds of testing, we have expanded the project 
team to ensure that a second researcher is available to act as an observer.  
Furthermore, due to implementation of the think aloud methodology, it was not possible to 
provide a measure of efficiency. This is a limitation of the study, as we were not able to 
provide an overall picture of usability (Brooke, 2013). In the second usability study, we plan 
to carry out a retrospective think aloud methodology, whereby following task completion, we 
will show the participant video footage of them carrying out the task, and ask them to 
comment on what they were thinking at the time. This will allow us to include an efficiency 
measure, by timing how long it takes participants to complete each of the tasks (without also 
having to think aloud). 
Considerations for the design of the second usability study that have been influenced by the 
limitations of our current study design are outlined in Table 28, and will be incorporated as 
part of the second usability study. 
Table 28 Description of current study design limitations, and considerations for second usability study design to overcome 
these 
Current study design limitations Considerations for second usability study 
design 
• Limited range of cognitive abilities were 
represented 
• We will recruit a bigger sample 
including participants with a range of 
prior digital experience and cognitive 
ability (including users with MCI) 
• There were no observers present 
during usability testing 
• We will expand the project team to 
ensure there will be an observer 
present during all usability testing 
sessions 
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• There were no measures of efficiency  • We will include measures of efficiency 
as part of the study design, such as task 
completion time. 
 
3.5.5.3 Conclusions  
This initial formative evaluation was carried out to evaluate the usability of NMS Assist for 
end users with and without previous smartphone experience.  
In line with my first hypothesis, there were no differences in perceived usability between 
experienced and inexperienced users, suggesting that perceived uability is not dependent on 
prior smartphone experience. However, differences in measures of effectiveness between 
groups revealed the app needs further refinement in order to meet the needs of end-users 
with low levels of digital literacy and poor cognition. 
In line with my second hypothesis, the think aloud method revleaed key areas of amendment 
related to navigation, content and accessibility.  
The findings from this evaluation have therefore informed necessary and appropriate 
solutions for future app development (see results, Table 27), as well as important study design 
considerations for the next usability study, to overcome the limitations of our current study 
design (see Table 28). 
It is hoped the amendments to app will increase overall usability, and these will be measured 
by efficiency, effectiveness and satisfaction measures in the second round of usability testing. 
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3.6 Overall chapter discussion  
In order to ensure NMS Assist is safe, usable, and successfully meets users’ needs, we 
employed an app development process guided by the MHRA Human Factors and Usability 
Engineering guidance for medical devices (Mhra, 2017). In addition to the MHRA guidance, 
the Department of Health and Social Care more recently (September 2018) published a set of 
principles in the code of conduct for data-driven health and care technology (DHSC, 2018). 
These principles complement the MHRA guidance, and are aligned with the digital design 
principles published by the NHS (NHS Digital, 2018). 
Our phases of app development (to date) include; (Part 1) identification of app use, users and 
environment, (Part 2) development of wireframe design and self-help materials, and (Part 3) 
a formative evaluation of the app. Each of these phases will be discussed in turn. 
3.6.1 Part 1: Identification of use and users 
A key principle outlined in the code of conduct (DHSC, 2018) that has been implemented as 
part of the app development process was to understand users, their needs and the context. 
A literature review and patient questionnaire were carried out in Part 1 to gain valuable 
insight into our users and their needs.  
In line with my hypothesis, the literature review revealed a wide range of user characteristics 
which could have an impact on users’ interaction with the app such as limited dexterity, vision 
and prior experience with smartphones. The patient questionnaire of patient experience of 
NMS provided insight into the clinical needs of end users, such as the generally high NMS 
burden of PwP, and the infrequency with which these are currently reviewed or monitored. 
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The patient questionnaire further provided insight into practical user needs, such as access to 
technology, current use of digital health technologies (DHT), and willingness to use a DHT in 
the future. 
Our findings from Part 1 were instrumental in understanding our user needs so that we could 
develop a suitable app. Services and products that are designed around users and their needs 
are more likely to be used, and will cost less in the long term by avoiding costly revisions 
further down the line (DHSC, 2018).The results of our literature search and patient 
questionnaire were therefore taken forward and incorporated as part of the next phase of 
app development.  
3.6.2 Part 2: Iterative design process 
Patient representatives continued to be closely involved during the development of the app 
wireframe and the self-help materials in Part 2. As mentioned previously, engagement with 
end users throughout the development of DHTs has been found to positively influence future 
engagement with and adoption of DHTs and so it was a priority for us to include patient 
representatives at every stage of the development process. 
Our patient representatives were key to identifying potential risks to patient safety so that 
relevant mitigations could be included as part of the app wireframe design. For example, a 
patient representative was concerned that users may not understand the purpose of a full 
NMS assessment. To mitigate for this risk, a screen was included prior to the full NMS 
assessment that explained the purpose and task instructions. Furthermore, during the 
development of the self-help materials, patient representatives were closely involved in the 
development of the scripts to be read aloud by the animation voiceovers, and the 
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development of the animations. Their involvement was integral to ensuring we selected 
terminology that was accessible to readers and easily understood, as well as being conveyed 
in an appropriate tone. 
Another key principle incorporated as part of the app development process was an iterative 
development process, meaning that we iteratively refined the design of the app to ensure all 
identified potential issues and risks to patient safety were addressed. An iterative 
development process is a key factor in the design of DHTs, and allows for prototype versions 
to be regularly tested and refined (MHRA, 2017). In order to achieve this, we required regular 
engagement with all members of the project group throughout all phases of development, to 
review and provide feedback on each aspect. 
Although valuable and necessary, this process required a central person to coordinate the 
feedback schedule (this role was carried out by myself). This included; sending the project 
group initial invites for feedback, chasing delayed replies, collating group feedback, and 
reporting the collated feedback to the project group as a whole, as well as to the app 
developers. Although worthwhile, this process was timely, and we required additional 
resource to carry out the changes made as a result of the feedback, as these exceeded the 
number of rounds of amendment that were originally quoted to us by the app designers. 
Furthermore, absence of project group members (due to holidays or sick leave) induced 
delays to the development process, particularly to the app wireframe design and the 
development of self-help materials, whereby the creators could not progress with the next 
iteration until they had received feedback from all members of the project group. A stricter 
schedule for feedback, and tools to assist with the oversight of this (such as project 
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management software) may help to improve this process as we move forwards, and reduce 
delays to project delivery. 
3.6.3 Part 3: Formative evaluation 
A further key principle outlined as part of the code of conduct is to generate evidence of 
effectiveness for the DHT’s intended use (DHSC, 2018). NICE has recently developed an 
evidence standards framework for DHTs (published in Dec 2018) that has been designed to 
complement the code of conduct principles (NICE, 2019). The framework aims to inform 
technology developers and evaluators about the types of evidence needed to show the 
effectiveness of a DHT. The framework further aims to provide standardised criteria against 
which DHTs can be assessed, dependent on the function of the DHT.  
The formative evaluation that we have carried out in Phase 3 provides some of evidence on 
the effectiveness of the device in line with that required by the framework, including an 
evaluation of user satisfaction and involvement of intended users in the development of the 
DHT.  
In line with my first hypothesis, there were no differences in perceived usability between 
experienced and inexperienced users, suggesting that perceived uability is not dependent on 
prior smartphone experience. However, differences in measures of effectiveness between 
groups revealed the app needs further refinement in order to meet the needs of end-users 
with low levels of digital literacy and poor cognition. 
In line with my second hypothesis, the think aloud method revleaed key areas of amendment 
related to navigation, content and accessibility that will be incorporated as part of the app 
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refinement process. The refined version of the app will then be evaluated as part of our next 
round of formative evaluation (planned for July 2019). In addition, limitations to study 
methodology identified as a result of our initial formative evaluation will also be addressed, 
such as the inclusion of an observer, measures of efficiency and participants with a wide range 
of cognitive abilities and digital literacy. It is hoped these amendments will increase the 
robustness of the second formative evaluations’ findings and inform the finalisation of the 
app design.  
A strength of this development process is that evaluations of usability were carried out at an 
early stage of development in a laboratory setting. A review of health information technology 
usability methodologies found that the majority of evaluation studies take place at a later 
development stage, once the product is in use. These studies identified by the review 
reported several barriers to adoption of DHTs, including usefulness and ease of use (Yen & 
Bakken, 2010). The authors conclude that some of these barriers may have been avoided by 
carrying out evaluation of the technology at an earlier stage in the app development process. 
However, in order to fully provide evidence of effectiveness in line with the framework, and 
to meet similar requirements outlined by the MHRA, further, more rigorous testing is needed. 
Following finalisation of design and minimisation of risks identified through formative testing, 
a summative evaluation of the finished app design will be carried out.  
The purpose of a summative evaluation will be to carry out testing of the app in the intended 
environment for use, and (as identified via the patient questionnaire, see section 3.2.6.10), 
this will primarily be in patients’ homes. We therefore plan to carry out an in-service 
summative evaluation, whereby patients and carers will be required to use NMS Assist at 
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home over the course of 12 weeks. Participants will receive app training, before being asked 
to complete a full NMS assessment at pre-specified time points over the course of 12 weeks, 
and a number of other tasks in-between these intervals that reflect the range of app 
functions; these will include accessing the self-help information; re-assessing troublesome 
symptoms and requesting a healthcare contact. At the end of the 12 weeks, user evaluations 
will be carried out to capture perception of change over the study duration, as well as a focus 
group to obtain more detailed insights into user experiences, perceptions, and satisfaction.  
A key element of the summative evaluation is ensuring that app training is tailored to user 
skills and knowledge, the acceptability of the training provided (in terms of timing, content, 
delivery and duration), and whether the training is effective. Training acceptability will be 
evaluated by questionnaire administered by telephone interview within 3 days of baseline 
visit. Training effectiveness will be evaluated by logging app use and user journey completion.  
3.6.4 Development of the app build  
The development of the app build was not included as part of this chapter, but is an ongoing 
part of the app development (led by SM). The app build process includes the development of 
the web portal element, whereby the clinical team will be able to view patients’ interactions 
with the app as well as view patient and carer NMS assessments. The web portal will therefore 
facilitate support and communication with patients and their carers as required. As outlined 
in  Figure 22, the app build followed a similar process of design as the wireframe and self-help 
materials, and will similarly be evaluated using a formative and then summative evaluation 
process in due course.  
262 
 
3.6.5 Further considerations 
There are further key principles outlined in the code of conduct that pertain to the app build 
and design, which will be considered throughout our ongoing app development process:   
3.6.5.1 Data protection 
The use of data will need to adhere to the recently updated Data Protection Act (2018). A key 
consideration will be that the minimum personal data necessary will be used to achieve the 
desired outcomes. In addition, the code of conduct outlines that developers should be fair, 
transparent and accountable about what data is being used. Data-sharing agreements with 
users must be implemented and adhered to (DHSC, 2018). 
3.6.5.2 Data security  
A core element of design and development will be to ensure security methodology has been 
incorporated. As part of the code of conduct, it is recommended that when developing an 
application, it is necessary to ensure the app meets the OWASP Application Security 
Verification Standard (OWASP, 2018) , which is used to determine a level of confidence in the 
security of applications. Furthermore, NHS digital provides information and resources 
relevant to securing medical devices as part of the ‘NHS Digital Data Security Knowledge 
Library’ ("NHS Digital”, 2019). It will be a priority to ensure these resources and guidelines are 
implemented and adhered to as part of the app build and development.  
3.6.5.3 Economic impact  
A key principle that pertains to all aspects of app development is providing evidence of the 
economic impact of the app. Section B of the NICE Evidence Standards Framework provides 
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the economic analysis that should be carried out for DHTs that present differing levels of 
economic risk. Risks are defined as any harm associated with the expected cost and system 
impact of commissioning a DHT. It is essential that the framework is adhered to in order to 
calculate the level of economic risk and subsequent economic impact that NMS Assist may 
present.  
3.6.6 Conclusions 
As a result of the first three phases of this ongoing app development process, we have: 
• Identified our user charactersitics and needs, and incorporated these throughout the 
design process.  
• Iteratively refined the app’s content, functionality and interface, with consideration 
of user needs and engagement from end users at all stages.  
• Carried out a formative evaluation in the laboratory setting, which revealed that while 
the app was rated as highly usable by our end-users, further refinement is needed to 
increase usability for inexperienced users.  
• Identified key areas of additional amendment to future app design including those 
related to navigation, content and accessibility.  
Findings from our formative evaluation will inform the next iteration of the app design, 
and important methodological considerations will be put in place to improve the 
robustness of this study design. Following finalisation of the app design (via the next round 
of formative testing), we plan to carry out an in-service summative evaluation to test NMS 
Assist in the environment of intended use, and in line with relevant guidelines and 
procedures for the development of digital health technologies (DHSC, 2018; Mhra, 2017). 
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Chapter 4 Evaluating the clinical utility of objective measurement in the remote 
management of people with Parkinson’s disease 
4.1 Introduction 
In recent years, a multitude of wearable technologies for the objective measurement of 
Parkinson’s disease (PD) symptoms have emerged (see (Del Din, Godfrey, et al., 2016; 
Maetzler et al., 2013)  for recent review). As discussed previously (see section 1.2.25.2.2), 
incorporating wearable devices as part of PD management may help to overcome some of 
the current challenges surrounding care provision and assessing symptom severity. For 
example, wearable devices allow for continual assessment of patients’ symptoms from within 
the home environment, resulting in data that is high in ecological validity, without the need 
for the patient to travel to clinic (Stamford et al., 2015). Furthermore, wearable devices have 
the potential to provide tailored information on a patient’s response to a therapeutic 
intervention, which can be used to further optimise treatment and identify areas of unmet 
need (Barker, 2017).  
Although other wearable devices are commercially available for the assessment of PD 
symptoms (e.g. (Mera, Heldman, Espay, Payne, & Giuffrida, 2012) see section 1.2.25.2.3.1), 
the Parkinson’s KinetiGraph (PKG™) is unique in that it offers continuous monitoring over a 
6-day period, and requires little interaction from the user (see section 1.2.25.2.3.2). 
In this chapter, I present a clinical evaluation on the use of the PKG™ as part of routine 
management of people with Parkinson’s disease (PwP) as well as the results of a patient 
evaluation investigating the feasibility and acceptability of the PKG™ for patients. 
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4.1.1 The PKG™ System: 
The Parkinson’s Kinetigraph (PKG™; Global Kinetics Corporation (GKC)) is a U.S. Food and Drug 
Administration (FDA) approved wrist worn device that provides continuous, objective and 
ambulatory assessment of PD symptoms. The PKG™ comprises 3-axis accelerometers and 
sufficient memory for 10 days of continuous recording (see Figure 39).  
 
The PKG™ is worn by patients on the wrist of the most affected side for 6-10 days, after which 
data is downloaded from the device and analysed by proprietary cloud-based algorithms, to 
calculate a bradykinesia score (BKS) (Griffiths et al., 2012) and a dyskinesia score (DKS) 
(Griffiths et al., 2012). In addition, the percentage of time that tremor was present (PTT score) 
is available (Braybrook et al., 2016), as well the percentage of time immobile (PTI score), 
indicative of excessive day time sleepiness (Kotschet et al., 2014).  Median PKG™ symptom 
scores (BKS, DKS, PTT and PTI scores) from throughout the waking day (9am-6pm), are used 
to represent overall severity.  
Figure 39 The PKGTM System (Generation 1) (pictured left) used by patients in this clinical evaluation. An updated version has 
since been released (Generation 2) (pictured right). 
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The PKG™ device (logger) is programmed with patient L-dopa medication times, and patients 
are required to acknowledge intake of medication by placement of a digit on the device 
(Generation 1) or swiping across the screen (Generation 2). This feature of the PKG™ has been 
used as a means to assess for impulse control disorder (ICD) (Evans et al., 2014).  
All propriety algorithms used as part of the PKG™ system have been previously validated, and 
are described in detail below. 
4.1.2 Validation of the PKG™ Propriety Algorithms  
4.1.2.1 Bradykinesia (BKS Scores) 
In the PKG™ algorithm, bradykinesia is recognised as epochs containing movements of lower 
acceleration and amplitude and with longer intervals between them (Griffiths et al., 2012). 
The specific details of this algorithm are proprietary, and are not available in the public 
domain.  
Griffiths et al (2012) carried out a validation study of the algorithm for BKS scores with data 
from PwP (n=34) and age matched controls (AMC) (n=10) after having worn the PKGTM for a 
duration of 10 days. The aim of their study was to validate the use of this algorithm against 
traditional clinical rating methods for bradykinesia.  
A dot slide task (an example of an alternating movements task used to measure bradykinesia 
in PD) correlated well with the BKS algorithm (p<.001) with a specificity of 88% and sensitivity 
of 95%. Additionally, the BKS score was found to correlate well with the Movement Disorders 
Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) motor subscale (Part III)  scores 
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(r=.64, p<.00005), with 1 MDS-UPDRS Part III unit calculated to equate to 1.3 BKS units 
(Griffiths et al., 2012).    
In addition, the distribution of the BKS was found to differ from controls. For instance, the 
BKS of a PwP with bradykinesia was greater than the 50th percentile of controls for almost 
90% of the time.  
The authors concluded that the close correlation between the BKS scores with existing 
established clinical measures, and the differentiation in scores from an age-matched control 
population helps to validate the PKG™ as a reliable measure of bradykinesia in PwP (Griffiths 
et al., 2012). 
4.1.2.2 Dyskinesia (DKS Scores) 
In the PKG™ algorithm, dyskinesia is recognised as epochs containing movements of normal 
amplitude and acceleration but with shorter intervals between them. As before, the specific 
details of this algorithm are proprietary, and therefore not available in the public domain.  
Griffiths et al (2012) carried out a validation of the algorithm for DKS scores as part of the 
same validation study for the BKS scores.  The aim of their study was to validate the use of 
the DKS algorithm against traditional clinical rating methods for dyskinesia.  
The correlation between the DKS score and the Abnormal Involuntary Movement Scale 
(AIMS) (a task used to measure dyskinesia in PD) was highly significant (r=.8, p<.0001). 
Furthermore, the DKS score achieved a smaller margin of error to a neurologist scoring the 
AIMS (Griffiths et al., 2012). 
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In addition, the distribution of the DKS was found to differ from controls. For instance, the 
DKS of a patient with dyskinesia was greater than the 50th percentile of controls almost all of 
the time. 
As with the algorithm for BKS, the authors concluded the close correlation between the DKS 
scores with existing established clinical measures, and the differentiation in scores from an 
age-matched control population helps to validate the PKG™ as a reliable measure of 
dyskinesia in PwP. 
4.1.2.2.1 Bradykinesia and Dyskinesia Summary Output 
Figure 40 displays an example of a bradykinesia and dyskinesia summary graph that the 
clinician receives after the patient has worn the PKGTM for the required duration (6 days). The 
thick lines represent median bradykinesia (blue lines) and median dyskinesia (green lines) 
from over the 6 days the PKGTM is worn, and the thin lines represent the interquartile range 
(IQR).  
The severity of BKS and DKS is based on the average 50th, 75th and 90th percentiles of the 
distribution of BKS and DKS from control subjects recordings (see (Griffiths et al., 2012)). 
These have been used to define four levels of severity for bradykinesia and dyskinesia; Level 
I: <50th percentile of controls, Level II: 50–75th percentile of controls, Level III: 75th −90th 
percentile of controls and Level IV: >90th percentile of controls.  
The red lines represent the pre-programmed prescribed L-dopa times, and the red diamonds 
indicate times when the patient registered taking their L-dopa.  
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Figure 40 An example of a PKGTM bradykinesia and dyskinesia summary graph. The thick lines represent median bradykinesia (blue lines) and dyskinesia (green lines) from over the duration the 
PKGTM was worn, and the thin lines represent the interquartile range (IQR). The red lines represent the pre-programmed prescribed L-dopa times, and the red diamonds indicate times when the 
patient registered taking their L-dopa. 
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4.1.2.3 Motor Fluctuations (FDS Score) 
Motor fluctuations refer to the presence of dyskinesia or the re-emergence of bradykinesia 
prior to the next dose of L-dopa (see section 1.2.16). An examination of the variation of 
bradykinesia and dyskinesia over the course of a dose of L-dopa may therefore reflect the 
severity of fluctuations a patient is experiencing. 
Horne (2015) used PKG™ data to investigate fluctuations by examining the combined 
variations in the BKS and DKS. 
The authors examined the IQR of BKS and DKS in 527 PwP who had worn a PKG™ over a period 
of 6 days. The IQR for each score was summed to produce a combined IQR.  
The median combined IQR was able to distinguish between populations of known fluctuators 
(patients on waiting list for Deep Brain Stimulation (DBS)) and non-fluctuators (disease 
duration ≤3 years) (p<.001). The area under the receiver operating characteristic (ROC) curve 
(AUC) for combined IQR was 0.98, and provided a sensitivity of 97.1% and a selectivity of 
87.5% (at combined IQR of 22.5).  
An algorithm was then developed to express the combined IQR as a formula for the PKGTM 
Fluctuation Score (FDS) (see Horne et al., 2015).  
The authors concluded that the combined IQR of BKS and DKS (FDS) provides a useful tool for 
identifying patients experiencing motor fluctuations, allowing for timely and effective 
intervention.  
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4.1.2.4 Tremor (PTT score) 
In the PKGTM algorithm, the accelerometry data from the 6 day recording period is sampled 
at 50 Hz and processed through a 250 sample sliding window in steps of 1 second (s). Tremor 
is identified when the accelerometery data meets certain frequency criteria including: 
• The peak spectral power in each 1 second step is larger than the spectral median 
between 1 Hz and 10 Hz. 
• The frequency of the spectral peak in each step is between 2.8 Hz and 10 Hz. 
• The frequency of the spectral peak within a step differ from the frequency of the 
spectral peak in the two immediately adjacent steps by no more than 0.4 Hz/s. 
The percentage of time that tremor is present (PTT) is then calculated for the duration of the 
waking day (9am-6pm). For full details of the tremor algorithm, see Braybrook (2016). 
Braybrook and colleagues (2016) were interested in exploring the potential of the PKG™ 
tremor algorithm to identify the presence of clinically diagnosed tremor, and to correlate its 
appearance with bradykinesia and dyskinesia (Braybrook et al., 2016).  
People with Parkinson’s were recruited to the study (n=194) who were either previously 
known to have had tremor (T+) or did not have tremor (T-). Data from PwP and 28 control 
subjects wore the PKG™ for 6 days on the most severely affected wrist. Following recording, 
the data was downloaded and analysed.  
A ROC curve was generated and performed to find the PTT score that discriminated between 
T(+) and T (-) with the greatest sensitivity and selectivity. 
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In the T(-) cohort, a PTT 0.8% had a selectivity and sensitivity of 92.5% and 92.9% respectively 
(AUC =0.92).  
In the T(+) cohort, a PTT of 0.8% again provided the best selectivity and sensitivity (90.3 and 
92.7 respectively: AUC=0.96). 
In relation to BKS and DKS scores, the authors found tremor to be present more frequently 
when the BKS is high than when it is low. There was little relationship between tremor and 
high DKS. 
4.1.2.4.1 Tremor Summary Output 
Figure 41 displays an example of a tremor summary plot that the clinician receives after the 
patient has worn the PKGTM for the required duration (6 days). 
Each 2-minute epoch in which tremor is present is plotted in the tremor summary as black 
markings on the corresponding days and times. The red lines on the summary represent the 
patient’s pre-programmed prescribed L-dopa times.  
Figure 41 An example of a PKGTM tremor summary. Each 2-minute epoch in which tremor is present is plotted in the tremor 
summary as black markings on the corresponding days and times. The red lines represent pre-programmed prescribed L-
dopa times. In this example, tremor is seen to cluster around medication times, suggesting dopa-responsiveness. 
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4.1.2.5 Immobility (PTI Scores)  
In the PKGTM algorithm, periods of immobility are identified as 2 minutes or greater in length, 
with the BKS being at or below the threshold of 80 BKS. The amount of time spent immobile 
is then calculated as a proportion of the waking day (Percentage Time Immobile, PTI (%)).  
Kotschet et al (2014) investigated PKG™ recordings from 68 PwP and 30 controls over a period 
of 10 consecutive days (Kotschet et al., 2014) to explore the potential of using the PKGTM PTI 
as a marker of daytime sleepiness. The PTI was compared against two widely accepted 
markers of Excessive Daytime Sleepiness (EDS), which were the Ambulatory daytime 
polysomnography (PSG) and the Epworth Sleepiness Scale (ESS) (Johns, 1991).  
Daytime ambulatory PSG was recorded simultaneously alongside the PKG™ recording, and 
the presence (+) or absence (-) of immobility (PTI Score) and sleep (PSG score) for each subject 
was explored. The Kappa statistic for the concordance of the two methods was high at 0.63, 
with the sensitivity at 0.83 and the selectivity at 0.89.  
When compared to the ESS, patients with an ESS ≥10 (considered ‘high’) had significantly 
higher PTI scores than subjects with a low ESS (p=.001).  
Furthermore, patients with a high PTI had higher BKS than those with low PTI (p<.0001). In 
contrast, dyskinesia as measured by the DKS was higher in patients with a low PTI than a high 
PTI (p<.0001). 
Due to the high levels of concordance between the PTI and established measures of EDS, the 
authors concluded that the PTI could be used as a useful surrogate marker of EDS (Kotschet 
et al., 2014).  
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4.1.2.5.1 Immobility Summary Output 
Figure 42 displays an example of an immobility summary plot that the clinician receives after 
the patient has worn the PKGTM for the required duration (6 days). Each 2-minute epoch in 
which immobility is present is plotted in the immobility summary as black markings on the 
corresponding days and times. Although there is no algorithm available for overnight sleep, it 
is possible to use the immobility summary to make a visual qualitative assessment of 
overnight sleep quality, by evaluating the duration and continuity of immobility during night 
time hours. 
Figure 42 An example of a PKGTM immobility summary. Each 2-minute epoch in which immobility is present is plotted in the 
immobility summary as black markings on the corresponding days and times. The red lines represent pre-programmed 
prescribed L-dopa times. In this example, the patient has good sleep overnight, but evidence of immobility throughout the 
day, suggestive of daytime somnolence. 
4.1.3 Clinical utility of the PKGTM  
There is evidence to support the use of the PKGTM to enhance clinical decision making in PD 
care. A recent survey study of movement disorder specialists using the PKG TM  as part of 
routine PD care revealed that the PKGTM provided novel additional information (beyond that 
routinely captured) in 41% of 112 visits, and resulted in an adjustment to a patient’s 
therapeutic management plan almost a third of the time overall (Santiago et al., 2019). 
The results demonstrated that the PKGTM most commonly provided new information in 
relation to daily OFF time, which highlights an area where the PKGTM can provide value to 
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clinicians. Furthermore, the survey indicated the PKGTM was found to be most useful when 
given to new patients to the service after their first patient visit, to establish a baseline 
assessment of symptoms and determine what next steps in medical management were 
needed.  
A Parkinson’s UK (PUK) evaluation on the clinical utility of the PKGTM involving information 
from 209 patients from seven centres across the UK (including University Hospitals Plymouth 
NHS Trust (UHPNT)) revealed similar findings (Carroll, Kobylecki, Silverdale, Thomas et al, 
2019). The PUK evaluation demonstrated information from the PKGTM provided additional 
information to inform clinical decision making in 45.5% cases. Changes in decision making 
included ten cases where the PKGTM results prompted a change to treatment when clinical 
assessment alone suggested no adjustments were needed. These findings further 
demonstrate potential for the PKGTM to add value to clinical decision making, and facilitate 
management of PwP. 
In addition, the PKG™ has been recently recommended for use by two expert panels of 
internationally recognized movement disorder specialists (Odin et al., 2018; Pahwa et al., 
2018). The groups promoted the utilisation of PKG™ measurements to improve the clinical 
management of PD. Furthermore, the panels discussed that while the PKG™ should be used 
by all clinicians, the least experienced may find it the most value, provided they were 
supported by guidance from experts.  
 
276 
 
4.1.4 Indicative Thresholds 
The use of indicative thresholds when utilising objective measurement in the clinical 
management of PwP has been identified as a key aspect of their implementation (Odin et al., 
2018).   
Indicative thresholds based on PKG™ normal target ranges for BKS and DKS scores have been 
developed to separate “treated” from “undertreated” symptoms, to allow for subsequent 
therapeutic intervention with the aim of moving a patient’s PKG™ scores to ‘within target’ of 
the desired BKS or DKS range  (Farzanehfar et al., 2018; Odin et al., 2018) (see Table 29).  
Previously published PKG™ indicative thresholds are summarised in Table 29. The slight 
differences in the thresholds displayed in Table 29 demonstrates these are still under 
evolution, and are expected to be refined further as the PKG™  is used more extensively on 
larger cohorts of patients. 
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Table 29 Previously published indicative thresholds for treated and undertreated bradykinesia and dyskinesia using the 
PKG™. 
 
Odin et. al, 2018 Farzanehfar et. al, 2018b 
GKS Parameters 
(Personal Communication 
from GKC personnel) 
BKS Treatment 
Range 
BKS FDS BKS FDS BKS FDS 
Optimally controlled <23 
Not 
specified 
<23 >8 <23 >8 
Acceptable control 
≥23 and 
≤25 
No 
fluctuations 
>23 <26 
Not 
specified 
>23<26 
And/or 
>7.5 
Uncontrolled >25 
Not 
specified 
>26 Or <7.5 >26 
And/or 
<7.5 
DKS Treatment 
Range 
DKS FDS DKS FDS BKS  
Optimally controlled <7 
And FDS 
<10.8 
<9 
Not 
specified 
<9 And <10.8 
Acceptable control 7-9 
And FDS 
<13 and no 
fluctuations 
Not specified 
Not 
specified 
>7<9 And <13 
Uncontrolled >9 
Not 
specified 
7-9 And >13 >7<9 And >13 
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Farzanehfar (2018) carried out a recent investigation of the PKG™ in an Australian PD cohort 
and demonstrated benefit from treating PD symptoms against indicative thresholds outlined 
in Table 29 (under column 2, Farzanehfar et. al, (2018)). Patients in the treated range (within 
target) had better motor (UPDRS III), non-motor (NMS, UPDRS total) and quality of life (PDQ-
39) scores than those in the undertreated range (Farzanehfar et al., 2018). These findings 
demonstrate the potential benefit of treating patients in line with predefined thresholds. 
4.1.5 Implementation of the PKGTM at University Hospitals Plymouth NHS Trust (UHPNT) 
As discussed previously, national standards of PD care suggest that PwP  with early PD should 
be seen at regular intervals of 6-12 months to review their diagnosis, with follow-up review 
increasing to 2-3 monthly intervals (according to clinical need) to assess the response to 
medication, titrate dosage and re-visit the diagnosis. In addition, NICE guidelines recommend 
that people with advanced PD may require review at frequent intervals (every 2–3 months) 
(NICE, 2017). Within our service, we have recently found that 46% of patients have consultant 
appointments delayed by more than 6 months, and 60% have not seen the community nurse 
within the last year. Our current waiting time is 12-24 months for a routine review 
appointment in the consultant clinic (see section 1.2.19). 
Due to the long wait between appointments in our service, we expect there will be a high 
number of patients with an unmet treatment need experienced between clinic appointments. 
Past research has demonstrated patients who do not have regular review by a PD specialist 
have a higher risk of an adverse outcome including falls, nursing home placement and death 
(Willis, Schootman, Evanoff, Perlmutter, & Racette, 2011). 
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New patients in our service follow the New Patient (NP) Pathway (see Figure 43). Within this 
pathway, patients are seen regularly at 2-3 month intervals over the first 18 months following 
diagnosis, with opportunities for titration of medication to optimise treatment at each clinic 
visit, as well as receiving education, treatment and advice about non-motor symptoms. 
Patients progress from this pathway at around 18 months (or once on a stable medication 
regime) onto the Follow Up (FU) pathway. 
In an attempt to address service pressures and to facilitate the remote monitoring of patients 
during long waits between clinic appointments, the PKGTM was implemented (since 2015) as 
part of routine PD care in almost 600 patients at University Hospitals Plymouth NHS Trust 
(UHPNT) in both FU and NP pathways.  
4.1.6 Research Question  
I undertook an evaluation of the utility of the PKGTM to identify patients experiencing unmet 
treatment needs inbetween clinic appointments. In addition, I undertook an evaluation of 
patient acceptability of the PKGTM. 
4.1.7 Hypothesis 
Due to the long wait between appointments in our service, I hypothesised the PKGTM would 
identify a high number of patients experiencing an unmet treatment need between clinic 
appointments. 
4.1.8 Chapter Outline 
This chapter will be divided into two parts.  
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Part One will describe a clinical service evaluation of the the utility of the PKGTM to identify 
patients experiencing unmet treatment needs inbetween clinic appointments.  
Part Two will describe an evaluation of patient acceptability of the PKGTM. 
Following Part One and Part Two, there will be an overall chapter discussion and conclusion.  
4.2 Part One 
4.2.1 Methods 
This was a clinical service evaluation of PKG™ use within routine clinical care pathways for 
PwP at University Hospitals Plymouth (UHPNT); as such ethical approval was not required.  
4.2.1.1 Participant Inclusion  
All PKG™ recordings included as part of the evaluation (n=217) were performed as part of 
routine care in either the Follow Up (FU) Pathway or the New Patient (NP) Pathway at UHPNT 
between July 2015 and January 2018, prior to the introduction of a web portal system 
(January 2018).  
4.2.1.2 The Follow Up (FU) Pathway 
Patients in the FU pathway (n=88) have progressed beyond their first year of care. The PKG™ 
was implemented to identify areas of unmet need between clinic visits. The PKGTM was 
arranged for patients for whom it was felt treatment changes were likely to be required prior 
to the next clinic appointment. 
281 
 
4.2.1.3 The New Patient (NP) Pathway 
Patients in the NP pathway (n=78) follow a nurse-led care pathway that encompasses the first 
year of care post diagnosis (summarised in Figure 43). The clinic appointments allow for 
detailed evaluation (as outlined below). 
 
Figure 43 The New Patient (NP) pathway at UHPNT. Prior to receiving the PKGTM, measures of cognition, quality of life and 
NMS-burden are administered. 
4.2.1.4 The PKGTM Process  
The PKG™ process is outlined in Figure 44. The PKGTM was applied in clinic and worn by 
patients for up to 6 days. During the clinic visit, the device was programmed with the patient’s 
medication regime and activated. The patient was then shown how to take the device on and 
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off and acknowledge medication reminders. Patients were provided with an information 
leaflet about the device as well as contact information should there be difficulties.  
All other processes, including reporting PKGTM findings and discussing with the patient any 
changes to treatment based on PKGTM findings, were carried out remotely (see Figure 44). 
After 6 days, patients returned the device by post, and the device was then connected to a 
tablet device which allowed upload of the data to the cloud. A PKGTM graph was emailed back 
to the clinician within a few minutes for interpretation and reporting. The graph included the 
graphical representation described previously (see section 4.1.2.2.1) as well as numerical 
values for BKS, DKS, FDS, PTT and PTI.  
Not all of these parameters were available in 2015; PTT was only available on later graphs. 
Following preparation of the report, the results were shared with the patient, community 
nurse and GP by letter, and copy of report and graph. The patient was then telephoned by a 
member of the hospital team to discuss the report; any treatment suggestions were 
discussed, and implemented if agreed. A copy of the reporting template is in appendix 21 
(section 8.21). 
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Figure 44  The PKG™ process at UHPNT. The blue circles represent processes that were remote, and the red circles represent 
the processes that took place in clinic. 
4.2.1.5 PKG™ Reporting 
A consultant neurologist and two Parkinson’s Disease Nurse Specialists (PDNS) were trained 
in PKG™ reporting, which required completing an online assessment and attending advanced 
reporting training. The neurologist oversaw the reporting of each of the PDNS until reporting 
was standardised. 
4.2.1.6 PKGTM database   
I developed the PKGTM database, in collaboration with the clinical team, to capture key 
information related to PKGTM recordings including; relevant PKGTM scores, patient 
demographics (age, sex, disease duration, LEDD), available clinical scores (e.g. prognosis 
score), reason for PKGTM request, clinical interpretation of PKGTM findings and treatment 
recommendations. Where available, I investigated follow up patient clinic letters to obtain 
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information on reported outcomes following a PKGTM, to see whether recommendations 
were adhered to. 
The PKG™ database was completed by the relevant member of the PD clinical team following 
completion of a PKG™ report (see appendix 22 (section 8.22).  
 
4.2.1.7 Standardisation of responses 
In order to standardise database entries and quantify responses for analysis, dropdown 
multiple choice options were available for each variable of the database (see Table 30). These 
options were designed in collaboration with the PD clinical team to best reflect clinical 
practice. If more than one of the multiple choice options applied per patient, the team 
member was able to select multiple options for each of the variables. 
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Table 30 The multiple choice dropdown options available in the PKGTM database 
 
Purpose of PKG™  PKG™  Finding Recommendation 
Baseline Assessment Delayed on Add another agent (constipation) 
Evaluate Bradykinesia Device failure Add another agent (mood) 
Evaluate Dyskinesia Dyskinesia Add another agent (other) 
Medication response Early morning off Add another agent (pain) 
Sleepiness/ Sleep cycle Excessive daytime sleepiness 
Add another agent (postural 
hypotension) 
Tremor extent Good quality sleep Add another agent (sleep) 
Wearing off No clear drug response 
Add another agent (motor control) 
amantadine 
Other Patient error 
Add another agent (motor control) 
oral DA 
 
Poor drug adherence 
Add another agent (motor control) 
oral ldopa 
 
Prevalent tremor 
Add another agent (motor control) 
MAOI 
 
Sleep fragmentation 
Add another agent (motor control) 
COMT I 
 
High BKS 
Add another agent (motor control) 
DA patch 
 
Varied drug response 
Add another agent (motor control) 
disp regime 
 
Wearing off Address sleep hygiene 
 
Well managed Advise exercise 
 
Improved Alter dose timings 
 
Other Increase dose of existing agent 
  
Increase frequency of existing agent 
  
Reduce an agent 
  
Switch agents 
  
Withdraw an agent 
  
Consider advanced therapy 
  
Bowel management advice 
  
Diet management advice 
  
No change 
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4.2.1.8 Statistical Analysis 
In order to evaluate the clinical utility of the PKGTM and the associated indicative thresholds 
to identify patients experiencing unmet treatment needs, I carried out a sensitivity and 
specificity analysis. Specifically, I was interested in comparing the patients identified as 
undertreated by the PKGTM indicative thresholds in comparison with the patients identified 
as undertreated by clinican interpretation of the PKGTM.    
To achieve this, the database was searched for patients who met the indicative threshold 
requirements for treated or undertreated bradykinesia or dyskinesia (see Table 29, column 1 
(Odin, 2018)). These parameters for identifying patients in the treated or undertreated range 
were used for analysis as they were published most recently, and were recommended by a 
panel of 11 internationally recognised movement disorder specialists as part of guidance on 
the incorporation of objective measurement into the management of PD (Odin et al., 2018).  
Patients that had been identified by clinican interpretation of the PKGTM report and graph as 
undertreated were also identified by highlighting any database entries that included the 
findings “early morning off”, “no clear drug response”, “varied drug response”, “wearing off”, 
“high BKS” and “dyskinesia”.  
4.2.2 Results  
4.2.2.1 Clinical Evaluation 
217 PKG™ recordings were carried out as part of routine PD care at UHPNT from July 2015 – 
January 2018. 
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Of the 217 recordings identified, 7 had incomplete data available, 4 experienced a device 
failure, and 4 were affected by patient error (eg. off wrist for long periods of recording), thus 
202 PKG™ recordings were available for analysis.  
Of the 202 complete and correct PKG™ recordings, 36 were repeat PKG™s. Due to the small 
number of repeat data available, repeat data was not included as part of the main analysis.   
One hundreded and sixty-six complete baseline PKG™ recordings were therefore included as 
part of the clinical evaluation. All patients included as part of the evaluation belonged to one 
of two PD management pathways as described previously (see section 4.2.1.1) (FU (n=88) and 
NP (n=78) pathways). 
4.2.2.2 Patient Demographics and PKGTM data 
Patient demographics and PKGTM data for the FU and NP pathways are summarised in Table 
31.  
Table 31 Patient demographics and PKG data in the FU and NP pathways, median (min-max range) 
 
FU 
(n=88) 
NP 
(n=78) 
Age (years) 
71 
(46-85) 
69 
(39-87) 
Disease Duration 
6yrs 
(4m- 23yrs) 
1yr 
(2m-13yrs) 
LEDD (mg) 
750 
(0-2674) 
375 
(0-1000) 
BKS 
27.2 
(6.9-55.9) 
29.6 
(15.9-40.5) 
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DKS 
1.9 
(.10-60.4) 
1 
(.1-11.2) 
FDS 
7.6 
(3.8-31.4) 
6.9 
(4-17) 
PTT 
1.35 
(0-50.1) 
3.1 
(.1-40.2) 
PTI 
5.4 
(.1-48.9) 
9.4 
(.3-35.4) 
 
4.2.3 Utility of the PKGTM indicative thresholds to identify patients experiencing unmet 
treatment needs 
Table 32 displays the frequency of patients (in the FU and NP pathways combined) identified 
by the PKG™ parameters (see Table 29 column 1 (Odin, 2018)) as undertreated from a motor 
perspective (undertreated bradykinesia and dyskinesia), the frequency of patients identified 
by clinican interpretation of the PKGTM report and graph as undertreated from a motor 
perspective, and the frequency of patients identified by both the PKG™ parameters and 
clinician interpretation of the PKGTM as undertreated.  
The median (min-max range) age, LEDD, disease duration and FDS scores for patients that 
were identified as undertreated by either the PKG™ parameters, the clinical team, or both, 
are also summarised in Table 32. 
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Table 32 Demographic information for patients identified as undertreated from a motor perspective by the PKG™ 
parameters, by the clinical teams or by both the PKG™ parameters and the clinical teams. Median (min-max range) values 
are presented. 
Undertreated Bradykinesia 
PKG™  Parameters only  Clinical team only Identified by both 
n= 10 (6%) n= 18 (11%) n=106 (64%) 
Age (years) 70.5 (54-85) 73 (51-80) 70 (48-87) 
LEDD 462.5 (53-750) 1100 (6-2674) 475 (0-2000) 
Disease duration (months) 29 (9-113) 78 (9-234) 38.5 (2-281) 
BKS Score 30.3 (25.1-40.9) 22.1 (16.9-25) 31.25 (25.2-55.9) 
FDS Score 7.15 (5.7-9.8) 9.55 (6.1-14.1) 6.8 (3.8-10.9) 
Undertreated Dyskinesia 
PKG™  Parameters only Clinical team only  Identified by both 
n=4 (2%) n= 10 (6%) n=9 (5%) 
Age (years) 66.5 (55-76) 70.5 (48-80) 65 (49-78) 
LEDD 400.5 (100-850) 1000 (325-2139) 1171 (225-1255) 
Disease duration (years) 46 (27-60) 131 (40-195) 105 (59-270) 
DKS Score 11.6 (9.5-13.8) 3.8 (.3-7.9) 16.7 (10.3-60.4) 
FDS Score 13.7 (12.2-17) 9.25 (6-14.2) 15.7 (11-31.40) 
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The data in Table 32 demonstrates that an additional 28 patients were identified by clinician 
interpretation of the PKG™ report as undertreated from a motor perspective that were not 
identified using the PKG™  indicative thresholds alone. 
4.2.3.1.1 Undertreated Bradykinesia 
The sensitivity and specificity of the indicative thresholds to correctly identify patients as 
undertreated from a bradykinesia perspective was calculated, as these were the patients with 
the greatest care need.  
The sensitivity of the BKS parameter was 0.85 (106/(106+18)), meaning the PKG™ indicative 
thresholds for undertreated BKS (BKS >25) (as defined by Odin and colleagues (2018)) will 
correctly identify 85% of patients who are undertreated from a bradykinesia perspective. 
The specificity of the BKS parameters was 0.76 (30/(30+9)), meaning the PKG™ indicative 
thresholds for undertreated BKS (BKS >25) (as defined by Odin and colleagues (2018)) will 
correctly identify 76% who are not undertreated from a bradykinesia perspective. 
It was of interest to investigate the reasons why either the clinical team or the PKG™ did not 
identify certain patients as undertreated from a motor perspective, and this will be explored 
below. 
Patients identified as undertreated from a bradykinesia perspective by the PKG™ parameter 
only (n=10):  
Clinic letters for three of the patients in this group were not available at the time of analysis. 
For two of the patients identified as undertreated by the PKG™ parameter only, they had high 
levels of immobility which limited the validity of the bradykinesia recording. Three of the 
291 
 
reports queried whether the reading was representative of true symptom severity, due to the 
PKG™ being carried out over the Christmas break. 
However, for two patients the main finding reported by the clinical team was prevalent 
tremor, which might have diverted attention away from their bradykinesia.  
Patients identified as having undertreated bradykinesia by the clinical team only (n=18): 
This group of patients showed signs of wearing off throughout the day, but had an optimal 
response on average, and so failed to be identified as undertreated using the PKG™ 
parameter. Some patients in this group also had no clear medication response, or delayed 
responses to medication (delayed on).  
Figure 45 and Figure 46 display a PKG™ graph and tremor summary plot respectively, for one 
of the patients in this group. The graph demonstrates this patient (from the NP pathway) was 
identified as having some wearing off and peri-dose tremor. The medications for this patient 
at the time of recording were Ropinirole XL 6mg a day at 13:00. Although the medication 
reminders should only be used for short acting dopa preparations, in this case they have been 
used as a dopamine agonist (DA) reminder. 
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Figure 45 PKG™ graph for a patient that was not identified by PKG™ parameter as undertreated from a bradykinesia perspective, despite demonstrating some wearing off.  The thick lines 
represent median bradykinesia (blue lines) and dyskinesia (green lines) from over the duration the PKGTM was worn, and the thin lines represent the interquartile range (IQR). The red lines 
represent the pre-programmed prescribed L-dopa times, and the red diamonds indicate times when the patient registered taking their L-dopa. 
The severity of BKS 
and DKS is based on 
the average 
distribution of BKS and 
DKS from control 
subjects. 
 
Level I: <50th 
percentile of controls 
Level II: 50–75th 
percentile of controls 
Level III: 75th −90th 
percentile of controls  
Level IV: >90th 
percentile of controls.  
 
Increasing 
Dyskinesia (DKS)  
Median of 
Control 
Worsening 
Bradykinesia 
(BKS) 
Evidence of wearing off  
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Figure 46 Tremor Summary for a patient that was not identified by PKG™ parameter as undertreated from a bradykinesia 
perspective, despite demonstrating reoccurrence of peri-dose tremor. Each black mark on summary plot represent every 
2min epoch where tremor is. The red lines represent the pre-programmed prescribed L-dopa time. 
The tremor score (PTT) for this patient was 3.8% which is above the suggested cut-off for 
acceptable level of tremor (1%) (Braybrook et al., 2016). Despite this finding, this patient was 
not identified as undertreated from a bradykinesia perspective in line with published 
indicative thresholds (this patient had a BKS score of 23). 
To ensure the PKG™ graph represented clinically meaningful information, I reviewed the 
follow up clinic letter for this patient. Wearing off in the afternoon was confirmed by the 
patient, although they reported they were managing well. It was agreed that the Ropinirole 
would be moved to an earlier time in the day to give the patient additional support when they 
are most active (this patient attended the gym most mornings). The clinician also discussed 
commencing levodopa medication with the patient. 
4.2.3.1.2 Undertreated Dyskinesia 
The sensitivity and specificity of the PKGTM indicative thresholds to correctly identify patients 
as undertreated from a dyskinesia perspective were calculated. 
The sensitivity of the PKG™ parameter was .47 (9/(9+10) = .47), meaning the PKG™  indicative 
thresholds for undertreated DKS (DKS >9) (as defined by Odin and colleagues (2018)) will 
correctly identify 47% of patients who are undertreated from a dyskinesia perspective. 
Evidence of peri-dose tremor 
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The specificity of the PKG™ parameter was .97 (156/(156+4)= .97) meaning the PKG™  
indicative thresholds for undertreated DKS (DKS >9) (as defined by Odin and colleagues 
(2018)) will correctly identify 97% who are not undertreated from a  dyskinesia perspective. 
It was of interest to investigate the reasons why either the clinical team or the PKG™ did not 
identify certain patients as undertreated from a dyskinesia perspective, and this will be 
explored below. 
Patients identified as undertreated from a dyskinesia perspective by the PKG™ parameter 
only (n=4): 
Three of the patients identified as undertreated by the PKGTM parameter were reported by 
the clinical team as having a good overall level of function. One patient was reported as having 
a striking dopa-responsive tremor with wearing off, and this was the overriding issue picked 
up on by the clinical team. The PKGTM graph and tremor summary for this patient is displayed 
in Figure 47 below.  
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Figure 47   PKG™ graph (above) for a patient that was identified by PKG™ parameter only as undertreated from a dyskinesia perspective, but was not identified by the clinical team. The thick 
lines represent median bradykinesia (blue lines) and dyskinesia (green lines) from over the duration the PKGTM was worn, and the thin lines represent the interquartile range (IQR). The red lines 
represent the pre-programmed prescribed L-dopa times, and the red diamonds indicate times when the patient registered taking their L-dopa. The tremor summary (below) demonstrates 
evidence of dopa-responsive tremor. Black marks on the summary plot represent every 2min epoch where tremor is. The red lines represent the pre-programmed prescribed L-dopa time. 
Increasing Dyskinesia 
(DKS)  
Median of 
Control 
Worsening 
Bradykinesia (BKS) 
Evidence of peri-dose 
tremor, contemporaneous 
with dyskinesia peaks. 
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The DKS trace (green line) and the tremor trace below (tremor summary) demonstrate that 
tremor can mimic DKS if it is of low frequency and large enough amplitude, and this is referred 
to as ‘tremor bleed through’.  
Patients identified as having undertreated dyskinesia by the clinical team only (n=10): 
Patients in this group were typically described as having mild-moderate peak dose dyskinesia, 
but had acceptable levels of dyskinesia overall, and so were not identified by the PKG™ 
parameter as having undertreated dyskinesia.  
Figure 48 is an example of a PKG™ graph that demonstrates some peak dose dyskinesia 
despite having acceptable levels of dyskinesia overall (DKS <9).  
The medications for this patient at the time of recording were as follows: Madopar 250mg 3 
times a day at 06:00, 11:30, 16:30, Madopar CR 250mg a day at 21:00 and Rotigotine 4mg a 
day at 08:00. As before, the red lines only indicate doses of L-dopa. 
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Figure 48 PKG™ graph for a patient that was not identified by PKG™ parameter as undertreated from a dyskinesia perspective despite demonstrating peak dose dyskinesia. The thick lines 
represent median bradykinesia (blue lines) and dyskinesia (green lines) from over the duration the PKGTM was worn, and the thin lines represent the interquartile range (IQR). The red lines 
represent the pre-programmed prescribed L-dopa times, and the red diamonds indicate times when the patient registered taking their L-dopa.
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Dyskinesia (DKS)  
Median 
of Control 
Worsening 
Bradykinesia 
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To ensure the PKG™ graph represented clinically meaningful information, the follow up clinic 
letter was reviewed. The clinician noted that the patient was mildly dyskinetic, but wearing 
off was the overriding symptom discussed in clinic, and was treated by an increase of 
Madopar to 250mg four times a day, in addition to the Madopar CR 250g dose at night, with 
a plan to review after a couple of weeks on this regime. 
 
4.3 Part Two 
To evaluate patient acceptability of the PKGTM, I carried out a patient evaluation. As this was 
a clinical service evaluation, ethical approval was not required.  
4.3.1 Method 
4.3.1.1 Item development 
A PKG™ project group comprising 4 patients who had expressed an interest in research areas 
that involved the use of technology in PD were contacted regularly via email and telephone 
to discuss the design of the patient evaluation and accompanying documentation (e.g. the 
cover letter), in collaboration with the PD clinical team. Once the patient evaluation items 
had been developed, the wording and formatting of the questionnaire were reviewed by the 
patient group to ensure it was understandable by patients, and necessary amendments were 
made.  
4.3.1.2 Evaluation Items 
The patient evaluation items (n=20) focussed on 5 key areas: (1) Usability of the device (4 
items) (2) PKG™ Results Communication (5 items) (3) Impact on Care (3 items) (4) Overall 
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satisfaction (5 items) and (5) Areas of concern (3 items). Appendix 23 (section 8.23) details 
the patient evaluation in full. 
All items concerning satisfaction were rated on a five point scale from 1, strongly 
unfavourable to 5, strongly favourable, or were YES/NO answers from which satisfaction 
could be inferred. A score >3 was considered favourable for five-point items and a score of >1 
was considered favourable for 2 point items. The total satisfaction score was obtained by 
summing the score of all satisfaction items (maximum possible score of 84 in total).   
Once finalised, 100 questionnaires were sent via post (Feb 2018) to the most recent PD 
patients to have received a PKG™ at UHPNT. Patients were provided with a freepost envelope 
to return their completed questionnaire within 28 days.  
4.3.1.3 Statistical Analysis:  
The median values for each of the satisfaction items was given as a value of central tendency. 
The reliability of the questionnaire was examined by Cronbach’s alpha (Cronbach, 1951). 
4.3.2 Part Two: Results 
61 patients (median age 71 years (39-87), median disease duration 2.5 years (11 months- 17 
years)) completed and returned their patient evaluation (61% return rate). As all evaluations 
were anonymised, it was not possible to identify which pathway responders belonged to (FU 
or NP).  
4.3.2.1 Items Scores  
In Table 33 the median scale scores are grouped in the five areas of the evaluation (described 
above). The percentage of favourable answers (scores >3 for five-point items and >1 for 2 
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point items) are also given. The mean total score was 48 (SD=11) out of a possible maximum 
total of 84. 
4.3.2.2 Evaluation Reliability 
To examine the internal consistency of evaluation items relating to satisfaction, the 
Cronbach’s alpha was calculated. The questionnaire reliability was found to have a 
Cronbach’s alpha of .94. 
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Table 33 Median scale score and percentage of favourable answers for each satisfaction item of the Patient Evaluation 
Area of Evaluation Max Score Median response % favourable 
PKG™  Usability 
   
Before you received the PKG™, what was your level of understanding about the 
purpose of the device? 
5 4 54 
How helpful was the information provided to you when you first received the PKG™ 
in explaining about the device? 
5 4 80 
How comfortable did you find wearing the device? 5 4 82 
How did you find the process of returning the device? 5 5 98 
PKG™  Results    
If applicable how useful did you find the letter? 5 3 46 
If applicable how useful did you find the telephone? 5 3.5 50 
If applicable how useful did you find the graph? 5 2.5 27 
If applicable how useful did you find the report? 5 3.5 50 
Did you feel that these results were reflective of your lived experience during the 
time the PKG™ was worn? 
5 4 56 
Impact on Care    
How useful were the medication reminders in assisting you with taking your 
medication on time? 
5 4 100 
302 
 
Area of Evaluation Max Score Median response % favourable 
If applicable, how useful was the PKG™ data in assisting with explaining your 
symptoms to your Doctor or Nurse? 
5 3 34 
How valuable was the PKG™ in providing data to your Doctor or Nurse about your 
symptoms that you could not have provided? 
5 4 63 
Overall Satisfaction    
What level of involvement do you feel you have had in your treatment as a result of 
receiving the PKG™? 
5 4 53 
What level of involvement do you feel your consultant has had in your treatment as 
a result of receiving the PKG™? 
5 3 45 
What level of involvement do you feel your Parkinson’s Nurse has had in your 
treatment as a result of receiving the PKG™? 
5 4 77 
Would you be happy not to travel to your appointments? 2 2 81 
Would you use the PKG™ in future? 2 2 98 
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Overall, the device was rated highly usable, with 80% finding the introductory information 
helpful and 98% finding the process of returning the device simple. All patients valued the 
medication reminders to assist compliance. Only around half of responders reported finding 
any form of the reporting process useful in explaining the PKGTM results to them. In keeping 
with this, only 56% reported finding the PKG™ results were reflective of lived experience. For 
example, five patients reported concerns the data did not represent a ‘typical’ week, with one 
patient expressing concern that the recording had been performed over a particularly 
sedentary week. 
However, 63% of patients reported the PKG™ was valuable in providing data to their PD 
clinical team about their symptoms that they otherwise could not have provided. 
As a result of receiving the PKG™, 77% of patients perceived the PD nurses to have a high level 
of involvement in their treatment; 45% felt their consultant had a high level of involvement 
in their treatment; and 53% of patients felt that they had a high level of involvement in their 
own treatment.  
Eighty-one percent of patients reported they were satisfied with not having had to travel to 
clinic for an appointment and 98% of patients reported being willing to continue using the 
PKG™ as part of their PD management.  
4.4 Chapter Discussion 
I carried out a clinical service evaluation to evaluate the utility of an objective monitoring 
device, the PKG™, and associated indicative thresholds to identify patients experiencing 
unmet treatment needs in between clinic appointmentments. In addition, I evaluated patient 
acceptability of the PKGTM.   
I hypothesised that the PKGTM would identify a high number of patients experiencing unmet 
treatment need experienced between clinic appointments. 
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In line with my hypothesis, the evaluation revealed the  use of the PKG™ indicative thresholds 
and clinican interpretation of the PKG™ report identified a high number of patients 
experiencing an unmet treatment need between clinic appointments.  
However, my sensitivity and specificity analysis revealed the PKG™ BKS parameter is slightly 
more effective at identifying patients who are undertreated from a bradykinesia perspective 
than identifying patients who are not undertreated. Whereas the PKGTM DKS parameter was 
more effective at identifying patients who are not undertreated from a dyskinesia perspective 
than detecting patients who are undertreated.  
These findings are important, as they demonstrate that the PKG™ indicative thresholds are 
not able to identify all patients with unmet treatment needs (undertreated patients) 
particularly for patients with undertreated dyskinesia. These findings suggest that it may not 
be clinically viable to use the PKG™ parameters in isolation to identify undertreated patients, 
as there is potential for patients who are not fully optimised to be overlooked. Furthermore, 
because the PKGTM scores are based on data recorded during the ‘waking day’ (0900-1800), 
wearing off later in the day or early morning off may not necessarily be captured by the PKGTM 
scores. Instead, these findings highlight the necessity for qualitative as well as quantitative 
interpretations. For example, my findings revealed that some patients may show an optimal 
response overall, but on closer inspection of the PKG™ graphs, some of the patients show 
delayed responses to medication, or pre-dose wearing off.  
In addition, a patient in the new patient pathway was not identified by PKG™ indicative 
thresholds as undertreated from a motor perspective, despite demonstrating peri-dose 
tremor. Although tremor is often resistant to therapy (Haeri, Sarbaz, & Gharibzadeh, 2005), 
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there are examples where this is not the case, such as for this patient, whereby tremor 
appears related to treatment. Moreover, the overall PTT score for this patient was 3.8% which 
is above the recommended cut-off for acceptable level of tremor (1%) (Braybrook et al., 
2016). Tremor is one of the more noticeable symptoms of PD socially, and is rated as highly 
burdensome by patients (Heusinkveld, Hacker, Turchan, Davis, & Charles, 2018). My findings 
highlight that the PKG™ parameters for identifying patients as undertreated from a motor 
perspective do not take into account the patients’ tremor score, and this finding may have 
gone unnoticed without a qualitative and more detailed evaluation of their PKG™ graph. 
The authors of a recent qualitative evaluation of the PKG™  in a PD clinic suggest that the 
PKG™  may be of use in non-speciality care centres, for use by clinicians with varying levels of 
experience with continuous objective measurement (Santiago et al., 2019).  My findings 
challenge this idea, as they demonstrate that it is not feasible to rely on the quantitative 
analysis provided by the PKG™ alone; expert clinical interpretation of PKG™ data is needed to 
successfully identify reports where there are other indicators of under treatment (such as 
tremor, wearing off or dose failures), identify confounders (such as tremor bleed through) 
and take account of patient mitigation (such as an unusually sedentary week). 
Within our service, all clinicians and nurses carrying out PKG™ reporting are required to 
undergo PKG™ reporting training, which involves an online assessment and attending 
advanced training. In addition, an experienced neurologist oversees the reporting of each of 
the PDNS until reporting is standardised. These measures ensure that the clinical team within 
our service have a high standard of expertise in interpreting the PKG™  data and identifying 
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patients who may be undertreated, which helps to overcome some of the insensitivity of the 
PKG™  parameters found in this evaluation.  
My findings therefore suggest high quality clinical interpretation in combination with the 
PKG™ quantitative data offers a potentially more sensitive measure to identify patients who 
may be undertreated, as opposed to using the PKG™ data in isolation. As a result of my 
findings, I would recommend high standards of training are provided for clinicians in other 
centres using the PKG™, to ensure accurate clinical interpretation of findings. Within our own 
service, we plan to triangulate information obtained via the expert clinician PKGTM report and 
the patient perception of symptoms, with patient reported outcomes (PROs) (such as 
measures of QoL).  This will allow us to more fully determine the value and validity of the 
PKGTM findings. 
Part Two explored the patient acceptability of the PKGTM , via a patient evaluation. Overall, 
the evaluation revealed high usability and acceptability of the device and the PKGTM process. 
However, a high percentage of patients reported finding the results difficult to interpret, 
which likely limited patients’ appreciation of their relevance. As part of our upcoming service 
re-design, we plan to discuss with PwP how our patient-facing reports could be improved to 
increase the accessibility of PKGTM findings. This finding also highlights the importance of 
discussing the results with the patient and their carer in addition to their receiving a printed 
copy. 
Importantly, and in line with previous reported benefits of continual objective monitoring 
(Odin et. al, 2018), the evaluation revealed over half of patients found the device useful in 
providing data to their healthcare team that they otherwise could not have provided, 
307 
 
thereby offering information that would have otherwise gone undetected and therefore 
untreated.  
Furthermore, 81% of patients reported they would be satisfied with not having to travel to 
clinic for an appointment, which supports the feasibility of remotely monitoring PwP.  
Finally, almost all patients (98%) reported willingness to continue using the PKG™ as part of 
their PD management, which suggests an overall high level of satisfaction with the device. 
4.5 Conclusions 
In this evaluation, I aimed to evaluate the clinical utility of the PKGTM and associated indicative 
thresholds to identify patients with undertreated bradykinesia and dyskinesia. I further aimed 
to evaluate the patient acceptability of the PKGTM.  
I hypothesised that the PKGTM would identify a high number of patients with an unmet 
treatment need experienced between clinic appointments. 
In line with my hypothesis, the evaluation revealed the PKG™ identified a high number of 
patients experiencing unmet treatment need between clinic appointments, however the 
sensitivity and specificity analysis demonstrated there is potential for patients who are not 
fully optimised to be overlooked when using the PKGTM  indicative thresholds in isolation.  
My findings therefore highlight the importance of including expert qualitative evaluation of 
the PKGTM graph and report by an experienced clinician, to ensure all PKGTM findings are 
identified and interpreted correctly. 
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The patient evaluation revealed that while patients are largely satisfied with the PKG™ 
service, there are key areas of service improvements required, including initiatives to help 
improve patient understanding of results, and increase perceived involvement in care. 
Overall, the clinical evaluation has demonstrated we were able to use the PKGTM to identify 
patients experiencing unmet treatment need between clinic appointments. Next, we would 
like to investigate whether acting on identified unmet need results in improved patient 
outcomes.  
To achieve a robust evaluation of response to treatment intervention, we would like to 
evaluate outcome data with repeated patient centred outcome measures, including QoL. In 
addition, we would like to evaluate patient outcomes following the use of the PKG™ 
compared with standard care. It is hoped that a pilot study of a homebased care pathway at 
UHPNT utilising the PKGTM to facilitate remote care will help to better quantify the benefit to 
using the PKG™ as part of routine clinical service.  
If successful, the remote management pathway will help deliver home-based care, thereby 
replacing the need for current time-locked clinical review, and overcoming some of the issues 
discussed previously, including reduced pressure on consultant follow up clinics and nurses 
time, in addition to providing timely care to patients.  
4.5.1 Challenges surrounding the use of the PKGTM  
While the benefits of continuous objective measurement are internationally recognised (Odin 
et al., 2018), there are several known limitations to the PKG™ device that should be 
considered.  
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The PKG™ is worn on the wrist of the most affected upper limb, and therefore does not 
provide information on axial symptoms including falls or freezing of gait. These symptoms 
have well established associated physical and psychosocial consequences, and often have a 
negative impact on patients’ quality of life (Bloem, Hausdorff, Visser, & Giladi, 2004). When 
using the PKG™ to monitor symptom severity, it is therefore important that the clinician is 
able to gain information from the patient on their experiences of axial symptoms in addition 
to the PKG™ data.  
Furthermore, apart from issues with sleep, the PKG™ does not capture data on NMS such as 
depression, anxiety or pain. As discussed previously, the impact of NMS on patient well-being 
is significant (Martinez-Martin et al., 2011), and are the main cause of institutional care 
(Muzerengi et al., 2007). It is therefore important that clinicians take into account the impact 
of NMS when making treatment decisions in combination with the available PKG™ data.  For 
this reason, we now routinely send self-report measures of NMS burden and QoL (NMSQ and 
PDQ8 respectively) with all PKG™ devices to capture contemporaneous NMS information. We 
hope to use these data, in combination with the PKG™ data, to help identify patients who are 
struggling from a NMS perspective and facilitate timely intervention. In addition, we are 
developing a mobile application (NMS Assist) to provide remote monitoring of NMS and 
triggered service support for PwP and their carers, as well as information on self-management 
of PD NMS (see Chapter 3). 
There were several PKG™ reports that we were not able to include as part of the evaluation 
due to patient error (n=4) and device failure (n=4). It is a priority that the functionality of the 
PKG™ is well explained to patients to avoid errors such as large amounts of off wrist time. 
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Furthermore, an expert panel have recommended that patients’ level of cognitive functioning 
is taken into consideration when administering a PKG™, suggesting that objective monitoring 
may not be suitable for people with limited cognition (Odin et al., 2018).  
Resource and data management requirements also impact the implementation of the PKG™ 
within routine clinical service.  
At the time of the evaluation, the annual licence for the PKG™ was £19,500, however there 
are additional costs associated with the PKG™, including the nurse time required to arrange 
the PKG™, time to report the PKG™, MDT discussion time and phoning the patient with the 
result.  
The initial costs associated with objective monitoring technologies have been identified as a 
challenge to their integration as part of PD care, with healthcare providers reluctant to adopt 
technologies due to concerns surrounding costs, despite their apparent benefits (Espay et al., 
2016). There is a subsequent need for compelling cost-effectiveness studies to demonstrate 
the feasibility of these devices and support business cases for their use in routine care. 
In addition, the time required to report PKG™s has been a challenging issue within our clinical 
team, and for staff that are new to the process, reporting requires further assistance and 
time. To address this issue, reporting templates (see appendix 21 (section 8.21)) were 
implemented to make the PKG™ reporting as simple and quick as possible. However time 
available to produce reports is still limited, and additional resource such as administrative 
support is required to ease these pressures.  
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Finally, the data extraction and analysis of the PKG™ findings was challenging, and highlighted 
the need for improved documentation of all aspects of the PKG™ process. The management 
and documentation of large datasets, which are typical in the use of objective monitoring 
devices, is a recognised challenge associated with objective monitoring in healthcare (Lee & 
Yoon, 2017). Technical expertise is required to reap the most from the large amount of data 
that is produced. Advanced techniques including machine learning show promise in the 
analysis of disease-relevant information (Espay et al., 2016) , however increased support and 
resource is required in order for services to successfully implement these techniques.  
In future, we aspire to patients having access to their own healthcare data, including objective 
measurements, with potential to titrate their own medications within agreed parameters. 
The Patient Knows Best Portal ("Patients Know Best Patient Portal",2019) is an example of an 
electronic personal health record which provides patients with an online platform to help 
better manage their healthcare, including opportunities for online consultation and sharing 
data with health professionals and family members. The portal gives patients control of their 
own medical records, and is approved for use by the NHS. 
While promising, it is expected this new era of patient access will bring further data 
management and resource challenges to busy services (Armstrong, 2017). Concerns have 
been previously raised surrounding increases in clinicians’ time required to address patient 
concerns (Walker, Meltsner, & Delbanco, 2015), and security challenges with regards to 
accessibility of patient data (Esch et al., 2015). These challenges will need to be addressed if 
we are to deliver safe and effective healthcare in line with the new era of personalised 
medicine.    
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Chapter 5 An evaluation of Parkinson’s disease neuroprotective trial design spanning the 
last 10 years 
5.1 Introduction 
In this chapter, I am going to explore the use of technology in clinical trial delivery, with a 
particular focus on neuroprotective studies. 
While the digital health technologies (DHTs) I have discussed in previous chapters have been 
presented as clinical measures, these technologies also have potential to be used as 
endpoints in clinical studies. For example, DHTs can be used to perform active protocols (such 
as finger tapping) to objectively measure specific symptoms, or to perform passive protocols 
(such as monitoring movement), to detect and monitor impairments occurring in everyday 
life (Espay et al., 2016; Lipsmeier et al., 2018). Additionally, there are potentially greater uses 
of DHTs than to measure the outcome of clinical tests or for monitoring purposes. For 
example, DHTs have potential to aid clinical trial delivery including recruitment and patient 
stratification, as well as facilitating communication with participants (Espay et al., 2016).  
As discussed previously, DHTs include a broad range of mobile health technologies, including 
wearable devices such as body-worn sensors and portable systems that can be utilised by the 
patient in clinic, and in the home environment (Espay et al., 2019). 
DHTs that use a smartphone interface provide an opportunity to collect a number of clinically 
important parameters via brief interaction from the patient with the device (Espay et al., 
2016). For example, a smartphone application developed by the Oxford Parkinson’s Disease 
Centre (OPDC) mentioned previously, has been validated to detect and monitor Parkinson’s 
disease (PD) symptoms and predict disease severity, demonstrating potential for the 
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application to be used to monitor disease progression (Arora et al., 2015). The OPDC 
smartphone application has since been used in a larger scale study to successfully distinguish 
participants with REM Sleep Behaviour Disorder (RBD) from controls (Arora et al., 2018) and 
from other PwP, which is an established risk factor associated with developing PD (Noyce, 
Lees, & Schrag, 2016).  
DHTs are also collected via computerised versions of pre-existing pen and paper tests, 
particularly for the administration of cognitive assessments, thereby providing a potential 
solution to problems with inconsistent administration and scoring of test data, which have 
been widely recognised (Luciana, 2003; Lukin, Dowd, Plake, & Kraft, 1985).  
DHTs therefore offer a number of potential advantages over current assessments used in 
clinical studies, as outlined by Lipsmeier and colleagues (2018). Firstly, DHTs offer the 
potential to quantify symptom severity with increased sensitivity and objectivity than is 
achievable using rater-dependent clinical scales. Secondly, DHTs allow for increased testing 
frequency, allowing for assessments of motor symptoms at both a single time point (e.g. at 
baseline) and change over an interval (Mera, Heldman, Espay, Payne, & Giuffrida, 2017). 
Thirdly, DHTs allow for assessments to be carried out in the home environment, which 
produces data that is high in ecological validity, and provides an opportunity to capture rare 
incidents such as falls that take place outside of the clinic environment (Espay et al., 2016), as 
well as complex multi-dimensional parameters like gait (Del Din, Hickey, et al., 2016). 
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Fourthly, DHTs allow the measurement of other parameters within constructs, which would 
not be measurable in the traditional version of the test (Del Din, Hickey, et al., 2016). 
5.1.1 Potential use of DHTs in PD clinical studies 
There is growing evidence to support that inclusion of DHTs in clinical studies may help to 
overcome some of the current issues surrounding neuroprotective trial design (Artusi et al., 
2018; Dorsey, Papapetropoulos, Xiong, & Kieburtz, 2017). Inadequacies of current 
neuroprotective trial design have been discussed in several recent reviews as possible reasons 
why no pharmacological agent has been shown to slow, halt or reverse the progression of PD, 
despite many agents showing promise in pre-clinical studies (Athauda & Foltynie, 2016; 
Dorsey, Papapetropoulos, et al., 2017; McGhee, Ritchie, Zajicek, & Counsell, 2016). 
McGhee and colleagues (2016) carried out a review of clinical trial designs used to detect a 
disease modifying effect of drug therapy in PD (McGhee, Ritchie, Zajicek, & Counsell, 2016). 
The authors concluded that the best available clinical trial design to demonstrate disease 
modification was a long term follow up trial which analyses for sustained divergence in 
outcome measures between treatment arms over time. The authors went on to recommend 
the use of a primary outcome that was simple and easy to collect, such as death, which can 
be collected from routine data (e.g. national death registries).  
While this may be the best available design for truly determining if a drug has neuroprotective 
potential, it raises the following challenges; long-term follow up studies are time consuming, 
and expensive to carry out. Furthermore, long duration studies run the risk of unacceptably 
high rates of attrition (McGhee et al., 2016). This is particularly challenging currently, when 
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new compounds and potential therapeutics are being developed more rapidly due to in silico 
drug discovery and repurposing strategies (Wu & Chiang, 2018).  
Therefore another solution would be to (a) enrich the study population with those more likely 
to derive benefit (eg LRRK2 mutation carriers for a mitochondrial drug) (b) enrich the study 
population with those more likely to progress (eg RBD, prognostic high risk) and (c) develop 
more sensitive outcome measures to facilitate studies with either reduced sample size 
requirements or of shorter duration, which is a need that might most easily be met by new 
technologies. 
The potential advantages of DHTs have also been described in a more recent review by 
Athauda and Foltynie (2016), who discussed several limitations of current neuroprotective 
trial design, including selection of inappropriate endpoints, and poor selection of patient 
cohorts, which do not take into account the heterogeneity of PD.  
The authors made several recommendations for future trial design, including using disease 
prognosis models to stratify patients to more homogeneous cohorts, and selecting suitable 
endpoints to measure disease progression (Athauda & Foltynie, 2016). The authors 
highlighted that the use of technology based devices to remotely collect objective data has 
potential to reduce variability in assessments and improve patient compliance, by reducing 
the need for clinic visits. 
In another review, Dorsey and colleagues (2017) suggested that the failure of Phase III studies 
to replicate earlier successful Phase II results was partly due to the use of artificial and 
imperfect outcome measures. Dorsey (2017) highlighted that the inter and intra variability of 
rater-dependent clinical assessments that are administered infrequently and in artificial 
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environments, reduces confidence in the replicability of findings, which can lead to 
considerable economic costs and deter future investments for clinical studies (Dorsey, 
Papapetropoulos, et al., 2017). 
Although DHTs have not been utilised extensively in neurodegenerative clinical studies, there 
is evidence of technologies beginning to emerge as secondary or exploratory outcome 
measures.  
A quantitative motor assessment of finger tapping and other hand movement tasks (“Q-
Motor”), was one of the first DHTs to be used in clinical studies of Huntington’s disease (HD) 
(Sampaio, Borowsky, & Reilmann, 2014). In comparison with traditional rater-based 
assessment of motor symptoms in HD (e.g. The Unified Huntington’s Disease Rating Sale Total 
Motor Score (UHDRS-TMS)), the Q-motor tasks did not appear to exhibit placebo effects 
(Reilmann et al., 2015). This finding highlights placebo effects may be rater-dependent, and 
there may be potential to greatly reduce these by the inclusion of DHTs as clinical trial 
endpoints. The “Q-Motor” tasks have since been used in a PD cohort to differentiate finger 
tapping performance between PwP and controls, as well as demonstrate associations with 
The Unified Parkinson’s disease Rating Scale (MDS-UPDRS) motor score (Maetzler et al., 
2015).  
In addition, a smartphone-based measure developed by Roche was recently deployed as an 
exploratory outcome measure in a 6-month Phase I PD clinical trial (Lipsmeier et al., 2018). 
The smartphone-based application comprised six active tests including finger tapping, 
sustained phonation (making continuous ‘ahh’ sounds) and a balance task, that were 
designed to assess PD motor symptoms including tremor, bradykinesia, and postural 
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instability. In addition, the smartphone-based measure carried out passive monitoring of 
symptoms via smartphone sensors, which required participants to carry the phone in their 
pocket. Participants were asked to complete the active tasks once daily, and carry the phone 
with them throughout the day.  
The results demonstrated that all active and passive tasks significantly differentiated PwP 
from controls, and correlated with MDS-UPDRS motor scores (Lipsmeier et al., 2018). In 
addition, passive tasks revealed significantly reduced mobility in PwP in comparison with 
controls. Moreover, the active tests detected significant abnormalities in PwP who were rated 
as having no evidence of abnormalities in the corresponding motor symptoms of the clinical 
assessment. This finding suggests the smartphone-based measure may have increased 
sensitivity in comparison to rater-based assessments. In addition, participant adherence with 
the device was found to be acceptable, with an average compliance of 61% over the 6 months. 
The authors describe this to be a similar overall adherence to the OPDC smartphone based 
application described previously (69% adherence) (Arora et al., 2015; Bot et al., 2016). This 
study demonstrates that the use of a smartphone based outcome measure in clinical studies 
is feasible, and can provide reliable and clinical meaningful outcome data that has been 
collected remotely, from the home environment.  
A recent review has further examined the existing use of DHTs as primary, secondary, or 
exploratory outcomes in ongoing and published clinical studies of neurodegenerative 
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disorders including PD (Artusi et al., 2018).  The reviewers did not apply limits on the type of 
intervention used.  
Of the ongoing neurodegenerative clinical studies identified as part of the review (n=1529), 
42 studies (2.7%) were found to use DHTs as primary, secondary or exploratory outcomes. Of 
these, 23 (54.8%) were PD studies. The review revealed that sensor-based DHTs were the 
most frequently used technology-based outcome measure used in PD studies (n=20 studies, 
87%) and gait was the most assessed domain using DHTs (n=10 studies, 43%).  
Although the results of this review suggest that the use of DHTs in neurodegenerative clinical 
studies is limited, there was evidence of an increased trend in the number of published clinical 
studies integrating DHTs over the years studied (from 1985 to 2015) (Artusi et al., 2018). 
Furthermore, in a survey carried out by the review authors, 85% of surveyed pharmaceutical 
companies (total surveyed n=12) stated they were considering integrating DHTs in future 
neurodegenerative clinical studies within the next five years (Artusi et al., 2018). These 
findings demonstrate the potential rise in the use DHTs in future clinical research. 
In order to explore the potential for DHTs to add value to current PD neuroprotective trial 
delivery, I undertook an evaluation of key elements of trial design in recent and current PD 
neuroprotective studies. 
5.1.2 Research Aims  
The aims of this evaluation were to assess whether there was an established methodology for 
(1) measuring disease progression, and (2) for stratifying patients for trial entry. If there was 
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no evidence of an established methodology in these areas, then I aimed to determine the 
areas of uncertainty where DHTs may add value. 
5.1.3 Hypotheses 
In light of previous suggestions that inadequacies of current PD neuroprotective trial design 
may be possible reasons why no pharmacological agent has been shown to slow, halt or 
reverse the progression of PD, I hypothesised:  
1. There would be little evidence of an established methodology for measuring disease 
progression.  
2. There would be little evidence of stratifying patients for trial entry. 
To investigate these hypotheses, I undertook a methodological systematic review mapping 
the research design and characteristics of Phase II and Phase III PD neuroprotective clinical 
studies, registered or published over the last 10 years (2008-2018).  
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5.2 Methods: 
This review was conducted according to Preferred Reporting Items for Systematic Reviews 
and Meta-analyses (PRISMA) guidelines (Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 
2009). 
The review was carried out in collaboration with patient representatives who acted as 
secondary independent reviewers. Role descriptions for each of the reviewers are outlined in 
Table 34.  
Table 34 Description of group roles 
Reviewer Role Description of role 
Thea Dominey (TD) Main reviewer, Researcher TD was responsible for 
carrying out the study search, 
carrying out initial assessment 
of studies for inclusion against 
the study eligibility criteria, 
the data extraction and the 
data analysis.  
   
Karen Raphael (KR) Secondary reviewer, Professor 
of Oral and Maxillofacial 
Pathology and Psychiatry*, 
and patient representative 
KR was responsible for 
independently assessing the 
studies for inclusion against 
the study eligibility criteria.  
Sue Buff (SB)  Secondary reviewer, patient 
advocate and co-author of ‘PD 
Trial Tracker’  
(“PDTrialTracker.info,” 2019) 
SB was responsible for 
independently carrying out 
data extraction for the 
included studies. 
 
Camille Carroll (CC)  Secondary Reviewer, 
Associate Professor and 
Honorary Consultant 
Neurologist 
CC was responsible for 
assisting the group to reach 
consensus when discrepancies 
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Reviewer Role Description of role 
in study eligibility or data 
extraction arose. 
* Professor in Oral Medicine at the New York University College of Dentistry, and in Psychiatry at the New York 
University School of Medicine, New York, NY. 
5.2.1 Study eligibility criteria 
The study eligibility criteria were developed using the PICOS (Population, Intervention, 
Comparator, Outcome and Study design) formula (Liberati et al., 2009), as exemplified in 
Table 35. 
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Table 35 Study eligibility criteria for the systematic review 
 
  
Criterion Inclusion Criteria Exclusion Criteria 
Population - Studies in patients with a 
confirmed diagnosis of PD 
at any stage of the disease 
- Studies in patients 
without a diagnosis of PD 
Intervention - Studies involving a 
potentially 
neuroprotective agent 
- Studies involving all other 
interventions (eg. 
symptomatic) 
- Studies involving no 
interventions (eg. 
observational studies) 
Comparator - A comparator, including 
an existing treatment, no 
treatment, or placebo was 
an essential requirement 
for inclusion 
- Studies with no 
comparator  
Outcome - Studies specifying a well-
defined primary outcome 
- No well-defined primary 
outcome specified 
Study design - Phase II and Phase III 
interventional, 
neurodegenerative  
randomised controlled 
studies (RCTs)  
- Single blind, double blind 
or open label  
- Published, or (if still 
ongoing) first registered 
from 2008 to 2018  
- Phase I RCTs 
- Phase II and Phase III RCTs 
outside the time frame of 
the search 
- Phase II and Phase III 
single group studies (no 
comparator) 
- Phase II and Phase III non-
randomised controlled 
studies 
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5.2.2 Principles of the search strategy  
The search methods used in this review are listed below, and were used to ensure the greatest 
number of relevant studies were retrieved, while reducing the number of irrelevant papers. 
Search methods included in this review:  
- Electronic database search / Clinical trial register search 
- Reference list scanning 
- Contacting authors of included studies 
- Google search 
5.2.3 Selecting the databases 
Three electronic databases were selected: MEDLINE (MEDLINE, 2019), Clinical Studies.gov 
(Clinical Studies.gov, 2019) and PD Trial Tracker (PDTrialTracker, 2019). 
5.2.4 Search strategy 
The following search terms were incorporated as part of the final search strategy:  
- Interventional Studies 
- Parkinson’s disease 
- Phase II 
- Phase III 
- 2008-2018  
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5.2.5 Supplementary searches: 
Reference lists of relevant review papers were searched to identify additional records. 
Authors were contacted to gain additional information that was not listed, or to gain access 
to articles. Google was used to search for press releases related to unpublished studies. The 
last search was performed on 27/06/2018.  
5.2.6 Study selection 
Studies retrieved from database searches were screened by evaluating records first by title, 
then abstract, then at full text level, against pre-specified study eligibility criteria (see Table 
35). Duplicated reports were excluded at title and abstract level. Eligibility assessments were 
performed independently by two reviewers (TD and KR) and discrepancies between reviewers 
were resolved by consensus, via discussion with CC. The study selection process is 
summarised in Figure 49.  
5.2.7 Risk of bias 
As the aim of the review was to map research design and characteristics of Phase II and Phase 
III PD neuroprotective clinical studies, we did not assess the risk of bias of individual studies.   
5.2.8 Data extraction 
The data extraction form (appendix 24 (section 8.24)) was created in Microsoft Excel and 
piloted by TD and SB. Piloting led to adaptations to improve its usability (e.g. inclusion of 
dropdown items).  
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5.2.9 Extracting the data  
Data extraction was performed independently by TD and SB; TD performed a check for 
accuracy and completeness. Any highlighted discrepancies were resolved by discussion 
between the group members and CC.  
5.2.10 Data Items 
Data were extracted from each study relating to: 
1) Study phase and (where appropriate) year of publication / year registered 
2) Intervention being investigated 
3) Number and location of study sites 
4) Number of site visits required 
5) Details of study design including: 
- masking (double blind, single blind or open label) 
- trial design (e.g. placebo controlled) 
6) Details of the inclusion/exclusion criteria for enrolment including: 
- disease stage  
- disease duration 
- H&Y stage 
- cognitive tests and relevant cut offs for inclusion  
- if drug naivety was required 
- genetic criteria 
7) Study outcomes including:  
- details of the primary outcome domain and measures used 
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- secondary outcome measures used, including whether these were mechanistic 
outcomes 
8) Details of patient reported outcomes used (only measures that were completed by 
patients (i.e. self-administered) were included as a PRO).  
5.2.11 Data synthesis  
Synthesis involved the combination and collation of the design choices of individual studies 
included in the review.  
5.2.12 Narrative synthesis  
Heterogeneity in the status of studies included as part of the review (eg. published or 
unpublished), in addition to heterogeneity in study design and outcome data precluded the 
use of a meta-analysis. A narrative synthesis was therefore used to summarise the results of 
included studies.  
5.2.13 Strength of evidence assessment  
As only RCT studies were included as part of the review, which are considered to be the gold 
standard of clinical trial design (Bhide, Shah, & Acharya, 2018), we did not include a GRADE 
approach as part of our review (Moher, Liberati, Tetzlaff, Altman, & PRISMA Group, 2009). 
5.3 Results 
5.3.1 Study selection  
Database searches identified 1098 records. 5 additional records were identified through 
supplementary searches. After adjusting for duplicates, 565 records remained. Of these, 312 
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studies were excluded at title level in line with the study eligibility criteria as outlined in Table 
35. Of the remaining 253 records evaluated at full text level, 203 were excluded for the 
reasons outlined in Figure 49 and in line with the study eligibility criteria as outlined in Table 
35 leaving a total of 50 studies included in the final analysis. Figure 49 summarises the study 
selection process.  
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(n= 163) 
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• Patients without Parkinson’s disease 
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• Phase One RCT (n= 18) 
• Insufficient information to include 
(n= 5) 
• Outside timeframe of search (n= 1) 
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Eligibility 
Included 
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Figure 49 PRISMA flow chart illustrating the study selection process. 
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5.3.2 Study demographics:  
Fifty studies (n=50) met the criteria for inclusion, with the lead site for each study 
representing 11 countries from four continents: Europe (n=12), North America (n= 28), Asia 
(n=8) and Oceania (n=2). For published studies, the year of publication is summarised in Figure 
50 and for ongoing studies, the year of registration is summarised. 
 
Figure 50 Number of studies registered (ongoing studies n= 23) or published (published studies n=28) per year (2008-18) 
Forty-three studies were Phase II and 7 studies were Phase III. Results will be presented 
separately for Phase II and Phase III studies throughout. 
5.3.3 Status 
The status and key design features of the Phase II and Phase III studies are summarised in 
Appendix 25 (section 8.25) and Appendix 26 (section 8.26) respectively.  
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Of the Phase II studies, 22 (51%) were completed and reported, of which 15 studies (68%) 
successfully met their primary endpoint. 
Of the Phase III studies, 6 (86%) were completed and reported, of which 2 studies (29%) 
successfully met their primary endpoint. 
Figure 51 summarises the status of the included studies.  
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(n=1) 
(n=2) (n=4) 
Figure 51 Flow chart illustrating the status of the included studies. 
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5.3.4 Study design 
The majority of Phase II studies used a double blind, placebo controlled design (n=39, 91%). 
Similarly, the majority of the Phase III studies also used a double blind, placebo controlled 
design (n=6, 86%). 
Details of the study designs used for included studies are described in Figure 52. 
 
Figure 52 Study design for included Phase II (n=43) and Phase III (n=7) studies 
5.3.5 Number of site visits required:  
Of the Phase II studies with available data (n=30), the median number of site visits required 
as part of the study was 7 (2-104 visits).  
Of the Phase III studies with available data (n=7), the median number of site visits required as 
part of the study was 10 (4-38 visits).  
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5.3.6 Measuring disease progression: 
Details of the outcome measures used in the Phase II and Phase III studies are summarised in 
Appendix 27 (section 8.27) and Appendix 28 (section 8.28) respectively.  
5.3.7 Primary Outcomes 
The primary outcome domains used in the Phase II and Phase III studies, and the number of 
measures used to assess these are summarised in Table 36. Across studies, there was disparity 
in the outcome measures chosen to assess each of the primary outcome domains, with a total 
of 31 different outcome measures being used to assess 10 domains. 
In addition, eight Phase II studies (19%) included more than one primary outcome. None of 
the Phase III studies included more than one primary outcome. 
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Table 36 Summary of the number of studies using different primary outcome domains, and the number of outcome 
measures used to assess these. 
 
Phase II  Phase III 
Outcome domain  Number of 
studies 
Number of 
measures 
Number of 
studies 
Number of 
measures 
Motor 26 3 6 2 
Safety  10 12 0 0 
Target engagement 1 1 0 0 
Site of action 
penetration 
1 1 0 0 
Mechanism of action 3 1 0 0 
Cognition 2 3 0 0 
Tolerability/Adherence 6 7 0 0 
Non-motor 1 1 0 0 
Time to start 
Levodopa 
2 1 0 0 
Combined 0 0 1 1 
 
The different primary outcome measures used by Phase II and Phase III studies will be 
discussed in turn.  
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5.3.8 Primary outcome measures used in Phase II studies 
5.3.8.1 Phase II Motor Outcomes 
The majority of the Phase II studies included a motor primary outcome (n=26, 60%). All of 
these studies used the MDS-UPDRS to assess motor impairment, however there was variation 
in the MDS-UPDRS sub-scale used. Of the studies using the MDS-UPDRS, 14 studies (54%) 
used the Part III motor sub-score, 11 studies (42%) used the MDS-UPDRS I-III total score, and 
1 study (4%) used Part II (motor experiences of daily living) and Part III (motor sub-score).  
The medication state that the MDS-UPDRS was carried out in (ON or OFF state) is summarised 
in  
 
Table 37. A number of studies (n= 5) did not specify which medication state the MDS-UPDRS 
assessment was carried out in.  
Some studies were recruiting patients yet to start dopamine-replacement therapy; for the 
purposes of this evaluation, these were included in the OFF state assessment category. 
The majority of studies completed the MDS-UPDRS assessment in the OFF medication state. 
Only one study provided justification for carrying out the MDS-UPDRS assessments in the ON 
state, stating that: 
 “We did not evaluate “OFF” phase MDS-UPDRS as the primary endpoint, because the waiting 
time in the out-patient clinic might have been insufficient to evaluate the symptoms of ‘OFF’ 
phase.”  (Yoritaka et al, 2015, p. 912). 
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Table 37 The number of studies stating the medication state in which the MDS-UPDRS assessment was to be carried out in 
(ON or OFF state) 
 ON OFF* Not specified 
MDS-UPDRS Part III 1 12 1 
MDS-UPDRS I-III Total 
Score 
1 6 4 
MDS-UPDRS Part II 
and III 
1 - - 
 
5.3.8.2 Phase II Safety Outcomes 
Twenty-three percent of Phase II studies (n=10) included a safety primary outcome. As 
summarised in Table 38, safety was measured across 10 studies by 11 different definitions, or 
was not defined. The various definitions of safety used across studies is outlined in Table 38. 
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Table 38  The definitions used to measure safety across Phase II studies (n=10) 
 
5.3.8.3 Tolerability/adherence Outcomes  
Fourteen percent of Phase II studies (n=6) used a tolerability/adherence primary outcome. 
Various definitions (n =6) were used to measure tolerability/adherence or were not defined, 
as outlined in Table 39. 
 
 
Definitions of Safety 
Number of 
studies 
Number of participants with abnormal lab values/adverse events/serious 
adverse events 1 
Number of treatment-related serious adverse events 2 
Number and severity of any adverse event (AE) 2 
Percentage of participants with AEs and SAEs 1 
Absence of serious adverse eperiences (SAEs) 1 
Exercise-related adverse events (e.g., strains/sprains, cardiovascular events). 1 
Falls and fall injuries in and out of boot camp  1 
Change in neuro and physical examination findings 2 
Change in ECGs 1 
Change in Suicidality Score – CSSRS 1 
Blood test 1 
Not specified 1 
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Table 39 The definitions used to measure tolerability across Phase II studies (n=6) 
Definitions of tolerability/adherence 
Number of 
studies 
Proportion of subjects who complete study or to the time of initiation 
of dopaminergic therapy 1 
Number of participants that attend a minimum number of sessions per 
week 3 
Ability to complete study on assigned dose 2 
Change in clin lab test data 1 
Maximum heart rate 1 
Drop-out rate  1 
Not Specified 1 
 
5.3.9 Primary outcome measures used in Phase III studies 
All 7 of the Phase III studies (100%) used an efficacy outcome as their primary outcome. None 
of the Phase III studies included a safety or tolerability/adherence outcome as their primary 
outcome. 
5.3.9.1 Phase III Motor Outcomes 
Eighty-six percent of the Phase III studies (n=6) used a motor primary outcome. Of these 
studies, 5 (71%) used the MDS-UPDRS I-III total score (all completed in the OFF state), and 1 
study (14%) used the MDS-UPDRS Part III (completed in the OFF state). 
One study out of the included Phase III studies did not use a motor primary outcome (Kieburtz 
et al., 2015). This study used a global statistical test (comprising the Modified Schwab and 
England Activities of Daily Living Scale, 39-Item Parkinson’s Disease Questionnaire (PDQ-39) 
Summary Index (PDSI), ambulatory capacity (the sum of 5 questions from the Unified 
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Parkinson Disease Rating Scale [UPDRS]), Symbol Digit Modalities Test, and the modified 
Rankin Scale) to measure function, activities of daily living, ambulation, cognition, and quality 
of life. The study authors cite that these measures were chosen because they are generally 
thought to be relatively resistant to dopaminergic therapy and were the hallmarks of 
worsening Parkinson disease (Kieburtz et al., 2015).  
5.3.10 Mechanistic secondary outcome measures  
Seventeen Phase II studies (40%) and 2 Phase III studies (29%) listed a mechanistic outcome 
measure as a secondary outcome measure. Mechanistic secondary outcomes were most 
commonly used to show penetration to site of action, target engagement or mechanism of 
action.  
The modality of secondary mechanistic outcome used in the included Phase II and Phase III 
studies is summarised in Table 40.  
Table 40 The frequency of mechanistic secondary outcome measures used across studies 
 Measure Phase II (n=17) Phase III (n=2) 
Blood Test 6 1 
CSF 2 0 
DaTSCAN 4 0 
MRI 4 0 
PET 0 0 
SPECT 1 1 
Brain imaging (not specified) 1 0 
Urine 0 0 
Not listed 0 0 
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5.3.11 Patient Reported Outcomes  
Of the Phase II studies, 8 studies (19%) used a patient reported outcome (PRO) as part of their 
primary or secondary study outcomes. 
Of the Phase III studies, 5 studies (71%) used a PRO as part of their primary or secondary study 
outcomes. 
Table 41 summarises the PROs that were used as primary or secondary outcomes in the 
included studies (n=50). Some studies used more than one PRO. 
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Table 41 The frequency and type of Patient Reported Outcomes used in Phase II and Phase III studies as primary or secondary outcomes 
 
Phase II (n=8) Phase III (n=5) 
 
Primary Outcome measures Secondary Outcome measures Primary Outcome measures Secondary Outcome measures 
NMSQ* 0 2 1 0 
EQ5D 0 1 0 3 
PDSS 0 1 0 0 
PDQ39 0 2 1 4 
PDQLQ 0 1 0 0 
IMI 1 0 0 0 
NeuroQoL 0 0 0 2 
Schwab and England Scale 0 0 1 2 
SCOPA Sleep Scale 0 0 0 1 
RBDSQ  0 0 0 1 
EQ VAS 0 0 0 1 
BDI 0 0 0 2 
PD FSQ 0 0 1 0 
PFS-16 0 0 1 0 
*Non Motor Symptoms Questionnaire (NMSQ), EuroQol (EQ5D), Parkinson’s Disease Sleep Scale (PDSS), Parkinson’s Disease Questionnaire (PDQ39), Parkinson’s Disease Quality of Life Questionnaire (PDQLQ), 
Intrinsic Motivation Inventory (IMI), Quality of Life in Neurological Disorders (NeuroQoL), Schwab and England Scale, SCOPA Sleep Scale, REM Sleep Behaviour Disorder Screening Questionnaire (RBDSQ), EuroQol-
Visual Analogue Scale (EQ VAS), Beck’s Depression Inventory (BDI), PD Functional Status Questionnaire (PD FSQ), PD Fatigue Scale (PFS-16). 
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5.3.12 Stratifying patients for trial entry 
The inclusion criteria for the included Phase II and Phase III studies were reviewed to assess 
whether any methods of stratification were used. Details of the inclusion criteria in the Phase II 
and Phase III studies are summarised in Appendix 29 (section 8.29) and Appendix 30 (section 8.30) 
respectively.  
5.3.12.1 Genetic criteria 
Of the Phase II studies, one study (MOVES PD) (2%) used a selective method of recruitment based 
on possible mechanism of action, by specifically recruiting patients with mutations of the 
glucocerebrosidase (GBA) gene to assess the safety of Ambroxol.  
No other Phase II or Phase III studies specified genetic criteria for inclusion. 
5.3.13 Disease duration  
A wide range of disease durations were specified as part of the included studies’ inclusion criteria 
from <1 month of symptoms to <15years since diagnosis. Table 42 details the disease durations 
listed as part of the inclusion criteria for the included Phase II and Phase III studies. Nineteen Phase 
II studies (44%) and 1 Phase III study (14%) did not specify disease duration of participants as part 
of their inclusion criteria.  
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Table 42 The frequency of disease durations specified for inclusion criteria for the included Phase II and Phase III studies (n=50) 
 Phase II  (n=43) Phase III (n=7) 
 
Frequency Percentage (%) Frequency 
Percentage 
(%) 
Not Specified 19 44 1 14 
<1 month of symptoms 1 2 0 0 
>2 years of symptoms 2 5 0 0 
6 months - 8 years since 
diagnosis 
0 0 0 0 
PD diagnosis 1 year prior to 
dementia 
1 2 0 0 
Within 18 months of diagnosis 2 5 1 14 
Within 2 years of diagnosis 1 2 1 14 
Within 3 years of diagnosis 5 12 2 29 
Within 5 years of diagnosis 4 9 2 29 
≥ 3 years of diagnosis 1 2 0 0 
≥ 5 years since diagnosis 5 12 0 0 
<10 years since diagnosis 1 2 0 0 
<15 years since diagnosis 1 2 0 0 
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5.3.14 Disease severity 
Twenty Phase II studies (47%) did not specify a required disease stage as part of their inclusion 
criteria. Of the studies that did specify disease stage, ‘Early PD’ was the most frequently specified 
(n=15, 35%).  
Two Phase III studies (29%) did not specify a required disease stage as part of their inclusion 
criteria. Of the remaining studies that did specify disease stage, ‘Early PD’ was the most frequently 
specified (n=5, 71%).  
Figure 53 summarises the disease stages specified as part of the included studies’ inclusion criteria. 
 
Figure 53 Disease stage as specified by study inclusion criteria for the included Phase II (n=43) and Phase III (n=7) studies. 
5.3.15 H & Y Scores 
Corresponding H&Y scores were extracted for the studies’ inclusion criteria that specified ‘Early 
PD’ (Phase II n=15, Phase III n=5). Figure 54 summarises the H&Y scores that were specified by the 
studies requiring patients with ‘Early PD’.  
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Figure 54 The number of ‘Early PD’ studies and corresponding H&Y stage specified as part of their inclusion criteria 
5.3.16 Drug Naivety 
Two of the included Phase II studies (5%) specified that participants had to have not yet started 
any anti-Parkinson’s medication (drug naïve) as part of their inclusion criteria. 
Two Phase II studies (5%) specified that participants must have stopped taking their anti-
Parkinson’s medication 1 month prior to baseline. 
Four of the included Phase II studies (10%) specified that participants had to have not yet started 
dopaminergic medication, but other anti-Parkinson’s medication such as MAO-B inhibitors were 
allowed. 
None of the Phase III studies (n=0) specified that participants had to have not yet started anti-
Parkinson’s medication (drug naïve) as part of their inclusion criteria. 
One of the Phase III studies (14%) specified that participants had to have not yet started 
dopaminergic medication, but MAO-B inhibitors were allowed. 
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5.3.17 Cognition  
For Phase II studies, the most frequently cited cognitive assessments included as part of cognition 
inclusion criteria were the MMSE (n=13, 30%) and the MOCA (n=11, 26%). Two studies (5%) used 
the MDRS, and 1 (2%) study used the Folstein Mini Mental Examination. 16 Phase II studies (37%) 
did not specify using any cognitive assessments as part of their inclusion criteria. 
For Phase III studies, the most frequently cited cognitive assessments included as part of cognition 
inclusion criteria for the included studies was the MMSE (n=3, 43%) and one study specified using 
the MOCA (14%). Three studies (43%) did not specify using any cognitive assessments as part of 
their inclusion criteria. 
There was disparity across the cut-offs used for each of the cognitive assessments. In Phase II 
studies, MMSE cut-off scores ranged from 16/30 – 26/30, and MOCA cut-off scores ranged from 
20/30 - 26/30.  In Phase III studies, MMSE cut-off scores ranged from and 25/30 - 26/30. 
5.4 Discussion  
I carried out a review of Phase II and Phase III PD neuroprotective trial design spanning the last 10 
years. My hypotheses were:  
1. There would be little evidence of an established methodology for measuring disease 
progression.  
2. There would be little evidence of stratifying patients for trial entry. 
Results of the review are discussed below in relation to each of these hypotheses, with 
recommendations for how DHTs may add value to each of these areas. 
347 
 
5.4.1 Hypothesis One: There would be little evidence of an established methodology for 
measuring disease progression. 
The review revealed that a wide range of primary outcome measures is used across Phase II and 
Phase III studies, therefore providing support for my first hypothesis. In total, 31 different outcome 
measures were used to assess 10 different domains, including motor, safety and tolerability as well 
as mechanistic outcomes.  
Of the Phase II studies, the most frequently assessed domain was motor, with 60% of studies 
including a motor primary outcome. While all of the Phase II studies used the MDS-UPDRS to assess 
motor function, there was variation in the sub-score used. Some studies used the MDS-UPDRS total 
score (parts I-III), which takes into account motor and non-motor experiences of daily living and 
motor ability, while other studies used the motor sub-score (part III) in isolation. There was also 
variation in whether the MDS-UPDRS was carried out while patients were in the ON or OFF 
medication state. 
Of the Phase III studies with a motor primary endpoint (86%), all of the studies chose the MDS-
UPDRS as their primary motor outcome. As with the Phase II studies, there was variation in the 
sub-score used (total score or Part III), as well as whether these were carried out in the ON or OFF 
medication state. 
In addition, there was large variation observed in the definition of safety used in Phase II studies, 
with 11 different definitions used across 10 studies. Similarly, tolerability outcomes lacked 
consensus in their definitions, with 6 definitions of tolerability being used across 6 Phase II studies. 
The variation in primary efficacy endpoints being used in PD neuroprotective studies illustrates the 
lack of an established methodology for measuring disease progression. Despite the MDS-UPDRS 
Part III OFF state having been widely accepted as the best available assessment of disease 
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progression (Ramaker, Marinus, Stiggelbout, & van Hilten, 2002), my review has highlighted that 
this measure is not always chosen as the primary efficacy outcome in Phase II and even Phase III 
neuroprotective studies. This may be due to several limitations of the scale.  
As discussed previously, the MDS-UPDRS Part III is a subjective measurement, generally assessed 
by an independent rater. Despite objective instructions for use, and a mandatory rater training 
process, there is evidence of notable intra and inter-rater variability associated with the scale (Post 
et al., 2005), which limits its use as a reliable measure of disease progression.  
DHTs may offer a potential solution to this issue, as they can provide rater-independent, objective 
appraisal of symptoms, and so are not susceptible to rater bias or differences in rater experience 
or expertise (Dorsey, Papapetropoulos, et al., 2017). DHTs further have potential to provide an 
automated scoring system, which would save time for clinicians or researchers, and reduce the 
chance of scoring errors (Heldman, Espay, Lewitt, & Giuffrida, 2014).  
In addition, the MDS-UPDRS assessment is typically administered during study visits often weeks 
or months apart, and only provides a ‘snap-shot’ of a patient’s symptoms, which can be variable 
from a day to day, or even hour to hour basis (Papapetropoulos et al., 2015). In contrast, DHTs 
such as wearable sensors offer the potential to carry out daily active tests or passive measurement, 
and can monitor status continuously over a prolonged period of time in highly naturalistic 
environments, which would provide a more accurate reflection of the patient’s symptom severity 
and would be ideally suited to longitudinal studies (Espay et al., 2019). In addition, the increased 
test frequency could lead to increased statistical power, allowing for the identification of 
impairment that may otherwise go undetected using infrequent in-clinic assessments (Dorsey, 
Papapetropoulos, et al., 2017). 
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Furthermore, as discussed previously, DHTs offer potential to capture rare incidents such as 
freezing or falls, that do not frequently occur in clinic (Espay et al., 2016) but which may be valuable 
indicators of disease progression (Maetzler et al., 2009). Indeed, gait disturbance has been 
identified as a potential prognostic marker in PD (Lord, Baker, Nieuwboer, Burn, & Rochester, 
2011), as well as a possible marker of disease progression (Maetzler et al., 2009), with gait 
variability having been reported to correlate more strongly than bradykinesia with disease 
duration (Hausdorff et al., 2003). DHTs that have the ability to quantitatively record these 
symptoms therefore have the potential to capture more complex data than would be achievable 
by using clinical rating scales, which are limited by the type of symptoms they can effectively 
capture. Currently, rare events such as falls are documented via patient diaries, however these can 
be burdensome for patients to complete, and their reliability is often limited due to recall bias and 
diary fatigue, particularly in patients with cognitive impairment which is common in PD 
(Papapetropoulos, 2012).  DHTs therefore have the potential to provide a greater complexity of 
symptom information, which may give insight into prognosis and disease progression.  
In addition, many patients find the requirement to attend study visits in the OFF medication state 
for determination of the OFF-state MDS-UPDRS Part III the highly burdensome, which can be a 
barrier to trial participation and retention (Athauda & Foltynie, 2016). Indeed, one of the Phase II 
studies listed the time required to carry out the MDS-UPDRS assessment in the ‘OFF’ state as a 
barrier to including an OFF state assessment as part of their study protocol (Yoritaka et al., 2015). 
Alternative markers for disease progression such as temporal gait parameters (including stride and 
swing duration) appear independent from dopaminergic medication (Blin, Ferrandez, Pailhous, & 
Serratrice, 1991), and so by implementing DHTs that have been designed to assess these (Del Din, 
Hickey, et al., 2016), the need for a patient to be assessed in an OFF medication state may be 
avoided.  
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As mentioned previously, objective quantitative assessments that have been introduced as clinical 
trial endpoints in other neurodegenerative disease areas (Huntington’s disease (HD)), have been 
found to exhibit no apparent placebo-response effect, whereas for traditional clinical rating scales, 
placebo-response effects were observed (Reilmann et al., 2015). This finding demonstrates 
placebo-response effects may be rater-dependent, and suggests there may be potential to greatly 
reduce these by using quantitative measures. In PD studies, positive clinical responses during 
placebo intervention can obscure identification of potential neuroprotective effects of active 
treatments in clinical studies (Goetz, Wuu, et al., 2008). In a previous PD randomised placebo-
controlled trial (DATATOP-Study), placebo responses were detected in rater-based assessments 
without substantial changes reported in patient-based ratings (Goetz, Leurgans, Raman, & 
Parkinson Study Group, 2002), which provides support for the idea that rater bias may be an 
important consideration of placebo-related improvement (Goetz, Wuu, et al., 2008) and may be 
overcome via the inclusion of independent and objective measures. 
5.4.2 Hypothesis Two: There would be little evidence of stratifying patients for trial entry. 
Of the studies included as part of the review, only one study (MOVES PD) stratified patients for 
trial entry, thereby providing support for my second hypothesis that there would be little evidence 
of stratifying patients. In the MOVES PD study, the authors used a selective method of recruitment 
based on possible mechanism of action, by specifically recruiting patients with mutations of the 
GBA gene to assess the safety of Ambroxol.  
For the remaining studies (n=49), recruitment strategies did not take into account the 
heterogeneity of clinical features, treatment responses or prognostic indicators of their sample. 
DHTs may be useful in facilitating the application of different methods of patient stratification to 
future clinical trial design, and these will be discussed in turn below: 
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5.4.3 Using PD subtypes as a method of stratification 
Recently, new attempts to provide defined criteria for different PD subtypes have been made, and 
it is thought implementation of these may aid patient stratification for clinical studies. As 
mentioned previously, Lawton and colleagues (2018) have identified 4 possible PD phenotypic 
subgroups with associated levodopa response, non-motor features and motor progression rates 
(Lawton, 2018). The authors highlighted that the mean difference in MDS-UPDRS motor scores 
between the fastest and slowest motor progression subtypes of their sample (n=1601) was 2.6 
points, which was equivalent to the primary endpoint of the ADAGIO study (Rascol et al., 2011). 
While the efforts to identify PD subtypes are still ongoing, these findings demonstrate the potential 
value of introducing methods for stratification based on patients’ phenotypic subtype, to allow for 
inclusion of patients to more homogeneous cohorts. 
DHTs may offer an opportunity to support stratification of patients into relevant PD subtypes. For 
instance, in line with the PD subtypes mentioned previously (Lawton, 2018), DHTs that are able to 
detect participants with tremor dominant symptoms (Braybrook et al., 2016) may indicate a poor 
levodopa response and slow motor progression, whereas DHTs that detect early cognitive 
impairment (Dwolatzky et al., 2003) may indicate patients with a poor levodopa response but 
faster motor progression.  
Wearable technologies allow for longitudinal data to be collected in the home environment, 
thereby providing large amounts of ecologically valid information on the prevalence and severity 
of symptoms that can be used to stratify patients to relevant disease subgroups (Camicioli et al., 
2018). While it is likely that capturing digital data will allow some overlap with the clusters defined 
by traditional clinical measures (as outlined above), DHTs may also facilitate the identification of 
novel clusters, which may prove useful in future stratification of patients for clinical studies.  
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By reducing existing levels of heterogeneity in patient populations, the statistical power of studies 
is expected to increase, which will result in more efficient data collection, and lower costs (Athauda 
& Foltynie, 2016).  
5.4.4 Early disease detection 
The majority of Phase II studies included as part of the review specified that participants were 
diagnosed within 5 years, and of the studies that specified disease stage, the majority of these 
requested patients with ‘early’ PD. Neuroprotective studies commonly recruit patients with early 
PD to maximise the potential of any neuroprotective effect (Athauda & Foltynie, 2016). However, 
in line with Braak’s (2013) prominent staging theory, neurodegeneration may have already begun 
outside of the substantia nigra in Stages 1 and 2, but not progressed to the point of a formal 
diagnosis of PD, which is dependent on the presence of motor symptoms. This phase (whereby 
symptoms and signs are present but not yet sufficient to meet diagnostic criteria for classical PD) 
is known as prodromal PD (Postuma et al., 2015).  
Being able to detect individuals in the PD prodromal phase is useful in PD research, as this cohort 
stand to gain the most benefit from a neuroprotective therapy, which could delay or prevent the 
onset of disease (Athauda & Foltynie, 2016). As described previously, the MDS has published 
diagnostic criteria for prodromal PD (Berg et al., 2015) based on a variety of non-motor 
manifestations including REM Sleep Behaviour Disorder (RBD), olfactory dysfunction, constipation, 
excessive daytime sleepiness (EDS), symptomatic hypotension, erectile dysfunction, urinary 
dysfunction and depression (see section 1.2.8).  
DHTs may prove useful in assisting with the identification of individuals in this prodromal phase.  
As mentioned previously, the OPCD smartphone application comprising evaluations of voice, 
balance, gait, finger tapping, reaction time, rest tremor and postural tremor, was found to 
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successfully distinguish participants with RBD not only from controls (mean sensitivity 89.5% (SD 
3.5%) and mean specificity 85.3% (SD 3.7%)), but from other PwP (mean sensitivity 83.4% (SD 3.5%) 
and mean specificity 87.5% (SD 2.8%)) (Arora et al., 2018). RBD is an established risk factor 
associated with developing PD, and is included as part of the MDS diagnostic criteria for prodromal 
PD described previously (Berg et al., 2015). This study therefore highlights the potential use of a 
DHT to identify individuals in the prodromal stage, via completion of a smartphone based 
assessment that takes participants no more than 7 minutes to complete.  
In addition to using DHTs to identify patients with prodromal disease (Arora et al., 2018) online 
methodologies have also been used to identify people at a high risk of developing PD. 
Predict PD (Noyce et al., 2017) is an example of an internet based pre-diagnostic cohort study. 
Participants aged between 60 to 80 years without pre-existing PD or other movement or 
neurological disorder  were required to visit the study website on a yearly basis to complete a 
series of online tests of early features and factors associated with increased risk of PD. The results 
of these tests were used to create a risk score using the PREDICT PD algorithm (Noyce et al., 2017). 
In order to gain information on established factors associated with high risk of PD (intermediate 
markers) against which the risk score could be compared, participants were required to carry out 
several further online tests. These included; the RBD Screening Questionnaire (RBDSQ) (Stiasny-
Kolster et al., 2007) which is a validated questionnaire designed to assess for RBD, and the 
‘Bradykinesia Akinesia Incoordination test’ (BRAIN test (Noyce et al., 2014)) which is an objective 
measure validated to assess upper limb motor function in Parkinson’s (specifically slow finger 
tapping). The University of Pennsylvania Smell Identification Test (UPSIT) (Doty, Shaman, & Dann, 
1984), which has been validated to assess olfactory disturbance in Parkinson’s, was sent to 
participants via post. 
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Risk scores calculated from online data at baseline and during each year of follow-up were 
significantly associated with intermediate markers of PD (olfactory disturbance, RBD and slow 
finger tapping) at follow up (Noyce et al., 2017). These findings suggest that Internet-based 
approaches could be used to identify individuals at risk of developing PD from the general 
population (Noyce et al., 2017), and while no risk predictor will be 100% sensitive and specific; this 
approach may allow for enrichment of study cohorts in neuroprotective studies.  
Rapsodi (“Rapsodi” 2018) is another web-based study that aims to recruit GBA gene carriers 
without a diagnosis of PD. The study uses online measures (similar to those used in PREDICT PD) 
to collect data linked to genotype. The study is a further example of using internet-based 
methodologies to recruit a large sample of participants for screening at low cost, and using low 
levels of resource. The study investigators hope to use Rapsodi as a platform for the targeting of 
bespoke genetic therapies.  
An additional tool to help identify individuals with prodromal PD, is a risk model that has recently 
been developed to help identify individuals at an increased risk of Parkinson’s within 5 years 
(Schrag, Anastasiou, Ambler, Noyce, & Walters, 2019).  In this study, a large primary care database 
was searched to identify individuals with a diagnosis of PD (n=8,166) and controls (n=46,755). First 
presentations of symptoms 5 years prior to the diagnosis of PD were included as part of the 
analysis. Multivariate logistic regression analysis was used to create an algorithm for the risk of 
diagnosis of PD within 5 years of first presentation of symptoms.  
The final model was found to have high predictive accuracy; the area under the curve (AUC) was 
0.8 (95% confidence interval (CI) 0.78-0.81). The authors applied a threshold of 5% to split patients 
into high-risk and low-risk groups based on their predictive risk. At a threshold of 5%, the model 
had high negative predictive value. Ninety-nine percent of those who were not classified as high 
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risk did not go on to receive a diagnosis of PD. The model had a slightly lower positive predictive 
value, with 37% of those classified as high risk receiving a diagnosis of PD within 5 years. 
Using routinely collected data, this risk model could be used by primary care services to help 
identify individuals with possible prodromal Parkinson’s from their caseload, allowing for early 
referral, as well as timely and effective treatment.  Furthermore, the model could be used to 
identify individuals for inclusion into studies, allowing for investigation of individuals in the 
prodromal phase.  
5.4.5 Prognostic indicators 
In the review, no studies were found to stratify recruitment according to prognostic risk. Several 
prognosis predictors have become available that may be useful in this area, which require 
automated calculations to compute. For example, a prognostic score, which is a composite score 
comprising age, MDS- UPDRS motor examination axial score and animal fluency score has been 
validated to indicate the risk of an adverse outcome at 5 years, comprising falls, dementia and 
death (Velseboer et al., 2016). It is feasible this score could be included as part of clinical trial 
stratification to recruit those with the highest risk of progression in order to be able to demonstrate 
a meaningful difference in progression rate within a reasonable time frame (12-18 months). To 
make this prognostic score clinically viable however, it would be necessary to use a computerised 
tool which has the embedded algorithm (such as an excel spreadsheet or similar) to automatically 
compute prognostic scores with maximal ease and efficiency. 
In addition, a separate cohort study aimed to identify clinical variables that were predictive of 
cognitive impairment in early PD, which has implications for clinical prognosis (Schrag, Siddiqui, 
Anastasiou, Weintraub, & Schott, 2017). Predictive values of baseline clinical variables were 
calculated using univariate and multivariate linear analyses, with change in MoCA scores at 2 years 
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as the dependent variable. After age (which was the strongest clinical predictor of cognitive 
impairment) the strongest clinical predictors of cognitive decline were reduced sense of smell 
(measured by the UPSIT), RBD (measured by the RBDSQ), depression (measured by the 15 item 
Geriatric Depression Scale (GDS), and motor impairment (measured by the MDS-UPDRS motor 
score). This study therefore highlighted the possibility to identify patients early on in the disease 
course at risk of developing cognitive impairment using clinical characteristics. Similar to the 
prognostic tool mentioned previously (Velseboer et al., 2016), it may be possible to use this 
predictive model to create an algorithm for risk of cognitive impairment, which could be calculated 
automatically using a computerised calculation tool. This automated tool could be used to help 
stratify patients for clinical studies. 
5.4.6 Facilitating trial delivery 
The review highlighted the median number of site visits required for the Phase II and Phase III 
studies was 7 and 10 visits respectively. However for many patients, particularly those living in 
rural areas, attending this many episodic site visits may be challenging. Indeed, concerns regarding 
expenses incurred as a result of participating in a trial has been identified as a barrier to PwP 
participating in clinical studies (Mathur, Dewitte, Robledo, Isaacs, & Stamford, 2015).  
DHTs offer opportunities to collect symptom data remotely from the home environment, as well 
as facilitating the delivery of ‘virtual research visits’ via teleconferencing (Dorsey et al., 2015). 
These methods reduce the need for in-person assessments carried out at a research centre 
(Athauda & Foltynie, 2016), which in turn can reduce participation burden and may improve 
acceptability for patients who find travel challenging (Dorsey et al., 2016). This may subsequently 
improve patient compliance and adherence, which could lead to decreased patient dropout.  
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5.4.7 Challenges and Limitations 
Despite the potential value DHTs might add to PD neuroprotective studies, there are several 
recognised barriers to their implementation.  
5.4.7.1 Added value 
Firstly, there is a need to demonstrate the additional measurement accuracy that is provided by 
DHTs, other than simply generating objective based versions of previously validated subjective 
scales (Artusi et al., 2018). For instance, movement data collected by a sensory based finger 
tapping task has been used to detect different patterns of change in amplitude, frequency and 
velocity in PwP compared with controls, which would be difficult to achieve through visual 
inspection alone (Lones et al., 2014). As mentioned previously, gait is another feature of PD that 
has been shown to be a useful marker of disease progression and medication response (Del Din, 
Hickey, et al., 2016) and is traditionally assessed by timing how long it takes patients to walk a 
short distance, as well as carrying out visual observations. Wearable sensors offer great potential 
in the assessment of gait, over and above what is possible by visual inspection, by offering precise 
quantification of clinically relevant spatio-temporal gait features (such as step time, step length 
and swing time) from which pace, rhythm, variability, asymmetry and postural control can be 
derived (Del Din, Hickey, et al., 2016).   
Furthermore, DHTs have demonstrated the potential to provide increased sensitivity or specificity 
than that achievable by existing measures, such as the Q-Motor HD measure described previously 
(Reilmann et al., 2015) and the Roche smartphone-based application in PD (Lipsmeier et al., 2018). 
Both of these DHTs detected significant motor abnormalities in patients who were not found to 
perform abnormally in corresponding assessments of motor symptoms using rater-dependent 
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clinical scales. These findings provide further support for DHTs to potentially provide increased 
sensitivity in comparison with existing measures. 
5.4.7.2 Validity 
Despite the potential for added value, further refinement to the algorithms that govern data 
processing of DHTs is needed, to ensure the reliable detection and measurement of specific motor 
and non-motor symptoms. It is expected that the reliability of these algorithms will be ascertained 
through future validation studies (Odin et al., 2018). The MDS Task Force on Technology discuss 
the need for improved compatibility amongst DHTs, as it remains difficult to combine data 
gathered by DHTs developed by different developers (Espay et al., 2016).  
Furthermore, it is a priority that DHTs are validated in their intended environment for use. For 
instance, DHTs that are designed to remotely collect data from the home environment will need 
to be highly robust, to account for extraneous variables that cannot be controlled for outside of a 
laboratory setting. Previous research of wearable accelerometers in HD however, has 
demonstrated that although there was increased variability in measures of gait assessed at home 
compared to those assessed in clinic, this variability was offset by the increased frequency of 
assessments achieved in the home environment (20 assessments of gait performed in clinic vs 
14,000 assessments of gait captured in 1 week outside of clinic) (Andrzejewski et al., 2016). This 
finding therefore supports the use of DHTs in naturalistic environments. 
5.4.7.3 Additional Challenges 
There are additional challenges surrounding the implementation of DHTs as part of PD 
neuroprotective studies, including: 
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• Long term adherence of participants to comply with the requirements of the DHT measure 
(e.g. continual wearing of a sensor-based device). 
• The usability and acceptability of DHTs for both participants and clinical research teams, 
so as not to cause burden or increase workload. 
• The development and provision of suitable data management systems in line with relevant 
policies (e.g. General Data Protection Regulations (GDPR)). 
• Funds to provide technical support and assistance to participants as well as research teams. 
Many of these challenges also pertain to the use of DHTs as part of routine clinical service 
provision, and so will be discussed in more detail as part of the overall thesis discussion (See 
Chapter 6). 
5.4.8 Limitations of the evaluation 
My systematic evaluation of PD neuroprotective studies has several limitations which should be 
considered. Firstly, I only included interventional clinical studies, which means I did not evaluate 
observational studies. Second, I only included randomised controlled studies (RCTs), meaning that 
nonrandomised studies were not included as part of the evaluation. Thirdly, I did not include Phase 
I studies, which may mean I missed other types of outcome measure that are not applied in Phase 
II and Phase III studies. In addition, I did not carry out a formal analysis of the study quality due to 
the wide range of study variables under measurement.  
5.4.9 Conclusions 
The results of the review have provided support for my hypotheses, by identifying variability in the 
choice of primary endpoint used across published and ongoing Phase II and Phase III PD 
neuroprotective studies, as well as a lack of a well-defined patient stratification process. These 
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findings illustrate the lack of consensus in designing both Phase II and Phase III neuroprotective 
studies. The review demonstrates that current trial design methodologies are crude in their 
attempts to recruit a broadly homogeneous population, which together with insensitive outcome 
measures may be partly responsible for the lack of positive outcome (Athauda & Foltynie, 2016).  
As discussed, DHTs hold promise in several domains, including providing an opportunity to 
remotely collect continuous objective data that may be used to measure disease progression, in 
addition to helping to stratify patients to more homogeneous cohorts, thereby reducing 
heterogeneity of samples. DHTs may also have potential to improve patient adherence and 
compliance, by reducing the need for in-person assessments.  
Increased inclusion of DHTs as exploratory or secondary outcomes in clinical studies is needed 
however, so that the feasibility and reliability of these measures can be ascertained and relevant 
refinements made to overcome some of the current limitations surrounding DHTs (Dorsey, 
Papapetropoulos, et al., 2017).  These steps are necessary prior to approval applications and the 
more extensive use of DHTs as primary endpoints in Phase II and Phase III neuroprotective clinical 
studies.  
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Chapter 6 Overall thesis discussion 
In this thesis, I have described a series of studies and evaluations of Digital Health Technologies 
(DHTs) for use in Parkinson’s disease (PD).  
6.1 Main findings 
In Chapter 2, I presented a computerised paced finger tapping task (PFT) that was found to 
correlate with a measure of letter fluency, suggesting there may be potential to implement the PFT 
as part of a wider finger tapping battery to be used as a screening tool for executive dysfunction in 
PD. 
In Chapter 3, I presented the development and formative evaluation of a DHT (NMS Assist) to 
enable regular assessment of non-motor symptoms (NMS) and provide self-help information for 
PwP and carers. NMS Assist was designed using an iterative design process in line with MHRA 
guidance, and with end user engagement throughout. The app was found to be highly usable 
(average SUS score = 80), and key areas of amendment were identified related to content, 
navigation and accessibility. These findings have informed the next round of formative evaluation 
which will lead to an in-service summative evaluation of the finalised product.  
In Chapter 4, I reported the findings from a clinical service evaluation of the Parkinson’s Kinetigraph 
(PKGTM), a remote monitoring device for use in PD. The findings revealed the PKGTM is useful for 
identifying patients with unmet treatment need even in newly diagnosed PwP who experience 
more frequent clinic review. These findings highlight the importance of continual monitoring in PD 
to allow for effective therapy optimisation. In addition, my findings demonstrated high quality 
clinical interpretation in combination with the PKG™ quantitative data offers a potentially more 
sensitive measure to identify patients who may be undertreated, as opposed to using the PKG™ 
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data in isolation. These findings challenge those reported previously, whereby the PKGTM has been 
recommended for use for inexperienced clinicians. Finally, the patient evaluation revealed the 
PKGTM was acceptable for patients, and deemed valuable in providing information to their clinician 
that would otherwise have not been available. This clinical service evaluation of the PKGTM will 
inform a funding application for a randomised controlled trial (RCT) to investigate the impact of 
the PKGTM on patient-reported outcomes and quality of life (QoL). 
Finally, in Chapter 5, the results of my systematic review of neuroprotective trials in PD revealed a 
lack of consensus among primary outcome measures used across Phase II and Phase III trials, which 
illustrates the lack of an established methodology for measuring disease progression in PD. In 
addition, there was little evidence of patient stratification, meaning studies did not take into 
account the heterogeneity of clinical features, treatment responses or prognostic indicators of 
their sample. The findings highlighted the potential for DHTs to improve the sensitivity of outcome 
measures and facilitate patient stratification, as well as improve clinical trial delivery.  
While I have presented evidence that supports the use of DHTs to a) quickly and easily identify 
potential areas of cognitive impairment b) provide regular assessment of NMS and self-help 
information for PwP and carers c) identify areas of unmet treatment need and d) improve the 
sensitivity of clinical trial endpoints and facilitate trial delivery, there are a number of associated 
challenges surrounding the use of DHTs that have been highlighted within my thesis and in the 
wider literature that must be considered.  
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6.2 Challenges 
6.2.1 Long term adherence 
A major challenge to the implementation of DHTs is the behaviour change that is required by 
patients, clinicians and researchers to ensure the long-term adoption and use of DHTs in 
healthcare.  
Although our patient evaluation of the PKGTM demonstrated that the majority of PwP found the 
PKGTM acceptable, with most patients reporting they would be willing to use the PKGTM as part of 
their PD management in the future, we are not yet able to report long-term compliance with the 
PKGTM, and this will only be available over time.  
Similarly, in relation to NMS Assist, we are not yet able to report long-term compliance with 
completing regular NMS assessments or engaging with self-help materials. To evaluate long-term 
compliance, feasibility studies will be carried out following the planned summative evaluation.  
In the wider literature, there is evidence to suggest that there is a lack of patient motivation to use 
DHTs on a long-term basis, with a recent study showing 32% of users stopped using wearables after 
6 months (Ledger & McCaffrey, 2014). In addition, in March 2015, the mPower app was launched 
with Apple’s Research Kit platform (Apple Inc.) (Bot et al., 2016) comprising surveys and tasks that 
were developed as part of the smartphone-based app described previously (Arora et al., 2015). 
Whilst over 1,000 PwP and over 5,000 controls completed at least one active test, adherence 
dropped considerably following download, with just 898 individuals contributing more than 5 days’ 
data over the first 6 months post-download (Lipsmeier et al., 2018).  
In order to maximise adherence, further research is needed to design systems that are acceptable 
to patients for long-term monitoring of symptoms (Espay et al., 2016). Consideration of end-user 
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characteristics is imperative when designing DHTs, and has been found to improve adoption rates, 
and reduce user frustration (Fisk, 2009). As mentioned previously, we considered 
recommendations for the design of technologies for the older adult population when designing 
NMS Assist, including: increased button size (to account for diminished fine motor control), 
modifiable text size (to account for visual acuity), customisable volume (to account for hearing 
impairments) and minimizing the steps required to complete a given action (to account for 
executive dysfunction and memory decline) (Lewis & Neider, 2017).  
Consideration will also be needed with regards to previous experience with digital technologies. 
Our formative evaluation of NMS Assist demonstrated that there were differences in app 
performance between experienced and inexperienced app users. This demonstrates that DHTs will 
need to be designed so that they are usable by people with little or no previous experience with 
digital technology, and that help or support is available for those that need it.   
A recent study investigating the feasibility of wearable sensors in PD (via a smart watch and 
smartphone) found that the provision of a personalised support centre (whereby scheduled calls 
were carried out to participants showing low adherence) improved compliance, by quickly 
resolving technology-related issues (Silva de Lima et al., 2017). This will be an important 
consideration in the ongoing development of NMS Assist. Currently, technical support for NMS 
Assist is to be provided by the app builders, however it has not yet been decided whether they 
have capacity or resource to provide a ‘support centre’ feature.  
Consideration of user characteristics and experiences as part of the design process should 
therefore help to create effective and safe technologies that will appeal to the end user, and can 
lead to sustained use and engagement (Lewis & Neider, 2017). Our findings from the formative 
evaluation of NMS Assist demonstrated this, as our iterative design process with end user 
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engagement throughout led to end-users rating the app as highly usable in the formative 
evaluation.  
In addition to ensuring DHTs are usable by patient populations, consideration is also needed as to 
the usability of these devices by clinical teams. Training for staff will need to be easily disseminated, 
and simple to understand, so as not to over-burden teams or deter investigators from 
implementing DHTs as part of their study protocols in a research setting.  
As mentioned previously, the training and the time required to report PKGTMs has been a 
challenging issue within our clinical team, and additional administrative support is required to ease 
this pressure. The impact of NMS Assist on a clinical team’s work load is yet to be determined, and 
will be evaluated as part of our summative evaluation. Some features to help minimise staff burden 
have already been incorporated however, such as a user-friendly web portal interface, whereby 
problem areas will be easily identifiable visually through the use of colour (see appendix 12 (section 
8.12)). Furthermore, by including PD specialists (Parkinson’s nurses and Parkinson’s Drs) as part of 
the project team, we hope to address potential risks to staff burden early on.  
6.2.2 Data Management and Analysis 
While DHTs are able to collect large amounts of data over a prolonged time frame, the ability to 
analyse this data to produce clinically relevant information remains limited (Espay et al., 2016). 
Advances in data analysis techniques such as machine learning hold promise in this regard (Lones 
et al., 2014), however further expertise is needed for clinicians to be able to confidently apply these 
techniques to the data obtained by DHTs. In addition, clinical centres and research sites need to 
be supported in developing suitable and secure data management systems for the storage of large 
amounts of data that are provided by DHTs. As mentioned previously, producing an effective and 
error-free data management system has been an ongoing challenge with the implementation of 
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the PKGTM, and was one of the areas identified by the service evaluation as requiring extra 
resource. 
In addition, measures including password protection and dual factor authentication will need to 
be implemented to ensure the data collected by DHTs is held securely, and in line with General 
Data Protection Regulations (GDPR, 2018). In relation to NMS Assist, identification is currently 
obtained via the use of a personalised token that is linked with users’ hospital details. The 
compatibility of this design with data protection regulations will be investigated as part of our 
ongoing design process.   
6.2.3 Infrastructure  
Challenges to infrastructure are another potential barrier to the implementation of DHTs, 
particularly for devices that require a wireless internet connection for reliable and efficient data 
transmission. As our patient evaluation revealed, the majority of patients use their smart devices 
in the home environment. Internet connectivity may not be available for patients residing in rural 
areas or in hospitals, where Wi-Fi connectivity can be temperamental.  
In addition, ongoing maintenance and support will need to be provided to research centres, clinical 
teams and patients, to allow for effective and quick solutions to any technical issues that may arise. 
At UHPNT, we have experienced several device failures (including with the PKGTM) that have led to 
missing data points and the need for patients to repeat assessments. The functionality of DHTs is 
therefore an important consideration, particularly with regards to remote monitoring, whereby 
errors may not be obvious until after the patient has worn the device. This will lead to frustration 
for both the clinician and patient, and could potentially increase the burden for patients, who 
would be required to wear the device for a second time.  
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6.2.4 Device Functionality 
Device functionality is a key issue surrounding DHTs that can impact on trust and long-term use 
(Karvonen & Kristiina, 2000).  
As discussed in Chapter 2, the sensitivity of the computerised paced finger tapping task (PFT) was 
compromised due to technical difficulties with the equipment, and we did not have the required 
resource to resolve these issues. This experience highlighted the development of DHTs requires 
ongoing expertise from researchers, clinicians, end-users and developers to ensure the DHT is 
working as it should. Additionally, regular validation is required, to ensure the DHT is working 
accurately and as sensitively as possible, and so that iterative changes can be made prior to use 
more widely. 
In addition, evaluating the performance of algorithms underlying DHTs is a complex issue. The 
MDS-Task force on technology discuss the difficulty of attempting to validate DHTs with “gold 
standard” clinical scales, due to the possibility that the DHT may outperform subjective clinical 
scales, which could lead to imperfect correlations (Espay et al., 2019). Nevertheless, the task force 
recommend that DHTs are validated with regards to accuracy (achieved via laboratory based 
validity tests), reliability (achieved via test-retest within and between sensors), sensitivity, and 
establishing minimal clinically significant differences for endpoints of interest. This can be achieved 
by testing the DHT against a robust measure of clinical meaningfulness (the MDS task force give an 
example of a pull test to compare a new DHT for balance) (Espay et al., 2019).  
6.2.5 Cost 
There are a number of costs associated with DHT’s including the development of the algorithms, 
maintaining technical support, the costs associated with data analysis, and the reporting costs. 
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Currently, all of these sit outside of current healthcare pathways and by extension, outside of 
existing contractual agreements.  
High quality research studies are therefore needed to demonstrate the cost-effectiveness of DHTs 
so these can be incorporated as part of healthcare pathways. For instance, studies that 
demonstrate improved patient health or a reduced number of unplanned hospitalisations would 
demonstrate how initial costs may be offset (Espay et al., 2019). One study has demonstrated the 
cost-effectiveness of the KinesiaTM system via improved functional status (UPDRS II, III; IV subscale 
score) over a one year follow up, in comparison to standard care (Cubo et al., 2017). As discussed 
previously, we are currently planning a randomised control trial (RCT) of the PKG™ to help better 
quantify the benefit of using the PKG™ (including potential cost savings, and improved QoL) as part 
of routine clinical service.  
6.2.6 Regulatory Approval 
A major challenge to the integration of DHTs as part of clinical trials and in healthcare is the 
acceptability of a DHT by the regulatory authorities, such as the Food and Drug Administration 
(FDA). The FDA has currently approved some DHTs for use (“Brandon Capital”, 2016), where 
sufficient evidence of value has been provided (Griffiths et al., 2012), but until recently, there has 
been no defined process for the development and regulation of technology based objective 
measures (Espay et al., 2016). 
As discussed previously, NHS guidelines have recently emerged that aim to aid developers, 
clinicians, and researchers to enable the development of DHTs that are safe, ethical and effective 
(DHSC, 2018). In addition, the NICE Evidence Standards Framework for DHTs (Evidence Standards 
Framework, 2019) provides clear standards for evidence for effectiveness that must be met prior 
to the implementation of a DHT as part of a clinical service.  
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The planned RCT of the PKGTM may provide evidence of its effectiveness in line with the Evidence 
Standards Framework (2019) including repeat patient quality of life data following a therapeutic 
intervention guided by the PKGTM data. In addition, as mentioned previously, following the 
finalisation of NMS Assist, we will carry out a high quality in service summative evaluation, which 
has been designed in line with the Evidence Standard Framework (2019), and will include patient 
reported outcomes (PROs) as well as user satisfaction measures.  
The increased availability of guidelines like these in recent months demonstrates the rise in DHTs 
being developed for use. The MDS Task Force for Technology have recently published a ‘roadmap’ 
for implementation of DHTs, with the aim of developing a framework for accessibility and long-
term adherence of DHTs to enhance care and research objectives related to PD (Espay et al., 2019).  
To address the increasing number of DHTs becoming available for use in PD, the MDS Task Force 
recommend the formation of a centralized, open-source, web-based structure where mobile 
health technologies can be integrated. This would help clinicians to gain a ‘global picture’ of a 
patient’s symptoms rather than capturing separate constructs of interest. For example, such a 
platform could allow for a patient’s PKGTM data to be presented along with their NMS assessments 
from NMS Assist, allowing for the clinician to consider both motor and non-motor symptoms, and 
helping to overcome the limited amount of non-motor information that is obtainable by using the 
PKGTM in isolation. As mentioned previously, the MDS Task Force on Technology is developing an 
e-Diary for PD which will act as an early, proof-of-concept integration platform for DHTs (Vizcarra 
et al., 2019). The findings from this initiative will inform the feasibility and effectiveness of such a 
platform.  
Therefore, despite the potential benefit of DHTs to improve the sensitivity and accuracy of 
symptom assessment, reduce demands on services, and promote self-management of symptoms, 
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there are a number of challenges to be resolved as we begin to implement DHTs as part of routine 
PD care and research. This will be an ongoing process over coming years as PD care moves into a 
new era of ‘digital healthcare’, and will involve input from researchers, clinicians, developers, and 
regulatory bodies to be achieved (Health Education England, 2018).  
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Chapter 7 Conclusion 
To conclude, in this thesis I have presented a series of studies and evaluations of digital health 
technologies (DHTs) to demonstrate how these may help to overcome current limitations of 
Parkinson’s disease (PD) service provision and clinical research.  
The findings from my own development of a computerised DHT demonstrated the potential for an 
automated paced finger tapping task to provide insight into executive function in PwP, while 
highlighting the associated challenges with developing a DHT for clinical use. 
I further identified key areas of amendment to the design of a novel DHT for the evaluation and 
monitoring of PD non-motor symptoms (NMS), designed using a user-centred iterative design 
process.  
My findings have further demonstrated the potential for an existing DHT (The Parkinson’s 
Kinetigraph (PKGTM)) to provide remote monitoring and identification of unmet treatment needs 
in PwP, while highlighting the importance of qualitative, expert evaluation alongside quantitative 
approaches. 
Additionally, my systematic evaluation of PD neuroprotective clinical trial design demonstrated the 
potential for DHTs to add value in this field, by increasing the sensitivity of trial endpoints, allowing 
for patient stratification and improving methods of recruitment.  
A number of challenges associated with the use of DHTs were also identified throughout. As a 
result of the research undertaken as part of this thesis, I am planning two studies to address the 
associated challenges surrounding the use of DHTs. A randomised control trial (RCT) of the PKGTM 
will allow for better quantification of the cost and patient benefit of using the PKGTM as part of our 
PD service, and a summative evaluation of NMS Assist will allow for an evaluation of the device in 
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its intended environment of use (patient homes). It is hoped the results of these studies will 
support the use of DHTs in our routine PD service at University Hospitals Plymouth NHS Trust 
(UHPNT), allowing for the delivery of a remote, home-based care pathway. 
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8 Appendices  
8.1 Appendix 1 – Ethics approval from the local NHS Research Ethics Committee 
 
 
South West - Cornwall & Plymouth Research Ethics Committee 
 
21 October 2016 
Dr Rupert Noad 
Department of Neuropsychology, 
Level 9 Derriford Hospital 
Plymouth 
PL6 8AH 
 
Dear Dr Noad, 
 
Study title: 
 
REC reference: 
 
Amendment number: 
Amendment date: 
IRAS project ID: 
 
Computerised cognitive assessments in neurodegenerative 
disorders 
12/SW/0227 
6 
02 October 2016 
108254 
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The above amendment was reviewed by the Sub-Committee in correspondence. 
 
Ethical opinion 
 
The members of the Committee taking part in the review gave a favourable ethical 
opinion of the amendment on the basis described in the notice of amendment form and 
supporting documentation. 
 
The Sub-Committee reviewed the following amendment: 
 
1. Throughout the protocol improvements have been made to presentation. 
 
2. Addition of Dr Craig Newman as Principle Investigator and Dr Camille 
Caroll, Mr Donnchadh Murphy and Ms Thea Dominey as Co-Investigators. 
 
3. Addition of participants from non-clinical normative groups into the descriptions of 
cohorts of patients. 
 
4. Removal of the word ‘Hospital’ specialist clinics. 
5. Addition of option to collect additional data from non-clinical populations. 
6. Addition of option to recruit from non-NHS specialist clinics. 
7. Addition of option to recruit from Joint Dementia Research (JDR) database. 
8. Clarification/changes to recruitment section. 
9. Addition of sites. 
10. Additional of seeking consent for video recording of specific assessments. 
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Approved documents The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Covering letter on headed paper [CoCoA Study, Ethical  17 October 2016 
Ammendment, Covering letter, 02.10.2016]   
Letters of invitation to participant [Letter of invitation v2 
02.10.2016, 2 02 October 2016 
CoCoA-AD2]   
Letters of invitation to participant [Letter of Invitation, v2, 
tracked 2 02 October 2016 
changes, 02.10.2016, CoCoA-AD2]   
Letters of invitation to participant [Letter of Invitation, v3, 3 02 October 2016 
02.10.2016, CoCoA-PD2]   
Letters of invitation to participant [Letter of Invitation, v3, 
tracked 3 02 October 2016 
changes, 02.10.2016, CoCoA-PD2]   
Notice of Substantial Amendment (non-CTIMP) [CoCoA 
Substantial 6 02 October 2016 
Ammendment form]   
Participant consent form [Consent Form patient, v4, 
02.10.2016, 4 02 October 2016 
CoCoA-AD2]   
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Participant consent form [Consent Form patient, v4, tracked 4 02 October 2016 
changes version, 02.10.2016 CoCoA-AD2]   
Participant consent form [Consent Form patient, v5, 
02.10.2016, 5 02 October 2016 
CoCoA-PD2]   
Participant consent form [Consent Form patient, v5, tracked 5 02 October 2016 
changes version, 02.10.2016, CoCoA-PD2]   
Research protocol or project proposal [CoCoA Study Protocol 
v11 11 02 October 2016 
clean version, 2.10.2016]   
Research protocol or project proposal [CoCoA Study Protocol 
v11, 11 02 October 2016 
2.10.2016, Changes highlighted Version]   
Research protocol or project proposal [CoCoA Protocol 
amendment 11 02 October 2016 
summary document, v11, 02.010.2016]   
 
 
Membership of the Committee 
 
The members of the Committee who took part in the review are listed on the 
attached sheet. 
 
R&D approval 
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All investigators and research collaborators in the NHS should notify the R&D office for the 
relevant NHS care organisation of this amendment and check whether it affects R&D 
approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures for 
Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/ 
 
 
12/SW/0227: Please quote this number on all correspondence 
 
Yours sincerely 
 
 
pp. 
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Canon Ian Ainsworth-Smith 
 
Chair 
 
E-mail: nrescommittee.southwest-cornwall-plymouth@nhs.net 
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8.2 Appendix 2 - Faculty Research Ethics Committee Approval 
  10th November 2016 
Dear Thea 
Application for Approval by Faculty Research Ethics Committee 
Reference Number: 16/17-674 
Application Title: Validation of a computerised measure of Executive Functioning- a 
pilot study.  
I am pleased to inform you that the Committee has granted approval to you to 
conduct this research. 
Please note that this approval is for three years, after which you will be required to 
seek extension of existing approval.   
Please note that should any MAJOR changes to your research design occur which 
effect the ethics of procedures involved you must inform the Committee.  Please 
contact Sarah Jones (email sarah.c.jones@plymouth.ac.uk). 
Yours sincerely 
Judy Edworthy PhD FAcSS 
Professor of Applied Psychology 
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Chair, Faculty Psychology Ethics Committee 
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8.3 Appendix 3 - Letter of invitation 
CoCoA (Computerised Cognitive Assessments in Neurodegenerative Disorders) 
Contact details for Chief Investigator: 
Dr. Rupert Noad, Consultant Neuropsychologist, NeuroCoRe, Clinical Neurology Research Group, N13, ITTC 
Building, Plymouth Science Park, PL6 8BX, Tel. 01752 315264 
Dear 
Computerised Cognitive Assessments in Neurodegenerative Disorders (CoCoA study) 
We are writing to you as you have previously expressed an interest in being contacted about 
participating in research. We are writing to let you know about a study we are currently running.  
We are organising a study here at the Plymouth University Peninsula Schools of Medicine and 
Dentistry, looking at new ways of measuring movement and thinking problems. We are particularly 
interested in the kinds of problems that people experience in Parkinson’s disease.  
We want to include people [aged 18 years or older] who have a diagnosis of Parkinson’s Disease.  
The study involves one visit which would be arranged at Plymouth University. The study takes about 
2 hours and involves completing some tests of your thinking and memory using both paper and pencil 
and a computer tablet. You do not need to have had any previous experience of using a computer or 
a computer tablet to be able to participate in the study.  
 
We have enclosed an information sheet which explains the study in more detail and a reply slip with 
a pre-paid envelope.  Please return this to the study team to let us know whether or not you are 
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interested in taking part in the study, or whether you would like to find out more about the study. If 
you have any other questions or would like to talk to the research team please contact: 
 
 
Thea Dominey: Clinical Neurology Group 
 
Tel : 07792119415  
Email : thea.dominey@plymouth.ac.uk  
Yours sincerely 
 
 
Dr Rupert Noad 
Consultant Neuropsycholgist, Derriford Hospital, Plymouth, UK 
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Computerised Cognitive Assessments in Neurodegenerative Disorders 
Reply Slip: 
Please complete and return this reply slip in the prepaid envelope to:  
Thea Dominey, Clinical Neurology Research Group, School of Psychology, Plymouth University, 
Drakes Circus, Plymouth,   PL4 8AA 
 
Name 
 
 
 
Address  
 
 
 
 
Home phone number  
 
 
Mobile number 
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Preferred contact time:  
 
daytime / evenings / weekends / anytime 
 
I have read the information in the subject information sheet and: 
(please tick one box)  
I would like to participate in the study. 
 
 
 
I would like to be contacted by a member of the research team so 
that I can get more information before I decide whether or not to 
take part. 
 
 
I do not wish to participate in the study.  
 
 
If you do not wish to participate it would be very helpful if you could let 
us know why not: 
 
 
 
 
Thank you for reading the information provided and replying.  
 
 
 
439 
 
8.4 Appendix 4 – Participant information sheet  
CoCoA PD2 ; 18.01.2017                                               PARTICIPANT INFORMATION SHEET: PATIENT  
 
Computerised Cognitive Assessments in Neurodegenerative Disorders 
 
Contact details for principal investigator:  
Dr. Rupert Noad, Consultant Neuropsychologist  
NeuroCoRe  
Clinical Neurology Research Group  
N13, ITTC Building  
Tamar Science Park PL6 8BX  
 
Tel. 01752 439779 
 
Contact details for research group: 
Clinical Neurology Research Group, 
Thea Dominey, 
School of Psychology, 
B223 Portland Square,  
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Plymouth University,  
Plymouth,  
PL4 8AA 
 
Tel: 07792119415 
Email: thea.dominey@plymouth.ac.uk 
Invitation for Research Participation  
 
Thank you for taking the time to consider participating in our research study.  
 
Please read the attached information sheet before deciding whether to take part.  
 
If you are interested in participating, please complete the reply slip attached to the 
invitation letter.  
  
The study is voluntary and deciding not to participate will not affect your treatment in any 
way.  
 
 
 
CoCoA PD2 ; 18.01.2017                                               PARTICIPANT INFORMATION SHEET: PATIENT  
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Participant information sheet for patients 
 
Investigating computerised cognitive assessments in neurodegenerative 
disorders 
 
We would like to invite you to participate in a research project. Before you decide 
whether you want to take part, it is important for you to understand why the research is 
being conducted and what your participation will involve. Please take time to read the 
following information carefully and discuss it with others if you wish. Ask us if there is 
anything that is not clear or if you would like more information.  
What is the study about?  
Neurodegenerative diseases, such as Parkinson’s disease, Alzheimer’s disease or 
Huntington’s disease affect a large number of people in the UK, the majority of patients 
developing disease in middle to later life. As the population as a whole ages, these 
diseases will become more common. Neurodegenerative diseases can cause problems 
with thinking and memory, and also problems with movement. We want to learn more 
about the way that thinking and memory problems can be assessed in these diseases, 
and whether using a computer might give more accurate information and make it easier 
for patients to complete the tests.  
Why have you been asked to take part?  
You have been invited to take part in this study as you are someone with a 
neurodegenerative condition.  
Do I have to take part?  
No. Participation in this study is entirely voluntary and it is up to you to decide whether or 
not to take part. If you do decide to take part you will be asked to sign a consent form, 
but you are still free to withdraw at any time in the future without giving a reason. You 
will be given a copy of this information sheet to keep and you will also keep a copy of 
your signed consent form. If you decide not to take part, or you withdraw from the study 
at any point, your usual medical care will not be affected in any way.  
Is this a medical assessment?  
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This is a research project not a medical assessment. You will not be told the scores of 
your assessments. All data collected during the study will be anonymous. If you feel that 
you are developing problems with your thinking/memory please contact your GP to 
discuss this further. We will send a letter to your GP informing them of your participation, 
but we will not send them any details of the assessments.  
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What will I have to do?  
If you are interested in taking part in the study, you can contact us, either by completing 
the reply slip (attached to the invitation letter) or by telephoning the study team on 
07792119415 . We will then contact you by telephone to discuss the study with you, ask 
you a couple of questions and see if you want to take part. If you are happy to take part 
we will arrange a time to do the assessment, in a study clinic at Plymouth University. 
During the assessment we will ask you for some brief details about yourself. You will 
then be asked to complete a series of tests of memory and thinking. Some of these tests 
will involve you being asked questions by the researcher. Some tests will be paper and 
pencil based. Some tests will be using a computer which the researcher will bring with 
them. You will then be asked for some feedback on how you found the computer-based 
tests. The assessment will take around 2 hours in total including a 15 minute break. You 
can ask for a break at any point during the assessment. You will also be asked whether 
you would be willing to complete another assessment in the future, looking at a different 
computer-based test or the same test in more detail.  
Will the information collected during the study be kept confidential?  
The study will be conducted in accordance with the Data Protection Act (1998). All 
information collected about you during the study will remain strictly confidential.  
Your personal details will be stored securely on a computer in the Peninsula Medical 
School in Plymouth, accessible only by members of the study team. Your name and 
address will not appear on any study forms or questionnaires so that you cannot be 
recognised from them. All other information collected about you during this study will be 
entered onto a separate, secure database and will only be identifiable by a study 
number and initials. Only members of the study team will have direct access to these 
data.  
If you consent to take part in the study, your medical records may be inspected by the 
doctors looking after you.  
If you agree to take part we will inform your general practitioner, unless you specifically 
ask us not to. 
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What are the benefits to me of taking part in this study?  
There are no direct benefits to you from taking part in this study. By completing the study 
you are helping us design tests that will help in future studies of these symptoms. 
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What are the risks to me?  
You should not experience any adverse effects from taking part in the study. Some 
people may find some of the questions difficult or upsetting, for example questions about 
thinking and memory. However, the data collected will be held anonymously as the 
forms will have only your study number (not your name or date of birth), and you are free 
to withdraw from the study at any point. If you would like to discuss any aspect of the 
study then please call a member of the study team on: 07792119415  
Will I have to pay for travel? 
If your assessment is taking place at a study clinic, then your travel expenses will be 
reimbursed.  
What if I have more questions or do not understand something?  
If you have further questions please contact the study team on 07792119415 who will try 
to answer your queries.  
What happens now if I decide to take part?  
If you are happy to take part in the study, please complete the reply slip attached to the 
letter of invitation and return to us in the freepost envelope provided. A member of the 
study team will be in touch to arrange a time for your assessment.  
What happens if I do not wish to take part? 
  
Your participation in this study is entirely voluntary. You do not have to take part, or give 
a reason if you choose not to. If you do not wish to take part it will not affect your future 
treatment or care.  
What will happen if I don’t want to carry on with the study?  
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You are free to withdraw from the study at any time. You do not have to give a reason. If 
you do not wish to continue in the study it will not affect your future treatment or care.  
What to do if something goes wrong?  
We do not expect any harm to come to you as a result of taking part, thus special 
compensation arrangements do not arise. If you have any concerns about the way that 
you have been approached or treated during this study, you are free to follow the usual 
NHS complaints procedure. 
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If you are harmed due to someone's negligence then you may have grounds for legal 
action but you may have to pay for this yourself. Your right to claim for compensation for 
injury where you can prove negligence is not affected. If you do have any complaints 
about your experiences with us, please address them to PALS Plymouth: 08451558121  
What will happen to the results of the study?  
We intend to publish the study results in a medical journal within a year of completion of 
the study and also to present the results at medical and scientific meetings. Each 
participant will receive a summary of the results at the time of publication. We will also 
publish the results of the study in patient newsletters.  
Contact for further information  
If you require any further information about this project, or have any questions please 
contact the research team on 07792119415 during office hours and a member of the 
project team will be able to help you.  
Who is organising and funding the study?  
The project is being organised by the Neuropsychology and Clinical Neurology 
Research teams at the Peninsula Medical School in Plymouth. It is being led by Dr 
Rupert Noad and coordinated by Thea Dominey.   
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8.5 Appendix 5 – Consent form 
Participant ID   
Computerised Cognitive Assessments in Neurodegenerative 
Disorders. 
    PARTICIPANT CONSENT FORM  
                                             
       Please initial 
Boxes 
 
1. I confirm I have read the patient information sheet (v2 25/07/12). 
2. I confirm that I have had the opportunity to discuss the study. I do not 
have any further questions regarding the project. 
3.  I understand that information collected about me and my health 
during this project will remain strictly confidential and accessible only to 
appropriate individuals. 
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4. I give permission for my GP to be informed that I am taking part in 
this study (optional). 
5.  I understand that sections of my medical records, including possibly 
my GP records, relating to my participation in this project may be 
inspected by members of the research team. 
6.  I understand that I am free to withdraw from the study at any time, without having 
to give a reason. 
7.  I understand that I will not receive a medical assessment; therefore I 
will not receive feedback about my individual performance. 
8. I consent to allowing the research team to make a video recording of 
my performance on the TULIA assessment and for this to be scored by 
other members of the CoCoA research team at a later date (optional). 
9. I agree to take part in this study. 
 
  
 
Participant’s Name (BLOCK CAPITALS): 
 
 
__________________________________________________________________ 
 
Participant’s Signature:             ________________________Date: ______________ 
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8.6 Appendix 6 – Histograms  
 
 
Figure 55 Distribution of mean tapping percentage error in the paced condition (250ms) 
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Figure 56 Distribution of mean tapping percentage error in the paced condition (500ms) 
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Figure 57 Distribution of mean tapping percentage error in the paced condition (1000ms) 
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Figure 58 Distribution of mean tapping percentage error in the paced condition (2000ms) 
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Figure 59 Distribution of mean tapping percentage error in the unpaced condition (250ms) 
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Figure 60 Distribution of mean tapping percentage error in the unpaced condition (500ms) 
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Figure 61 Distribution of mean tapping percentage error in the unpaced condition (1000ms) 
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Figure 62 Distribution of mean tapping percentage error in the unpaced condition (2000ms) 
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Figure 63 Distribution of letter fluency scores 
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Figure 64 Histogram of ACE III Scores 
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8.7 Appendix 7 – NMS App Project Group Roles 
Table 43 Description of main project group members and roles 
Group Member Role Description of role  
Dr Camille Carroll (CC) Associate Professor and 
Honorary Consultant 
Neurologist 
CC is the project lead, and 
responsible for all decisions 
related to the project.  
Thea Dominey (TD) Researcher TD is responsible for leading 
the design and delivery of 
the usability studies, and 
ensuring the app meets user 
requirements. TD is also 
responsible for the 
maintenance of the MHRA 
Site File. 
Dr Stephen Mullin (SM) Clinical Lecturer SM is a user representative 
(HCP) and is responsible for 
liaising with the app builders. 
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Group Member Role Description of role  
Dr Craig Newman* (CN) Mobile health technology 
innovation lead 
CN contributed towards the 
initial app and portal design. 
Sue Whipps (SW) Care partner  SW is a user representative 
(care partner). 
John Whipps (JW) PwP JW is a user representative 
(PwP). 
Emma Edwards (EE) Parkinson’s Nurse Specialist 
(PDNS) 
EE is a user representative 
(HCP) and assisted with 
carrying out the formative 
usability testing**.  
Inocencio Maramba (IM) Research Assistant, Human 
Computer Interface and 
Design 
IM joined the project group 
in December 2018, and 
assisted with the set up and 
of the Usability testing. 
* Iona Gillies (IG) was N’s project student and assisted with various elements of project delivery between July 
2017 and July 2018.  
** Cathryn Harries (CM) was an Undergraduate Psychology Student and assisted with carrying out the 
formative usability testing. 
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Table 44 Description of external collaborators, contractors and roles 
Group Member Role Description of role  
Prof Ray Chaudhuri (RC) Professor of Neurology/ 
Movement Disorders, Kings 
College London 
Author of NMS-Quest. RC 
contributed to development 
of the scripts for the self-
help videos. 
Ron Postuma (RP) Movement Disorders 
Neurologist, McGill University  
Author of ‘A Guide to the 
Non-Motor Symptoms of 
Parkinson’s Disease’ (A Guide 
to the Non-Motor Symptoms 
of Parkinson’s Diseas>, n.d.).  
Ben Stirling (BS) App designer (Made with 
Maturity) 
Responsible for designing the 
app wireframe and 
developing the animations in 
line with group comments 
and feedback. 
Peter Hannon (PH)  App builder (SUVO) Responsible for the build of 
the app final prototype and 
nurse portal based on the 
usability testing findings. 
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Group Member Role Description of role  
Ruth D’arcey-Daniels (RD) User Experience Researcher Advised TD on the usability 
testing design, methodology, 
and objectives. 
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8.8 Appendix 8 – NMS Questionnaire  
Survey Title: Parkinson’s non-motor symptoms: self-help behaviours 
In addition to the well-known movement symptoms in Parkinson’s, other problems can 
sometimes occur as part of the condition or its treatment. These problems are referred to as 
non-motor symptoms, and some examples of non-motor symptoms in Parkinson’s are listed 
below. We are interested to find out how frequently you seek help for these problems, and 
what methods you use to do so.  
Some examples of non-motor symptoms in Parkinson’s (please note: this is not an extensive 
list, there are others; not all people with Parkinson’s will experience all of these symptoms): 
• Changes in taste and smell  
• Sleep problems 
• Changes in mood 
• Dizziness 
• Constipation 
• Urinary problems 
• Problems with thinking and memory  
• Pain 
• Urinary problems 
• Gastrointestinal dysfunction 
• Sexual problems 
 
Please start the survey by pressing the start button below, all responses will remain 
anonymous.  
 
Demographics: 
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• Age / date of birth 
• Gender  
• Date of diagnosis 
• Country 
• City/Region 
1. How troublesome do you find your non-motor symptoms? 
• Extremely troublesome 
• Troublesome 
• Moderately troublesome 
• Rarely troublesome 
• Not troublesome 
2. How long is it between appointments with your Parkinson’s doctor? 
• Less than 6 months 
• Between 6 and 12 months 
• Between 12 and 18 months  
• Longer than 18 months 
3. How often do you see your GP about your Parkinson’s?  
• More than twice in six months 
• About twice a year 
• About once a year 
• About once every 18 months 
• Never 
 
 
4. How long is it between appointments with your Parkinson’s Nurse?  
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• Less than 6 months 
• Between 6 and 12 months 
• Between 12 and 18 months  
• Longer than 18 months 
• I don’t have a Parkinson’s Nurse 
 
5. How frequently do you discuss non-motor symptoms with your Parkinson’s doctor 
in clinic? 
• Never  
• About  a quarter of appointments  
• Half of clinic appointments 
• 75% of clinic appointments 
• At almost all clinic appointments 
 
6. How frequently do you discuss non-motor symptoms with your GP at 
appointments? 
• Never 
• About  a quarter of appointments  
• Half of clinic appointments 
• 75% of clinic appointments 
• At almost all clinic appointments 
 
7. How frequently do you discuss non-motor symptoms with your Parkinson’s Nurse 
at appointments? 
• Never 
• About  a quarter of appointments  
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• Half of clinic appointments 
• 75% of clinic appointments 
• At almost all clinic appointments 
8. How frequently do you seek help from professionals about your non-motor 
symptoms? 
• Very infrequently 
• Infrequently 
• Occasionally 
• Frequently  
• Very frequently 
9. Whom do you seek help from? (you can select more than one) 
• Parkinson’s Nurse 
• Parkinson’s Doctor 
• GP 
• Other 
10. How frequently do you seek self-help advice for your non-motor symptoms? 
• Very infrequently 
• Infrequently 
• Occasionally 
• Frequently  
• Very frequently 
11. In which format would you prefer self-help information? 
• Text 
• Videos of Expert giving advice 
• Animation 
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• In person 
• Other (please give details) 
 
12. What information sources do you currently use to seek self-help advice related to 
your non-motor symptoms? (You can select more than one):  
• Websites –please give details  
• Support Groups – please give details  
• Reading material – please give details  
• Online videos – please give details  
• Apps – please give details  
• Clinic visits or consultations 
• Other – please give details  
13. Do you currently use (or have you previously used) any apps associated with your 
Parkinson’s?   
• Yes- please give details  
• No 
 
14. In future, would you consider using an app to gain self-help advice on how to 
manage your non-motor symptoms? 
• Yes 
• No 
15. Please select the devices you currently have access to (you can select more than 
one): 
• Smartphone  
• Tablet or iPad 
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• Computer 
• None of the above 
 
16. In which environments do you use these devices? (You can select more than one):  
• At home 
• In clinic 
• Out in public (eg. cafes, on buses, the library) 
Many thanks for completing this questionnaire; your data will remain anonymous. 
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8.9 Appendix 9 – Creative Brief  
Storyboard Creative Brief  
Please complete all sections of this form giving as much information as possible. This allows us to 
allocate the proper time and resource to each shoot.  
From:  Dr Camille Carroll    Date:  28/06/2018 
To:  Multimedia Teams 
 
Project working title: Non Motor Symptoms (NMS) Application 
 
Background: In addition to the motor symptoms most commonly associated with 
Parkinson’s disease (PD), individuals often develop other health 
problems, known as non-motor symptoms (NMS), which include 
problems with decreased swallow and daytime sleepiness. These 
symptoms often lead to reduced quality of life and increased disease 
burden for patient and carer. We are developing a non-motor 
symptom application (NMS Assist) to help individuals manage these 
symptoms of their Parkinson’s. In the app we will include short 
(approx. 45 secs) videos to describe, explain and advise on the non-
motor symptoms. The videos will use animations to provide 
information on non-motor symptoms, so that there is potential to 
produce the videos in multiple languages. In the first instance, we 
would like to focus on using storyboards for 2 of the videos (drooling 
and excessive daytime sleepiness) to get a feel for what the rest of 
the animations might look and feel like. 
Objectives: These 2 animation storyboards are aimed at gaining insight into how 
animation may be used to aid individuals’ self-management of PD by 
educating them on the non-motor symptoms associated with the 
disease. 
Courses: These animation videos will incorporate information from the 
Postuma guide to Non-Motor Symptoms of PD. (Link below) 
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https://www.parkinson.bc.ca/media/33807/guide-to-the-non-
motor-symptoms-of-parkinsons-disease.pdf 
Key messages: Aid individuals’ self-management of PD by providing education and 
advice on the varying non-motor symptoms associated with the 
disease. 
Secondary message: Direct individuals to additional sources of information regarding PD 
symptoms. 
Inspirations: Refer to Dr Carroll’s previous videos discussing Parkinson’s research 
(generated by Plymouth University). 
Animation at end of films for schools: 
https://www.parkinsons.org.uk/professionals/resources/short-film-
teachers-listen-my-thoughts 
People: The videos will use animations to provide relevant information on 
PD non-motor symptoms.  
Locations: As the videos will use animations, all of the video production will be 
carried out in-house, at the site of the relevant media team. 
Schedule: July-Aug 2018 
Delivery Deadline: Sep-Oct 2018 
Length: Approx. 23 Videos, each 45- 60 secs in length. 
Target audiences: Individuals/carers of Individuals with Parkinson’s Disease. 
Deliverables: Deliver storyboards for 2 of the non-motor symptom videos 
(drooling and excessive daytime sleepiness) that will reflect the style 
of animation to be used as part of the final 23 animation videos.  
These storyboards  will give some idea of how the information on 
the relevant non-motor symptoms might be conveyed through 
animation, with the aim to support the information that the patient 
has heard, and facilitate learning of this information.  
This information is derived from Ronald Postuma’s guide; using the 
prepared scripts (attached).  
Information is likely to be sectioned into 3 components:  
Why does this symptom happen? 
Why is this symptom important in Parkinson’s Disease? 
What can be done to help this? 
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Usage: These story boards will be used to gain insight into how the 
animation videos may be used to convey relevant information and 
aid individuals’ self-management of PD. 
Formats required: E.g. Uploaded on University YouTube channel and provided on a 
DVD or USB. 
Budget: Max £10,000 for all 23 videos (Funding currently available through 
the Hoover foundation and Plymouth Hospitals Charities) 
Who has final sign-off: Who is the overall owner of this film? 
Contacts: Project Leads: Dr Camille Carroll, Dr Craig Newman 
Research Assistants: Iona Gillies, Thea Dominey 
Patient and carer representatives: Sue Whipps, John Whipps 
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8.10 Appendix 10 – Initial wireframe design 
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8.11 Appendix 11 – Symptom severity scale  
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8.12 Appendix 12 – Nurse Portal Mock Up 
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8.13 Appendix 13 – Symptom Script  
NMS App – Symptoms Script 
Only read text in bold. 
Theme: Psychosis/behaviour 
Hallucinations:  
What is it? 
Hallucinations mean hearing or seeing things that are not really there and may affect up to one 
third of people with Parkinson’s. They commonly begin as minor, non-threatening visual images. 
For example, a spot on the floor or the wall may move, or the spot may look like an insect. If 
hallucinations progress, you may see children, animals or people. Most people are aware that the 
hallucinations are not real.  
Why is this important in Parkinson’s disease?  
They are partially related to medications and partially related to Parkinson’s itself.  
What can I do? 
Often hallucinations do not need to be treated but you should discuss them with your Parkinson’s 
team, particularly if you are finding them upsetting. Specialist treatments are available.  
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Key Points: 
• Up to one third of people with Parkinson’s may have hallucinations. 
• Hallucinations are almost always visual (you see things that are not there). 
Delusions 
What is it? 
Delusions are false beliefs that are not based on reality or fact and may be linked to believing 
hallucinations are real. They can lead to suspicions directed at family members. Common 
delusions include paranoia, cheating spouses or theft. 
Why is this important in Parkinson’s disease?  
Typically, delusions occur in people who have other problems with thinking and memory. Often, 
Parkinson’s medications can make delusions worse. Delusions may be triggered or worsened by 
infections.  
What can I do? 
• If this has suddenly started or worsened, please speak to your GP in case there is an 
underlying infection.  
• Seek specialist help; it may be that medication adjustments are required. 
Seek carer support on a Facebook group  
Don’t read this link…(https://www.facebook.com/groups/1734404233474754/?ref=share),  
or phone the Parkinson’s UK helpline (0808 800 0303).  
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Key Points: 
• Delusions are false beliefs not based on fact. 
• Delusions often include cheating spouses and theft.  
• Specialist treatments are available.  
Impulse Control Behaviours 
What is it? 
Impulse control behaviours can occur in people on Parkinson’s medications. These can include: 
• Excessive gambling 
• Hyper sexuality 
• Binge eating 
• Compulsive shopping 
• Excessive pursuit of hobbies 
• Punding (repetitive performance of meaningless tasks) 
What can I do? 
If you notice any of these behaviours for the first time or an increase in these behaviours, then you 
must speak to your Parkinson’s team.  
Seek carer support on a Facebook group.  
Don’t read this link (https://www.facebook.com/groups/1734404233474754/?ref=share).  
Key Points: 
• People on some Parkinson’s medications can develop impulse control behaviours.  
• Excessive gambling and hyper sexuality are the most common ICBs.  
 
 
479 
 
• Specialist treatment advice should be sought. 
 
Theme: Falling and balance  
Feeling Lightheaded on Standing 
What is it? 
Feeling lightheaded on standing is due to a drop in blood pressure. Headache and shoulder or neck 
pain can also occur. If this is severe, you could black out and fall.  
Why is this important in Parkinson’s disease?  
This blood pressure drop can be due to Parkinson’s itself, and can be made worse by Parkinson’s 
medications and possibly other blood pressure tablets. 
What can I do? 
If you have this problem avoid standing up quickly; try counting to 10 before you move off. 
Increasing salt intake can help. Drink at least 2 litres of water per day and avoid caffeinated drinks. 
Full length compression stockings may be helpful. Specialist treatments are available.  
Key Points: 
• Main symptom: Feeling light-headed when standing up. 
• Other symptoms include: Shoulder pain, headache or blacking out when standing up. 
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• Make sure you have adequate salt in your diet and drink at least 2L of water a day. 
Theme: Gastrointestinal Tract   
Drooling  
What is it? 
Drooling is a common problem in Parkinson’s disease. It is caused by decreased swallowing.  
What can I do? 
Chewing gum or sucking on a boiled sweet can help; keep your head positioned upright and 
remember to swallow. A Speech and Language Therapist can discuss swallow timers which may be 
helpful. At night, try re-positioning your head to a more upright position or covering the pillow 
with a towel. Specialist medications may be available.  
Key Points: 
• Up to one half of people with PD drool.  
• Saliva pools in the mouth and leaks out. 
• It is caused by decreased mouth movements and swallowing. 
• Chew gum or suck sweets. 
• Specialist treatments are available.   
Difficulty Swallowing 
What is it? 
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Occasionally patients notice difficulty in swallowing food, drink, tablets or even saliva.  
Why is this important in Parkinson’s disease?  
Swallowing is a very complex process that requires a high degree of muscle coordination. Food 
going down the wrong way can lead to chest infections. 
What can I do? 
It is important not to rush your meals; eating small mouthfuls and sipping water regularly 
throughout can help. Remember to sit upright and not to talk whilst eating. Adding mango or 
banana to drinks to make them thicker may help, as well as taking tablets with yoghurt. Try and 
time meals for when your Parkinson’s medications are working well. 
Key Points: 
• One half of people with PD have trouble swallowing. 
• Trouble swallowing can result in choking or chest infections. 
• Take frequent sips of water with meals. 
• Consider banana or mango to thicken drinks. 
• Time meals for when your Parkinson’s medications are working well. 
Nausea and Vomiting: 
Why is this important in Parkinson’s disease?  
The most common cause of nausea is starting a new Parkinson’s drug. However, a feeling of 
stomach bloating can also be present in Parkinson’s, usually related to slow stomach movements. 
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What can I do? 
If nausea and vomiting appear with a new drug, these symptoms often go away by themselves 
even if you stay on the medication. Taking your medication with meals (or with a small snack) may 
help. Managing your constipation may also help (link to constipation page).  
You should be aware that over-the-counter sickness medications often block the effect of 
dopamine and can make Parkinson’s worse. Specialist prescribed treatments may be available.  
Key Points: 
• Nausea often begins when starting a new Parkinson’s drug. 
• This symptom may not persist when related to a new drug.  
• Beware of over-the-counter treatments. 
Constipation: 
What is it? 
Constipation is defined as having less than three soft, bulky bowel movements a week, or 
excessive straining to pass stool. It affects three out of four people with Parkinson’s. Generally, 
constipation is an easy symptom to recognise. Other than the difficulty moving your bowels, you 
may also feel you are unable to completely empty your bowels or that you are unable to 
completely relax the muscles that prevent bowel movements.  
Why is this important in Parkinson’s disease?  
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Constipation can affect medication absorption and urinary symptoms, as well as causing feelings 
of nausea. Very severe constipation can cause obstruction of the bowels, with medical 
complications.  Constipation is part of the disease itself, not usually caused by Parkinson’s 
treatment.  
What can I do? 
Constipation can be treated, and the Bristol Stool Chart can help provide you with an idea of your 
stool so you can recognise signs of constipation. Drinking at least 2L of water per day, as well as 
doing moderate exercise and adding fibre to your meals can help relieve symptoms. Foods rich in 
fibre include: bran fibre, whole wheat products, lentils and beans, prunes or prune juice, dried 
apricots. 
Over-the-counter medications may not be that effective. There are stool softeners that can be 
prescribed.  
Key Points: 
• Three in four people with PD suffer from constipation.  
• This can be an early sign of Parkinson’s disease. 
• Treatment options: Drink water, eat fibre, exercise and use bulking agent, or prescribed 
stool softeners. 
Uncontrolled Loss of Stool  
Loss of stool is not necessarily due to diarrhoea. It refers more to an inability to control bowel 
movements, with incontinence, or ‘accidents’.  
 
 
484 
 
Why is this important in Parkinson’s disease?  
This is quite a rare feature of Parkinson’s; you may have a small amount of leakage when you pass 
gas. 
What can I do? 
You can find a range of (incontinence) products at health supply stores. Ensure that you are not 
constipated, aiming for a soft bulky stool passed every day.  
Key Points: 
• Rare. 
• Parkinson’s medications can improve uncontrolled loss of stools. 
Theme: Mood and memory:  
Problems with Thinking and Memory  
What is it? 
Problems with thinking and memory are common in Parkinson’s.  
Why is this important in Parkinson’s disease?  
This can include problems with planning tasks and concentrating which may be worse when your 
Parkinson’s medications are wearing off.  
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What can I do? 
There is increasing evidence that keeping your brain active can maintain memory and 
concentration. Consider discussing this with people around you as it may be affecting them too. It 
is important to keep generally healthy with regular exercise, good diet and good blood pressure 
control. Specialist treatments may be available.   
Key Points: 
• Problems with thinking and memory occur with Parkinson’s.  
• Common symptoms include: difficulty with planning, focussing attention, slowing of 
thought, decreased memory. 
• Some forgetfulness can occur normally with aging.  
• Keep mentally and physically active. 
Depression and Anxiety 
What is it? 
Depression is very common in Parkinson’s. If you are depressed, you may not be able to 
experience joy. You may stop hobbies that you once enjoyed, and you may not want to carry out 
your daily routine. Learning new hobbies may also not interest you. Fatigue is commonly linked 
with depression. Depression can also affect both your appetite and sleeping patterns. Anxiety 
often also occurs in Parkinson’s. Some have bursts of anxiety called ‘panic attacks’. Or you can 
have excessive worry about everyday things that you cannot control. Anxiety is also common 
during ‘off’ periods.  
What can I do? 
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Keep yourself active socially and physically as much as possible. Exercise, particularly while 
outside, may help.  Seek specialist advice early.  
Key Points: 
• Depression and anxiety are common in Parkinson’s.  
• Parkinson’s disease affects areas of the brain that control mood.  
• Anxiety can occur in ‘off’ periods. This can be improved by preventing the ‘off’ times. 
Theme: Sexual Function 
Sexual Dysfunction 
What is it? 
Sexual dysfunction is common in Parkinson’s. For men, it can be hard to obtain or maintain an 
erection. Problems with having an orgasm or decreased sex drive can also occur. An increased sex 
drive can occur with some Parkinson’s medications.  
 
What can I do? 
Regular exercise helps develop stamina for sexual intercourse. Also you may want to consider 
other forms of intimacy. See the web link below for more information. Don’t read this link 
(https://www.parkinsons.org.uk/information-and-support/sex-and-parkinsons) Speak with your 
partner and decide what is best for your relationship. Your local Parkinson’s Disease Nurse 
Specialist can provide you with more information on what help is available. This may include 
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speaking with physiotherapists who could advise you on positions. Specialist treatments are 
available; please let your Parkinson’s team know if you think there may be a link with your 
medications.  
Key Points: 
• Sexual dysfunction is common in Parkinson’s.  
• Sexual dysfunction can include: difficulty with erections (men) or orgasm (women), or 
decreased sex drive (both men and women), increased sex drive related to medications. 
• Consider other forms of intimacy (https://www.parkinsons.org.uk/information-and-
support/sex-and-parkinsons). 
Theme: Urinary 
Bladder Problems 
 What is it? 
One third of people experience a bladder related problem with Parkinson’s. The most common 
problem is an over-active bladder. An overactive bladder can cause a sense of urgency, needing to 
rush to the bathroom, urinate frequently (less than every two hours) as well as get up multiple 
times at night to go to the bathroom. With Parkinson’s, you may also experience an underactive 
bladder. Symptoms include difficulty starting urination, a sensation of not completely emptying 
your bladder and the leakage of urine.  
What can I do?  
 
 
488 
 
Try to plan out and schedule bathroom trips at regular intervals. Try to avoid excessive tea and 
coffee consumption and reduce your liquid intake prior to going to bed. Make sure you keep well 
hydrated during the day. Ensure you are not constipated. Consider bladder training exercises. 
Specialist treatments are available. 
Key Points:  
• One third of people with Parkinson’s have bladder dysfunction.  
• Common symptoms: getting up to urinate at night, frequently passing urine and urgency to 
pass urine.  
• Treatment options: Keep well hydrated, ensure you are not constipated, avoid excess 
caffeine and plan toilet trips.  
•  
• Sleep/Fatigue  
Excessive Daytime Sleepiness 
What is it? 
Excessive daytime sleepiness means falling asleep easily or frequently during the day. 
Why is this important in Parkinson’s disease?  
Daytime sleepiness can be part of Parkinson’s, but can also be made worse by Parkinson’s 
medications, poor sleep at night, and other conditions such as sleep apnea (see ‘Insomnia’ page). 
  
What can I do? 
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Drinking some extra coffee or tea, going outside, as well as scheduling naps may help. Avoid other 
medication that can make you feel drowsy such as antihistamines. Specialist treatment is 
available. Make sure you keep yourself and others safe. Avoid driving if you feel even slightly 
sleepy. It is important to distinguish daytime sleepiness from sleep attacks. With a sleep attack 
you will have a sudden desire to sleep which can occur while eating, working, walking or reading. 
You may even have sleep attacks while driving. If you have sleep attacks, you must seek specialist 
help. 
Key Points: 
• Feeling sleepy during the day is common with Parkinson’s. 
• Always think twice about driving, even if you are just a little bit tired. 
• Extra tea and coffee, and scheduled naps may help. 
Problems Sleeping 
What is it? 
Sleep problems are common in Parkinson’s and are mostly due to the underlying condition. People 
with Parkinson’s usually have trouble staying asleep more than falling asleep. 
What can I do? 
• Falling Asleep: The first step you should take to treat falling asleep problems is ‘sleep 
hygiene’. Sleep hygiene includes making your bedtime and waking time as regular as 
possible, not spending too long in bed, and not lying in bed for over half an hour if you are 
struggling to fall asleep. Get up and do something relaxing and then try to sleep again 
later. Exercise during the day. Reduce naps during the day. Additionally, avoiding (blue 
light) electronic gadgets can help.  
  
 
 
490 
 
• Staying Asleep: If you have trouble staying asleep consider whether this may be due to: 
a. Mobility problems/off periods overnight- satin sheets or bed rails may help. 
b. Waking to empty your bladder (see ‘Bladder’ page). 
c. Vivid dreams in REM Sleep Behaviour Disorder (see ‘RBD’ page). 
d. Sleep fragmentation due to Parkinson’s. 
e. Anxiety (see ‘Anxiety’ page). 
f. Restless leg syndrome (see Restless Leg page).  
It might also be useful to review if these sleep problems are due to an overnight off period or 
mobility issues. 
Key Points:  
• With insomnia you may have difficulty falling and staying asleep. 
• Insomnia contributes to feeling tired during the day. 
• Treatment options: try sleep hygiene. 
• Specialist Treatments are available. 
REM Sleep Behaviour Disorder 
What is it? 
REM Sleep Behaviour Disorder (RBD) may cause you to act out your dreams. REM, or Rapid Eye 
Movement sleep is the stage in which the majority of dreaming occurs. Normally, you stop 
yourself moving during REM sleep, so that you don’t act out your dreams; this is lost in RBD. You 
may punch, kick, shout or talk during this stage, which may cause you to fall out of bed and injure 
yourself or your bed partner. RBD occurs most often in the early hours of the morning.  You may 
be unaware that this is happening. 
What can I do? 
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If RBD is non-troublesome, no treatment may be needed. If you are having very active 
movements, think about safety in bed such as bed rails, pillows or mattresses beside the bed. If 
your RBD is disturbing your bed partner, consider sleeping apart. Specialist treatment is available.  
Key Points: 
• RBD is common. 
• With RBD, dreams are acted out. This includes: shouting, kicking, punching etc. 
• Injuries may occur. 
• Specialist treatments are available.  
Restless Legs Syndrome 
What is it? 
Restless Legs Syndrome (RLS) is an urge to move the legs, often with pain or difficult-to-describe 
uncomfortable sensations. Generally, this is felt when sitting or lying down. RLS is worse in the 
evening, and at night, movement of the legs provides temporary relief. RLS may cause trouble 
falling asleep.  
What can I do? 
RLS symptoms can be made worse by caffeine and alcohol. Taking a walk and hot shower before 
bed can sometimes help. Specialist treatments are available.  
Key Points: 
• With RLS, you feel an urge to move legs because of uncomfortable or odd feelings. 
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• RLS tends to be worse at night and can affect sleep. 
• Avoid bedtime caffeine and alcohol. 
• Specialist treatments are available. 
Theme: Miscellaneous 
Pain  
What is it? 
Pain related to other conditions, such as arthritis, lower back pain etc. can be made worse by 
Parkinson’s. However, pain without any explanation may be caused by Parkinson’s. One third of 
people with Parkinson’s have pain. This pain can feel like stiffness, cramps, spasms or muscle pain. 
Often it occurs when medications are ‘wearing off’. The cause of pain in Parkinson’s is not always 
clear. Many people have different types of pain all at once.  
What can I do? 
Stretching the muscles, massage, or warm baths can help. For joint pain in particular, regular 
exercise and physiotherapy may be beneficial. Over-the-counter painkillers can help. Keeping a 
pain diary may be helpful to determine if the pain is helped by your Parkinson’s medications. 
Specialist pain treatments are available.     
Key Points: 
• One third of people with Parkinson’s have pain.  
• Treatment options: try over-the-counter pain medications if pain persists. 
• Keep a pain diary, in relation to medication timing. 
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Unexplained Changes in Weight 
What is it? 
In general, weight loss is more common than weight gain. 
Why is this important in Parkinson’s disease?  
Weight loss can be related to nausea from medications. It can also be caused by dyskinesia 
(excessive movements), as well as issues with nutrient absorption. Excessive eating and weight 
gain can be due to an impulse control disorder related to some medications.  
What can I do? 
If nausea/vomiting are stopping you from eating, please click link to ‘Nausea Section’. Try taking 
meals during ‘on’ times (times when the medication is working well), when swallowing and using 
cutlery may be easier. If weight loss appears to be associated with constipation, please click link to 
‘Constipation Section’. You should make sure that you are eating enough; eating frequent, smaller 
meals may help you achieve this. Consider using milkshakes or calorie supplements (eg. Ensure, 
Boost). Specialist dietary advice is available. For those struggling with weight gain, consider 
increasing levels of exercise. Seeking advice from a dietician may help. 
Key Points: 
• Unexplained changes in weight can happen in PD. 
• Treatment option: Try correcting any underlying problems (eg. nausea). Also, eat during ‘on’ 
times. 
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Leg Swelling 
What is it? 
Leg swelling is common in Parkinson’s disease. The lower part of the legs often become bigger, 
and seemed to be ‘filled with water’.  
Why is this important in Parkinson’s disease? 
Legs can also swell as a side effect of Parkinson’s treatment. It is important to make sure that 
there is not another cause such as conditions affecting the heart. If you are concerned, discuss this 
with your GP.  
What can I do? 
Leg swelling can be made worse by periods of sitting; try and keep active with regular walking. 
When leg swelling happens in Parkinson’s it usually does not need treating. Compression stockings 
can be helpful. When sitting, keep your legs raised. 
Key Points 
• Some people with Parkinson’s have swollen legs.  
• Swelling can be related to Parkinson’s itself or its treatment. 
• Other conditions can cause leg swelling (e.g. heart disease). 
Double Vision 
What is it? 
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Double vision is when you see two images of the same object. Most often, double vision happens 
while reading.  
Why is this important in Parkinson’s disease?  
In Parkinson’s, double vision is usually caused by the eye muscles working slowly (just like the rest 
of the muscles in your body). However, there are many other causes for double vision besides 
Parkinson’s. 
What can I do? 
You may wish to see an optician to rule out other causes. Double vision may be better when your 
Parkinson’s medications are working well.  
Key Points: 
• Double vision is when you see two images of a single object. 
• Many other conditions can cause double vision. 
Excessive Sweating 
What is it? 
With excessive sweating, you may find yourself sweating with no exercise, or sweating profusely 
with mild exercise.  
Why is this important in Parkinson’s disease?  
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Excessive sweating may be worse during off periods or dyskinesia.  
What can I do?  
There is no specific treatment for excessive sweating. However, you can help limit the amount 
that you sweat. Try these steps: 
• Avoid hot or humid environments. 
• Avoid strenuous activity in the heat. 
• Set the house thermostat lower. 
• Wear appropriate clothing. 
• Always keep well hydrated. 
Key Points: 
• One third of people with Parkinson’s develop excessive sweating. 
• Sweating if often associated with ‘off periods’ or dyskinesias (excessive movements). 
• Some practical tips can help (see above). 
Change in Taste and Smell  
What is it? 
Sense of smell is reduced in almost all people with Parkinson’s; this can affect your sense of taste. 
You may have difficulty detecting odours such as smoke, gas, or stale food. 
What can I do? 
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Loss of smell sensation can result in some loss of appetite. Beware of the dangers. Ensure you 
have working smoke and other gas detectors. Check use-by dates carefully. Monitor your weight 
and eat healthily.  
Key Points:Almost all people with PD have altered sense of taste and smell. Be aware of the dangers. 
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8.14 Appendix 14 – Group feedback document  
Group feedback: Storyboards:  
Please see below the storyboards from Ben. Please leave feedback using the prompts below each 
storyboard. Some things to consider: 
1. The arrows on the storyboards signify movement in the animation.  
 
2. The annotations help to explain what is happening in the animation or may describe noises 
that you will hear in the animation. 
 
3. The text beneath the storyboards is what they voice over will be saying.  
Group feedback: Sensitive issues  
Ben has sent some initial ideas for how to convey some of the more sensitive topics – please see his 
ideas below and leave any comments you may have.  
Erectile Dysfunction:  
• Image of a plant and have it ‘flop’ and grow.  
• A character inflating a balloon and deflating. Orgasms represented as the balloon being let 
go and flying around the room.  
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Please give comments below on the appropriateness of these ideas/ if you think will be clear to the 
user: 
Comments:  
The group felt that while humorous, they would prefer an image similar to the one below for erectile 
dysfunction, as they felt it was more direct, easy to interpret, and should not cause any embarrassment.  
Story board: Double Vision 
Feedback:  
The group were confused by the numbers on the screen, and were unsure how these were related 
to double vision. Otherwise this mood board was liked by the group. 
 Story board: Nausea & vomiting 
Feedback:  
The group felt that the bloating in this storyboard looked like somebody being sick. The group 
suggested that an abdomen swelling slightly might be clearer, but they are open to suggestion. 
The group were unsure on the interaction of the anti-sickness pills with dopamine – it needs to be 
clearer what is happening in this scene. 
Instead of making a link to google for constipation, we would like this link to take users to the 
constipation video – perhaps this could be made clearer in the video. 
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Story board: Taste and Smell 
Feedback:  
It was suggested that the food in the first and second screen is replaced by something with a more 
obvious smell, such as a hot roast dinner or a curry. 
The group felt that the picture relating to gas could be made clearer with the addition of a broken 
gas pipe/flames. 
The group felt the slide with the person holding their nose could be improved with the addition of a 
strong smell image – such as rotting vegetables in the background. 
The group felt that the picture of the person standing on the scales could be interpreted as someone 
expecting to gain weight, not lose it. A picture of someone normal size and then skinny in same 
clothes hanging off them was suggested instead. 
Storyboard: uncontrolled loss of stool  
Feedback: 
The group felt that the pictures are to the point and tell the story well. It was requested if a sound 
could be added to demonstrate passing gas.   
The group thought there could be a link available to the constipation advice.  
Story board: Sleepiness  
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Feedback:  
The group would like variety in the characters being displayed over the clip. 
The group said slide 2 could instead reflect a person falling asleep in a comfy chair when it’s 
obviously daytime outside – this is common in Parkinson’s.Storyboard: Drooling 
Feedback:  
SALT will need explaining – Speech and Language Therapist (apologies if this was not in the text we 
sent). 
General comments:  
The group suspect you have used a limited number of characters in the storyboard for simplicity, but 
they would like to see more variety of characters being used in the final versions. 
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8.15 Appendix 15 – Faculty Research Ethics Approval 
16th July 2018 
 
Dear Craig, 
Application for Approval by Faculty Research Ethics and Integrity Committee 
Reference Number:   17/18-961 
Application Title:    A Usability and feedback study on a novel mobile 
application for the self-management of Parkinson’s Disease (NMS Assist) to 
gauge patients’ experiences and views of using the App. 
I am pleased to inform you that the Committee has granted approval to you to 
conduct this research. 
CONFIDENTIAL 
Dr Craig Newman 
N13 ITTC North Building 
Plymouth University Peninsula School of Medicine and Dentistry 
Plymouth Science Park 
Davy Road 
Plymouth 
PL6 8BX 
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Please note that this approval is for the duration of the research as requested on the 
application form (1st August 2018 to 31st August 2019), after which you will be 
required to seek extension of existing approval.   
Please note that should any MAJOR changes to your research design occur which 
effect the ethics of procedures involved you must inform the Committee.  Please 
contact the Faculty Research Administrator, Maurice Bottomley (email 
hhsethics@plymouth.ac.uk ). 
Yours sincerely 
Professor Paul H Artes, PhD MCOptom 
Professor of Eye and Vision Sciences  
Co-Chair, Research Ethics and Integrity Committee -  
Faculty of Health & Human Sciences and 
Faculty of Medicine & Dentistry 
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8.16 Appendix 16 – Participant Information Sheet  
NMS App Usability Study Information Sheet 
The University of Plymouth is working in collaboration with Kings College London and 
University Hospitals Plymouth NHS Trust to develop a smart phone app, known as NMS 
ASSIST, to encourage and assist people with Parkinson’s in the self-management of their 
condition. The aim of this study is to gather data on the way users interact with and receive 
the app. 
Why have I been invited to take part? 
You have been invited to take part in this study as you have Parkinson’s, or are the 
partner/carer of someone with Parkinson’s. 
What is the purpose of the study? 
We are interested in recording the overall experience and satisfaction of people using this app; for 
example, how easy you find the app to use. Your responses will enable the team to identify areas for 
improvement that may be modified in later versions of the app.  
Do I have to take part in the study? 
Participation in this study is completely voluntary. You do not have to take part and can 
withdraw from the study at any time.  
Is this a medical assessment? 
This is a research project not a medical assessment. All data collected during the study will be 
anonymous. 
What will I have to do? 
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The study session will be held at Plymouth Science Park (PSP). On arrival to the session, a member of 
the research team will discuss the study with you, and there will be an opportunity for you to ask 
any questions you may have. If you are happy to proceed, you will be asked to sign a consent form. 
Following consent, there will be some assessments of your Parkinson’s, including a thinking and 
memory task and a quick physical examination. 
You will then be asked to interact with the app on a smartphone device.  
You will be guided through several different ‘user journeys’ with the app, and you will be asked to 
talk aloud while navigating the app. Following this, you will be asked some questions about your 
experience, and then guided through a usability questionnaire at the end, as well as a questionnaire 
about your non-motor Parkinson’s symptoms.  
The study session will be undertaken by 3 members of the research team, one will guide you 
through the questionnaires and assessments, and the other 2 will guide you through the ‘user 
journeys’ and take notes. The session may be filmed or recorded. We expect the session to last 
approximately 2 hours. 
What happens to my responses? 
Your responses and any recording of the session will be stored securely on a Plymouth University 
server managed by the research team. Responses will be stored for 10 years after publication during 
which only approved members on the research team will be able to access them. 
Will the information collected during the study be kept confidential?  
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This study will be completed in accordance with GDPR guidance and the Data Protection Act 
(1998) and all information collected will be held with the strictest of confidence. All of the 
data will remain completely anonymous and information will be identifiable only by a 
unique participant number. Any identifiable data that we keep during the study will be held 
securely, and only members of the research team will have access to it. Electronic data 
collected will be password protected and also only accessible to members of the research 
team.  
Who is organising and supporting the study? 
The project has received ethical approval from the University of Plymouth Faculty Research Ethics 
and Integrity Committee and is supported by PHNT Charitable Fund and The Hoover Foundation. It is 
being led by Dr Camille Carroll.  
Will I receive payment for taking part? 
You will not receive any payment for taking part in the study, however your travel expenses will be 
reimbursed and you will be provided with refreshments during the study visit.  
What if I have more questions, concerns or do not understand something? 
If you have further questions or concerns please contact Thea Dominey (Research Assistant) using 
the details provided below.  
Thea Dominey 
Research Assistant 
Email Address: thea.dominey@plymouth.ac.uk 
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Tel: 07792119415 
Thank you for considering taking part in this study, your participation is greatly appreciated. 
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8.17 Appendix 17 – Consent Form  
NMS App Usability Study: Participant Consent Form 
Thank you for considering taking part in this research study. 
Please initial the boxes if you agree with each section.  
 
1. I confirm that I have read the participant information sheet provided  
 
2. I confirm that I have had the opportunity to discuss the study and have had my 
questions answered.  
 
3. I understand that I will be filmed during the study, and that this recording will remain 
strictly confidential, stored on a secure Plymouth university server and accessible 
only to members of the research team. 
 
4. I understand that personally identifiable information and data collected during the 
study will be kept confidential and that only anonymised information will be 
published in a final report of the study. 
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5. I understand that I can withdraw from the study at any time without having to give a 
reason.  
 
6. I agree to take part in this study. 
 
Participants name (BLOCK CAPITALS) 
                                                                                                                                        
 
Participant’s Signature:                                                           Date:                               
 
Investigators Name:  
Investigators signature:                      
Date: _ _/ _ _/ _ _ _ _ 
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8.18 Appendix 18 – Discussion Guide  
Discussion Guide 
This discussion guide sets out the format and tasks for the moderator to use 
during the upcoming NMS App user research.   
Contact details 
If you have any questions regarding this discussion guide, please contact: 
Thea Dominey 
thea.dominey@plymouth.ac.uk  
07792119415 
About this document 
This discussion guide details the research project about to be undertaken by the NMS App Project 
Group. The purpose of this document is to make clear all aspects of the research so there are no 
surprises. 
Please note that the tasks in this guide don’t represent a definitive script to be stuck to absolutely; 
rather, it is intended to provide a basic structure. It is better to remain flexible and to follow the 
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participants’ natural order as much as possible. This often means letting the participant carry on 
uninterrupted as they would do normally, then coming back to points for further clarification later. 
Also be aware, usability testing is conducted in a way that solicits participants’ thinking and feelings 
without interfering with his or her, own discovery process.  No judgment should be apparent to the 
user about their activities, and no direct help is offered as it biases the results.   
About this research 
The research will consist of one study session, lasting approximately 2 hours. The session will be 
conducted on a prototype simulating the NMS App (NMS Assist).  
Usability testing involves measuring the ease with which users can complete common tasks. The 
tasks have been designed following discussions with People with Parkinson’s, their care partners and 
healthcare providers. It is also an opportunity to elicit feedback on the overall user experience. 
The session will be moderated by an experienced researcher who will probe and question the 
participant to understand their needs, behaviour and attitudes – participants will not be led or 
directed 
The on-screen interactions by the participant will be filmed using ‘Mr Tappy’ a screen recording 
device. Audio will be recording using a dictaphone. 
Task list 
Each participant will be asked to attempt to perform the following tasks.  
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Montreal Cognitive Assessment (MOCA) (10 mins) 
Non-motor symptoms questionnaire (NMSQ) – PwP only (15mins) 
Hoeh & Yahr rating scale – PwP only (5 mins) 
Think aloud warm up (5 mins) 
User journey 1 – Reading the instructions and requesting contact from the nurse 
User journey 2 – NMS full assessment 
User journey 3 – NMS partial assessment  
User journey 4 – Symptom summary and self-help for an improving symptom 
User journey 5 – Accessing self-help information for 2 x symptoms (pain and hallucinations) 
User journey 6 – Accessing the drop down menu and turning off alerts 
Moderator’s introduction 
Moderator welcomes the research participant. 
Thank you very much for coming in today and agreeing to take part in our study which is all about an 
app to help manage non motor symptoms in Parkinson’s. The app is called ‘NMS Assist’.  
The app is designed to be used by both People with Parkinson’s and their care partners.  
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(patients only)The app requires you to fill out an assessment on your non-motor symptoms, similar 
to the one that you just completed.  
(to carers only) The app requires you to fill out an assessment on your opinion of the non-motor 
symptoms the person you care for experiences. 
(to both) The app also offers the opportunity to learn more information about non-motor symptoms 
and how to best manage these, through a series of self-help videos. 
Finally, the app allows you to request contact from a Parkinson’s Nurse if you feel like you or your 
partner are running into trouble from a non-motor symptoms perspective.  
We’re constantly trying to improve NMS Assist and getting your honest feedback is a really important 
part of that. 
Today’s session is approximately 45 minutes so we’ll be finished at [specify time]. 
I’d like to emphasise that I’m not testing you and there are no right or wrong answers. I’m just 
interested in finding out what you think of our non-motor symptoms app and to see how you get on 
using it. 
And of course, you’re free to take a break or stop at any time during the session. 
I’d like to start by asking you to complete some warm up tasks. Then I’ll show you the app and ask 
you to complete some tasks. As you work through the tasks, I’d like you to think aloud - this means 
that you should try to give a running commentary on what you think at each stage.  
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As you complete the tasks, please tell me if there is anything you like/dislike, if you find anything 
confusing or if there’s something you don’t understand. This will really help us. If there’s any point at 
which you think, in real life, you would stop and wouldn’t carry on please tell me – I’ll probably ask 
you to carry on, but I do need you to tell me. If you get stuck, I’m going to encourage you to do what 
you would do if I wasn’t here as it’s important for me to see where it might not be easy or obvious, 
and lots of other people are likely to have the same difficulty – but don’t worry, I will of course help 
you if you get completely stuck! 
I didn’t design this, so you won’t hurt my feelings or flatter me. In fact, frank, candid feedback is the 
most helpful, so I’d really appreciate your honesty. It’s the only way we can make sure the app does 
meet your needs. 
Remember, there are no right or wrong answers and I’m not testing you. I just want to hear what you 
think and understand what the experience is like for you. 
Today we’re going to use a prototype of the app on this iPhone 6 - it looks and feels very similar to 
how the real thing will look like, but if you run into something that’s not working, I’ll let you know. 
We are using this camera to record your interactions with the app, are you able to see the phone 
screen ok from there? Sorry if it is in your way a little, but it is important that we are able to record 
your experience today. 
Do you have any questions before we start? 
Moderator answers any questions. 
Moderator starts recording of audio file and Mr Tappy. 
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Think aloud warm up questions (5mins) 
Think aloud warm up: 
As I said previously, as I work through each of the tasks, I would like for you to think aloud - this 
means that you should try to give a running commentary on what you think at each stage of the task.  
As you complete the tasks, please tell me what you are doing, if there is anything you like/dislike, if 
you find anything confusing or if there’s something you don’t understand. 
As a practice, we are going to do a quick warm up exercise.  
Please can describe your journey today from reception, to the room you were in just now. 
 If user just gives answer without very much detail: 
Thank you for your answer. Next time, please try to give some more detailed information about what 
you saw, what you were thinking, and the decisions you made along the way. 
If user just gives answer without very much detail: 
Thank you for your answer, now I know a bit more about your thoughts on your journey. Let me give 
you an example [give detailed thought process]. Would you like to have another go? 
That’s great thank you, please continue thinking in this way aloud throughout today’s session. 
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8.19 Appendix 19 – Debrief  
NMS App Usability Study Debrief 
Thank you for taking the time to complete this study. Your participation is greatly appreciated.  
This study aimed to examine the usability of the NMS app, such as how easy it is to use, and gather 
users’ opinions of the app.  The responses collected from this study will help to identify areas which 
can be improved and guide the development of later versions of the app.  
Your personal details will be stored securely on a Plymouth University computer, accessible only by 
members of the study team. Your name and address will not appear on any study forms or 
questionnaires so that you cannot be recognised from them. All other information collected about 
you during this study will be entered onto a separate, secure database and will only be identifiable 
by a designated study number.  
If you would like to ask any questions, offer feedback or request withdrawal from the study, please 
contact the Principal Investigator for this study:  
Dr Camille Carroll  
Tel: 01752 439829 
Email: camille.carroll@plymouth.ac.uk 
Address: 
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N14, ITTC Building 
Plymouth Science Park 
Plymouth  
PL6 8BX 
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8.20 Appendix 20 – Research Report 
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8.21 Appendix 21 – PKG Reporting Template  
PKG Reporting: Outcome of PD MDT assessment  
Patient name:   
Patient DOB:   
Hosp number:    
Date of PKG:    
Date of Report:  
Reported by:   
Reviewed by:    
Purpose of recording (including any therapy change that is being evaluated):  
Medications at time of recording: 
Date of (most recent) previous recording (if applicable): _ _ / _ _ / _ _ 
Medications at time of (most recent) previous recording: 
Bradykinesia 
No treatment required: 
 BKS < 23 
 No wearing off 
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Consider treatment: 
 BKS ≥ 23 
 Any wearing off (not due to sleep or possible hypotension) 
Comments:  
BKI (50%) 
BKII (25%) 
BKIII (15%) 
BKIV (10%) 
Dyskinesia 
No treatment required: 
 DKS < 7 
Consider treatment: 
 DKS ≥ 7 
 FDS > 13 
 Observable peak dose dyskinesia (if peak > 9, not due to exercise, not due to tremor 
bleed through) 
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Comments:  
Sleep 
Overnight sleep: 
 Evidence of fragmentation 
Excessive daytime somnolence: 
 Evidence of daytime somnolence 
Comments:  
Tremor 
Evidence of tremor: 
 Tremor absent (PTT < 0.6%) 
 Tremor present (PTT > 1.0%) 
Tremor evidence of wearing off: 
 Tremor worse peri-dose 
 
Comments:  
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PKG Value Prev.  record 
Date: 
Current 
Score 
Controls 
    
Bradykinesia score (BKS)   18.6 (aim for ≤ 23) 
Dyskinesia score (DKS)   4.3 
Fluctuation score (FDS)   7.8–12.8 controlled fluctuations  
Percent time that tremor was 
present (PTT) 
  >1% indicates tremor 
<0.6% absence of tremor 
0.6 - 1% not conclusive 
Percent time immobile (PTI)   >5% abnormal 
 
Summary: 
Treatment Suggestions:  
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8.22 Appendix 22 – PKG Database Variables  
PKG 
record 
Sex Initials Surname First 
Name 
PKG 
Practitioner 
Consultant DoB 
        
Pathway Prognosis 
Score 
Prognosis 
Category 
Hosp 
number 
NHS 
number 
Date of PKG Date of 
report 
Clinical 
Question(s) 
        
BKS DKS FDS PTT (%) PTI (%) PKG 
Findings 
Recommend. Outcome 
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8.23 Appendix 23 – PKG patient evaluation  
PKG Service Questionnaire 
 
 
 
 
 
We would like to evaluate your experience of the Parkinson’s Kinetigraph™ (PKG) service that has 
formed part of your Parkinson’s care. It is important that we regularly collect opinions of service 
users to ensure a high standard of current and future care. Thank you for taking the time to 
complete this questionnaire. Once completed, please return in the freepost envelope provided. All 
responses will remain anonymous. Please think about your most recent PKG as you answer the 
questions throughout. 
General Information (please complete in dd/mm/yyyy format) 
TODAY’S DATE:  
Date of 
most 
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recent 
PKG: 
D.O.B:  
DATE OF 
DIAGNOSIS:  
 
Receiving the PKG (please tick responses) 
 
How many times have you had a PKG fitted?  
 1  2  3 Other  
 
How did you receive your most recent PKG device? 
 By post                              In clinic 
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Before you received the PKG, what was your level of understanding about the purpose of the 
device? 
 No Understanding  
 1 
 
 2  
 
 3 
 
 4 
 
5 
Excellent 
Understanding 
 
 
How helpful was the information provided to you when you first received the PKG in explaining 
about the device? 
Not at all helpful   
 1 
 
 2  
 
 3 
 
 4 
 
 5 
Extremely Helpful 
 
Using the PKG 
 
How comfortable did you find wearing the device? 
Not at all comfortable       Extremely comfortable  
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 1  2  3  4  5 
 
Please give details:  
 
 
 
 
 
 
 
Did you experience any technical difficulties with the device? 
 Yes |  No 
 
If ‘YES’ please give details:  
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How did you return the PKG device? 
 By post                              In clinic 
 
How did you find the process of returning the device? 
       Not at all simple  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely simple  
 
Please let us know how this process could have been improved:  
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PKG Results 
After returning the PKG, how long did it take to receive your results? 
 Under a month  1-2 months  2-3 months 
3-4 months >4months  
Did you receive your results by letter? 
 Yes      No     
If ‘YES’, how useful did you find the information? 
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       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful  
 
Did you receive your results by email? 
 Yes      No     
If ‘YES’, how useful did you find the information? 
       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful  
 
Did you receive your results by telephone? 
 Yes      No     
 
 
If ‘YES’, how useful did you find the information? 
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       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful  
 
Did you receive a copy of the graph (pictured)? 
 Yes      No     
 
If ‘YES’, how useful did you find the information? 
       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful  
 
Did you receive a copy of the report (pictured)? 
 Yes      No   
 
If ‘YES’, how useful did you find the information? 
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       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful  
 
How would you like to receive PKG results in future? (Please tick more than one if necessary) 
 By letter  By phone  By email 
 In a report  In a graph    In a report 
Did you feel that these results were reflective of your lived experience during the time the PKG was 
worn? 
       Not at all reflective  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely reflective 
Impact on care 
 
 
How useful were the medication reminders in assisting you with taking your medication on time? 
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       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
5 
Extremely useful 
 
If applicable, how useful was the PKG data in assisting with explaining your symptoms to your Doctor 
or Nurse? 
       Not at all useful  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely useful 
 
How valuable was the PKG in providing data to your Doctor or Nurse about your symptoms that you 
could not have provided? 
       Not at all valuable  
 1 
  
 2 
 
 3 
 
 4 
 
 5 
Extremely valuable 
 
 
Were any changes to your treatment recommended as a result of the PKG results? 
 
 
547 
 
 Yes |  No 
If ‘YES’ please give details:  
 
 
 
 
 
 
 
If ‘YES’ were these changes made? 
 Yes |  No 
 
 
If ‘YES’, how long did it take for these changes to be made from the time of receiving the results? 
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1-4 weeks  1-2 months  2-3 months 
3-4 months >4months  
PKG Service Satisfaction 
 
What level of involvement do you feel you have had in your treatment as a result of receiving the 
PKG? 
       Not at all involved  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely involved 
 
What level of involvement do you feel your consultant has had in your treatment as a result of 
receiving the PKG? 
       Not at all involved  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely involved 
What level of involvement do you feel your Parkinson’s Nurse has had in your treatment as a result 
of receiving the PKG? 
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       Not at all involved  
 1 
 
 2 
 
 3 
 
 4 
 
 5 
Extremely involved 
Please put a tick next to the statement you agree with most: 
 “I was happy with the PKG as it meant I did not have to travel for my appointment.” 
 
 “I  would have preferred to travel to have a clinic appointment.” 
 
  Neither of the above.  
Areas of concern: 
Please tick any areas of concern you may have with the PKG service: 
The PKG device itself  Consultant Involvement  Treatment 
No concerns Other 
Please give any details of these concerns below: 
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Would you be willing to use the PKG again to assist in the management of your Parkinson’s Disease 
in the future? 
 Yes |  No 
Thank you 
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Thank you for taking the time to fill in this questionnaire on the PKG service. Please share any 
additional comments in the space below. 
 
 
 
 
 
 
 
Please return your completed questionnaire using the freepost return envelope provided. 
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8.24 Appendix 24 – Data Extraction Form 
 
Study Title Drug Name Year of 
Publication  
Year of 
Registration  
CT link  No. of site 
visits 
      
Phase Status Lead Site Masking Trial design Group 
design 
      
Dose Ranging No. pps Study length Treatment 
duration 
Length of 
follow up 
Extension 
      
Method of 
distinguish 
symptomatic 
effect 
Min/Max Age Disease Stage Disease duration  H & Y  Cognitive 
test 
      
Drug Naiive PD Drug 
stability 
Changes to PD 
regime 
Primary 
Outcome 
Secondary 
Outcome 
Mechanistic 
Outcome 
      
No. of primary 
outcomes 
Patient 
Reported 
Outcome 
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8.25 Appendix 25 - Status and key design features of the Phase II Studies  
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PASADENA - PR002 Open + 
recruiting 
11 300 double 
blind 
placebo 
controlled 
48 12 27 - 
Ambroxol as 
a Treatment 
for PD 
Dementia 
- Ambroxol  Open + 
recruiting 
11 75 double 
blind 
placebo 
controlled 
37 12 12 - 
PD Nilotinib - Nilotinib Finished 
recruiting 
Not 
kno
wn 
75 double 
blind 
placebo 
controlled 
42 12 15 wash out - 3 
months 
NILO-PD - Nilotinib Open + 
recruiting 
11 75 double 
blind 
placebo 
controlled 
35 6 8.5 - 
Intermittent 
Bilateral 
GDNF for PD 
- GDNF Completed 
+ reported 
21 42 double 
blind 
placebo 
controlled 
27 9 9 - 
EXENATIDE-
PD 
2017 Exenatide Completed 
+ reported 
6 60 double 
blind 
placebo 
controlled 
26 11 14 wash out - 3 
months 
LixiPark - Lixisenatide Open + 
recruiting 
Not 
kno
wn 
158 double 
blind 
placebo 
controlled 
38 12 12 wash out - 2 
months 
MOVES-PD - GZ/SAR402
67 
Open + 
recruiting 
8 243 double 
blind 
placebo 
controlled 
63 15 15 - 
Deferipron 
PD 
2017 Iron 
Chelator 
Deferipron
e 
Completed 
+ reported 
3 36 double 
blind 
placebo 
controlled 
22 6 6 - 
FAIR-PARK-I 2015 Iron 
Chelator 
Deferipron
e 
Completed 
+ reported 
4 40 double 
blind 
placebo 
controlled 
24 18 18 delayed start - 6 
months 
FAIRPARK-II - Iron 
Chelator 
Deferipron
e 
Open + 
recruiting 
4 338 double 
blind 
placebo 
controlled 
34 9 10 wash out - 1 
month 
SKY - Deferipron
e 
Open + 
recruiting 
7 140 double 
blind 
placebo 
controlled 
39 9 9 - 
NIC-PD - Transderm
al NICotine 
Completed 
+ 
unreported 
Not 
kno
wn 
160 double 
blind 
placebo 
controlled 
50 12 14 wash out - 2 
months 
STEADY-PD 2013 Isradipine Completed 
+ reported 
10 99 double 
blind 
placebo 
controlled 
31 12 12 - 
Investigation 
of the Safety 
and Efficacy 
of NTCELL 
2017 NTCELL Completed 
+ reported 
Not 
kno
wn 
18 double 
blind 
placebo 
controlled 
38 6 Lifelong 
follow up 
- 
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Lovastatin as 
a 
Neuroprotect
ive Treatment 
for Early 
Stage PD 
- Lovastatin Open + 
recruiting 
7 80 double 
blind 
placebo 
controlled 
31 11 12 wash out- 1 
month 
PD STAT - Simvastatin  Finished 
recruiting 
8 235 double 
blind 
placebo 
controlled 
49 24 26 wash out- 2 
months 
N-
Acetylcystein
e for 
Neuroprotect
ion in 
Parkinson's 
Disease 
- N-
Acetylcystei
ne 
Completed 
+ 
unreported 
2 50 double 
blind 
placebo 
controlled 
55 1 1 - 
GM1 
Ganglioside 
Effects on PD 
- GM1 
Ganglioside 
Completed 
+ reported 
6 93 double 
blind 
placebo 
controlled 
127 28 52 wash out - 24 
months, 
delayed start 6 
months 
Pioglitazone 
in Early PD 
2015 Pioglitazon
e  
Completed 
+ reported 
5 210 double 
blind 
placebo 
controlled 
38 10 10 - 
Safety and 
Efficacy of 
CERE-120 in 
Subjects With 
PD 
2013 CERE-120 Completed 
+ reported 
Not 
kno
wn 
60 double 
blind 
placebo 
controlled 
100 - 
surgi
cal 
proc
edur
e 
36 - 
Safety and 
Efficacy of 
DA-9805 for 
PD 
-  DA-9805 Open + 
recruiting 
Not 
kno
wn 
60 double 
blind 
placebo 
controlled 
13 3 3 - 
Clinical Trial 
on the 
Effectiveness 
of Traditional 
Chinese 
Medicinal 
Mixture in PD 
- Traditional 
Chinese 
Medicinal 
Mixture  
- Not 
Kno
wn 
144 double 
blind 
placebo 
controlled 
21 12 13 wash out - 1 
month 
Clinical Trial 
on the 
Effectiveness 
of Herbal 
Medicinal 
Mixture in PD 
- Herbal 
Medicinal 
Mixture  
Completed 
+ 
unreported 
Not 
Kno
wn 
158 double 
blind 
placebo 
controlled 
30 12 13 wash out - 1 
month 
Ubiquinol in 
PD: Safety, 
Tolerability, 
and Effects 
Upon 
Oidative 
Damage and 
Mitochondria
l Biomarkers 
- Ubiquinol Completed 
+ 
unreported 
Not 
Kno
wn 
11 double 
blind 
placebo 
controlled 
58 6 6 - 
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Study of the 
Neuro-
protective 
Effect of 
Granulocyte-
colony 
Stimulating 
Factor on 
Early Stage 
PD 
- Granulocyt
e-colony 
Stimulating 
Factor 
Terminated Not 
kno
wn 
4 double 
blind 
placebo 
controlled 
42 12 12 - 
Exendin-4 as 
a Treatment 
for PD - Pilot 
Study 
2013 Exendin-4  Completed 
+ reported 
4 44 single blind open label 32 12 14 wash out - 2 
months 
Double- blind 
multicentre,s
ham surgery 
controlled 
study of cere-
120 in 
subjects with 
pd 
2010 Cere-120 Completed 
+ reported 
 58 double 
blind 
placebo 
controlled 
24 12 12 - 
MIREILLE 2016 Bee Venom Completed 
+ reported 
14 50 double 
blind 
placebo 
controlled 
33 12 12 - 
SPARK 2018 Exercise  Completed 
+ reported 
104 128 single blind open label 54 6 6 - 
A Trial of 
MitoQ for the 
treatment of 
people with 
PD  
2010 MitoQ Completed 
+ reported 
7 128 double 
blind 
placebo 
controlled  
18 12 13 wash out - 1 
month 
Efficacy and 
safety of 
Trigonella 
seeds as an 
adjuvant to L-
Dopa 
2013 Trigonella 
Seeds 
Completed 
+ reported 
7 50 double 
blind 
placebo 
controlled  
Not 
known 
6 6 - 
Randomized, 
double-blind, 
placebo-
controlled 
pilot trial of 
reduced 
coenzyme 
Q10 for 
Parkinson's 
disease.  
2015 coenzyme 
Q10 
Completed 
+ reported 
7 31 double 
blind 
placebo 
controlled 
24 11 13 - 
Effect of the 
myeloperoida
se inhibitor 
AZD3241 on 
microglia: a 
PET study in 
PD 
2015  AZD3241 Completed 
+ reported 
3 24 double 
blind 
placebo 
controlled 
9 2 2.3 - 
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Safety and 
Efficacy of 
Liraglutide in 
PD 
- Liraglutide Open + 
recruiting 
9 57 double 
blind 
placebo 
controlled 
29 12 14 - 
Pilot study of 
H2 therapy in 
PD 
2012 H2 Completed 
+ reported 
Not 
kno
wn 
17 double 
blind 
placebo 
controlled 
Not 
known 
11 11 - 
High-dose 
transdermal 
nicotine in 
Parkinson’s 
disease 
patients 
2017 Transderm
al Nicotine 
Completed 
+ reported 
4 40 single blind open label  51 10.4 12 wash in 2.5 
months, wash 
out - 1.4 
months 
SURE-PD 2014 Inosine Completed 
+ reported 
12 75 double 
blind 
placebo 
controlled 
42 24 25 wash in - 3 
months, wash 
out - 1month 
GAP-PD 2014 GM 608 Completed 
+ reported 
10 6 double 
blind 
placebo 
controlled 
13 0.5 3 - 
A Study to 
Assess Safety 
and 
Tolerability of 
Oral AZD3241 
in Patients 
With PD 
2014 Oral 
AZD3241 
Completed 
+ reported 
6 51 double 
blind 
placebo 
controlled 
8 2.7 3.2 wash out - 2 
weeks 
SPARK - BIIB054 Open + 
recruiting 
38 311 double 
blind 
placebo 
controlled 
54 12 24 - 
Study of 
Zonisamide in 
Early PD 
- Zonisamide In set-up, 
not yet 
started 
7 60 double 
blind 
placebo 
controlled 
14 12 12 - 
High-intensity 
Exercise and 
Fall 
Prevention 
Boot Camp 
for PD 
- Exercise Completed 
+ 
unreported 
25 27 double 
blind 
open label 16 2 8 - 
PASADENA - PR002 
Open + 
recruiting 
11 300 
double 
blind 
placebo 
controlled 
48 12 27 
- 
Ambroxol as 
a Treatment 
for PD 
Dementia 
- Ambroxol  
Open + 
recruiting 
11 75 
double 
blind 
placebo 
controlled 
37 12 12 
- 
PD Nilotinib - Nilotinib 
Finished 
recruiting 
Not 
kno
wn 
75 
double 
blind 
placebo 
controlled 
42 12 15 wash out - 3 
months 
NILO-PD - Nilotinib 
Open + 
recruiting 
11 75 
double 
blind 
placebo 
controlled 
35 6 8.5 
- 
Intermittent 
Bilateral 
GDNF for PD 
- GDNF 
Completed 
+ reported 
21 42 
double 
blind 
placebo 
controlled 
27 9 9 
- 
EXENATIDE-
PD 
2017 Exenatide 
Completed 
+ reported 
6 60 
double 
blind 
placebo 
controlled 
26 11 14 wash out - 3 
months 
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LixiPark - Lixisenatide 
Open + 
recruiting 
Not 
kno
wn 
158 
double 
blind 
placebo 
controlled 
38 12 12 wash out - 2 
months 
MOVES-PD - 
GZ/SAR402
67 
Open + 
recruiting 
8 243 
double 
blind 
placebo 
controlled 
63 15 15 
- 
Deferipron 
PD 
2017 
Iron 
Chelator 
Deferipron
e 
Completed 
+ reported 
3 36 
double 
blind 
placebo 
controlled 
22 6 6 
- 
FAIR-PARK-I 2015 
Iron 
Chelator 
Deferipron
e 
Completed 
+ reported 
4 40 
double 
blind 
placebo 
controlled 
24 18 18 
delayed start - 6 
months 
FAIRPARK-II - 
Iron 
Chelator 
Deferipron
e 
Open + 
recruiting 
4 338 
double 
blind 
placebo 
controlled 
34 9 10 
wash out - 1 
month 
SKY - 
Deferipron
e 
Open + 
recruiting 
7 140 
double 
blind 
placebo 
controlled 
39 9 9 
- 
NIC-PD - 
Transderm
al NICotine 
Completed 
+ 
unreported 
Not 
kno
wn 
160 
double 
blind 
placebo 
controlled 
50 12 14 wash out - 2 
months 
STEADY-PD 2013 Isradipine 
Completed 
+ reported 
10 99 
double 
blind 
placebo 
controlled 
31 12 12 
- 
Investigation 
of the Safety 
and Efficacy 
of NTCELL 
2017 NTCELL 
Completed 
+ reported 
Not 
kno
wn 
18 
double 
blind 
placebo 
controlled 
38 6 
Lifelong 
follow up 
- 
Lovastatin as 
a 
Neuroprotect
ive Treatment 
for Early 
Stage PD 
- Lovastatin 
Open + 
recruiting 
7 80 
double 
blind 
placebo 
controlled 
31 11 12 
wash out- 1 
month 
PD STAT - Simvastatin  
Finished 
recruiting 
8 235 
double 
blind 
placebo 
controlled 
49 24 26 wash out- 2 
months 
N-
Acetylcystein
e for 
Neuroprotect
ion in 
Parkinson's 
Disease 
- 
N-
Acetylcystei
ne 
Completed 
+ 
unreported 
2 50 
double 
blind 
placebo 
controlled 
55 1 1 
- 
GM1 
Ganglioside 
Effects on PD 
- 
GM1 
Ganglioside 
Completed 
+ reported 
6 93 
double 
blind 
placebo 
controlled 
127 28 52 
wash out - 24 
months, 
delayed start 6 
months 
Pioglitazone 
in Early PD 
2015 
Pioglitazon
e  
Completed 
+ reported 
5 210 
double 
blind 
placebo 
controlled 
38 10 10 
- 
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Safety and 
Efficacy of 
CERE-120 in 
Subjects With 
PD 
2013 CERE-120 
Completed 
+ reported 
Not 
kno
wn 
60 
double 
blind 
placebo 
controlled 
100 
- 
surgi
cal 
proc
edur
e 
36 
- 
Safety and 
Efficacy of 
DA-9805 for 
PD 
-  DA-9805 
Open + 
recruiting 
Not 
kno
wn 
60 
double 
blind 
placebo 
controlled 
13 3 3 
- 
Clinical Trial 
on the 
Effectiveness 
of Traditional 
Chinese 
Medicinal 
Mixture in PD 
- 
Traditional 
Chinese 
Medicinal 
Mixture  
- 
Not 
Kno
wn 
144 
double 
blind 
placebo 
controlled 
21 12 13 
wash out - 1 
month 
Clinical Trial 
on the 
Effectiveness 
of Herbal 
Medicinal 
Mixture in PD 
- 
Herbal 
Medicinal 
Mixture  
Completed 
+ 
unreported 
Not 
Kno
wn 
158 
double 
blind 
placebo 
controlled 
30 12 13 
wash out - 1 
month 
Ubiquinol in 
PD: Safety, 
Tolerability, 
and Effects 
Upon 
Oidative 
Damage and 
Mitochondria
l Biomarkers 
- Ubiquinol 
Completed 
+ 
unreported 
Not 
Kno
wn 
11 
double 
blind 
placebo 
controlled 
58 6 6 
- 
Study of the 
Neuro-
protective 
Effect of 
Granulocyte-
colony 
Stimulating 
Factor on 
Early Stage 
PD 
- 
Granulocyt
e-colony 
Stimulating 
Factor 
Terminated 
Not 
kno
wn 
4 
double 
blind 
placebo 
controlled 
42 12 12 
- 
Exendin-4 as 
a Treatment 
for PD - Pilot 
Study 
2013 Exendin-4  
Completed 
+ reported 
4 44 single blind open label 32 12 14 
wash out - 2 
months 
Double- blind 
multicentre,s
ham surgery 
controlled 
study of cere-
120 in 
subjects with 
pd 
2010 Cere-120 
Completed 
+ reported 
 58 
double 
blind 
placebo 
controlled 
24 12 12 
- 
MIREILLE 2016 Bee Venom 
Completed 
+ reported 
14 50 
double 
blind 
placebo 
controlled 
33 12 12 
- 
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SPARK 2018 Exercise  
Completed 
+ reported 
104 128 single blind open label 54 6 6 
- 
A Trial of 
MitoQ for the 
treatment of 
people with 
PD  
2010 MitoQ 
Completed 
+ reported 
7 128 
double 
blind 
placebo 
controlled  
18 12 13 
wash out - 1 
month 
Efficacy and 
safety of 
Trigonella 
seeds as an 
adjuvant to L-
Dopa 
2013 
Trigonella 
Seeds 
Completed 
+ reported 
7 50 
double 
blind 
placebo 
controlled  
Not 
known 
6 6 
- 
Randomized, 
double-blind, 
placebo-
controlled 
pilot trial of 
reduced 
coenzyme 
Q10 for 
Parkinson's 
disease.  
2015 
coenzyme 
Q10 
Completed 
+ reported 
7 31 
double 
blind 
placebo 
controlled 
24 11 13 
- 
Effect of the 
myeloperoida
se inhibitor 
AZD3241 on 
microglia: a 
PET study in 
PD 
2015  AZD3241 
Completed 
+ reported 
3 24 
double 
blind 
placebo 
controlled 
9 2 2.3 
- 
Safety and 
Efficacy of 
Liraglutide in 
PD 
- Liraglutide 
Open + 
recruiting 
9 57 
double 
blind 
placebo 
controlled 
29 12 14 
- 
Pilot study of 
H2 therapy in 
PD 
2012 H2 
Completed 
+ reported 
Not 
kno
wn 
17 
double 
blind 
placebo 
controlled 
Not 
known 
11 11 
- 
High-dose 
transdermal 
nicotine in 
Parkinson’s 
disease 
patients 
2017 
Transderm
al Nicotine 
Completed 
+ reported 
4 40 single blind open label  51 10.4 12 
wash in 2.5 
months, wash 
out - 1.4 
months 
SURE-PD 2014 Inosine 
Completed 
+ reported 
12 75 
double 
blind 
placebo 
controlled 
42 24 25 
wash in - 3 
months, wash 
out - 1month 
GAP-PD 2014 GM 608 
Completed 
+ reported 
10 6 
double 
blind 
placebo 
controlled 
13 0.5 3 
- 
A Study to 
Assess Safety 
and 
Tolerability of 
Oral AZD3241 
in Patients 
With PD 
2014 
Oral 
AZD3241 
Completed 
+ reported 
6 51 
double 
blind 
placebo 
controlled 
8 2.7 3.2 
wash out - 2 
weeks 
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SPARK - BIIB054 
Open + 
recruiting 
38 311 
double 
blind 
placebo 
controlled 
54 12 24 
- 
Study of 
Zonisamide in 
Early PD 
- Zonisamide 
In set-up, 
not yet 
started 
7 60 
double 
blind 
placebo 
controlled 
14 12 12 
- 
High-intensity 
Exercise and 
Fall 
Prevention 
Boot Camp 
for PD 
- Exercise 
Completed 
+ 
unreported 
25 27 
double 
blind 
open label 16 2 8 
- 
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STEADY-PD III 2017 Isradipine Comple
ted + 
reporte
d 
12 (336) dou
ble 
blin
d 
place
bo 
contr
olled 
paral
lel 
grou
p 
N 54 36 36 - 
- 
SURE-PD3 - Inosine Finishe
d 
recruiti
ng 
14 (270) dou
ble 
blin
d 
place
bo 
contr
olled 
paral
lel 
grou
p 
N 50 24 27 - wash in - 
3 
months, 
wash 
out- 3 
months 
Study of 
Mirapex 
Pramipeole 
for the Early 
Treatment of 
Parkinson's 
disease  
2013 Pramipeo
le 
Comple
ted + 
reporte
d 
6 (535) dou
ble 
blin
d 
place
bo 
contr
olled  
paral
lel 
grou
p 
N 35 15 15 - 
delayed 
start- 9 
months 
NET-PD LS-1 
Creatine in 
Parkinson's 
Disease 
2015 Creatine Termin
ated 
9 (1741
) 
dou
ble 
blin
d 
place
bo 
contr
olled  
paral
lel 
grou
p 
N 86 60 60 - 
- 
QE3 2014 Coenzym
e Q10 
with 
Vitamin E 
Termin
ated 
5 (600) dou
ble 
blin
d 
place
bo 
contr
olled  
paral
lel 
grou
p 
Y 32 16 16 - 
- 
PD4PD 2012 Partnered 
Dance 
Comple
ted + 
reporte
d 
4 62 singl
e 
blin
d 
place
bo 
contr
olled 
paral
lel 
grou
p 
N 23 12 12 - 
- 
ADAGIO 2009 Rasagiline Comple
ted + 
reporte
d 
11 (1176
) 
dou
ble 
blin
d 
place
bo 
contr
olled 
paral
lel 
grou
p 
Y 43 16.5 16.5 - 
delayed 
start- 8 
months 
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Tr
ia
l 
Y
e
ar
 
p
u
b
lis
h
e
d
 
A
ct
iv
e
 
ag
e
n
t(
s)
 
St
at
u
s 
P
ri
m
ar
y 
En
d
p
o
in
ts
 
m
e
t 
P
ri
m
ar
y 
O
u
tc
o
m
e
 
D
o
m
ai
n
(s
) 
O
u
tc
o
m
e
 
M
e
as
u
re
(s
) 
N
u
m
b
e
r 
o
f 
P
ri
m
ar
y 
O
u
tc
o
m
e
 
M
e
as
u
re
s 
M
e
ch
an
is
ti
c 
Se
co
n
d
ar
y 
O
u
tc
o
m
e 
P
at
ie
n
t 
R
e
p
o
rt
e
d
 
O
u
tc
o
m
e 
PASADENA - PR002 Open + 
recruitin
g 
- Motor MDS-UPDRS I-
III total score 
(OFF state) 
1 DaTSCA
N, 
Blood 
Test 
N 
Ambroxol as a 
Treatment for 
PD Dementia 
- Ambroxol  Open + 
recruitin
g 
- Cognition Alzheimer's 
Disease 
Assessment 
Scale - 
cogntive 
subscale 
(ADAS-cog), 
ADCS - 
Clinican's 
Global 
impression of 
change (CGIC) 
2 CSF, 
Blood 
Test, 
MRI 
N 
PD Nilotinib - Nilotinib Finished 
recruitin
g 
- Safety Number of 
participants 
with abnormal 
lab 
values/advers
e 
events/serious 
adverse 
events 
1 CSF N 
NILO-PD - Nilotinib Open + 
recruitin
g 
- Safety, Tolerability Number of 
treatment-
related serious 
adverse 
events, Ability 
to complete 
study on 
assigned dose 
2 - N 
Intermittent 
Bilateral GDNF 
for PD 
2016 GDNF Complet
ed + 
reported 
N Motor MDS-UPDRS 
Part III (OFF) 
1 MRI, 
PET 
N 
EXENATIDE-
PD 
2017 Exenatide Complet
ed + 
reported 
Y Motor MDS-UPDRS 
Part III (OFF) 
1 - N 
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LixiPark - Liisenatide Open + 
recruitin
g 
- Motor MDS-UPDRS 
Part III (ON) 
1 - N 
MOVES-PD - GZ/SAR402
67 
Open + 
recruitin
g 
- Motor MDS-UPDRS 
Part II and III 
score (OFF/ON 
state not 
reported) 
1  N 
Deferipron PD 2017 Iron 
Chelator 
Deferipron
e 
Complet
ed + 
reported 
Y Safety, Mechanism 
of Action 
Blood, MRI 2 - N 
FAIR-PARK-I 2015 Iron 
Chelator 
Deferipron
e 
Complet
ed + 
reported 
Y Mechanism of 
Action 
 MRI 1 Blood 
Test, 
CSF, 
MRI 
Y 
FAIRPARKII - Iron 
Chelator 
Deferipron
e 
Open + 
recruitin
g 
- Motor MDS-UPDRS I-
III total score 
(OFF state) 
1 - N 
SKY - Deferipron
e 
Open + 
recruitin
g 
- Motor MDS-UPDRS 
part III 
(OFF/ON state 
not reported) 
1 Blood 
Test 
N 
NIC-PD - Transderma
l NICotine 
Complet
ed + 
unreport
ed 
- Motor MDS-UPDRS I-
III total score 
(OFF/ON state 
not reported) 
1 - N 
STEADY-PD 2013 Isradipine Complet
ed + 
reported 
Y Tolerability Proportion of 
subjects who 
complete 
study or to the 
time of 
iniation of 
dopaminergic 
therapy 
1 - Y 
Investigation 
of the Safety 
and Efficacy of 
NTCELL 
2017 NTCELL Complet
ed + 
reported 
Y Safety the incidence 
of treatment 
emergent 
adverse 
events 
1 - Y 
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Lovastatin as a 
Neuroprotecti
ve Treatment 
for Early Stage 
PD 
- Lovastatin Open + 
recruitin
g 
- Motor MDS-UPDRS 
part III (OFF) 
1 PET  N 
PD STAT - Simvastatin  Finished 
recruitin
g 
- Motor MDS-UPDRS 
Part III (OFF) 
1 - N 
N-
Acetylcysteine 
for 
Neuroprotecti
on in 
Parkinson's 
Disease 
- N-
Acetylcystei
ne 
Complet
ed + 
unreport
ed 
- Mechanism of 
Action 
MRI 1 - Y 
GM1 
Ganglioside 
Effects on PD 
- GM1 
Ganglioside 
Complet
ed + 
reported 
Y Motor MDS-UPDRS I-
III total score 
(week 24) 
(OFF), MDS-
UPDRS I-III 
total score 
(week 120) 
(OFF) 
2 - N 
Pioglitazone in 
Early PD 
2015 Pioglitazon
e  
Complet
ed + 
reported 
N Motor MDS-UPDRS I-
III total score 
(OFF) 
1 - N 
Safety and 
Efficacy of 
CERE-120 in 
Subjects With 
PD 
2013 CERE-120 Complet
ed + 
reported 
N Motor MDS-UPDRS 
part III (OFF) 
1 Brain 
Imaging 
N 
Safety and 
Efficacy of DA-
9805 for PD 
-  DA-9805 Open + 
recruitin
g 
- Motor MDS-UPDRS 
part III (OFF) 
1 - N 
Clinical Trial 
on the 
Effectiveness 
of Traditional 
Chinese 
Medicinal 
Miture in PD 
- Traditional 
Chinese 
Medicinal 
Miture  
- - Motor MDS-UPDRS I-
III total score 
(OFF/ON state 
not reported) 
1 - N 
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Ubiquinol in 
PD: Safety, 
Tolerability, 
and Effects 
Upon Oidative 
Damage and 
Mitochondrial 
Biomarkers 
- Ubiquinol Complet
ed + 
unreport
ed 
- Safety Number and 
severity of any 
adverse event 
1 MRI N 
Study of the 
Neuro-
protective 
Effect of 
Granulocyte-
colony 
Stimulating 
Factor on 
Early Stage PD 
- Granulocyt
e-colony 
Stimulating 
Factor 
Terminat
ed 
- Motor MDS-UPDRS 
part III (OFF) 
1 - N 
Exendin-4 as a 
Treatment for 
PD - Pilot 
Study 
2013 Eendin-4  Complet
ed + 
reported 
Y Motor MDS-UPDRS 
part III (OFF) 
1 DaTSCA
N 
N 
Clinical Trial 
on the 
Effectiveness 
of Herbal 
Medicinal 
Mixture in PD 
- Herbal 
Medicinal 
Mixture  
Complet
ed + 
unreport
ed 
- Time to event Levodopa 
Equivalent 
Dose (LED) 
1 - N 
Double- blind 
multicentre,sh
am surgery 
controlled 
study of cere-
120 in 
subjects with 
pd 
2010 Cere-120 Complet
ed + 
reported 
N Motor MDS-UPDRS 
part III (OFF) 
1 - N 
MIREILLE 2016 Bee Venom Complet
ed + 
reported 
N Motor MDS-UPDRS 
part III (OFF) 
1 DaTSCA
N 
N 
SPARX 2018 Exercise  Complet
ed + 
reported 
Y Adherence Maximum 
heart rate  
1 - N 
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A Trial of 
MitoQ for the 
treatment of 
people with 
PD  
2010 MitoQ Complet
ed + 
reported 
N Motor MDS-UPDRS I-
III total score 
(OFF) 
1 - N 
Efficacy and 
Safety of 
Trigonella 
seeds as 
adjuvant to L-
Dopa 
2013 Trigoneela 
L seeds 
Complet
ed + 
reported 
Y Motor MDS-UPDRS I-
III total score 
(OFF/ON state 
not reported) 
1 - N 
Randomized, 
double-blind, 
placebo-
controlled 
pilot trial of 
reduced 
coenzyme 
Q10 for 
Parkinson's 
disease.  
2015 coenzyme 
Q10 
Complet
ed + 
reported 
Y Motor MDS-UPDRS I-
III total score 
(ON) 
1 - N 
Effect of the 
myeloperoida
se inhibitor 
AZD3241 on 
microglia: a 
PET study in 
PD 
2015  AZD3241 Complet
ed + 
reported 
N Target Engagement PET 1 Blood N 
Liraglutide - Liraglutide Open + 
recruitin
g 
- Motor, Non-motor, 
Cognition 
MDS-UPDRS 
Part III (OFF), 
NMSS score, 
MADRS-2 
score 
3 Blood Y 
H2 Therapy 2012 H2 Complet
ed + 
reported 
Y Motor MDS-UPDRS I-
III total score 
(OFF/ON state 
not reported) 
1 - N 
High-dose 
transdermal 
nicotine in 
Parkinson’s 
disease 
patients 
2017 Transderma
l Nicotine 
Complet
ed + 
reported 
- Motor MDS-UPDRS 
Part III (OFF) 
1 DaTSCA
N, Urine 
Y 
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SURE-PD 2014 Inosine Complet
ed + 
reported 
Y Tolerability, Safety, 
Site of action  
Extent 
assigned 
treatment 
could continue 
without 
prolonged 
dose 
reduction due 
to adverse 
experiences 
(AEs) at 6 and 
24 months, 
absence of 
serious AEs, 
CSF Urate 
levels 
3 - N 
GAP-PD 2014 GM 608 Complet
ed + 
reported 
Y Motor, Safety, 
Tolerability 
MDS-UPDRS I-
III total score 
(OFF), 
Safety/tolerabi
lity outcomes 
not specified 
3 - N 
A Study to 
Assess Safety 
and 
Tolerability of 
Oral AZD3241 
in Patients 
With PD 
2014 Oral 
AZD3241 
Complet
ed + 
reported 
Y Safety, Tolerability change in vital 
sign 
measurements
, number and 
severity of 
Aes, change in 
neuro/phyiscal 
examination 
or clin lab test 
data, ECGs, 
Suicidality 
Score, CSSRS 
6 Blood 
Test 
Y 
SPARK - BIIB054 Open + 
recruitin
g 
- Safety Percentage of 
participants 
with Aes  
1 Blood 
Test, 
SPECT 
N 
Study of 
Zonisamide in 
Early PD 
- Zonisamide In set-up, 
not yet 
started 
- Time to Event Time to need 
dopaminergic 
therapy 
1 - N 
High-intensity 
Exercise and 
Fall 
Prevention 
Boot Camp for 
PD 
- Exercise Complet
ed + 
unreport
ed 
Y Tolerability/Adhere
nce/ Safety  
Number of 
participants 
that complete 
exercise, AEs 
7 Blood 
Test 
Y 
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8.28 Appendix 28 - Outcome measures in Phase III studies  
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STEADY-PD III 2017 Isradipine 
Complete
d + 
reported 
N Motor 
MDS-UPDRS I-
III total score 
(OFF) 
1 - Y 
SURE-PD3 - Inosine 
Finished 
recruiting 
- Motor 
MDS-UPDRS I-
III total score 
(OFF) 
1 - Y 
Study of Mirapex 
Pramipeole for the 
Early Treatment of 
Parkinson's disease  
2013 
Pramipexol
e 
Complete
d + 
reported 
N Motor 
MDS-UPDRS I-
III total score 
(OFF) 
1 SPECT Y 
NET-PD LS-1 
Creatine in 
Parkinson's Disease 
2015 Creatine 
Terminate
d 
N Efficacy 
Global 
outcome 
combined 
information 
from Schwab 
England ADL, 
PDQ-39, 
Ambulatory 
capacity,Symb
ol digit 
modalitites, 
modified 
rankin 
1 - Y 
QE3 2014 
Coenzyme 
Q10 with 
Vitamin E 
Terminate
d 
N Motor 
MDS-UPDRS I-
III total score 
(OFF) 
1 Blood Y 
PD4PD 2012 
Partnered 
Dance 
Complete
d + 
reported 
Y Motor 
MDS-UPDRS 
part III (OFF) 
1 - N 
ADAGIO  2009 Rasagiline 
Complete
d + 
reported 
Y Motor 
MDS-UPDRS I-
III total score 
(OFF) 
1 - N 
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8.29 Appendix 29 – Inclusion criteria Phase II studies  
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PASADENA - PR002 
Open + 
recruiti
ng 
40 80 - early 1 or 2 - MMSE  >25 -  N/A N 
Ambroxol 
as a 
Treatment 
for PD 
Dementia 
- 
Ambroxo
l  
Open + 
recruiti
ng 
50 - 
PD 
diagno
sis 1 yr 
prior to 
demen
tia 
early-
advan
ced 
2-3.5 - 
MOCA 
≤  24 
and 
MMSE 
≥16 
≤  24 
and 
≥16  
-  N/A N 
PD 
Nilotinib 
- Nilotinib 
Finishe
d 
recruiti
ng 
40 90 -  
mode
rate 
≥2.5 
≤ 3 
- MOCA ≥22 -  N/A N 
NILO-PD - Nilotinib 
Open + 
recruiti
ng 
40 79 
> 5yrs 
since 
diagno
sis 
mod - 
advan
ced 
>2<4 ON MOCA ≥21 Becks ≤ 17 N 
Intermitte
nt Bilateral 
GDNF for 
PD 
- GDNF 
Compl
eted + 
report
ed 
35 75 
≥ 5yrs 
since 
diagno
sis 
early- 
mod 
≤3  OFF MOCA ≥24 Becks  <14 N 
EXENATIDE
-PD 
2017 
Exenatid
e 
Compl
eted + 
report
ed 
25 75 -  early ≤ 2.5 ON MDRS ≥120 
MADR
S 
≤ 16 N 
LixiPark - 
Lixisenati
de 
Open + 
recruiti
ng 
40 75 
Within 
3 yrs of 
diagno
sis 
early-
mod 
<3 ON MOCA >26 -  N/A N 
MOVES-PD - 
GZ/SAR4
0267 
Open + 
recruiti
ng 
18 80 
≥2 yrs 
of 
sympto
ms 
early ≤ 2 - MOCA ≥20 -  N/A N 
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Deferipron 
PD 
2017 
Iron 
Chelator 
Deferipr
one 
Compl
eted + 
report
ed 
50 75 
Within 
5 years 
of 
diagno
sis 
early 1-2 ON 
None 
Specifi
ed 
N/A -  N/A N 
FAIR-PARK-
I 
2015 
Iron 
Chelator 
Deferipr
one 
Compl
eted + 
report
ed 
30 80 
< 2-3 
Years 
early- 
mod 
< 3 OFF MMSE  >24 -  N/A N 
FAIRPARKII - 
Iron 
Chelator 
Deferipr
one 
Open + 
recruiti
ng 
18 80 
Within 
18 
months 
of 
diagno
sis 
early- 
mod 
<3 - MMSE  ≥24 -  N/A Y 
SKY - 
Deferipr
one 
Open + 
recruiti
ng 
18 80 
Within 
3 yrs of 
diagno
sis 
early- 
mod 
<3 - 
None 
Specifi
ed 
N/A -  N/A N 
NIC-PD - 
Transder
mal 
NICotine 
Compl
eted + 
unrepo
rted 
30 - 
Within 
18 
months 
of 
diagno
sis 
early ≤ 2 - MMSE  >24 Becks ≤ 24 N 
STEADY-PD 2013 
Isradipin
e 
Compl
eted + 
report
ed 
30 - -  early ≤ 2.5 - MMSE  ≥26 Becks ≤ 15 N 
Investigati
on of the 
Safety and 
Efficacy of 
NTCELL 
2017 NTCELL 
Compl
eted + 
report
ed 
40 65 
> 5yrs 
since 
diagno
sis 
- - - 
None 
Specifi
ed 
N/A -  N/A N 
Lovastatin 
as a 
Neuroprot
ective 
Treatment 
- 
Lovastati
n 
Open + 
recruiti
ng 
30 90 -  early 1 OFF 
None 
Specifi
ed 
N/A -  N/A N 
 
 
572 
 
 
   Participant Characteristics 
Tr
ia
l 
Y
e
ar
 
p
u
b
lis
h
e
d
 
A
ct
iv
e
 
ag
e
n
t(
s)
 
St
at
u
s 
M
in
 A
ge
 
M
a 
A
ge
 
D
is
e
as
e
 
D
u
ra
ti
o
n
 
In
fe
rr
e
d
 
D
is
e
as
e
 
St
ag
e 
H
&
Y
 S
ta
ge
 
H
&
Y
 O
n
/O
ff
 
St
at
e 
In
cl
u
si
o
n
 
C
ri
te
ri
a:
 
C
o
gn
it
io
n
 
C
u
t-
o
ff
 S
co
re
 
In
cl
u
si
o
n
 
C
ri
te
ri
a:
 
D
e
p
re
ss
io
n
 
C
u
t-
o
ff
 S
co
re
 
D
ru
g 
n
aï
ve
 
for Early 
Stage PD 
PD STAT - 
Simvasta
tin  
Finishe
d 
recruiti
ng 
40 90 -  
early-
mod 
≤  3 ON MOCA ≥21 
MADR
S 
≤ 31 N 
Trial 
Year 
publis
hed 
Active 
agent(s) 
Status 
Min 
Age 
Ma 
Age 
Diseas
e 
Durati
on 
Inferr
ed 
Disea
se 
Stage 
H&Y 
Stage 
H&Y 
On/O
ff 
State 
Inclusi
on 
Criteri
a: 
Cogniti
on 
Cut-
off 
Score 
Inclusi
on 
Criteri
a: 
Depres
sion 
Cut-
off 
Score 
Drug 
naïve 
N-
Acetylcyste
ine for 
Neuroprot
ection in 
Parkinson's 
Disease 
- 
N-
Acetylcy
steine 
Compl
eted + 
unrepo
rted 
50 75 
<15 
years 
since 
diagno
sis 
- - - MMSE  >24 -  N/A N 
GM1 
Gangliosid
e Effects 
on PD 
- 
GM1 
Gangliosi
de 
Compl
eted + 
report
ed 
39 85 -  
early-
mod 
1-3 OFF MMSE  >25 Becks <10 N 
Pioglitazon
e in Early 
PD 
2015 
Pioglitaz
one  
Compl
eted + 
report
ed 
30 - 
Within 
5 years 
of 
diagno
sis 
early <2 - 
None 
Specifi
ed 
N/A -  N/A N 
Safety and 
Efficacy of 
CERE-120 
in Subjects 
With PD 
2013 
CERE-
120 
Compl
eted + 
report
ed 
35 70 -  
early-
mod 
≤  3 OFF 
None 
Specifi
ed 
N/A -  N/A N 
Safety and 
Efficacy of 
DA-9805 
for PD 
-  DA-9805 
Open + 
recruiti
ng 
30 79 
Within 
2 years 
of 
diagno
sis 
early 1 or 2 - MMSE  ≥24 -  N/A N 
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Clinical 
Trial on the 
Effectivene
ss of 
Traditional 
Chinese 
Medicinal 
Miture in 
PD 
- 
Tradition
al 
Chinese 
Medicina
l Miture  
- 50 - -  
early-
mod 
1-3 - 
None 
Specifi
ed 
N/A -  N/A N 
Ubiquinol 
in PD: 
Safety, 
Tolerability
, and 
Effects 
Upon 
Oidative 
Damage 
and 
Mitochond
rial 
Biomarkers 
- 
Ubiquino
l 
Compl
eted + 
unrepo
rted 
40 75 
Within 
5 years 
of 
diagno
sis 
- - - MMSE  >26 -  N/A N 
Study of 
the Neuro-
protective 
Effect of 
Granulocyt
e-colony 
Stimulating 
Factor on 
Early Stage 
PD 
- 
Granuloc
yte-
colony 
Stimulati
ng 
Factor 
Termin
ated 
40 65 -  
early-
mod 
1-3 OFF MMSE  >24 -  N/A N 
Exendin-4 
as a 
Treatment 
for PD - 
Pilot Study 
2013 Eendin-4  
Compl
eted + 
report
ed 
45 70 
> 5yrs 
since 
diagno
sis 
early 2-2.5 - MDRS >120 
MADR
S 
<16 N 
Clinical 
Trial on the 
Effectivene
ss of 
Herbal 
Medicinal 
Miture in 
PD 
- 
Herbal 
Medicina
l Miture  
Compl
eted + 
unrepo
rted 
50 - -  
early-
mod 
1-3 - 
None 
Specifi
ed 
N/A -  N/A N 
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Double- 
blind 
multicentr
e,sham 
surgery 
controlled 
study of 
cere-120 in 
subjects 
with pd 
2010 Cere-120 
Compl
eted + 
report
ed 
35 75 
≥ 5yrs 
since 
diagno
sis 
N/A - - 
Folstei
n Mini 
Mental 
eamin
ation 
>27 -  N/A N 
MIREILLE 2016 
Bee 
Venom 
Compl
eted + 
report
ed 
40 - -  
early-
mod 
1.5-3 OFF MMSE  ≥24 -  N/A N 
SPAR 2018 Exercise  
Compl
eted + 
report
ed 
40 80 
Within 
5 years 
of 
diagno
sis 
early 1-2 - MOCA 
>26/
30 
Becks <13 N 
Trial 
Year 
publis
hed 
Active 
agent(s) 
Status 
Min 
Age 
Ma 
Age 
Diseas
e 
Durati
on 
Inferr
ed 
Disea
se 
Stage 
H&Y 
Stage 
H&Y 
On/O
ff 
State 
Inclusi
on 
Criteri
a: 
Cogniti
on 
Cut-
off 
Score 
Inclusi
on 
Criteri
a: 
Depres
sion 
Cut-
off 
Score 
Drug 
naïve 
A Trial of 
MitoQ for 
the 
treatment 
of people 
with PD  
2010 MitoQ 
Compl
eted + 
report
ed 
30 - -  early <2.5 - 
None 
Specifi
ed 
N/A 
Hamilt
on 
Scale 
<10 N 
Trigonella               
Randomize
d, double-
blind, 
placebo-
controlled 
pilot trial 
of reduced 
coenzyme 
Q10 for 
Parkinson's 
2015 
coenzym
e Q10 
Compl
eted + 
report
ed 
48 75 
Not 
known 
early 1 - 
None 
Specifi
ed 
N/A -  N/A Y 
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disease. 
Group A 
Effect of 
the 
myeloperoi
dase 
inhibitor 
AZD3241 
on 
microglia: 
a PET 
study in PD 
2015 
 
AZD3241 
Compl
eted + 
report
ed 
35 70 
≥ 3 
years 
or 
treated 
by L-
dopa 
for ≥2 
years 
with 
motor 
fluctua
tions 
early - 
advan
ced 
4 ma 
(OFF) 
and 3 
ma 
(ON) 
Eithe
r 
Mattis  >125 -  N/A N 
Safety and 
Efficacy of 
Liraglutide 
in PD 
- 
Liragluti
de 
Open + 
recruiti
ng 
25 85 
>2 yrs 
of 
sympto
ms 
- - - MOCA ≥22 Becks ≤ 29 N 
H2 therapy               
High-dose 
transderm
al nicotine 
in 
Parkinson’
s disease 
patients 
2017 
Transder
mal 
Nicotine 
Compl
eted + 
report
ed 
45 65 -  
early-
mod 
1-3 - MOCA ≥26 -  N/A N 
SURE-PD 2014 Inosine 
Compl
eted + 
report
ed 
30 - 
Within 
3 yrs of 
diagno
sis 
- - - 
None 
Specifi
ed 
N/A -  N/A N 
GAP-PD 2014 GM 608 
Compl
eted + 
report
ed 
30 - 
<10 
years 
since 
diagno
sis 
early-
mod 
<3 - 
None 
Specifi
ed 
N/A -  N/A N 
A Study to 
Assess 
Safety and 
Tolerability 
of Oral 
AZD3241 
2014 
Oral 
AZD3241 
Compl
eted + 
report
ed 
30 80 -  early 1-2.5 - 
None 
Specifi
ed 
N/A -  N/A N 
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in Patients 
With PD 
SPARK - BIIB054 
Open + 
recruiti
ng 
40 80 
Within 
3 yrs of 
diagno
sis 
early ≤ 2.5 - MOCA ≥ 23 -  N/A N 
Study of 
Zonisamid
e in Early 
PD 
- 
Zonisami
de 
In set-
up, not 
yet 
started 
45 85 
<1 
month 
of 
sympto
ms 
- - - 
None 
Specifi
ed 
N/A -  N/A Y 
High-
intensity 
Exercise 
and Fall 
Prevention 
Boot Camp 
for PD 
 
 
 
- 
Exercise 
Compl
eted + 
unrepo
rted 
62 73 -  
early-
mod 
1-3 ON 
None 
Specifi
ed 
N/A -  N/A N 
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STEADY-
PD III 
2017 Isradipi
ne 
Comple
ted + 
reporte
d 
30 - Withi
n 3 yrs 
of 
diagn
osis 
early ≤ 2 - MOCA ≥26 Becks ≤ 15 N 
SURE-
PD3 
- Inosine Finishe
d 
recruiti
ng 
30 - Withi
n 3 yrs 
of 
diagn
osis 
early 1-2.5 - MMS
E  
≥25 -  N/A N 
Study of 
Mirapex 
Pramipe
ole for 
the Early 
Treatme
nt of 
Parkinso
n's 
disease  
2013 Pramip
eole 
Comple
ted + 
reporte
d 
30 79 Withi
n 2 yrs 
of 
diagn
osis 
early 1-2 - None 
Specif
ied 
N/A -  N/A N 
NET-PD 
LS-1 
Creatine 
in 
Parkinso
n's 
Disease 
2015 Creatin
e 
Termina
ted 
- - Withi
n 5 yrs 
of 
diagn
osis 
N/A - - None 
Specif
ied 
N/A -  N/A N 
QE3 2014 Coenzy
me Q10 
with 
Vitamin 
E 
Termina
ted 
30 - Withi
n 5 yrs 
of 
diagn
osis 
early <2.5 - MMS
E  
>25 Hamil
ton 
Scale 
<11 N 
PD4PD 2012 Partner
ed 
Dance 
Comple
ted + 
reporte
d 
30 - -  early-
advan
ced 
1-4 OFF None 
Specif
ied 
N/A -  N/A N 
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ADAGIO 2009 Rasagili
ne 
Comple
ted + 
reporte
d 
30 80 < 18 
mont
hs 
since 
diagn
osis 
early-
mod 
<3 - MMS
E 
≥26 Becks  <15 N 
 
 
